Handbook of Experimental Pharmacology
Volume 182
Editor-in-Chief K. Starke, Freiburg i. Br. Editorial Board S. Duckles, Irvine, CA M. Eichelbaum, Stuttgart D. Ganten, Berlin F. Hofmann, München C. Page, London W. Rosenthal, Berlin G. Rubanyi, San Diego, CA
Jürgen Schüttler • Helmut Schwilden Editors
Modern Anesthetics Contributors J. Ahonen, G. Akk, B. Antkowiak, M. Arras, V. Billard, P. Bischoff, T.W. Bouillon, J.G. Bovill, D. Brian, F. Camu, A. De Wolf, B. Drexler, J. Fechner, B.M. Graf, C. Grashoff, J.F.A. Hendrickx, T.K. Henthorn, R. Jurd, E. Kochs, K. Kück, G. Kullik, S. Lambert, J. Manigel, M. Maze, S. Mennerick, J.-U. Meyer, C. Nau, K.T. Olkkola, M. Perouansky, U. Rudolph, R.D. Sanders, W. Schlack, G. Schneider, J. Schüttler, H. Schwilden, F. Servin, S.L. Shafer, B. Sinner, D.R. Stanski, J.H. Steinbach, B.W. Urban, C. Vanlersberghe, N.C. Weber, N. Wruck, A. Zeller
Prof. Dr. h.c. Jürgen Schüttler Klinik fu¯r Anästhesiologie Friedrich-Alexander-Universität Erlangen-Nürnberg Krankenhausstr. 12 D-91054 Erlangen Germany
[email protected]
ISBN: 978-3-540-72813-9
Prof. Dr. Dr. Helmut Schwilden Klinik fu¯r Anästhesiologie Friedrich-Alexander-Universität Erlangen-Nürnberg Krankenhausstr. 12 D-91054 Erlangen Germany
[email protected]
e-ISBN: 978-3-540-74806-9
Handbook of Experimental Pharmacology ISSN 0171-2004 Library of Congress Control Number: 2007936361 © 2008 Springer-Verlag Berlin Heidelberg This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Cover Design: WMXDesign GmbH, Heidelberg Printed on acid-free paper 9 8 7 6 5 4 3 2 1 springer.com
Preface
Some important constraints of anesthesia must be taken into consideration when the pharmacological properties of modern anesthetics are discussed. The most important of these could be that the target effect be achieved preferably within seconds, at most within a few minutes. Similarly, offset of drug action should be achieved within minutes rather hours. The target effects, such as unconsciousness, are potentially life-threatening, as are the side effects of modern anesthetics, such as respiratory and cardiovascular depression. Finally, the patient’s purposeful responses are not available to guide drug dosage, because, either the patient is unconscious, or more problematically, the patient is aware but unable to communicate pain because of neuromuscular blockade. These constraints were already recognised 35 years ago, when in 1972 Volume XXX entitled “Modern Inhalation Anesthetics” appeared in this Handbook Series. The present volume is meant as a follow up and extension of that volume. At the beginning of the 1970’s anesthesia was commonly delivered by inhalation, with only very few exceptions. The clinical understanding of that time considered anesthesia as a unique state achieved by any of the inhalation anesthetics, independent of their specific molecular structure. “The very mechanism of anesthetic action at the biophase” was discussed within the theoretical framework of the “unitary theory of narcosis”. This theoretical understanding was based on the MeyerOverton correlation and the apparent additivity of MAC when several inhalational anesthetics were given simultaneously, MAC being the measure of anesthetic potency and anesthetic depth developed in the mid-1960’s. Since the 1980’s this understanding has changed completely. Today “general anesthesia” is commonly considered a collection of neurophysiologically very different states, achieved by a multitude of very different drugs (delivered not only by inhalation) acting on a plethora of subcellular structures. Unconsciousness and absence of pain are always included in this collection of different states. Three main factors contributed to this changed understanding: 1) the increasing use of intravenous anesthesia, facilitated by the development of new intravenous anesthetics, not only for the induction but also for the maintenance of anesthesia 2) the discovery of non-additive types of anesthetic interactions,
v
vi
Preface
3) the development of molecular techniques (biological, pharmacological and physiological) to study the interaction of anesthetic drug molecules with receptive cell structures. For these reasons, when the outline of this Handbook was discussed at a brainstorming meeting in Erlangen in February 2005, it became clear that it should be entitled “Modern Anesthetics” and contain in addition to a section on “Inhalation Anesthetics” one on “Intravenous Anesthetics”, preceded by another on “Molecular Mechanisms of Anesthetic Action”. Emphasis was put on the term “molecular” to draw attention to the discovery in the past decades of a great many findings on the interaction of anesthetic compounds with subcellular entities. On the other hand, this emphasis was to underline the lack of our understanding concerning the summation of all the different interactions from the molecular level through the progressive stages of integration within the CNS, which needs to be studied in the future. While these considerations may be considered mainstream of current research in experimental anesthetic pharmacology, it was strongly felt that the particularities of anesthetic drug therapy discussed above require not only specific drugs, but also very particular modes of their delivery and administration. It is not only the properties of the compounds but the combination of compounds plus drug delivery system which turns the compounds into a clinically effective and safe drug. It was therefore thought necessary to integrate a fourth section on “Pharmacokinetics-Pharmacodynamics based Administration of Anesthetics”. This final section illustrates a strategy, still at an experimental stage, in which the integration of drug, medical technology and computational medicine leads to optimized anesthetic therapeutic systems. We wish to thank all colleagues and authors for their endurance and willingness to contribute all their efforts and a considerable amount of time, to share freely their outstanding expertise and knowledge for this Handbook. Special thanks go to those who took responsibilities for each of the four sections: to Bernd Urban for “Molecular Mechanisms of Anesthetic Action”, to Jim Bovill for “Modern Inhalation Anesthetics”, to Frederic Camu for “Modern Intravenous Anesthetics”, and to Don Stanski for “Phamacokinetics-Pharmacodynamics based Administration of Anesthetics”. Erlangen, Germany
Jürgen Schüttler Helmut Schwilden
Contents
Part I Molecular Mechanisms of Anesthetic Action Section Editor: B.W. Urban The Site of Anesthetic Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B.W. Urban Inhibitory Ligand-Gated Ion Channels as Substrates for General Anesthetic Actions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Zeller, R. Jurd, S. Lambert, M. Arras, B. Drexler, C. Grashoff, B. Antkowiak, and U. Rudolph Actions of Anesthetics on Excitatory Transmitter-Gated Channels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G. Akk, S. Mennerick, and J.H. Steinbach
3
31
53
Voltage-Gated Ion Channels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Nau
85
G-Protein-Coupled Receptors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R.D. Sanders, D. Brian, and M. Maze
93
Part II
Modern Inhalation Anesthetics Section Editor: J.G. Bovill
Inhalation Anaesthesia: From Diethyl Ether to Xenon . . . . . . . . . . . . . . . . 121 J.G. Bovill General Anesthetics and Long-Term Neurotoxicity . . . . . . . . . . . . . . . . . . . 143
vii
viii
Contents
M. Perouansky Special Aspects of Pharmacokinetics of Inhalation Anesthesia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 J.F.A. Hendrickx and A. De Wolf Inhalational Anaesthetics and Cardioprotection . . . . . . . . . . . . . . . . . . . . . 187 N.C. Weber and W. Schlack Non-Immobilizing Inhalational Anesthetic-Like Compounds. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209 M. Perouansky Part III
Modern Intravenous Anesthetics Section Editor: F. Camu
Propofol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227 C. Vanlersberghe and F. Camu Pharmacokinetics and Pharmacodynamics of GPI 15715 or Fospropofol (Aquavan Injection) – A Water-Soluble Propofol Prodrug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253 J. Fechner, H. Schwilden, and J. Schüttler Etomidate and Other Non-Barbiturates . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267 C. Vanlersberghe and F. Camu Remifentanil and Other Opioids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283 F.S. Servin and V. Billard Ketamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313 B. Sinner and B.M. Graf Midazolam and Other Benzodiazepines . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335 K.T. Olkkola and J. Ahonen Part IV
Pharmacokinetics-Pharmacodynamics Based Administration of Anesthetics Section Editor: D.R. Stanski
The Effect of Altered Physiological States on Intravenous Anesthetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363 T.K. Henthorn
Contents
ix
Anesthetics Drug Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379 P. Bischoff, G. Schneider, and E. Kochs Defining Depth of Anesthesia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409 S.L. Shafer and D.R. Stanski Target Controlled Anaesthetic Drug Dosing . . . . . . . . . . . . . . . . . . . . . . . . . 425 H. Schwilden and J. Schüttler Advanced Technologies and Devices for Inhalational Anesthetic Drug Dosing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451 J.-U. Meyer, G. Kullik, N. Wruck, K. Kück, and J. Manigel Hypnotic and Opioid Anesthetic Drug Interactions on the CNS, Focus on Response Surface Modeling. . . . . . . . . . . . . . . . . . . . 471 T.W. Bouillon Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489
Contributors
J. Ahonen Helsinki University Central Hospital, Department of Anesthesia and Intensive Care Medicine, Women’s Hospital, P.O. Box 140 (Haartmaninkatu 2), FIN-00029 Hus, Finland,
[email protected] G. Akk Department of Anesthesiology, Washington University School of Medicine, 660 South Euclid Avenue, Saint Louis, MO 63110, USA B. Antkowiak Section of Experimental Anesthesiology, University of Tübingen, Tübingen, Baden-Württemberg, Germany M. Arras Institute of Laboratory Animal Sciences, University of Zurich, Zurich, Switzerland V. Billard Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France,
[email protected] P. Bischoff Klinik und Poliklinik für Anästhesiologie, Universitätsklinikum HamburgEppendorf, Gebäude O50, Martinistraße 52, 20246 Hamburg, Germany,
[email protected] T.W. Bouillon Novartis Pharma AG, PH346, Modeling & Simulation, CHBS, WSJ-027.4.048, Lichtstraße 35, CH-4056 Basel, Switzerland,
[email protected] J.G. Bovill Department of Anaesthesiology, Leiden University Medical Centre, P.O. Box 9600, NL-2300 RC Leiden, The Netherlands,
[email protected] xi
xii
Contributors
D. Brian Academic Anaesthetics, Imperial College, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK F. Camu Department of Anesthesiology, V.U.B. Medical Center, University of Brussels, Laarbeeklaan 101, B-1090 Brussels, Belgium,
[email protected] A. De Wolf Department of Anesthesiology, Feinberg School of Medicine, Northwestern University, 251 E. Huron St, F5-704, Chicago, IL 60611, USA,
[email protected] B. Drexler Section of Experimental Anesthesiology, University of Tübingen, Tübingen, Baden-Württemberg, Germany J. Fechner Klinik fu¯r Anästhesiologie, Universität Erlangen-Nürnberg, Krankenhausstr. 12, 91054 Erlangen, Germany,
[email protected] B.M. Graf Zentrum Anästhesiologie, Abt. Anästhesiologie I, Universitätsklinikum Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany,
[email protected] C. Grashoff Section of Experimental Anesthesiology, University of Tübingen, Tübingen, Baden-Württemberg, Germany J.F.A. Hendrickx Department of Anesthesiology and Intensive Care, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium,
[email protected] T.K. Henthorn Department of Anesthesiology, University of Colorado HSC, 4200 E. 9th Avenue, Denver, CO 80262, USA,
[email protected] R. Jurd Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland E. Kochs Klinik für Anästhesiologie, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany,
[email protected]
Contributors
xiii
K. Kück Drägerwerk Aktiengesellschaft, Moislinger Allee 53-55, 23542 Lübeck, Germany G. Kullik Drägerwerk Aktiengesellschaft, Moislinger Allee 53-55, 23542 Lübeck, Germany S. Lambert Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland J. Manigel Drägerwerk Aktiengesellschaft, Moislinger Allee 53-55, 23542 Lübeck, Germany M. Maze Head of Department of Anaesthetics, Imperial College London, Chelsea and Westminster Hospital, 369, Fulham Road, London SW10 9NH, UK,
[email protected] S. Mennerick Departments of Psychiatry and Anatomy & Neurobiology and the Neurosciences Program, Washington University School of Medicine, 660 South Euclid Avenue, Saint Louis, MO 63110, USA J.-U. Meyer Drägerwerk Aktiengesellschaft, Moislinger Allee 53-55, 23542 Lübeck, Germany,
[email protected] C. Nau Klinik fu¯r Anästhesiologie, Universität Erlangen-Nürnberg, Krankenhausstr. 12, 91054 Erlangen, Germany,
[email protected] K.T. Olkkola Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital, PO Box 52 (Kiinamyllynkatu 4-8), FI-20521 Turku, Finland,
[email protected] M. Perouansky Department of Anesthesiology, Room 43, Bardeen Labs, 1300 University Ave., Madison, WI 53792-3272, USA,
[email protected] U. Rudolph Laboratory of Genetic Neuropharmacology, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA,
[email protected]
xiv
Contributors
R.D. Sanders Academic Anaesthetics, Imperial College, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK W. Schlack Department of Anaesthesiology, University of Amsterdam (AMC), Meibergdreef 9, NL-1100 DD Amsterdam, The Netherlands,
[email protected] G. Schneider Klinik für Anästhesiologie, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany J. Schüttler Klinik fu¯r Anästhesiologie, Universität Erlangen-Nürnberg, Krankenhausstr. 12, 91054 Erlangen, Germany,
[email protected] H. Schwilden Klinik fu¯r Anästhesiologie, Universität Erlangen-Nürnberg, Krankenhausstr. 12, 91054 Erlangen, Germany,
[email protected] F.S. Servin Service d’Anesthésie-Réanimation chirurgicale, Hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris Cedex 18, France,
[email protected],
[email protected] S.L. Shafer Department of Anesthesiology, Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA 94305A, USA,
[email protected] B. Sinner Zentrum für Anaesthesie, Rettungs- und Intensivmedizin, Georg August Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany D.R. Stanski 3903 Albemerle N.W., Washington, DC 20016, USA,
[email protected] J.H. Steinbach Department of Anesthesiology, Washington University School of Medicine, 660 South Euclid Ave, Saint Louis, MO 63110, USA,
[email protected] B.W. Urban Klinik für Anästhesiologie, Universität Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany,
[email protected]
Contributors
xv
C. Vanlersberghe Department of Anesthesiology, V.U.B. Medical Center, University of Brussels, Laarbeeklaan 101, B-1090 Brussels, Belgium,
[email protected] N.C. Weber Department of Anaesthesiology, University of Amsterdam (AMC), Meibergdreef 15, M0-128, NL-Amsterdam 1105 AZ, The Netherlands,
[email protected] N. Wruck Drägerwerk Aktiengesellschaft, Moislinger Allee 53-55, 23542 Lübeck, Germany A. Zeller Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
The Site of Anesthetic Action B.W. Urban
1 2
Introduction.......................................................................................................................... Anesthetics and Their Targets .............................................................................................. 2.1 General Anesthetics in Clinical Use ........................................................................... 2.2 General Anesthetics in Experimental Use .................................................................. 2.3 Anesthetic Potency...................................................................................................... 2.4 Identifying Molecular Targets..................................................................................... 3 Physical and Chemical Nature of Anesthetic Interactions................................................... 3.1 Thermodynamic Approaches ...................................................................................... 3.2 Weak Forces Stabilizing Structures of Biological Macromolecules........................... 3.3 Ion–Ion Interactions .................................................................................................... 3.4 Ion–Dipole Interactions .............................................................................................. 3.5 Van der Waals Interactions (Dipole–Dipole) .............................................................. 3.6 Hydrogen Bonding ...................................................................................................... 3.7 Hydrophobic Interactions ........................................................................................... 4 Molecular Sites of Anesthetic Action .................................................................................. 4.1 Introduction ................................................................................................................. 4.2 Lipid Bilayers ............................................................................................................. 4.3 Protein Binding Sites .................................................................................................. 4.4 Hydrophobic Pockets (Cavities) in Proteins ............................................................... 4.5 Hydrophilic Crevices in Proteins ................................................................................ 4.6 Lipid/Protein Interfaces .............................................................................................. 4.7 Protein/Protein Interfaces............................................................................................ 4.8 Relevant Sites for Anesthetics .................................................................................... References ..................................................................................................................................
4 4 4 6 6 7 8 8 10 11 11 13 15 17 18 18 19 19 20 22 22 23 24 25
Abstract The mechanisms of general anesthesia constitute one of the great unsolved problems of classical neuropharmacology. Since the discovery of general anesthesia, hundreds of substances have been tested and found to possess anesthetic activity. Anesthetics differ tremendously in their chemical, physical, and pharmacological properties, greatly varying in size, in chemically active groups, and in the combinations of interactions and chemical reactions that they can undergo. The B.W. Urban Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
[email protected] J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
3
4
B.W. Urban
large spectrum of targets makes it obvious that dealing with anesthetics pharmacologically is different from dealing with most other drugs used in pharmacology. Anesthetic potency often correlates with the lipophilicity of anesthetic compounds, i.e., their preference for dissolving in lipophilic phases. This suggests as a main characteristic of anesthetic interactions that they are weak and that for many of them there is overall an approximate balance of nonspecific hydrophobic interactions and weak specific polar interactions. These include various electrostatic (ions, permanent and induced dipoles, quadrupoles), hydrogen bonding, and hydrophobic interactions. There are many molecular targets of anesthetic action within the central nervous system, but there are many more still to be discovered. Molecular interaction sites postulated from functional studies include protein binding sites, protein cavities, lipid/protein interfaces, and protein/protein interfaces.
1
Introduction
The mechanisms of general anesthesia remain one of the great unsolved problems of classical neuropharmacology (Miller 1985). Definitions, concepts, and hypotheses concerning general anesthesia have been discussed at length elsewhere (Urban and Bleckwenn 2002; Urban 2002; Campagna et al. 2003; Sonner et al. 2003; Rudolph and Antkowiak 2004; Franks 2006; Evers and Crowder 2005; Koblin 2005). Since there is no agreement on the mechanisms of general anesthesia, sites for interactions of general anesthetics will be discussed without attempting to decide whether or not they are relevant for general anesthesia. The first section will review which drugs produce general anesthesia both clinically and experimentally, and which targets they affect. The next section will describe the molecular interactions that anesthetics are capable of undergoing with their targets. The final section will discuss molecular sites of anesthetic actions that have been investigated in detail.
2
Anesthetics and Their Targets
Since the discovery of general anesthesia hundreds of substances have been tested and found to possess anesthetic activity (Urban et al. 2006). Only very few of these have ever been introduced into clinical practice. The ability of an anesthetic drug to produce experimental general anesthesia is a necessary but not a sufficient condition for its use in humans. It is their side effects that rule out most general anesthetics for clinical use.
2.1
General Anesthetics in Clinical Use
Only a few anesthetics are listed by Goodman and Gilman’s The Pharmacological Basis of Therapeutics (Hardman et al. 2001) as being used in clinical practice
The Site of Anesthetic Action
5
today. They comprise the halogenated ethers sevoflurane, desflurane, isoflurane and enflurane, the halogenated alkane halothane, nitrous oxide, a few barbiturates, a few benzodiazepines, etomidate (imidazole derivative), propofol (phenol derivative), ketamine (phencyclidine derivative), and the opioid analgesics (Fig. 1). While the use of halothane, enflurane, and nitrous oxide is clearly declining, the noble gas xenon is about to be introduced into clinical practice. Barbiturates serve mainly as agents for induction of anesthesia. Opioids are predominantly used as analgesics. Although their use as general anesthetics is controversial (Hug 1990), as an adjuvant they help to reduce the amount of other anesthetic agents needed. Most of these compounds, however, be they modern halogenated inhalation anesthetics or intravenous anesthetics, cannot be used by themselves as universally as diethyl-ether once was. For example, the intravenous anesthetic ketamine is not
Fig. 1 Anesthetics and anesthesia adjuvants widely used in clinical practice, except for diethyl ether, which is shown for historical reasons
6
B.W. Urban
given by itself, but is commonly co-administered with benzodiazepines to counteract the possible undesirable psychological reactions which occur during awakening from ketamine anesthesia (Reves et al. 2000). Almost all halogenated ethers such as isoflurane or desflurane lack sufficient analgesic potency and may even possess hyperalgesic properties (Antognini and Carstens 2002). Intravenous anesthetics such as barbiturates or propofol also lack analgesic potency. Modern general anesthetic techniques in clinical use typically involve the co-administration of a hypnotic drug, an analgesic drug, and possibly a muscle relaxant, allowing the reduction of hypnotic drug concentrations and thereby reducing side effects.
2.2
General Anesthetics in Experimental Use
Hundreds of substances have been examined as general anesthetics in experimental anesthesia (Adriani 1962; Seeman 1972; Lipnick 1991; Miller 2004; Urban et al. 2006). Volatile and nonvolatile anesthetics form two major divisions of anesthetic compounds. On the whole, the volatile drugs are relatively inert molecules that are mostly nonreactive in the body. The nonvolatile drugs, on the other hand, tend to be reactive and are subject to modification by biochemical mechanisms. Anesthetics differ tremendously in their chemical, physical, and pharmacological properties, greatly varying in size, and in chemically active groups. Quite possibly the anesthetics are the most heterogeneous class in all of pharmacology. The large spectrum of targets makes it obvious that dealing with anesthetics pharmacologically is different from dealing with most other drugs used in pharmacology.
2.3
Anesthetic Potency
All clinical measures of anesthetic potency are but surrogate measures. The clinically most prevalent measure of anesthetic potency is MAC (minimal alveolar concentration). It measures the end-tidal concentration of inhaled anesthetic that suppresses purposeful movement in response to surgical incision in 50% of a test population (Eger et al. 1965). It has now become clear that MAC reflects more of a spinal than a cortical response (Antognini and Carstens 2002). MAC and movement responses to noxious stimuli are no longer as useful in clinical practice because of the extensive use of muscle relaxants. It has become clear that clinical anesthetic potency has to be quantified separately for the different components of general anesthesia such as consciousness, amnesia, analgesia, or reflex activities. Different physiological responses have been tried as alternatives to monitor adequate anesthesia: heart rate, arterial pressure, the rate and volume of ventilation in spontaneously breathing subjects, eye movement, the diameter and reactivity of pupils to light, and other autonomic signs such as sweating (Stanski and Shafer 2004). Using a combination of some of these parameters, Evans (1987)
The Site of Anesthetic Action
7
developed the PRST score (pressure, heart rate, sweating, tear production) that, however, is not widely used. Spontaneous electroencephalograms (EEG) and evoked potentials (EG) are electrical brain activities that have been employed to quantify the hypnotic component (Stanski and Shafer 2004). Stanski criticized the fact that clinical measures with poor or unpredictable utility when evaluated scientifically (blood pressure or pulse) have become the mainstay of clinical assessments of depth of anesthesia in routine clinical practice (Stanski and Shafer 2004). It still remains true today that no numerical measure of clinical potency and no monitor, but rather many years of experience, will tell an anesthesiologist whether or not a patient is adequately anesthetized. The only “hard numbers” available at present are either MAC values and their equivalent Cp50 values for intravenous agents (Glass et al. 2004) or empirical doses and concentrations recommended by textbooks and typically given in the operating rooms. The importance of carefully defining functional endpoints when assessing anesthetic potency of in vivo or in vitro experiments has been discussed elsewhere (Urban et al. 2006); there is also a need to establish complete concentrationresponse curves for each functional endpoint.
2.4
Identifying Molecular Targets
As the publications from the most recent Seventh International Conference on Molecular and Basic Mechanisms of Anaesthesia and previous conferences (Fink 1975; Fink 1980; Roth and Miller 1986; Rubin et al. 1991; Richards and Winlow 1998; Urban and Barann 2002; Mashimo et al. 2005) have shown, there are a great many molecular targets of anesthetic actions within the central nervous system. While in the past much attention has focused on ion channels, other proteins have been found to be sensitive to anesthetics as well (Urban et al. 2006). Currently under investigation and definitely of interest are, for example, metabotropic receptors, which modulate synaptic transmission and partly bind the same ligands as ligand-gated ion channel receptors. Other proteins affected by anesthetics are protein pumps, G proteins, protein kinases, and phosphatases, as well as adrenergic receptors, prostanoid receptors, motility proteins, SNARE (soluble N-ethylmaleimidesensitive factor attachment protein receptor) proteins, or fatty acid amide hydrolase (FAAH) (Urban et al. 2006). Still, relatively speaking, the anesthetic sensitivities of only a few proteins have been investigated, when compared with the estimated number of at least 12,000 different membrane proteins, of which ion channels are only a small fraction. The known list of molecular anesthetic targets (Urban et al. 2006) is steadily increasing as ongoing research on other molecular targets is constantly revealing new targets. There is a great deal of discussion and dissent on which molecular targets and which molecular mechanisms are relevant for general anesthesia (Urban and Bleckwenn 2002; Urban 2002; Campagna et al. 2003; Sonner et al. 2003; Rudolph
8
B.W. Urban
and Antkowiak 2004; Franks 2006; Evers and Crowder 2005; Koblin 2005). This is perhaps not surprising since many levels of integration within the central nervous system have to be passed before an anesthetic action at the molecular level is sensed at the systemic level. As long as the detailed architecture of these pathways and networks remains mostly obscure, a final judgment on the relevance of molecular anesthetic targets should be postponed. Several points can be made by surveying the existing information on anesthetic actions on the molecular targets: (1) Even at clinical concentrations, anesthetics act on many different molecular targets. (2) Wherever investigated in detail, it has been found that any single anesthetic suppresses proteins by more than one action, i.e., anesthetics affect not just one but several different aspects of any particular molecular target. (3) No two anesthetics appear to act alike on the same target; they all have their individual spectra of effects. (4) Anesthetics differ not only quantitatively in the relative strengths of their various effects but also qualitatively, in that both suppression as well as potentiation may occur.
3
Physical and Chemical Nature of Anesthetic Interactions
Two fundamentally different approaches have been used in order to characterize interactions between anesthetics and their targets: thermodynamic descriptions and molecular descriptions. Thermodynamic descriptions consider averages over many individual interactions, while molecular descriptions attempt to measure directly individual interactions between anesthetic molecules and their molecular targets. The thermodynamic approach has been largely replaced by molecular approaches as increasingly refined molecular methods have become available to investigate interactions between anesthetics and their targets.
3.1
Thermodynamic Approaches
3.1.1
Solution Theories
Although anesthetically active substances may vary greatly in size and in other physical and physiochemical properties—not to mention their pharmacological behavior—they do have something in common. More than 100 years ago Meyer and Overton independently discovered that anesthetic potency correlated with the preference of anesthetics to dissolve in lipophilic rather than in polar phases (Urban et al. 2006). They found a linear relationship between the logarithm of anesthetic potency and the logarithm of the oil/water partition coefficients, with unity slope, now called the Meyer-Overton correlation (Urban et al. 2006). The Meyer-Overton correlation was found long before the concept of cell membranes existed, and the researchers therefore concluded that anesthesia
The Site of Anesthetic Action
9
was brought about by anesthetics dissolving the lipophilic moieties of a cell. A thermodynamic description of solutions and interactions of solutes with solvents was used in order to describe anesthetic action. These descriptions of anesthetic interactions could be easily transferred to membranes once their concept had been established. Anesthetic potencies were described in terms of chemical potentials partitioning between different solvents and various solubility parameters (Butler 1950; Ferguson 1939; Kaufman 1977; Mullins 1954; Hildebrand and Scott 1964). These descriptions did not concentrate so much on how these interactions brought about anesthesia. Instead, they sought to identify parameters that would predict at what concentration any given substance would produce anesthesia.
3.1.2
Meyer-Overton Rule
To date, no other rule based on physiochemical or structural parameters has been as useful as the Meyer-Overton rule in predicting anesthetic potency. The knowledge of the partition coefficient of a substance is in most cases sufficient to predict its anesthetic potency quite accurately, provided the substance is chemically not too complex (Urban et al. 2006). When anesthetic potency data collected from various in vivo and in vitro systems were plotted against the same consistent set of octanol/water partition coefficients, comparison of the resulting different lipophilicity plots led to the following observations (Urban et al. 2006). First, different classes of anesthetics give rise to different correlations that are shifted with respect to each other. Second, intravenous anesthetics are, on the whole, considerably more potent than inhalation anesthetics. Third, different proteins may differ in their sensitivities to anesthetics, depending on the group of anesthetics involved. The macroscopic Meyer-Overton rule does not provide any direct microscopic insight. However, the existence of so many Meyer-Overton correlations appears to imply that the hydrophobic component of the anesthetic interaction is roughly equal to weak polar components and therefore is not being masked by them (Urban et al. 2006). Consistent with anesthetic interactions being weak is the observation that IC50 values in the millimolar and micromolar range are characteristic in general anesthesia, and that large quantities of anesthetic drugs (in the order of grams or at least milligrams) have to be administered during inhalation anesthesia and intravenous anesthesia (barbiturate, propofol, ketamine, etomidate).
3.1.3
Multiple Linear Regression Analyses of Various Physical Properties
Without examining hydrophobic and weak polar interactions directly on the molecular level, attempts have been made to identify their contributions by using multiple linear regression analysis on thermodynamic parameters. Equations similar to the following have been used to quantify the relative contributions of various
10
B.W. Urban
physical properties of an anesthetic (i.e., its ability to donate or accept a hydrogen bond, its dipolarity and polarizability, and its size) to the magnitude of partition coefficients or concentrations of anesthetic endpoints (Abraham et al. 1991; Davies et al. 1974): log (P) = c+s·p + d·d + a·a + b·b +n·V where P is the partition coefficient between two solvents or the potency of an anesthetic. The solute parameters in this equation represent the following interactions: π, the solute dipolarity/polarizability; δ, a polarizability correction term; α, the solute (hydrogen-bond donor) acidity; β, the solute (hydrogen-bond acceptor) basicity; and V, the solute volume. Solute volume is so closely correlated with lipophilicity (or hydrophobicity) that the coefficient (n) of V can be considered to be a measure of the lipophilicity of the condensed phase being investigated. The constants c, s, d, a, b, and ν are determined, for a large set of anesthetics, using the method of multiple linear regression analysis. The results obtained (Abraham et al. 1991; Davies et al. 1974) suggest that all the factors contained in the equation, i.e., hydrophobicity, dipolarity, polarizability, and hydrogen-bonding, contribute to the overall interaction.
3.2
Weak Forces Stabilizing Structures of Biological Macromolecules
Biological macromolecules, the complex functional units of biochemical systems, are held together by several reversible and noncovalent interactions and associations. These play a pivotal role in the folding of proteins, the recognition of substrates, and the interactions between receptors and ligands. The weak forces responsible for the right structure and functioning of biological macromolecules consist of electrostatic interactions, van der Waals forces, hydrogen bonds, and hydrophobic interactions (ChemgaPedia 2006). The process of the breaking and remaking of hydrogen bonds enables functional proteins to change from one conformation to another. For example, neurotransmitter substances, themselves capable of forming hydrogen bonds and interacting through van der Waals forces and hydrophobic forces, lead to conformational changes by breaking hydrogen bonds in proteins (Celie et al. 2004; Reeves et al. 2003). Not only neurotransmitter molecules but many anesthetic molecules are capable of interacting by such weak forces also, and they have therefore the potential of disrupting functions of biologically important macromolecules such as proteins. As already suggested in the previous section when multiple linear regression analyses of thermodynamic parameters were discussed, different weak forces may combine and superimpose in anesthetic actions. For example, the functional effects of the binding of ligands such as the neurotransmitter acetylcholine or serotonin are thought to depend on the simultaneous interactions involving several hydrogen bonds, cation–π interactions, dispersion forces, and hydrophobic forces (Celie et al.
The Site of Anesthetic Action
11
2004; Reeves et al. 2003; Thompson et al. 2005). The effect of a combination may well be more than just the sum of the different interaction energies and lead to synergistic effects. Therefore, even small contributions may become very important in a combination of different contributing forces. Depending on the proteins and neuronal networks involved for any particular effect of anesthesia, different combinations of these weak forces may become relevant.
3.3
Ion–Ion Interactions
Ion–ion interactions involve the strongest of the Coulombic electrostatic forces (ChemgaPedia 2006). Typical energies for ion–ion interactions at a distance of 0.5 nm are 250 kJ/mol (ChemgaPedia 2006). Many intravenous anesthetics can be ionized and are present, at neutral pH, both in their neutral and their charged forms. Clinical compounds that are partly ionized at neutral pH include, for example, the barbiturates, ketamine, etomidate, and the benzodiazepines. There are examples demonstrating distinct actions of charged intravenous anesthetics and their neutral counterparts (Kendig 1981; Frazier et al. 1975). While direct evidence for ion–ion interactions is yet lacking for general anesthetics, electrostatic repulsion between the charged form of lidocaine and a Na+ ion in the selectivity filter has been suggested to occur in voltage-dependent sodium channels (Tikhonov et al. 2006).
3.4
Ion–Dipole Interactions
The strength of ion–dipole interactions is weaker than that of ion–ion interactions, and it decreases rapidly with distance (ChemgaPedia 2006). The typical energies for ion–dipole interactions at a distance of 0.5 nm are 15 kJ/mol (ChemgaPedia 2006). In biochemical processes this type of interaction plays an important role, e.g., during hydration, complex formation, and cation–π interactions. For the squid axon, it has been suggested that alcohols and anesthetics adsorb at the membrane interface, thereby changing its electric field and the membrane potential through their dipole moments (Haydon and Urban 1983). These changes are then postulated to impact on the gating mechanisms that involve the translocation of net charges (Hille 2001). In gramicidin A pores, it has been proposed that their electrical conductance, i.e., ion flow through them, is affected by dipole potentials generated by n-alkanols adsorbed at the membrane interface (Pope et al. 1982).
3.4.1
Hydration
When ions dissolve in water, the dipolar water molecules will be attracted to them and associate with them depending on their partial charges (ChemgaPedia 2006). The
12
B.W. Urban
water molecules form several layers (hydration shells), the first layer depending primarily on ion–dipole interactions, and further layers being held together by hydrogen bonds. The number of coordinating water molecules depends on the size of the ion and its charge. The hydration shells of ions effectively increase the ionic radius, thereby influencing their diffusion through pores and ion channels (Hille 2001). The selectivity filters of ion channel proteins contain such ions that are in contact with water (Hille 2001). In addition, most biological macromolecules carry negative charges and are surrounded by their own hydration shells that help in stabilizing their conformations. The water molecules in these hydration shells are much more ordered and structured than they are in bulk water. Anesthetics can through the process of clathrate formation interfere with the structure of water in these hydration shells, as was first observed by Pauling (1961) and Miller et al. (1961) independently.
3.4.2
Cation–p Interactions
Cation–π interactions are strong electrostatic interactions that occur between a π-electron cloud and an atom that carries a full or partial positive charge (ChemgaPedia 2006). Cations involved are mainly metal ions or partially positively charged side chains that interact with the aromatic side chains of phenylalanine, tyrosine, or tryptophane (Fig. 2). Thus these positive charges can interact with the surfaces of nonpolar, aromatic structures. As a first approximation, these interactions arise from electrostatic attraction between the positive charge of the cation and the quadrupole moment of the aromatic system. Studies to estimate the strength of such interactions suggest that it may contribute as much as several kilocalories per mole of energy to stabilize the binding of ligand to protein (Beene et al. 2002). Because binding affinity is related logarithmically to binding energy, cation–π interactions may enhance binding affinity by several orders of magnitude (Raines 2005). Cation–π interactions have been recognized as an important noncovalent force in biochemical macromolecules, particularly in proteins. They have been identified in the function of acetylcholine receptor channels and 5-HT3 receptor channels (Beene et al. 2002), generally as a component in ligand-receptor interactions and in
Fig. 2 Cation–π interaction: strong electrostatic interactions between a π-electron cloud of an aromatic ring and an atom that carries a full or partial positive charge
The Site of Anesthetic Action
13
the stabilization of α-helices, in the binding reaction between proteins and DNA, and for the permeation of metal ions through ion channels. Thus by virtue of their π-electron clouds, aromatic anesthetics may engage in attractive electrostatic interactions with cationic atomic charges on protein targets. For example, volatile aromatic drugs inhibit N-methyl-d-aspartate (NMDA) receptor-mediated currents with potencies that are highly correlated with their abilities to engage in cation–π interactions (Raines 2005).
3.5
Van der Waals Interactions (Dipole–Dipole)
Often the term “van der Waals interaction” is loosely used as a synonym for weak intermolecular forces (ChemgaPedia 2006). In the narrower sense it describes intermolecular forces with attractive interaction energies that decrease with the sixth power of distance, because they arise from dipole–dipole interactions (ChemgaPedia 2006). These interactions occur between all kinds of atoms and molecules, even when those are nonpolar. Van de Waals forces can be attractive and repulsive, attraction dominating for larger distances between the interacting parts. Typical energies for dipole–dipole interactions at a distance of 0.5 nm are 0.3–2 kJ/mol (ChemgaPedia 2006). Thus van der Waals forces are quite weak, but they are additive. Their strengths grow with increasing sizes and polarizabilities of the molecules involved. When contact becomes too close, there will be strong repulsion caused by positively charged nuclei as well as by fully occupied orbitals (Pauli exclusion principle). The attractive and repulsive forces of van der Waals interactions are described mathematically by the Lennard-Jones potential. Van der Waals interactions become particularly important in biological systems when two molecules consisting of many atoms approach each other. The interaction between ligand and receptor is primarily of electrostatic origin. Electrostatic forces govern the approach and the alignment of the ligand toward the protein. The probability that a sizable number of atoms of a ligand have by chance just the right distance to the atoms of the binding regions is very low. Thus the high selectivity and stereospecificity of ligand and protein interactions arises quite substantially from van der Waals interactions (ChemgaPedia 2006). Three components of van der Waals interactions are distinguished and described in the following: permanent dipole–permanent dipole, permanent dipole–induced dipole, and fluctuating dipole–induced dipole.
3.5.1
Permanent Dipole–Permanent Dipole
Of the three kinds of dipole interactions those between permanent dipoles (Fig. 3) are the strongest (ChemgaPedia 2006). There are many anesthetics that possess a permanent dipole moment, including the halogenated ethers and alkanes, while cyclopropane and xenon have none. The dipole moment of sevoflurane (3.3 debye) is quite similar in magnitude to that of a peptide bond (3.7 debye). Therefore, apart
14
B.W. Urban
Fig. 3 Permanent dipole–permanent dipole interaction: dipoles can associate either head to tail or in an antiparallel orientation
from interactions with side chains of amino acids, anesthetics carrying permanent dipole moments may interact with proteins in several ways at many positions. Binding of anesthetics to human serum albumin has been suggested to involve permanent dipole interactions (Eckenhoff 1998).
3.5.2
Permanent Dipole–Induced Dipole (Induction Effect)
Dipole interactions may be observed between a dipole and a nonpolar molecule if the latter is polarizable (ChemgaPedia 2006). Polarizability arises if the electron cloud of an atom is distorted in the presence of a strong dipole moment (Fig. 4). For example, as noble gases are polarizable, a permanent dipole will be able to induce a dipole in them, giving rise to electrostatic Debye forces between the permanent and the induced dipole. Thus even the inert gas and anesthetic xenon are capable of interacting with proteins. Polarizability increases with atomic size, and thus should become more prominent in those inhalation anesthetics that contain larger halogens such as chlorine or bromine. Eckenhoff and Johansson (1997) have observed that, for a given structure, both anesthetic potency and degree of metabolism are progressively increased as heavier halogens are substituted (Harris et al. 1992; Targ et al. 1989), suggesting that this type of van der Waals force may be important in producing anesthetic binding interactions in some relevant target.
3.5.3
Fluctuating Dipole–Induced Dipole (Dispersion or London Forces)
Dispersion forces, also called London forces, arise from spontaneous fluctuations of electron densities within atoms and molecules (ChemgaPedia 2006). The constant motion of the electrons in the molecule causes rapidly fluctuating dipoles even in the most symmetrical molecule such as monatomic molecules and noble gases. These fluctuations give rise to the formation of temporary electric dipoles that, in turn, will induce further dipoles in adjacent molecules (Fig. 5). Dispersion forces may act between completely apolar molecules. They are the weakest of all dipole–dipole interactions.
The Site of Anesthetic Action
15
Fig. 4 Permanent dipole–induced dipole interaction: a strong permanent dipole can induce a temporary dipole in a polarizable nonpolar molecule
Fig. 5 Fluctuating dipole–induced dipole interaction: spontaneous fluctuations of electron densities within a symmetrical, apolar molecule create dipoles that, in turn, can induce dipoles in another polarizable, nonpolar molecule
The ease with which the electrons of a molecule, atom or ion are displaced by a neighboring charge is called polarizability. Anesthetic molecules are polarizable, even noble gases such as helium or the clinical anesthetic xenon. Thus, contrary to what their names suggest, they are not completely inert. The more electrons there are, and the larger the distance over which they can move, the bigger the possible temporary dipoles and therefore the bigger the dispersion forces. This is why bigger molecules can interact more strongly and why the boiling points of the noble gases increase from helium (−269°C) to xenon (−108°C). A special case of London forces are π–π interactions between aromatic rings (ChemgaPedia 2006). They are stronger than ordinary London forces because the charges are more mobile in conjugated π-systems. These aromatic interactions occur either as π-stacking or as face-to-face interactions (Fig. 6). π–π interactions are particularly responsible for shaping the tertiary structure of proteins with aromatic side chains. Propofol, etomidate, ketamine, benzodiazepines (such as midazolam), droperidol, morphine, and its fentanyl derivatives are but some examples of intravenous anesthetic compounds containing aromatic rings.
3.6
Hydrogen Bonding
Interactions of the form D-H···|A between a proton donor D-H and a proton acceptor |A are called hydrogen bonds (ChemgaPedia 2006). D and A are generally strongly electronegative atoms such as F, O, and N. The most common hydrogen bonds are formed between oxygen and nitrogen atoms, which can act both as proton acceptors and as proton donors due to their free electron pairs (Fig. 7). In many hydrogen bonds the distance between the atoms A and D is shorter than the sum of the van der Waals radii. Hydrogen bonds are directional and strongest when all three atoms involved in the bond are on a straight line. The interaction energy of
16
B.W. Urban
Fig. 6 π–π interactions between aromatic rings: a special case of London forces but stronger, these occur either as π-stacking or as face-to-face interactions
Fig. 7 Hydrogen bonds: the most common hydrogen bonds are formed between oxygen and nitrogen atoms, which can act either as proton acceptors (shaded area) or as proton donors (not shaded area) due to their free electron pairs
hydrogen bonds consists both of electrostatic contributions (dipole–dipole and dipole–ion interactions) and covalent contributions (three-center four-electron bonds). Energies for hydrogen bonds D-H···A range between 1 and 50 kJ/mol, energies between 10 and 50 kJ/mol are typical. In low barrier hydrogen bonds (F-H···F, O-H···O−) the hydrogen atom is evenly spaced between the donor and the acceptor. This bridge is symmetrical with an angle of 180°, F-H···F being the strongest of all hydrogen bonds. All other hydrogen bonds are high-barrier bonds. Of these, O-H···O, O-H···N, N-H···O are the strongest. N-H···N form weaker hydrogen bonds, and the weakest are between O-H and π-electrons. lnfrared spectroscopists have known for more than half a century that aromatic rings (Ar in the following) can serve as acceptors for weak hydrogen bonds, with typical interaction energies of 4–8 kJ/mol (Sandorfy 2004). Indeed, amino acids like tryptophan, tyrosine, and phenylalanine possess aromatic rings. The existence of N-H···Ar, or OH···Ar hydrogen bonds in proteins was successfully demonstrated (Sandorfy 2004). These H-bonds are thought to play a pivotal role in determining the conformations and motions of proteins (Sandorfy 2004). They could be targets for a number of intravenous anesthetics that also possess aromatic rings. For example, the effect of aromatic amino acid
The Site of Anesthetic Action
17
side-chain structure on halothane binding to four-helix bundles has been studied in detail (Johansson and Manderson 2002). Hydrogen bonds are formed between single molecules (intermolecular) or within a molecule (intramolecular); they are the most important inter- and intramolecular interactions of all of biochemistry. Protein function depends on transitions between different conformations, which involve the breaking of old and remaking of new hydrogen bonds. Any substance such as anesthetics that can compete for hydrogen bonds would be disruptive to protein function. Polar interactions and the breakage of hydrogen bonds appear to be important factors for halogenated hydrocarbons containing an acidic hydrogen (Abraham et al. 1971; Davies et al. 1976; Urban and Haydon 1987), including the clinical anesthetics isoflurane, enflurane, sevoflurane, desflurane, halothane, and the obsolete clinical anesthetic chloroform. Hydrogen bonds may even be broken by substances that by themselves do not form hydrogen bonds as has been suggested for the interaction of n-alkanes with gramicidin A (Hendry et al. 1978; Elliott et al. 1983).
3.7
Hydrophobic Interactions
Hydrophobic interactions are weak interactions resulting from the tendency of hydrophobic molecules or hydrophobic portions of macromolecules to avoid contact with water (ChemgaPedia 2006; Tanford 1980; Tanford 1997). Hydrophobic forces are responsible for generating lipid bilayers that form the backbone of biological membranes. In aqueous solutions, water molecules close to hydrophobic interfaces are arranged such that their hydrogen bonds point away from the hydrophobic areas. This reduces the mobility of water molecules, leading to a breakdown of the free cluster structure of water. Because water molecules adjacent to a hydrophobic interface are highly ordered, they exist in a thermodynamically unstable state, favoring self-aggregation and minimization of the hydrophobic interfaces (Fig. 8). Thus hydrophobic interactions do not result from the van der Waals attraction of hydrophobic moieties but rather from the exclusion of water molecules from areas between hydrophobic interfaces (Fig. 8), resulting in a gain of entropy within the system. In contrast to hydrogen bonds, hydrophobic interactions are not directional. The hydrophobic effect contributes significantly to the binding energies of ligands, for example, in 5-HT3 receptors (Thompson et al. 2005) or nicotinic acetylcholine receptors (Schapira et al. 2002). Hydrophobic interactions are also important for the stabilization of peptide conformations by aliphatic and aromatic side chains (Lins and Brasseur 1995; Kauzmann 1959; Tanford 1997). In processes such as the hydrophobic collapse it plays an important role in protein folding. The contribution is proportional to the surface of the hydrophobic moieties involved. The observation that the Meyer-Overton rule holds in so many interactions between proteins and anesthetics (Urban et al. 2006) underscores the importance of hydrophobic effects in anesthetic action.
18
B.W. Urban
Fig. 8 Hydrophobic interactions: water molecules adjacent to a hydrophobic interface (shaded areas) are highly ordered, thus in a thermodynamically unstable state. Self-aggregation minimizes the hydrophobic interfaces
4 4.1
Molecular Sites of Anesthetic Action Introduction
Following the previous sections’ review of anesthetic targets and the various interactions that anesthetics can undergo, we shall finally consider molecular sites of anesthetic action that have been identified. This subject has been reviewed extensively, so only a selection of references is given here (Evers and Crowder 2005; Franks 2006; Koblin 2005; Urban et al. 1997; Sonner et al. 1950; Rudolph and Antkowiak 2004; Richards 1980; Miller 1985; Little 1996; Campagna et al. 1954; Urban 2002; Urban and Bleckwenn 2002; Overton 1901; Seeman 1972). Unfortunately, in the end, most investigations still represent black box approaches, despite the fact that the molecular configuration of the investigated anesthetics and related drugs can be varied systematically and although the molecular structure of the target sites can be altered methodically through site-directed mutagenesis. However, the spatial and temporal resolution needed for visualizing directly anesthetic action on molecular structures at the atomic scale is mostly beyond anything that is technically feasible today; the resolution of the static ion channel structure is currently limited to about 0.2 nm (Valiyaveetil et al. 2006; Unwin 2005). Therefore, for any one particular interaction it is in most cases impossible to be certain of which and how many molecular structures a drug is contacting, which conformational changes are triggered, and whether amino acid substitutions have altered the secondary and tertiary structures of proteins even before drugs interact with them. The simpler the molecular constitution of an anesthetic-related drug, the more likely it is that it interacts not only with several molecular sites within a biological macromolecule but also with a whole range of different biological macromolecules. Thus the functional endpoint determined in experiments will only in very rare circumstances result from just a single molecular interaction but rather from an integration over time and space of several and dynamic molecular actions. Even
The Site of Anesthetic Action
19
seemingly small molecular changes in either drug constitution or target site structure may thus not be attributable to a change in just a single molecular force or site. Unless time-resolved visualization in the 0.1-nm range and below can be achieved for interactions between drugs and their molecular targets, their identification will remain indirect, depending on the observation of function instead.
4.2
Lipid Bilayers
Lipid bilayers consisting of a bimolecular leaflet of lipids are the backbone of biological membranes. In the early 1960s it became possible to form artificial lipid bilayers. Their physicochemical properties were systematically characterized (Tosteson 1969; Haydon and Hladky 1972) and it was discovered that anesthetics have many actions on lipid bilayers (Koblin 2005; Miller 1985; Seeman 1972). Purely hydrophobic anesthetics were found to be located preferentially in the lipid membrane hydrocarbon core, while amphipathic molecules tended to be localized predominantly in the membrane interface (North and Cafiso 1997; Tang et al. 1997; Pohorille et al. 1996). Purely hydrophobic anesthetics increase membrane thickness and raise their surface tension (Haydon et al. 1977). Lateral pressure profiles in membranes are also changed (Cantor 1997). The insertion of anesthetic molecules into lipid membranes causes them to become more fluid and disordered (Firestone et al. 1994). The increase in lipid fluidity resulting from the absorption of inhaled agents can vary considerably (Ueda et al. 1986) and depends on the lipid system examined, the position within the membrane, and the method of fluidity measurement (Baber et al. 1995; North and Cafiso 1997; Tsuchiya 2001; Vanderkooi et al. 1977). Phase transition temperatures of bilayer membranes may decrease (Galla and Trudell 1980; Tsuchiya 2001; Vanderkooi et al. 1977). Lateral phase separation may result (Trudell 1977). Anesthetics may also change membrane electrical properties such as membrane dielectric constant (Enders 1990) or surface dipole potentials (Reyes and Latorre 1979). Inhaled agents have been reported to increase the ion permeability of liposomes in a concentration-related manner (Andoh et al. 1997; Barchfeld and Deamer 1985; Miller et al. 1972).
4.3
Protein Binding Sites
While there are many studies showing effects of anesthetics on protein function, in general they often fail to prove that anesthetics first bind to the proteins involved before they bring about the observed effects (Eckenhoff and Johansson 1997). Even in reconstituted lipid bilayer systems, for example, consisting only of highly purified sodium channels and no more than two different kinds of lipid molecules (Wartenberg et al. 1994), it is difficult to prove that the observed functional effects of anesthetics are only due to anesthetic binding to the protein. Indeed, it could be
20
B.W. Urban
shown that lipid bilayer composition modulated some functional anesthetic effects on purified sodium channels (Rehberg et al. 1995). Thus caution is advised when making inferences about binding based on functional studies. Nuclear magnetic resonance (NMR) spectroscopy and photoaffinity labeling have been used as more direct approaches to study anesthetic binding to proteins (Evers and Crowder 2005). 19F-NMR spectroscopic studies showed that isoflurane binds to approximately three saturable binding sites on bovine serum albumin, a fatty acid-binding protein (Dubois and Evers 1992). These results were confirmed by Eckenhoff and colleagues when they used 14C-labeled halothane to photoaffinity label anesthetic binding sites on bovine serum albumin (Eckenhoff and Shuman 1993). They were able to identify the specific amino acids that were photoaffinity labeled by [14C]halothane. This binding was eliminated by co-incubation with oleic acid, consistent with the assumption that isoflurane binds to the fatty acid-binding sites on albumin. Other clinical anesthetics, such as halothane and sevoflurane, competed with isoflurane for binding to bovine serum albumin (Dubois et al. 1993). These studies provide suggestive evidence that at least certain anesthetics can compete for binding to the same site on a protein. Currently, NMR and photoaffinity labeling techniques can only be applied to purified proteins available in relatively large quantities. The muscle-type nicotinic acetylcholine receptor is one of the few membrane proteins that has been purified in large quantities. It could be shown that halothane binds to this protein, but the pattern of photoaffinity labeling is complex, indicative of multiple binding sites (Eckenhoff 1996). Binding to specific sites on the nicotinic acetylcholine receptor could also be shown with a new and different technique involving 3-diazirinyloctanol. Most recently, Miller and colleagues have developed a general anesthetic that is an analog of octanol and functions as a photoaffinity label (Husain et al. 1999). Other approaches to identify the location and structure of anesthetic binding sites have involved site-directed mutagenesis of candidate anesthetic targets in combination with molecular modeling. Using this strategy the location and structure of the alcohol binding site on γ-aminobutyric acid (GABA)A and glycine receptors has been predicted (Wick et al. 1998). An additional approach involves the use of model proteins such as gramicidin A (Hendry et al. 1978; Tang and Xu 2002; Pope et al. 1982) or four α-helix bundles with a hydrophobic core that can bind volatile anesthetics (Johansson et al. 1998).
4.4
Hydrophobic Pockets (Cavities) in Proteins
Considerable attention has been focused on preformed cavities within proteins as binding sites for inhaled anesthetics. Hydrophobic cavities within proteins are apparently quite common in proteins (Eckenhoff 2001). When proteins fold into complex structures, packing defects known as “cavities” are generated. These cavities are thought to introduce the necessary instabilities that facilitate
The Site of Anesthetic Action
21
conformational changes accompanying protein function (Eckenhoff 2001). The size of some of these cavities permits the occupation by anesthetic molecules. A recent screen of the Protein Data Bank for potential targets of halothane identified 394,766 total cavities, of which 58,681 cavities satisfied the fit criteria for halothane (Byrem et al. 2006). Experimental data support the hypothesis that small molecules can bind in cavities formed between α-helices in proteins (Trudell and Bertaccini 2002). X-ray diffraction crystallography has been used to reveal details of the threedimensional structure of anesthetic sites that NMR and photoaffinity techniques cannot provide (Evers and Crowder 2005). Because X-ray diffraction requires crystallized membrane proteins, it has so far only been used for a small number of proteins. One of the first studies of this type was performed with myoglobin. It was shown that the anesthetic molecules xenon and cyclopropane were able to bind in the hydrophobic core of a protein and that the size of the hydrophobic binding pocket could account for a cutoff in the size of anesthetic molecules that can bind in that cavity (Schoenborn et al. 1965; Schoenborn 1967). Another example of a hydrophobic pocket has been demonstrated with X-ray diffraction for halothane binding deep within the enzyme adenylate kinase (Sachsenheimer et al. 1977). The halothane binding site was identified as the binding site for the adenine moiety of adenosine monophosphate, a substrate for adenylate kinase. Another example of anesthetics binding to endogenous ligand binding sites is provided by firefly luciferase, where two molecules of the anesthetic bromoform bind in the luciferin pocket, one of them competitively with luciferin and the other one noncompetitively (Franks et al. 1998). Human serum albumin has also been successfully crystallized and the X-ray crystallographic data show binding of propofol as well as of halothane to preformed pockets that had been shown previously to bind fatty acids (Bhattacharya et al. 2000). The binding energies of anesthetics to these sites of action appear to be small, so that these molecules bind presumably adventitiously to preexisting cavities or sites. Consequently, the binding event is not thought to cause an “induced fit” in a protein site or even provide substantial reorganization of an internal cavity (Harris et al. 2002). Anesthetic binding to these cavities affects protein stability depending on their native sizes: proteins having intermediate pre-existing cavities are destabilized, presumably resulting from preferential binding of the anesthetic to less stable intermediates with enlarged cavities. Proteins containing larger cavities are stabilized by the anesthetic, indicative of binding to the native state (Miller 2002; Eckenhoff 2002). The volume of the cavity or binding pocket constitutes a constraint on the anesthetic molecules that may bind. This volume may depend on the conformation of the protein. This has been shown for glycine receptor channels, possessing binding pockets with volumes that are different in the resting (smaller) and in the activated (larger) state (Harris et al. 2002). The volume of the cavity and proposed anesthetic binding site in GABAA receptor channels is estimated to range between 0.25 and 0.37 nm3, quite likely constituting a common site of action for the anesthetics isoflurane, halothane, and chloroform (Jenkins et al. 2001). Modulation of human
22
B.W. Urban
5-HT3A-mediated currents by volatile anesthetics exhibits a dependence on molecular volume similar to n-alcohols, suggesting that both classes of agents may enhance 5-HT3A receptor function via the same mechanism (Stevens et al. 2005). The data suggest an apparent size of 0.120 nm3 for the cavity (Stevens et al. 2005), which modulates anesthetic and n-alcohol enhancement of agonist action on the 5-HT3A receptor. These and other studies have demonstrated that possible sites of anesthetic action exist within the transmembrane subunits of the superfamily of ligand-gated ion channels. The exact molecular arrangement of this transmembrane region remains at intermediate resolution with current experimental techniques (Eckenhoff 2001). In order to produce a more exact model of this region, homology modeling methods combined with experimental data have been used. This approach produced a final structure possessing a cavity within the core of a four-helix bundle. Converging on and lining this cavity are residues known to be involved in modulating anesthetic potency. Thus cavities formed within the core of transmembrane four-helix bundles may be important binding sites for volatile anesthetics in the ligand-gated ion channels (Bertaccini et al. 2005).
4.5
Hydrophilic Crevices in Proteins
Water-filled crevices in proteins, apart from hydrophobic cavities, have also been implicated as molecular sites of anesthetic action. Akabas et al. (2002) suggest that crevices and cavities form in the membrane-spanning domains during GABAA receptor gating. Since a vacuum is energetically unfavorable, water moves in, thereby facilitating conformational change. These water-filled crevices extend from the extracellular surface into the interior of the GABAA receptor protein. Anesthetics, by preferentially filling these crevices/cavities, could stabilize receptor conformations other than the resting state, altering the probability of channel opening (Akabas et al. 2002). While this site is still quite hypothetical at present, it considers the possibility that anesthetics may enter proteins by transfer to an annular ring formed by the four-component interface of the ligand-binding and transmembrane domains of the protein, the phospholipid bilayer, and the interfacial water layer. This route that anesthetics may take constitutes an alternative to diffusion down the water-filled lumen of the ion channel or dissolution in the phospholipid bilayer followed by transfer through the lipid–protein interface of the ion channel (Trudell and Bertaccini 2002).
4.6
Lipid/Protein Interfaces
Integral membrane proteins are essential for mediating numerous physiological functions. In order to function successfully, membrane proteins must perform
The Site of Anesthetic Action
23
properly within, and at the same time interact with, the lipid membrane in which they undergo conformational changes while carrying out their complex functions. There is much evidence for a strong effect of the properties of lipid bilayers on the function of membrane proteins (Trudell and Bertaccini 2002; Rebecchi and Pentyala 2002). Reconstitution studies have provided the best evidence that the lipid environment may significantly affect the properties of integral membrane proteins. In reconstitution studies it is actually possible to reinsert proteins, which have been removed from their native membranes, into artificial lipid bilayer membranes of defined lipid composition. A number of diverse reconstituted proteins have been found to have altered functions, depending on the composition of the surrounding lipids (Zakim 1986). Specific properties of phospholipids, such as head group composition, and general properties of the hydrophobic bilayer, such as micro viscosity, can have dramatic effects on protein function. This leads to the expectation that if the properties of lipid bilayers have been changed by anesthetics in a comparable way, then protein function should also be altered. Nash (2002) takes issue with the fact that lipid targets of anesthetic action have fallen from favor. He argues that he knows of no decisive experiment that eliminates lipid targets from contention, particularly if one acknowledges the possibility that subtle alterations of bilayers by volatiles anesthetics might impact on the function of proteins imbedded in them. The function of the ion channel-forming polypeptide gramicidin A is modulated by the lipid environment (Hendry et al. 1978; Pope et al. 1982). Anesthetic changes of membrane parameters have been postulated to directly affect sodium channel and potassium channel function in the squid giant axon (Urban 1993). The lipid environment alters the actions of pentobarbital on purified sodium channels reconstituted in planar lipid bilayers (Rehberg et al. 1995). Studies using sitedirected mutations in ligand-gated ion channels combined with molecular modeling suggest that a primary point of action of anesthetics is in the transmembrane domain of these channels (Trudell and Bertaccini 2002). Another example involves certain protein kinases where anesthetics might operate at the protein/lipid interface by changing the lateral pressure profile (Rebecchi and Pentyala 2002).
4.7
Protein/Protein Interfaces
The possibility that anesthetics might be able to act at the interface between protein subunits or at the interface between different proteins has not been explored extensively. It has been suggested that anesthetics binding to such sites might disrupt, for example, allosteric transitions at domain/domain interfaces of protein kinases or prevent agonist-induced dissociation of receptor from the heterotrimeric G proteins (Rebecchi and Pentyala 2002).
24
4.8
B.W. Urban
Relevant Sites for Anesthetics
Figure 9 summarizes sites of anesthetic action that have been identified in lipid bilayers and in ion channels, the latter representing the best-studied class of membrane proteins in this context. Anesthetics may differ in the spectrum of interaction sites depending on their physicochemical properties and the structures of the biological macromolecules. Within the bilayer, anesthetics may act (1) at the interface between the lipid and the aqueous phase, (2) within the hydrophobic interior of the lipid bilayer itself (Urban et al. 1991; Trudell and Bertaccini 2002), or (3) between the lipid and membrane proteins. Anesthetics may bind to protein binding sites in contact with the aqueous phase, located either (4) inside the channel lumen of ion channels (Dilger 2002; Scholz 2002), or (5) at the water/protein interface. (6) Water-filled crevices or water channels inside or adjacent to membrane proteins have been implicated (Trudell and Bertaccini 2002). Anesthetics may bind (7) within the core of the membrane protein itself, between hydrophobic α-helices (Frenkel et al. 1990) and form hydrophobic or lipophilic pockets (Trudell and Bertaccini 2002). (8) Anesthetics may disturb interactions between subunits of a protein or between different proteins (Trudell and Bertaccini 2002; Rebecchi and Pentyala 2002). In addition, Sandorfy (2002) has pointed out that carbohydrates that are covalently attached to membrane proteins may also constitute sites of anesthetic actions. Which of the molecular sites are relevant for clinical anesthesia? The answer to this question requires knowledge of the neuronal networks critical to general anesthesia or to one of its essential clinical components. When these relevant neuronal networks will have been identified, it should then become possible to assess which molecular sites contribute to clinical anesthesia.
Fig. 9 Summary of identified molecular sites of anesthetic action in membranes and in embedded proteins
The Site of Anesthetic Action
25
References Abraham MH, Lieb WR, Franks NP (1991) Role of hydrogen bonding in general anesthesia. J Pharm Sci 80:719–724 Adriani J (1962) The chemistry and physics of anesthesia. Charles C Thomas, Springfield Akabas MH, Horenstein J, Williams DB, Bali M, Bera AK (2002) GABA- and drug-induced conformational changes detected in the GABAA receptor channel-lining segments. In: Urban BW, Barann M (eds) Molecular and basic mechanisms of anesthesia. Pabst Science Publishers, Lengerich, pp 130–142 Andoh T, Blanck TJJ, Nikonorov I, Recio-Pinto E (1997) Volatile anaesthetic effects on calcium conductance of planar lipid bilayers formed with synthetic lipids or extracted lipids from sarcoplasmic reticulum. Br J Anaesth 78:66–74 Antognini JF, Carstens E (2002) In vivo characterization of clinical anaesthesia and its components. Br J Anaesth 89:156–166 Baber J, Ellena JF, Cafiso DS (1995) Distribution of general anesthetics in phospholipid bilayers determined using 2H NMR and 1H-1H NOE spectroscopy. Biochemistry 34:6533–6539 Barchfeld GL, Deamer DW (1985) The effect of general anesthetics on the proton and potassium permeabilities of liposomes. Biochim Biophys Acta 819:161–169 Beene DL, Brandt GS, Zhong W, Zacharias NM, Lester HA, Dougherty DA (2002) Cation-p interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry 41:10262–10269 Bertaccini EJ, Shapiro J, Brutlag DL, Trudell JR (2005) Homology modeling of a human glycine alpha 1 receptor reveals a plausible anesthetic binding site. J Chem Inf Model 45:128–135 Bhattacharya AA, Curry S, Franks NP (2000) Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J Biol Chem 275:38731–38738 Butler TC (1950) Theories of general anesthesia. J Pharmacol Exp Ther 98:121–160 Byrem WC, Armstead SC, Kobayashi S, Eckenhoff RG, Eckmann DM (2006) A guest moleculehost cavity fitting algorithm to mine PDB for small molecule targets. Biochim Biophys Acta 1764:1320–1324 Campagna JA, Miller KW, Forman SA (2003) Mechanisms of actions of inhaled anesthetics. N Engl J Med 348:2110–2124 Cantor RS (1997) The lateral pressure profile in membranes: a physical mechanism of general anesthesia. Biochemistry 36:2339–2344 Celie PH, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, Sixma TK (2004) Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 41:907–914 ChemgaPedia (2006) Chemgapedia. Vernetztes Studium–Chemie. http://www.chemgapedia.de/ vsengine/topics/de/vlu/Chemie/index.html. Fachinformationszentrum Chemie GmbH, Berlin. Cited 23 June 2007 Davies RH, Bagnall RD, Jones WGM (1974) A quantitative interpretation of phase effects in anaesthesia. Int J Quant Chem Quant Biol Symp 1:201–212 Davies RH, Bagnall RD, Bell W, Jones WGM (1976) The hydrogen bond proton donor properties of volatile halogenated hydrocarbons and ethers and their mode of action in anaesthesia. Int J Quant Chem Quant Biol Symp 3:171–185 Dilger JP (2002) The effects of general anaesthetics on ligand-gated ion channels. Br J Anaesth 89:41–51 Dubois BW, Evers AS (1992) 19F-NMR spin-spin relaxation (T2) method for characterizing volatile anesthetic binding to proteins. Analysis of isoflurane binding to serum albumin. Biochemistry 31:7069–7076 Dubois BW, Cherian SF, Evers AS (1993) Volatile anesthetics compete for common binding sites on bovine serum albumin: a 19F-NMR study. Proc Natl Acad Sci U S A 90:6478–6482
26
B.W. Urban
Eckenhoff RG (1996) An inhalational anesthetic binding domain in the nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A 93:2807–2810 Eckenhoff RG (1998) Do specific or nonspecific interactions with proteins underlie inhalational anesthetic action? Mol Pharmacol 54:610–615 Eckenhoff RG (2001) Promiscuous ligands and attractive cavities: how do the inhaled anesthetics work? Mol Interv 1:258–268 Eckenhoff RG (2002) Promiscuous ligands and attractive cavities. In: Urban BW, Barann M (eds) Molecular and basic mechanisms of anesthesia. Pabst Science Publishers, Lengerich, p 75 Eckenhoff RG, Johansson JS (1997) Molecular interactions between inhaled anesthetics and proteins. Pharmacol Rev 49:343–367 Eckenhoff RG, Shuman H (1993) Halothane binding to soluble proteins determined by photoaffinity labeling. Anesthesiology 79:96–106 Eger EI, Saidman LJ, Brandstater B (1965) Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology 26:756–763 Elliott JR, Needham D, Dilger JP, Haydon DA (1983) The effects of bilayer thickness and tension on gramicidin single-channel lifetime. Biochim Biophys Acta 735:95–103 Enders A (1990) The influence of general, volatile anesthetics on the dynamic properties of model membranes. Biochim Biophys Acta 1029:43–50 Evans JM (1987) Clinical signs and autonomic responses. In: Rosen M, Lunn JN (eds) Consciousness, awareness and pain in general anaesthesia. Butterworth, London, pp 18–34 Evers AS, Crowder CM (2005) Cellular and molecular mechanisms of anesthesia. In: Barash PG, Cullen BF, Stoelting RK (eds) Clinical anesthesia. Lippincott Williams & Wilkins, Philadelphia, pp 111–132 Ferguson J (1939) The use of chemical potentials as indices of toxicity. Proc R Soc Lond B Biol Sci 127:387–404 Fink BR (1975) Molecular mechanisms of anesthesia. Raven Press, New York Fink BR (1980) Molecular mechanisms of anesthesia 2. Raven Press, New York Firestone LL, Alifimoff JK, Miller KW (1994) Does general anesthetic-induced desensitization of the Torpedo acetylcholine receptor correlate with lipid disordering? Mol Pharmacol 46:508–515 Franks NP (2006) Molecular targets underlying general anaesthesia. Br J Pharmacol 147 [Suppl 1]:S72–S81 Franks NP, Jenkins A, Conti E, Lieb WR, Brick P (1998) Structural basis for the inhibition of firefly luciferase by a general anesthetic. Biophys J 75:2205–2211 Frazier DT, Murayama K, Abbott NJ, Narahashi T (1975) Comparison of the action of different barbiturates on squid axon membranes. Eur J Pharmacol 32:102–107 Frenkel C, Duch DS, Urban BW (1990) Molecular actions of pentobarbital isomers on sodium channels from human brain cortex. Anesthesiology 72:640–649 Galla HJ, Trudell JR (1980) Asymmetric antagonistic effects of an inhalation anesthetic and high pressure on the phase transition temperature of dipalmitoyl phosphatidic acid bilayers. Biochim Biophys Acta 599:336–340 Glass PS, Shafer SL, Reves JG (2004) Intravenous drug delivery systems. In: Miller RD (ed) Anesthesia. Churchill Livingstone, Philadelphia, pp 439–480 Hardman JG, Limbird LE, Gilman AG (2001) The pharmacological basis of therapeutics. McGraw-Hill, New York Harris JW, Jones JP, Martin JL, LaRosa AC, Olson MJ, Pohl LR, Anders MW (1992) Pentahaloethane-based chlorofluorocarbon substitutes and halothane: correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid excretion with calculated enthalpies of activation. Chem Res Toxicol 5:720–725 Harris RA, Mascia MP, Lobo IA (2002) Sites of anesthetic action on a ligand-gated ion channel. In: Urban BW, Barann M (eds) Molecular and basic mechanisms of anesthesia. Pabst Science Publishers, Lengerich, pp 174–178
The Site of Anesthetic Action
27
Haydon DA, Hladky SB (1972) Ion transport across thin lipid membranes: a critical discussion of mechanisms in selected systems. Q Rev Biophys 5:187–282 Haydon DA, Urban BW (1983) The action of alcohols and other non-ionic surface active substances on the sodium current of the squid giant axon. J Physiol 341:411–427 Haydon DA, Hendry BM, Levinson SR, Requena J (1977) Anaesthesia by the n -alkanes. A comparative study of nerve impulse blockage and the properties of black lipid bilayer membranes. Biochim Biophys Acta 470:17–34 Hendry BM, Urban BW, Haydon DA (1978) The blockage of the electrical conductance in a pore-containing membrane by the n-alkanes. Biochim Biophys Acta 513:106–116 Hildebrand JH, Scott RL (1964) The solubility of non-electrolytes. Dover Publications, New York Hille B (2001) Ion channels of excitable membranes. Sinauer Assoc., Sunderland Hug CCJ (1990) Does opioid “anesthesia” exist? Anesthesiology 73:1–4 Husain SS, Forman SA, Kloczewiak MA, Addona GH, Olsen RW, Pratt MB, Cohen JB, Miller KW (1999) Synthesis and properties of 3-(2-hydroxyethyl)-3-n-pentyldiazirine, a photoactivable general anesthetic. J Med Chem 42:3300–3307 Jenkins A, Greenblatt EP, Faulkner HJ, Bertaccini E, Light A, Lin A, Andreasen A, Viner A, Trudell JR, Harrison NL (2001) Evidence for a common binding cavity for three general anesthetics within the GABAA receptor. J Neurosci 21:RC136 Johansson JS, Manderson GA (2002) The effect of aromatic amino acid side-chain structure on halothane binding to four-helix bundles. In: Urban BW, Barann M (eds) Molecular and basic mechanisms of anesthesia. Pabst Sciences Publishers, Lengerich, pp 23–28 Johansson JS, Gibney BR, Rabanal F, Reddy KS, Dutton PL (1998) A designed cavity in the hydrophobic core of a four-alpha-helix bundle improves volatile anesthetic binding affinity. Biochemistry 37:1421–1429 Kaufman RD (1977) Biophysical mechanisms of anesthetic action: historical perspective and review of current concepts. Anesthesiology 46:49–62 Kauzmann W (1959) Some factors in the interpretation of protein denaturation. Adv Protein Chem 14:1–63 Kendig JJ (1981) Barbiturates: active form and site of action at node of Ranvier sodium channels. J Pharmacol Exp Ther 218:175–181 Koblin DD (2005) Mechanisms of action. In: Miller RD (ed) Anesthesia. Churchill Livingstone, Philadelphia, pp 105–130 Lins L, Brasseur R (1995) The hydrophobic effect in protein folding. FASEB J 9:535–540 Lipnick RL (1991) Studies of narcosis: Charles Ernest Overton. Chapman and Hall, London Little HJ (1996) How has molecular pharmacology contributed to our understanding of the mechanism(s) of general anesthesia? Pharmacol Ther 69:37–58 Mashimo T, Ogli K, Uchida I (2005) Basic and systemic mechanisms of anesthesia. Invited papers of the 7th International Conference on Basic and Systematic Mechanisms of Anesthesia, Nara, Japan, 25–27 February 2005. Elsevier, Amsterdam Miller KW (1985) The nature of the site of general anesthesia. Int Rev Neurobiol 27:1–61 Miller KW (2002) The nature of sites of general anaesthetic action. Br J Anaesth 89:17–31 Miller KW, Paton WD, Smith EB, Smith RA (1972) Physicochemical approaches to the mode of action of general anesthetics. Anesthesiology 36:339–351 Miller RD (2004) Anesthesia, 6th edn. Churchill Livingstone, Philadelphia Miller SL (1961) A theory of gaseous anesthetics. Proc Natl Acad Sci USA 47:1515–1524 Mullins LJ (1954) Some physical mechanisms in narcosis. Chem Rev 54:289–323 Nash HA (2002) In vivo genetics of anaesthetic action. Br J Anaesth 89:143–155 North C, Cafiso DS (1997) Contrasting membrane localization and behavior of halogenated cyclobutanes that follow or violate the Meyer-Overton hypothesis of general anesthetic potency. Biophys J 72:1754–1761 Overton E (1901) Studien über die Narkose. Verlag Gustav Fischer, Jena Pauling L (1961) A molecular theory of general anesthesia. Science 134:15–21
28
B.W. Urban
Pohorille A, Cieplak P, Wilson MA (1996) Interactions of anesthetics with the membrane-water interface. Chem Phys 204:337–345 Pope CG, Urban BW, Haydon DA (1982) The influence of n-alkanols and cholesterol on the duration and conductance of gramicidin single channels in monoolein bilayers. Biochim Biophys Acta 688:279–283 Raines DE (2005) Cation-p interactions modulate the NMDA receptor inhibitory potencies of inhaled aromatic anesthetics. In: Mashimo T, Ogli K, Uchida I (eds) Basic and systemic mechanisms of anesthesia. Elsevier, Amsterdam, pp 85–89 Rebecchi MJ, Pentyala SN (2002) Anaesthetic actions on other targets: protein kinase C and guanine nucleotide-binding proteins. Br J Anaesth 89:62–78 Reeves DC, Sayed MF, Chau PL, Price KL, Lummis SC (2003) Prediction of 5-HT(3) Receptor agonist-binding residues using homology modeling. Biophys J 84:2338–2344 Rehberg B, Urban BW, Duch DS (1995) The membrane lipid cholesterol modulates anesthetic actions on a human brain ion channel. Anesthesiology 82:749–758 Reves JG, Glass PSA, Lubarsky DA (2000) Nonbarbiturate intravenous anesthetics. In: Miller RD, Cuchiara RF, Miller ED, Reves JG, Roizen MF, Savarese JJ (eds) Anesthesia. Churchill Livingstone, Philadelphia, pp 228–272 Reyes J, Latorre R (1979) Effect of the anesthetics benzyl alcohol and chloroform on bilayers made from monolayers. Biophys J 28:259–279 Richards CD (1980) The mechanisms of general anaesthesia. In: Norman J, Whitwam JG (eds) Topical reviews in anaesthesia. John Wright & Sons, Bristol, pp 1–84 Richards CD, Winlow W (1998) Molecular and cellular mechanisms of general anesthesia. Elsevier, New York Roth SH, Miller KW (1986) Molecular and cellular mechanisms of anesthetics. Plenum Medical Book, New York Rubin E, Miller KW, Roth SH (1991) Molecular and cellular mechanisms of alcohol and anesthetics. Ann N Y Acad Sci 625:1–848 Rudolph U, Antkowiak B (2004) Molecular and neuronal substrates for general anaesthetics. Nat Rev Neurosci 5:709–720 Sachsenheimer W, Pai EF, Schulz GE, Schirmer RH (1977) Halothane binds in the adeninespecific niche of crystalline adenylate kinase. FEBS Lett 79:310–312 Sandorfy C (2002) Towards a comprehensive theory of general anesthesia. In: Urban BW, Barann M (eds) Molecular and basic mechanisms of anesthesia. Pabst Science Publishers, Lengerich, pp 66–73 Sandorfy C (2004) Hydrogen bonding and anaesthesia. J Mol Struct 708:3–5 Schapira M, Abagyan R, Totrov M (2002) Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMC Struct Biol 2:1 Schoenborn BP (1967) Binding of cyclopropane to sperm whale myoglobin. Nature 214:1120–1122 Schoenborn BP, Watson HC, Kendrew JC (1965) Binding of xenon to sperm whale myoglobin. Nature 207:28–30 Scholz A (2002) Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth 89:52–61 Seeman P (1972) The membrane actions of anesthetics and tranquilizers. Pharmacol Rev 24:583–655 Sonner JM, Antognini JF, Dutton RC, Flood P, Gray AT, Harris RA, Homanics GE, Kendig J, Orser B, Raines DE, Trudell J, Vissel B, Eger EI (2003) Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Analg 97:718–740 Stanski DR, Shafer SL (2004) Monitoring depth of anesthesia. In: Miller RD (ed) Anesthesia. Churchill Livingstone, Philadelphia, pp 1227–1264 Stevens RJ, Rusch D, Davies PA, Raines DE (2005) Molecular properties important for inhaled anesthetic action on human 5-HT3A receptors. Anesth Analg 100:1696–1703 Tanford C (1980) The hydrophobic effect. Wiley, New York Tanford C (1997) How protein chemists learned about the hydrophobic factor. Protein Sci 6:1358–1366
The Site of Anesthetic Action
29
Tang P, Xu Y (2002) Large-scale molecular dynamics simulations of general anesthetic effects on the ion channel in the fully hydrated membrane: the implication of molecular mechanisms of general anesthesia. Proc Natl Acad Sci U S A 99:16035–16040 Tang P, Yan B, Xu Y (1997) Different distribution of fluorinated anesthetics and nonanesthetics in model membrane: a 19F NMR study. Biophys J 72:1676–1682 Targ AG, Yasuda N, Eger EI, Huang G, Vernice GG, Terrell RC, Koblin DD (1989) Halogenation and anesthetic potency. Anesth Analg 68:599–602 Terrell RC, Speers L, Szur AJ, Treadwell J, Ucciardi TR (1971) General anesthetics. 1. Halogenated methyl ethyl ethers as anesthetic agents. J Med Chem 14:517–519 Thompson AJ, Price KL, Reeves DC, Chan SL, Chau PL, Lummis SC (2005) Locating an antagonist in the 5-HT3 receptor binding site: a modeling and radioligand binding study. J Biol Chem 280:20476–20482 Tikhonov DB, Bruhova I, Zhorov BS (2006) Atomic determinants of state-dependent block of sodium channels by charged local anesthetics and benzocaine. FEBS Lett 580:6027–6032 Tosteson DC (1969) The molecular basis of membrane function. Prentice-Hall, Englewood Cliffs Trudell JR (1977) A unitary theory of anesthesia based on lateral phase separations in nerve membranes. Anesthesiology 46:5–10 Trudell JR, Bertaccini E (2002) Molecular modelling of specific and non-specific anaesthetic interactions. Br J Anaesth 89:32–40 Tsuchiya H (2001) Structure-specific membrane-fluidizing effect of propofol. Clin Exp Pharmacol Physiol 28:292–299 Ueda I, Hirakawa M, Arakawa K, Kamaya H (1986) Do anesthetics fluidize membranes? Anesthesiology 64:67–71 Unwin N (2005) Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 346:967–989 Urban BW (1993) Differential effects of gaseous and volatile anaesthetics on sodium and potassium channels. Br J Anaesth 71:25–38 Urban BW (2002) Current assessment of targets and theories of anaesthesia. Br J Anaesth 89:167–183 Urban BW, Barann M (2002) Molecular and basic mechanisms of anesthesia. Pabst Science Publishers, Lengerich Urban BW, Bleckwenn M (2002) Concepts and correlations relevant to general anaesthesia. Br J Anaesth 89:3–16 Urban BW, Haydon DA (1987) The actions of halogenated ethers on the ionic currents of the squid giant axon. Proc R Soc Lond B Biol Sci 231:13–26 Urban BW, Frenkel C, Duch DS, Kauff AB (1991) Molecular models of anesthetic action on sodium channels, including those from human brain. Ann N Y Acad Sci 625:327–43:327–343 Urban BW, Bleckwenn M, Barann M (2006) Interactions of anesthetics with their targets: nonspecific, specific or both? Pharmacol Ther 111:729–770 Valiyaveetil FI, Leonetti M, Muir TW, MacKinnon R (2006) Ion selectivity in a semisynthetic K+ channel locked in the conductive conformation. Science 314:1004–1007 Vanderkooi JM, Landesberg R, Selick H, McDonald GG (1977) Interaction of general anesthetics with phospholipid vesicles and biological membranes. Biochim Biophys Acta 464:1–18 Wartenberg HC, Wang J, Rehberg B, Urban BW, Duch DS (1994) Molecular actions of pentobarbitone on sodium channels in lipid bilayers: role of channel structure. Br J Anaesth 72:668–673 Wick MJ, Mihic SJ, Ueno S, Mascia MP, Trudell JR, Brozowski SJ, Ye Q, Harrison NL, Harris RA (1998) Mutations of gamma-aminobutyric acid and glycine receptors change alcohol cutoff: evidence for an alcohol receptor? Proc Natl Acad Sci U S A 95:6504–6509 Zakim D (1986) Interface between membrane biology and clinical medicine. Am J Med 80:645–657
Inhibitory Ligand-Gated Ion Channels as Substrates for General Anesthetic Actions A. Zeller, R. Jurd, S. Lambert, M. Arras, B. Drexler, C. Grashoff, B. Antkowiak, and U. Rudolph(* ü)
1 Introduction ........................................................................................................................ 2 Inhibitory Ligand-Gated Ion Channels: GABAA and Glycine Receptors .......................... 3 Targeted Mutations in GABAA Receptor Subunit Genes ................................................... 3.1 GABAA Receptor Subunit Knockout Mice ............................................................... 3.2 GABAA Receptor Subunit Knockin Mice ................................................................. 4 Studies of General Anesthetic Actions In Vivo ................................................................. 4.1 Intravenous Anesthetics: Etomidate and Propofol .................................................... 4.2 Barbiturates ............................................................................................................... 4.3 Volatile Anesthetics .................................................................................................. 4.4 Ethanol ...................................................................................................................... 5 Conclusion ........................................................................................................................... References ..................................................................................................................................
31 32 33 33 34 36 36 43 44 45 46 47
Abstract General anesthetics have been in clinical use for more than 160 years. Nevertheless, their mechanism of action is still only poorly understood. In this review, we describe studies suggesting that inhibitory ligand-gated ion channels are potential targets for general anesthetics in vitro and describe how the involvement of γ-aminobutyric acid (GABA)A receptor subtypes in anesthetic actions could be demonstrated by genetic studies in vivo.
1
Introduction
In 1846 the first public demonstration of anesthesia with ether by William T. Morton at the Massachusetts General Hospital in Boston heralded a new era in medical practice, in particular enabling the performance of sophisticated surgical operations that would not be possible without general anesthesia. It was soon discovered that a variety of substances have general anesthetic actions. About a century ago, Meyer U. Rudolph Laboratory of Genetic Neuropharmacology, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA
[email protected] J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
31
32
A. Zeller et al.
and Overton independently discovered a strong correlation between anesthetic potency and solubility in oil (Meyer-Overton rule). These observations led to the view that general anesthetics act in the lipid bilayer of the neuronal plasma membrane by an unspecific mechanism (lipid theory). However, Franks and Lieb demonstrated that general anesthetics can interact directly with proteins (protein theory), and that the interaction with proteins also fulfills the predictions of the Meyer-Overton rule (Franks and Lieb 1984). The fact that optical isomers of some anesthetics differ in potency also cannot be explained by a nonspecific action (Franks and Lieb 1994). Moreover, substances have been identified that would be predicted by the MeyerOverton rule to be anesthetic, but they are in fact not (“non-immobilizers”), and the “long chain alcohol cutoff,” i.e., the observation that alcohols that exceed a certain size are inactive, also cast doubt on the lipid theory (Koblin et al. 1994). Today there is ample evidence that anesthetics directly modulate ion channels. These interactions can be both specific and unspecific in nature (Urban et al. 2006). Over time it became apparent that general anesthetics modulate the activity of ion channels in the membrane of nerve cells at clinically relevant concentrations (Krasowski and Harrison 1999; Yamakura and Harris 2000). With respect to the inhibitory ligand-gated ion channels, it is noteworthy that etomidate, propofol, barbiturates, isoflurane, and sevoflurane significantly increase the activity of γ-aminobutyric acid (GABA)A receptors at clinically relevant concentrations, while ketamine and nitrous oxide apparently do not modulate the activity of GABAA receptors to a significant degree at these concentrations. At the glycine receptor, isoflurane and sevoflurane significantly increase glycine-induced chloride currents at clinically relevant concentrations, while propofol, etomidate, barbiturates, and nitrous oxide display smaller effects (Belelli et al. 1999). Ketamine does not modulate the glycine receptor (Krasowski and Harrison 1999). However, one should note that the observation that a certain general anesthetic modulates a specific class of ligand-gated ion channels or a subtype thereof in vitro does not tell us whether this ion channel subtype is responsible for mediating any of the effects of this general anesthetic in vivo. Another caveat is that recombinant systems may not contain receptor-associated proteins that may influence anesthetic sensitivity of a particular receptor.
2
Inhibitory Ligand-Gated Ion Channels: GABAA and Glycine Receptors
GABAA receptors are involved in the regulation of vigilance, anxiety, memory, and muscle tension. They are pentameric complexes with six α-, three β-, one δ-, one ε-, one π-, one θ-, and three ρ-subunit genes known. Most GABAA receptors appear to consist of α-, β-, and γ-subunits, believed to be assembled in a 2:2:1 stoichiometry. Preferred combinations include α1β2γ2 (representing ca. 60% of all GABAA receptors in the brain), α2β3γ2 (15%), and α3βnγ2 (10%–15%). The subunit combinations α4β2γ, α4βnδ, α5β1/3γ2, α6β2/3γ2, and α6βnδ each represent less than 5% of all receptors in the brain (McKernan and Whiting 1996; Mohler et al. 2002). GABAA receptors can be found in both synaptic and extrasynaptic locations.
Inhibitory Ligand-Gated Ion Channels
33
For practical purposes, GABAA receptors are frequently classified on the basis of their α- and β-subunits as αn-containing GABAA receptors and βn-containing GABAA receptors, respectively. Glycine receptors also belong to the family of ligand-gated ion channels. They appear to be particularly prevalent in the brain stem and spinal cord. There are four α-subunits and a single β-subunit known, with receptors comprising α-homomers or αβ-heteromers. Most glycine receptors in adult animals are of the α1β type. Volatile anesthetics such as halothane, isoflurane, and sevoflurane strongly potentiate the glycine-induced chloride currents at clinically relevant concentrations in recombinant systems and also in neurons (Harrison et al. 1993; Downie et al. 1996; Mascia et al. 1996; Krasowski and Harrison 1999), while the potentiation by propofol at clinically relevant concentrations is much smaller, suggesting that if glycine receptors play a significant role in clinical anesthesia, this would likely be restricted to volatile anesthetics (Belelli et al. 1999; Grasshoff and Antkowiak 2004). The enflurane- or isoflurane-induced depression of spontaneous action potential firing in ventral horn interneurons in spinal cord cultures has recently been found to be mediated almost equally by GABAA receptors and glycine receptors (Grasshoff and Antkowiak 2006). Clearcut in vivo data demonstrating that glycine receptors would mediate specific anesthetic actions are currently unavailable. As pointed out previously, it has been known for some time that most general anesthetics modulate the activity of GABAA receptors in vivo at clinically relevant concentrations (Krasowski and Harrison 1999). In vitro studies suggest that ketamine and nitrous oxide do not act via GABAA receptors (Krasowski and Harrison 1999). GABAA receptor agonistic actions of ketamine have been proposed based on pharmacological in vivo data (Irifune et al. 2000), but other in vivo studies reported that the GABAA antagonist gabazine did not block ketamine-induced anesthesia (Nelson et al. 2002; Sonner et al. 2003). It has also been reported that nitrous oxide, tested at a concentration (100%, 29.2 mM) that is higher than that used clinically, increases the efficacy of GABA at recombinant GABAA receptors (Hapfelmeier et al. 2000). At higher concentrations, some general anesthetics also directly activate the GABAA receptor in the absence of GABA; the pharmacological relevance of this observation is currently unknown. Since most general anesthetics modulate the activity of a variety of neuronal ion channels, in particular ligand-gated ion channels, it is impossible to draw conclusions from in vitro data as to which neuronal ion channels (or other neuronal targets) mediate clinically relevant actions of general anesthetics.
3 3.1
Targeted Mutations in GABAA Receptor Subunit Genes GABAA Receptor Subunit Knockout Mice
Knockout mice with deletions of specific GABAA receptor subunits potentially provide a valuable tool for assessing physiological or pharmacological functions of the respective GABAA receptor subunits. For various reasons this approach has met
34
A. Zeller et al.
with variable success. Potential problems include compensatory mechanisms, e.g., upregulation of related subunits, and influence on the expression of neighboring genes due to enhancers in the neomycin expression cassette. This is especially problematic for GABAA receptor subunits since the genes are arranged in clusters (Uusi-Oukari et al. 2000) and multiple impairments may make it difficult to distinguish primary and secondary effects of a knockout. In mice with a knockout of the β3 subunit (Homanics et al. 1997) the duration of the loss of the righting reflex in response to midazolam and etomidate–but not to pentobarbital, enflurane, halothane, and ethanol–was reduced compared to wildtype mice, and the immobilizing action of halothane and enflurane, as determined in the tail clamp withdrawal test, was decreased (Quinlan et al. 1998). These results point to a role of β3-containing GABAA receptors in the hypnotic and immobilizing actions of the drugs mentioned, but it is also worth noting that when the enflurane-induced depression of spinal cord neurotransmission was examined in spinal cord slices of these mice, it was found that other targets substitute for the role that is normally played by β3containing GABAA receptors (Wong et al. 2001). In δ-subunit knockout mice, the duration of the loss of the righting reflex was significantly decreased in response to the neuroactive steroid alphaxalone and the neurosteroid pregnenolone, but not in response to midazolam, etomidate, propofol, pentobarbital, and ketamine, indicating the potential involvement of δ-containing GABAA receptors in the actions of neurosteroidal anesthetics (Mihalek et al. 1999). Another mouse model that has provided valuable information on targets mediating actions of general anesthetics is the α5 knockout mouse (Collinson et al. 2002). In α5 knockout mice, the duration of the loss of the righting reflex in response to etomidate was indistinguishable from wildtype mice, indicating that α5-containing GABAA receptors do not mediate the hypnotic action of etomidate (Cheng et al. 2006). It was, however, found that the amnestic action of etomidate in a contextual fear conditioning paradigm and in the Morris water maze (a test for hippocampal learning) are absent in α5 knockout mice, indicating that these actions of etomidate are mediated by α5-containing GABAA receptors (Cheng et al. 2006).
3.2
GABAA Receptor Subunit Knockin Mice
In an attempt to circumvent some of the problems encountered when studying knockout mice, knockin mice carrying point mutations were generated. These point mutations were designed to alter the sensitivity of the respective receptor subtype to CNS-depressant drugs, while largely maintaining the sensitivity for the physiological neurotransmitter GABA. Even if the mutations are not completely “silent,” knockin mice offer substantial insights into the functions of defined GABAA receptors in the actions of general anesthetics (Rudolph and Mohler 2004). A conserved histidine residue in the extracellular N-terminal domain of α1, α2, α3, and α5 subunits is required for binding of classical benzodiazepines like
Inhibitory Ligand-Gated Ion Channels
35
diazepam (Wieland et al. 1992; Kleingoor et al. 1993; Benson et al. 1998). In mice with the a1(H101R) mutation in the α1 subunit, diazepam does not reduce motor activity, indicating that the sedative action of diazepam is mediated by α 1containing GABAA receptors (Rudolph et al. 1999; Crestani et al. 2000; McKernan et al. 2000). It is noteworthy that in α1 knockout mice diazepam still decreases locomotor activity, even more strongly than in wildtype mice (Kralic et al. 2002b; Reynolds et al. 2003a), so that studies in knockout and knockin mice would apparently lead to opposing conclusions. Interestingly, L-838,417, a benzodiazepine site ligand that is an antagonist at α1-containing GABAA receptors but a partial agonist at α2-, α3-, and α5-containing GABAA receptors, also has no sedative action (McKernan et al. 2000), confirming the conclusion obtained with the a1(H101R) knockin mice by two independent groups and suggesting that the strong upregulation of the α2 and α3 subunits in the α1 knockout mice (Sur et al. 2001; Kralic et al. 2002a) makes these mice sensitive to diazepam-induced sedation. Furthermore, α1 knockout mice have been found to display an increased tonic GABAA receptormediated current in cerebellar granule cells, which is likely due to a reduction of GABA transporter (GAT) activity, which thus might represent another adaptive mechanism (Ortinski et al. 2006). Studies with a1(H101R) knockin mice also suggest that α1-containing GABAA receptors mediate the anterograde amnesic action and in part the anticonvulsant actions of diazepam (Rudolph et al. 1999). The anxiolytic-like action of diazepam is absent in a2(H101R) mice, indicating that sedation and anxiolysis are mediated by distinct receptor subtypes and can be separated pharmacologically (Low et al. 2000). The myorelaxant action of diazepam, determined in the horizontal wire test, is mediated primarily by α2-, but also by α3- and α5-containing GABAA receptors (Crestani et al. 2001, 2002). In pioneering studies using recombinant receptors, amino acid residues in the second and third transmembrane domain of α- and β-subunits have been identified that are crucial for the action of many general anesthetic agents on GABAA receptors. Sites on both α- and β-subunits have been found to be involved in the action of volatile anesthetics such as enflurane and isoflurane. These include (but are not limited to) α1-S270, α1-A291, β2/3-N265, and β2/3-M286 (Belelli et al. 1997; Mihic et al. 1997; Krasowski et al. 1998; Siegwart et al. 2002, 2003). In contrast, only sites on the β-subunits have been found to be relevant for the actions of the intravenous anesthetics etomidate and propofol (Belelli et al. 1997; Krasowski et al. 1998). The replacement of an asparagine in position 265 of β2 or β3 with methionine [the residue found in the homologous position of the Drosophila melanogaster Rdl GABAA receptor, which is insensitive to etomidate (Pistis et al. 1999)] results in a profound decrease of the modulatory and direct (i.e., GABA-independent) actions of etomidate and propofol (Belelli et al. 1997; Siegwart et al. 2002, 2003). The potency of etomidate is roughly ten times smaller at β1- compared to β2- and β3-containing GABAA receptors (Hill-Venning et al. 1997). The β1 subunit contains a serine residue at position 265 that is responsible for this property (Belelli et al. 1997; Hill-Venning et al. 1997). Although the β2- and β3-containing GABAA receptors appear to be the prime targets for etomidate, it cannot be formally excluded that β1-containing GABAA receptors still
36
A. Zeller et al.
may contribute to the clinical actions of etomidate. Moreover, multiple known [e.g., 11β-hydroxylase, α2B and α2C adrenoceptors (Paris et al. 2003)] and potentially also unknown targets for etomidate exist. If a mutation e.g., in the GABAA receptor β2 subunit renders the respective GABAA receptor subtype insensitive to etomidate, one should be careful with the conclusion that any remaining etomidate action is mediated by β3-containing GABAA receptors, although this is not unlikely. Furthermore it has been shown recently that GABAA receptor subtypes containing β1 and rare subunits such as θ may be sensitive to etomidate. Specifically, recombinant α3β1θ GABAA receptors have a higher efficacy for etomidate compared to α3β1 or α3β1γ2 receptors, although the potency for etomidate was apparently unchanged (Ranna et al. 2006).
4
Studies of General Anesthetic Actions In Vivo
4.1
Intravenous Anesthetics: Etomidate and Propofol
4.1.1
Immobilization and Hypnosis
The first knockin mouse model harboring a GABAA receptor insensitive to a clinically used general anesthetic was the b3(N265M) knockin mouse (Jurd et al. 2003). In vitro, this point mutation completely abolished the modulatory and direct effects of etomidate and propofol and substantially reduced the modulatory action of enflurane. However, the modulatory action of the neuroactive steroid alphaxalone was preserved (Siegwart et al. 2002). In neocortical slices of b3(N265M) knockin mice, etomidate and enflurane were less effective at decreasing spontaneous action potential firing (Jurd et al. 2003). In hippocampal CA1 pyramidal neurons, the modulatory action of etomidate was reduced, consistent with the β3 subunit being the predominant, but not exclusive, β-subunit in these cells (Jurd et al. 2003). Motor activity and hot plate sensitivity were unchanged in the absence of drugs (Jurd et al. 2003). As a measure of the immobilizing action of etomidate and propofol, the hindlimb withdrawal reflex, which is lost in response to these drugs, was studied. The absence of this reflex is indicative of surgical tolerance (Arras et al. 2001). In the b3(N265M) knockin mice the loss of the hindlimb reflex in response to etomidate and propofol that is invariably seen in wildtype mice was absent, indicating that the immobilizing action of these agents is apparently completely dependent on β3-containing GABAA receptors (Fig. 1; Jurd et al. 2003). To monitor the hypnotic action of etomidate and propofol, the righting reflex was studied. Etomidate and propofol abolished the righting reflex in wildtype mice. In the b3(N265M) knockin mice the duration of the loss of the righting reflex in response to these drugs was significantly reduced, indicating that the hypnotic action of etomidate and propofol is mediated in part by β3-containing GABAA receptors (Fig. 1; Jurd et al. 2003). This essential phenotype of the b3(N265M)
Inhibitory Ligand-Gated Ion Channels
37
Fig. 1 Behavioral responses to i.v. anesthetics in wildtype and b3(N265M) mice. Reduction in the duration (in minutes) of the loss of righting reflex (LORR) induced by a etomidate and b propofol in b3(N265M) mice vs wildtype. Etomidate (15 mg/kg) and propofol (40 mg/kg) were lethal for 50% and 58% of the wildtype, respectively, but none of the b3(N265M) mice. c Alphaxalone [mixed in a 3:1 ratio with alphadolone, Saffan (Vet Drug, Dunnington, UK)] induced a similar duration (also given in minutes) of LORR in both genotypes. At 30 mg/kg, alphaxalone was lethal in 67% of wildtype mice and 50% of b3(N265M) mice. d Etomidate (10, 15 mg/kg) and e propofol (20, 30 mg/kg) failed to induce loss of the hind limb withdrawal reflex (LHWR) in b3(N265M) mice in contrast to wildtype mice (p < 0.01, Fischer’s exact test). f Alphaxalone (15, 30 mg/kg) induced LHWR with similar duration in b3(N265M) and wildtype mice. All drugs were administered intravenously. Wildtype mice, black shading, b3(N265M) mice, gray shading. **p < 0.01, ***p <0.001, compared with wildtype; median test (n=6–12 per group). (Reprinted with permission from FASEB Journal, Jurd et al. 2003)
knockin mice has now been observed on three different genetic backgrounds (129X1/SvJ×129/Sv (87.5%/12.5%) (Jurd et al. 2003), 129X1/SvJ (10 backcrosses), and C57BL/6J (9 backcrosses) (Zeller et al. 2007a), indicating that this
38
A. Zeller et al.
phenotype is very robust and also that Gabrb3, which is located between 57.4 and 57.7 Mb, is different from a gene that has been described as lorp1(loss or righting reflex in response to propofol), which has been mapped with a 99% confidence interval to 71.4–89.7 Mb on mouse chromosome 7 (Simpson et al. 1998); in addition, an etomidate-sensitivity quantitative trait locus (QTL) has also been identified in this chromosome region (Christensen et al. 1996; Downing et al. 2003). Thus, there is good evidence that the lack of immobility and partial lack of hypnosis in response to etomidate and propofol is really due to the N265M point mutation in the Gabrb3 gene. In a parallel experiment performed by another group, the asparagine-265 residue in the β2 subunit was replaced by a serine residue. A serine residue is found in the homologous position of the “etomidate-insensitive” β1 subunit. This mutation abolishes the action of etomidate, but not of propofol. In cerebellar Purkinje cells of b2(N265S) knockin mice, which predominantly contain α1β2γ2 GABAA receptors, the modulatory effect of etomidate was substantially reduced (Reynolds et al. 2003b). The pedal withdrawal reflex in response to etomidate was still present in b2(N265S) knockin mice, although its duration was reduced (Reynolds et al. 2003b). Injection of propofol led to a loss of the reflex in both wildtype and b2(N265S) knockin mice, compatible with the point-mutated β2-containing receptors being sensitive for propofol (Reynolds et al. 2003b). The duration of the loss of the righting reflex in response to etomidate was reduced in b2(N265S) knockin mice compared to wildtype mice, whereas the response to propofol was identical in both genotypes, consistent with the mutant receptors being sensitive to propofol (Reynolds et al. 2003b). The results of these studies with b3(N265M) and b2(N265S) knockin mice suggest that the immobilizing action of etomidate and propofol is mediated largely by β3-containing GABAA receptors, whereas its hypnotic action is mediated by both β2- and β3-containing GABAA receptors. While the neurocircuitry responsible for the righting reflex are largely unknown, previous research has shown that the immobilizing actions of propofol are mediated at the spinal cord level (Antognini and Schwartz 1993; Rampil et al. 1993; Rampil 1994; Antognini et al. 2000). Thus, it is conceivable that β3-containing GABAA receptors in the spinal cord play an important role in mediating the immobilizing action of etomidate and propofol. Furthermore, the GABAA receptor antagonists gabazine systemic und picrotoxin increased the ED50 for propofol-induced immobilization in rats (Sonner et al. 2003), and the GABAA receptor antagonist bicuculline antagonized the hypnotic action of propofol (Irifune et al. 2003). While these studies provide strong evidence for an involvement of GABAA receptors in propofol-induced immobilization, they did not identify which GABAA receptor subtype would mediate this action. In another study, muscimol (an agonist of the GABAA receptor at the GABA site), propofol, and pentobarbital, administered intracerebroventricularly, led to a loss of the righting reflex [which these authors termed “sedation” but which in our terminology represents “hypnosis” (see also Rudolph and Antkowiak 2004)]. The actions of these drugs were attenuated by systemic gabazine (Nelson et al. 2002). All three agents were found to increase c-fos staining in the ventrolateral preoptic nucleus (VLPO)
Inhibitory Ligand-Gated Ion Channels
39
and decrease c-fos-staining in the tuberomammillary nucleus (TMN), indicating that they increase neuronal activity in the VLPO and decrease neuronal activity in the TMN, which is an arousal-producing nucleus (Nelson et al. 2002). The VLPO is known to release GABA into the TMN, thus likely causing inhibition of the TMN, which releases histamine in the cortex. Direct injection of muscimol into the TMN results in a loss of the righting reflex, indicating that the action of muscimol in the TMN is sufficient for its hypnotic effect (Nelson et al. 2002). When propofol and gabazine are administered systemically, gabazine, administered into the TMN, reduced the duration of the loss of the righting reflex, indicating that the TMN plays a role in the hypnotic actions of propofol and pentobarbital (Nelson et al. 2002). Since VLPO and TMN are known to be a part of the non-rapid eye movement (REM) sleep-promoting pathway, this work provides an interesting potential connection between anesthesia and sleep.
4.1.2
Sedation
At subanesthetic doses, etomidate decreases motor activity, i.e., exerts a sedative action. This sedative action is observed in b3(N265M) knockin mice (Zeller et al. 2005), but not in b2(N265S) knockin mice (Reynolds et al. 2003b). These results suggest that the sedative action of etomidate is mediated by β2-containing GABAA receptors but not by β3-containing GABAA receptors. α1β2γ2 is the most abundant GABAA receptor subtype in the central nervous system (McKernan and Whiting 1996; Mohler et al. 2002). The observations that the sedative action of diazepam is mediated by α1-containing GABAA receptors (Rudolph et al. 1999; McKernan et al. 2000) and that the sedative action of etomidate is mediated by β2-containing GABAA receptors (Reynolds et al. 2003b) suggest that the α1β2γ2 receptor subtype is the relevant subtype mediating the sedative, i.e., motor depressing actions, of CNS-depressant drugs. It is currently unknown which circuits or neuronal populations are involved in these actions. The observation that general anesthetics reduce activity prominently in cortical networks at sedative concentrations suggests that the cortex might play a prominent role (Hentschke et al. 2005). Etomidate caused impairment of motor performance in a rotating rod test that is indistinguishable between α5 knockout mice and wildtype mice, which suggests that α5-containing GABAA receptors do not mediate the motor impairing action of etomidate in this assay (Cheng et al. 2006).
4.1.3
Hypothermia
At anesthetic doses, etomidate also has a strong hypothermic action. This action is strongly reduced in β2(N265S) knockin mice (Cirone et al. 2004) and only slightly reduced in β3(N265M) knockin mice (Zeller et al. 2005), indicating that it is largely mediated by β2-containing GABAA receptors and only to a small degree by β3containing GABAA receptors.
40
4.1.4
A. Zeller et al.
Respiratory and Cardiac Depression
When studying the immobilizing actions of etomidate and propofol in b3(N265M) knockin mice and wildtype mice, Jurd and collaborators noticed that high doses of these drugs (etomidate 15 mg/kg i.v., propofol 40 mg/kg i.v.) are lethal for approximately 50% of the wildtype mice but not for b3(N265M) knockin mice. Interestingly, alphaxalone/alphadolone (30/10 mg/kg i.v.) were lethal for approximately 50% of both wildtype and b3(N265M) knockin mice (Jurd et al. 2003). These results suggest that the potentially lethal response is mediated by β3-containing GABAA receptors. We hypothesized that either the cardiac depressant action or the respiratory depressant action of these general anesthetics might be responsible for the lethality observed. In wildtype mice, etomidate and propofol induce a significant decrease in the heart rate. This decrease is also present in b3(N265M) knockin mice, indicating that targets other than β3-containing GABAA receptors mediate this effect (Zeller et al. 2005). Heart rate and temperature were determined at the same time. It is possible that the reductions in temperature and heart rate are interrelated and not independent phenomena. Respiratory depression was assessed by monitoring arterial blood gases (PaO2, PaCO2) and pH values in samples taken from the carotid artery. After application of etomidate or propofol, the PaO2 was significantly higher in b3(N265M) knockin mice and the PaCO2 was significantly lower in b3(N265M) knockin mice compared to wildtype mice (Fig. 2; Zeller et al. 2005). The pH values were significantly higher in b3(N265M) knockin mice compared to wildtype mice (Zeller et al. 2005). In contrast, there was no genotype difference in these parameters after application of a mixture of the neurosteroid anesthetics alphaxalone and alphadolone, demonstrating that b3(N265M) knockin mice respond normally to these agents (Zeller et al. 2005). These results indicate that the respiratory depressant action of etomidate and propofol is largely mediated by β3-containing GABAA receptors. Cardiac and respiratory depressant actions of general anesthetics have apparently not been studied in β2(N265S) mice. 4.1.5
Amnesia
The anterograde amnestic action of propofol was studied in the passive avoidance paradigm and found to be indistinguishable between b3(N265M) knockin mice and wildtype mice, indicating that this effect of propofol is not mediated by β3-containing GABA A receptors (Zeller et al. 2007a). Thus, the immobilizing and the anterograde amnestic actions of propofol are mediated by distinct targets. This result is in line with the observation that the anterograde amnestic action of diazepam in the same paradigm is mediated by α 1-containing GABAA receptors (Rudolph et al. 1999). It is therefore tempting to speculate that the anterograde amnestic action of GABAA receptor-modulating drugs in
Inhibitory Ligand-Gated Ion Channels
paO2 (mmHg)
a
110 100 90 80 70 60 50 40 30 20
***
41 *** wt β3(N265M)
Propofol i.v. Etomidate i.v. Alphaxalone 40mg/kg 15 mg/kg i.v. 30mg/kg
b paCO2 (mmHg)
80
***
***
wt β3(N265M)
70 60 50 40 30 20 Propofol i.v. Etomidate i.v. Alphaxalone 40mg/kg 15 mg/kg i.v. 30mg/kg
c
7.5 7.4
pH
7.3
***
***
wt β3(N265M)
7.2 7.1 7.0 6.9 6.8 Propofol i.v. Etomidate i.v. Alphaxalone 40mg/kg 15 mg/kg i.v. 30mg/kg
Fig. 2 Assessment of anesthetic-induced respiratory depression by blood gas analysis. a, b In b3(N265M) mice injected with etomidate and propofol, PaO2 was higher and PaCO2 was lower compared with wildtype mice, indicating the dependence of the respiratory depressant effects of these anesthetics on β3-containing GABAA receptors. The neurosteroid anesthetic alphaxalone (mixed in a 3:1 ration with alphadolone, Saffan), whose action is not affected by the b3(N265M) mutation in vitro, elicits changes in blood gases without a difference between genotypes. c Similarly, after etomidate and propofol, but not after alphaxalone, pH was higher in b3(N265M) mice compared with wildtype. The horizontal bars that span the graphs indicate normal values. n=10; ***p < 0.001. (Reprinted with permission from FASEB Journal, Zeller et al. 2005)
42
A. Zeller et al.
the passive avoidance paradigm is mediated by the most abundant GABAA receptor subtype, α1β2γ2. θ-Oscillations (4–12 Hz) are commonly observed during spatial learning and memory tasks. In neocortical slice cultures, local field potentials were recorded and the actions of 0.2 µM etomidate, which causes sedation and amnesia and is approximately 15% of the concentration inducing immobility, were studied. Episodes of ongoing activity occurred spontaneously at a frequency of approximately 0.1 Hz and persisted for several seconds, and toward the end of these periods θ-oscillations developed. In slice cultures from wildtype mice etomidate did not depress θ-oscillations, whereas in slice cultures from b3(N265M) knockin mice θ-oscillations were significantly depressed (Drexler et al. 2005). These results suggest that etomidate has opposing actions on θ-oscillations. These oscillations are enhanced by etomidate acting via β3-containing GABAA receptors, and they are decreased by the action of etomidate via receptors other than β3-containing GABAA receptors, most likely β2containing GABAA receptors (Drexler et al. 2005). These findings of an opposing action of etomidate on a specific physiological parameter potentially via different GABAA receptor subtypes have uncovered a so far unrecognized complexity of etomidate action on GABAA receptors. The α5 knockout mice display an improved performance in the Morris water maze compared to wildtype mice in the absence of drugs (Collinson et al. 2002). Moreover, the a5(H105R) knockin mice, which represent a partial α5 knockout, show increased freezing in trace fear conditioning, which is hippocampusdependent, but not in delay or context fear conditioning, which is not hippocampus-dependent (Crestani et al. 2002). These results led to the concept that inverse agonists selective for the α5-containing GABAA receptor would be suitable as cognitive enhancers (Chambers et al. 2004; Sternfeld et al. 2004). Etomidate was found to decrease freezing in contextual fear conditioning in wildtype mice but not in α5 knockout mice, and etomidate was also found to impair spatial learning in the Morris water maze in wildtype mice but not in α5 knockout mice, indicating that α5-containing GABAA receptors mediate the actions of etomidate in these tests (Cheng et al. 2006). In these assays, ketamine, a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, was equally effective in α5 knockout and wildtype mice, indicating that the α5 knockout mice respond normally to agents most likely not acting via the GABAA receptor system (Cheng et al. 2006). The studies on α5 knockout mice suggest that the amnestic actions of etomidate are mediated at least in part by α5-containing GABAA receptors. 4.1.6
Electrocardiography
Etomidate and propofol increased heart rate variability and prolonged intervals in the ECG (RR, PQ, QRS, QT). All these changes are also seen in β3(N265M) knockin mice, indicating that these are largely independent of β3-containing GABAA receptors (Zeller et al. 2007a).
Inhibitory Ligand-Gated Ion Channels
4.2
43
Barbiturates
In in vitro studies, barbiturates have a wide range of targets, modulating the activity of GABAA receptors, nicotinic acetylcholine receptors, S-alpha-amino-3-hydroxy5-methyl-4-isoxazolepropionic acid (AMPA) receptors, kainate receptors, and glycine receptors (Krasowski and Harrison 1999), and it is largely unknown which of these ion channels, if any, would mediate the clinical actions of barbiturates. In b3(N265M) knockin mice the barbiturate pentobarbital had no immobilizing action, indicating that the immobilizing action of pentobarbital is mediated by β3-containing GABAA receptors (Zeller et al. 2007b). The hypnotic action of pentobarbital is significantly reduced in the b3(N265M) knockin mice, indicating that this action is partially mediated by β3-containing GABAA receptors (Zeller et al. 2007b). Thus, with respect to the immobilizing and hypnotic actions, etomidate, propofol, and pentobarbital appear to be dependent on the same drug target, i.e., β3-containing GABAA receptors. The respiratory depressant action of pentobarbital was, however, indistinguishable in b3(N265M) knockin mice and wildtype mice, based on the observation that there are no genotypic differences in the PaO2, PaCO2, and pH values (Zeller et al. 2007b). Thus, the respiratory depressant action of pentobarbital is independent of the β3-containing GABAA receptors. How can the observation be explained that while pentobarbital clearly binds to β3-containing GABAA receptors and the β3-containing GABAA receptors can mediate respiratory depression, pentobarbital is respiratory depressant in b3(N265M) mice? The generation of respiratory rhythms occurs in a network of neurons originating from the pre-Bötzinger complex (Richter et al. 2003). Synaptic interactions involving AMPA, NMDA, GABAA, GABAB, and glycine receptors are thought to play a major role in regulating this network. Etomidate- and propofol-induced respiratory depression is mediated by β3-containing GABAA receptors, but it is currently unknown which neurons specifically mediate this effect. The observation that pentobarbital induces respiratory depression in b3(N265M) knockin mice indicates that this effect is not mediated by β3-containing GABAA receptors or, if it is to some degree, that pentobarbital can also induce respiratory depression via other, currently unknown targets. Both an increase in the inhibitory GABAergic drive and a decrease in excitatory glutamatergic drive can lead to respiratory depression. It is conceivable that pentobarbital might induce respiratory depression by decreasing the glutamatergic drive. This side effect is thus mediated by different receptors or circuits in etomidate- and propofol-induced anesthesia compared to pentobarbital-induced anesthesia. It is tempting to speculate that this mechanistic difference between etomidate and propofol on one hand and pentobarbital on the other underlies the significantly smaller therapeutic range of barbiturates compared to etomidate and propofol. The hypothermic action of pentobarbital was slightly but significantly diminished in b3(N265M) knockin mice, indicating that this action is mediated to a small extent by β3-containing GABAA receptors, but mostly by other targets (Zeller et al. 2007b). Similarly, the heart rate depressant action of pentobarbital is diminished in b3(N265M) knockin mice, suggesting that this action is mediated
44
A. Zeller et al.
both by β3-containing GABAA receptors and by other targets (Zeller et al. 2007b). As mentioned previously, we cannot exclude the possibility that the hypothermic action and heart rate depressant action are interdependent. Pentobarbital increased heart rate variability and ECG intervals (PQ, QT) in both b3(N265M) knockin mice and wildtype mice, suggesting that these actions are largely independent of β3-containing GABAA receptors (Zeller et al. 2007b).
4.3
Volatile Anesthetics
The immobilizing action of volatile anesthetics such as isoflurane has been shown to be mediated largely by targets in the spinal cord (Antognini and Schwartz 1993; Rampil et al. 1993; Rampil 1994). The immobilizing response to enflurane, halothane, and isoflurane was moderately decreased in b3(N265M) knockin mice (Jurd et al. 2003; Lambert et al. 2005; Liao et al. 2005) consistent with the hypothesis that the action of these volatile anesthetics are mediated by multiple targets, one of them being β3-containing GABAA receptors in the spinal cord. The hypnotic action of these drugs appears to be largely independent of β3-containing GABAA receptors (Jurd et al. 2003; Lambert et al. 2005). A pharmacological study using the GABAA receptor antagonist picrotoxin suggested that isoflurane-induced immobilization would likely not involve GABAA receptors (Zhang et al. 2004). This conclusion was largely based on the discrepancy that isoflurane strongly potentiates recombinant GABAA receptors, in contrast to xenon and cyclopropane, while picrotoxin infusion in the rats increased the EC50 for all three anesthetics by approximately 40%. The assumption was that if GABAA receptors contributed to isoflurane immobilization, picrotoxin should block isoflurane-induced immobilization to a much larger degree than xenon or cyclopropane-induced immobilization. The picrotoxin-induced increase in EC50 for xenon and cyclopropane was considered to be unspecific (since the agents apparently do not modulate the GABAA receptor in vitro), and since the picrotoxin-induced EC50 for isoflurane is similar, it was concluded that GABAA receptors do not mediate isoflurane-induced immobilization. The apparent difference between this study and the study with the knockin mice might be explained by the fact that the pharmacological study may be unable to detect a relatively limited contribution of the GABAA receptor. Another point to consider is that there is a multitude of GABAA receptor subtypes, and despite recent advances the exact subunit composition of the GABAA receptor-mediating immobility is unknown. Thus, the finding that the activity of one or more recombinant GABAA receptor subtypes is not increased by an anesthetic does not imply that this is true for all GABAA receptor subtypes expressed in the CNS. Furthermore, recombinant systems lack the natural environment of the GABAA receptor, and this might have an influence on the responses of this GABAA receptor to a drug. A recent example of a drug with a discrepancy between its in vitro and in vivo profiles is the anxiolytic ocinaplon, which has no sedative action in
Inhibitory Ligand-Gated Ion Channels
45
humans, but no selectivity for α2- or α3-containing GABAA receptors (which are presumably mediating anxiolysis) over α1-containing GABAA receptors (which are mediating sedation) (Lippa et al. 2005). In neocortical neurons in cultured slices, enflurane at concentrations between minimal alveolar concentration (MAC)-awake and MAC-immobility depresses spontaneous action potential firing. Enflurane blocks inhibitory postsynaptic current decay and decreases peak amplitudes, thus exerting dual prolonging and blocking effects on GABAA receptors. In slices from b3(N265M) mice, both prolonging and blocking effects were almost absent, indicating that the β3(N265M) point mutation essentially abolishes both actions and that β3-containing GABAA receptors contribute to the depressant action of enflurane (Drexler et al. 2006). The hypothermic and heart rate depressant actions of isoflurane have also been found to be slightly but significantly inhibited in b3(N265M) knockin mice compared to wildtype mice, suggesting that these actions are mediated mostly by targets other than β3-containing GABAA receptors (Zeller et al. 2007a). Isoflurane increased heart rate variability and prolonged ECG intervals (PQ, QRS, QT) in both wildtype and b3(N265M) knockin mice (with the exception that the increase in the QRS interval was not significant in the mutant mice, possibly due to the small number of animals studied), indicating that these effects are mediated by other targets (Zeller et al. 2007a).
4.4
Ethanol
The targets mediating the effects of ethanol at concentrations as they occur after social drinking have not been identified. Attempts are being made to render individual GABAA receptor subtypes insensitive to ethanol in recombinant systems and in mice. In recombinant receptors, the a1(S270H) mutation has been shown to convey insensitivity to isoflurane (Borghese et al. 2006b). This mutation also increases the GABA sensitivity (Borghese et al. 2006b). When it is combined with a second point mutation, α1(L277A), the GABA sensitivity is near normal in heterologous systems, but the maximal current was decreased (Borghese et al. 2006b), with the current decay time constant higher in wildtype than in α1(S270H:L277A)β2γ2 receptors(Borghese et al. 2006b). Recombinant GABAA receptors containing the double point mutation are essentially insensitive to modulation by high concentrations of ethanol (Borghese et al. 2006b). In hippocampal CA1 pyramidal neurons, 20 mM and 40 mM ethanol (which might be considered to represent concentrations exceeding those seen with “social” drinking with the legal limit for driving in many jurisdictions being 17.4 mM) increased the GABAA inhibitory postsynaptic current (IPSC) to the same degree in wildtype mice and mutant mice; however, at 80 mM the increase was substantially reduced in the mutant mice compared to wildtype (Werner et al. 2006). Ethanol-induced hypnosis, locomotor stimulation, cognitive impairment, ethanol preference, and ethanol consumption were indistinguishable in mutant and wildtype
46
A. Zeller et al.
mice (Werner et al. 2006). a1(S270H:L277A) mice are spontaneously hyperactive (Borghese et al. 2006b). They recover more quickly than wildtype mice from the motor impairing action of ethanol and etomidate, but not pentobarbital (Werner et al. 2006). These studies indicate that α1-containing GABAA receptors are involved in only a defined subset of ethanol actions. In recombinant systems, it has been found that the activity of GABAA receptors containing α4(or α6)β3(or β2)δ are enhanced by ethanol concentrations as low as 3 mM, whereas the activity of α1β2γ2 GABAA receptors are only enhanced by 100 mM ethanol (Sundstrom-Poromaa et al. 2002; Wallner et al. 2003). Other laboratories have been unable to reproduce this finding, suggesting that currently unidentified factors might play a role in ethanol effects at δ-containing GABAA receptors (Borghese et al. 2006a; Yamashita et al. 2006). Ethanol potently and competitively inhibits binding of the alcohol antagonist Ro15-4513 to α4/6β3δ GABAA receptors (Hanchar et al. 2006), and the low-dose alcohol actions on α4β3δ GABAA receptors are reversed by Ro15-4513 (Wallner et al. 2006), providing further evidence that ethanol might exert some of its effects by interaction with a specific site on a defined GABAA receptor subtype. Interestingly, the β3(N265M) point mutation abolished the effects of high (anesthetic) ethanol concentrations at α4β3(N265M)δ GABAA receptors, without affecting ethanol enhancement at low doses, suggesting that α4β3δ GABAA receptors have two distinct alcohol modulation sites (Wallner et al. 2006). A R100Q polymorphism in the cerebellar GABAA receptor α6 subunit, which increases enhancement of GABA-induced chloride currents in recombinant α6β3δ receptors, has been found to enhance granule cell tonic inhibition and to increase alcohol-induced impairment of motor coordination. This suggests that α6-containing GABAA receptors in the cerebellum, which are located extrasynaptically, might mediate at least some of the behavioral responses to ethanol (Hanchar et al. 2005).
5
Conclusion
GABAA receptors have been investigated as molecular targets for the action of a variety of general anesthetics. The intravenous anesthetics etomidate and propofol, as well as pentobarbital, have been shown to exert their immobilizing action and in part their hypnotic action through β3-containing GABAA receptors. The proposed roles of β3-containing GABAA receptors and other targets for the actions of etomidate and propofol are summarized in Fig. 3. For the immobilizing action of volatile anesthetics, this receptor subtype apparently plays a relatively minor role. While demonstrating a significant role for a specific GABAA receptors subtype in the action of particular intravenous anesthetics, with respect to volatile anesthetics the data reviewed in this article point to a multisite model of general anesthetic action.
Inhibitory Ligand-Gated Ion Channels Drug
Target
47 Action Immobility
β3(GABAA)
Respiratory Depression Etomidate Propofol
Hypnosis
other targets e.g. β2(GABAA)
Sedation Hypothermia Heart Rate Depression
Fig. 3 Proposed roles of etomidate and propofol on GABAA receptor subtypes. These assignments are based on the following tests: immobility—lost of hind limb withdrawal reflex; respiratory depression—increase in PaCO2 and decrease in PaO2 and pH; hypnosis—loss of righting reflex; sedation—decrease in motor activity; hypothermia—decrease in core body temperature; cardiac depression—decrease in heart rate. Data are based on this study and previous work. (Reprinted with permission from FASEB Journal, Zeller et al. 2005)
References Antognini JF, Schwartz K (1993) Exaggerated anesthetic requirements in the preferentially anesthetized brain. Anesthesiology 79:1244–1249 Antognini JF, Wang XW, Piercy M, Carstens E (2000) Propofol directly depresses lumbar dorsal horn neuronal responses to noxious stimulation in goats. Can J Anaesth 47:273–279 Arras M, Autenried P, Rettich A, Spaeni D, Rulicke T (2001) Optimization of intraperitoneal injection anesthesia in mice: drugs, dosages, adverse effects, and anesthesia depth. Comp Med 51:443–456 Belelli D, Lambert JJ, Peters JA, Wafford K, Whiting PJ (1997) The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. Proc Natl Acad Sci U S A 94:11031–11036 Belelli D, Pistis M, Peters JA, Lambert JJ (1999) General anaesthetic action at transmitter-gated inhibitory amino acid receptors. Trends Pharmacol Sci 20:496–502 Benson JA, Low K, Keist R, Mohler H, Rudolph U (1998) Pharmacology of recombinant gammaaminobutyric acidA receptors rendered diazepam-insensitive by point-mutated alpha-subunits. FEBS Lett 431:400–404 Borghese CM, Storustovu S, Ebert B, Herd MB, Belelli D, Lambert JJ, Marshall G, Wafford KA, Harris RA (2006a) The delta subunit of gamma-aminobutyric acid type A receptors does not confer sensitivity to low concentrations of ethanol. J Pharmacol Exp Ther 316:1360–1368 Borghese CM, Werner DF, Topf N, Baron NV, Henderson LA, Boehm SL 2nd, Blednov YA, Saad A, Dai S, Pearce RA, Harris RA, Homanics GE, Harrison NL (2006b) An isoflurane- and alcohol-insensitive mutant GABA(A) receptor alpha(1) subunit with near-normal apparent affinity for GABA: characterization in heterologous systems and production of knockin mice. J Pharmacol Exp Ther 319:208–218 Chambers MS, Atack JR, Carling RW, Collinson N, Cook SM, Dawson GR, Ferris P, Hobbs SC, O’Connor D, Marshall G, Rycroft W, Macleod AM (2004) An orally bioavailable, functionally
48
A. Zeller et al.
selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. J Med Chem 47:5829–5832 Cheng VY, Martin LJ, Elliott EM, Kim JH, Mount HT, Taverna FA, Roder JC, Macdonald JF, Bhambri A, Collinson N, Wafford KA, Orser BA (2006) Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J Neurosci 26:3713–3720 Christensen SC, Johnson TE, Markel PD, Clark VJ, Fulker DW, Corley RP, Collins AC, Wehner JM (1996) Quantitative trait locus analyses of sleep-times induced by sedative-hypnotics in LSXSS recombinant inbred strains of mice. Alcohol Clin Exp Res 20:543–550 Cirone J, Rosahl TW, Reynolds DS, Newman RJ, O’Meara GF, Hutson PH, Wafford KA (2004) Gamma-aminobutyric acid type A receptor beta 2 subunit mediates the hypothermic effect of etomidate in mice. Anesthesiology 100:1438–1445 Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, Smith A, Otu FM, Howell O, Atack JR, McKernan RM, Seabrook GR, Dawson GR, Whiting PJ, Rosahl TW (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 22:5572–5580 Crestani F, Martin JR, Mohler H, Rudolph U (2000) Resolving differences in GABAA receptor mutant mouse studies. Nat Neurosci 3:1059 Crestani F, Low K, Keist R, Mandelli M, Mohler H, Rudolph U (2001) Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 59:442–445 Crestani F, Keist R, Fritschy JM, Benke D, Vogt K, Prut L, Bluthmann H, Mohler H, Rudolph U (2002) Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A 99:8980–8985 Downie DL, Hall AC, Lieb WR, Franks NP (1996) Effects of inhalational general anaesthetics on native glycine receptors in rat medullary neurones and recombinant glycine receptors in Xenopus oocytes. Br J Pharmacol 118:493–502 Downing C, Shen EH, Simpson VJ, Johnson TE (2003) Mapping quantitative trait loci mediating sensitivity to etomidate. Mamm Genome 14:367–375 Drexler B, Roether CL, Jurd R, Rudolph U, Antkowiak B (2005) Opposing actions of etomidate on cortical theta oscillations are mediated by different gamma-aminobutyric acid type A receptor subtypes. Anesthesiology 102:346–352 Drexler B, Jurd R, Rudolph U, Antkowiak B (2006) Dual actions of enflurane on postsynaptic currents abolished by the gamma-aminobutyric acid type A receptor beta3(N265M) point mutation. Anesthesiology 105:297–304 Franks NP, Lieb WR (1984) Do general anaesthetics act by competitive binding to specific receptors? Nature 310:599–601 Franks NP, Lieb WR (1994) Molecular and cellular mechanisms of general anaesthesia. Nature 367:607–614 Grasshoff C, Antkowiak B (2004) Propofol and sevoflurane depress spinal neurons in vitro via different molecular targets. Anesthesiology 101:1167–1176 Grasshoff C, Antkowiak B (2006) Effects of isoflurane and enflurane on GABAA and glycine receptors contribute equally to the depressant actions on spinal ventral horn neurones in rats. Br J Anaesth 97:687–694 Hanchar HJ, Dodson PD, Olsen RW, Otis TS, Wallner M (2005) Alcohol-induced motor impairment caused by increased extrasynaptic GABA(A) receptor activity. Nat Neurosci 8:339–345 Hanchar HJ, Chutsrinopkun P, Meera P, Supavilai P, Sieghart W, Wallner M, Olsen RW (2006) Ethanol potently and competitively inhibits binding of the alcohol antagonist Ro15-4513 to alpha4/6beta3delta GABAA receptors. Proc Natl Acad Sci U S A 103:8546–8551 Hapfelmeier G, Zieglgansberger W, Haseneder R, Schneck H, Kochs E (2000) Nitrous oxide and xenon increase the efficacy of GABA at recombinant mammalian GABA(A) receptors. Anesth Analg 91:1542–1549 Harrison NL, Kugler JL, Jones MV, Greenblatt EP, Pritchett DB (1993) Positive modulation of human gamma-aminobutyric acid type A and glycine receptors by the inhalation anesthetic isoflurane. Mol Pharmacol 44:628–632
Inhibitory Ligand-Gated Ion Channels
49
Hentschke H, Schwarz C, Antkowiak B (2005) Neocortex is the major target of sedative concentrations of volatile anaesthetics: strong depression of firing rates and increase of GABAA receptor-mediated inhibition. Eur J Neurosci 21:93–102 Hill-Venning C, Belelli D, Peters JA, Lambert JJ (1997) Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. Br J Pharmacol 120:749–756 Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL, Krasowski MD, Rick CE, Korpi ER, Makela R, Brilliant MH, Hagiwara N, Ferguson C, Snyder K, Olsen RW (1997) Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc Natl Acad Sci U S A 94:4143–4148 Irifune M, Sato T, Kamata Y, Nishikawa T, Dohi T, Kawahara M (2000) Evidence for GABA(A) receptor agonistic properties of ketamine: convulsive and anesthetic behavioral models in mice. Anesth Analg 91:230–236 Irifune M, Takarada T, Shimizu Y, Endo C, Katayama S, Dohi T, Kawahara M (2003) Propofolinduced anesthesia in mice is mediated by gamma-aminobutyric acid-A and excitatory amino acid receptors. Anesth Analg 97:424–429 Jurd R, Arras M, Lambert S, Drexler B, Siegwart R, Crestani F, Zaugg M, Vogt KE, Ledermann B, Antkowiak B, Rudolph U (2003) General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J 17:250–252 Kleingoor C, Wieland HA, Korpi ER, Seeburg PH, Kettenmann H (1993) Current potentiation by diazepam but not GABA sensitivity is determined by a single histidine residue. Neuroreport 4:187–190 Koblin DD, Chortkoff BS, Laster MJ, Eger EI 2nd, Halsey MJ, Ionescu P (1994) Polyhalogenated and perfluorinated compounds that disobey the Meyer-Overton hypothesis. Anesth Analg 79:1043–1048 Kralic JE, Korpi ER, O’Buckley TK, Homanics GE, Morrow AL (2002a) Molecular and pharmacological characterization of GABA(A) receptor alpha1 subunit knockout mice. J Pharmacol Exp Ther 302:1037–1045 Kralic JE, O’Buckley TK, Khisti RT, Hodge CW, Homanics GE, Morrow AL (2002b) GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem. Neuropharmacology 43:685–694 Krasowski MD, Harrison NL (1999) General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci 55:1278–1303 Krasowski MD, Koltchine VV, Rick CE, Ye Q, Finn SE, Harrison NL (1998) Propofol and other intravenous anesthetics have sites of action on the gamma-aminobutyric acid type A receptor distinct from that for isoflurane. Mol Pharmacol 53:530–538 Lambert S, Arras M, Vogt KE, Rudolph U (2005) Isoflurane-induced surgical tolerance mediated only in part by beta3-containing GABA(A) receptors. Eur J Pharmacol 516:23–27 Liao M, Sonner JM, Jurd R, Rudolph U, Borghese CM, Harris RA, Laster MJ, Eger EI 2nd (2005) Beta3-containing gamma-aminobutyric acidA receptors are not major targets for the amnesic and immobilizing actions of isoflurane. Anesth Analg 101:412–418 Lippa A, Czobor P, Stark J, Beer B, Kostakis E, Gravielle M, Bandyopadhyay S, Russek SJ, Gibbs TT, Farb DH, Skolnick P (2005) Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc Natl Acad Sci U S A 102:7380–7385 Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, Fritschy JM, Rulicke T, Bluethmann H, Mohler H, Rudolph U (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290:131–134 Mascia MP, Machu TK, Harris RA (1996) Enhancement of homomeric glycine receptor function by long-chain alcohols and anaesthetics. Br J Pharmacol 119:1331–1336 McKernan RM, Whiting PJ (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 19:139–143 McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ (2000) Sedative but not
50
A. Zeller et al.
anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3:587–592 Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, DeLorey TM, Olsen RW, Homanics GE (1999) Attenuated sensitivity to neuroactive steroids in gammaaminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci U S A 96:12905–12910 Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE, Mascia MP, Valenzuela CF, Hanson KK, Greenblatt EP, Harris RA, Harrison NL (1997) Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 389:385–389 Mohler H, Fritschy JM, Rudolph U (2002) A new benzodiazepine pharmacology. J Pharmacol Exp Ther 300:2–8 Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M (2002) The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 5:979–984 Ortinski PI, Turner JR, Barberis A, Motamedi G, Yasuda RP, Wolfe BB, Kellar KJ, Vicini S (2006) Deletion of the GABA(A) receptor alpha1 subunit increases tonic GABA(A) receptor current: a role for GABA uptake transporters. J Neurosci 26:9323–9331 Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, Hein L (2003) Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 99:889–895 Pistis M, Belelli D, McGurk K, Peters JA, Lambert JJ (1999) Complementary regulation of anaesthetic activation of human (alpha6beta3gamma2L) and Drosophila (RDL) GABA receptors by a single amino acid residue. J Physiol 515:3–18 Quinlan JJ, Homanics GE, Firestone LL (1998) Anesthesia sensitivity in mice that lack the beta3 subunit of the gamma-aminobutyric acid type A receptor. Anesthesiology 88:775–780 Rampil IJ (1994) Anesthetic potency is not altered after hypothermic spinal cord transection in rats. Anesthesiology 80:606–610 Rampil IJ, Mason P, Singh H (1993) Anesthetic potency (MAC) is independent of forebrain structures in the rat. Anesthesiology 78:707–712 Ranna M, Sinkkonen ST, Moykkynen T, Uusi-Oukari M, Korpi ER (2006) Impact of epsilon and theta subunits on pharmacological properties of alpha3beta1 GABAA receptors expressed in Xenopus oocytes. BMC Pharmacol 6:1 Reynolds DS, O’Meara GF, Newman RJ, Bromidge FA, Atack JR, Whiting PJ, Rosahl TW, Dawson GR (2003a) GABA(A) alpha 1 subunit knock-out mice do not show a hyperlocomotor response following amphetamine or cocaine treatment. Neuropharmacology 44:190–198 Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Haythornthwaite A, Newman RJ, Myers J, Sur C, Howell O, Rutter AR, Atack J, Macaulay AJ, Hadingham KL, Hutson PH, Belelli D, Lambert JJ, Dawson GR, McKernan R, Whiting PJ, Wafford KA (2003b) Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. J Neurosci 23:8608–8617 Richter DW, Manzke T, Wilken B, Ponimaskin E (2003) Serotonin receptors: guardians of stable breathing. Trends Mol Med 9:542–548 Rudolph U, Antkowiak B (2004) Molecular and neuronal substrates for general anaesthetics. Nat Rev Neurosci 5:709–720 Rudolph U, Mohler H (2004) Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 44:475–498 Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Mohler H (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401:796–800 Siegwart R, Jurd R, Rudolph U (2002) Molecular determinants for the action of general anesthetics at recombinant alpha(2)beta(3)gamma(2)gamma-aminobutyric acid(A) receptors. J Neurochem 80:140–148
Inhibitory Ligand-Gated Ion Channels
51
Siegwart R, Krahenbuhl K, Lambert S, Rudolph U (2003) Mutational analysis of molecular requirements for the actions of general anaesthetics at the gamma-aminobutyric acidA receptor subtype, alpha1beta2gamma2. BMC Pharmacol 3:13 Simpson VJ, Rikke BA, Costello JM, Corley R, Johnson TE (1998) Identification of a genetic region in mice that specifies sensitivity to propofol. Anesthesiology 88:379–389 Sonner JM, Zhang Y, Stabernack C, Abaigar W, Xing Y, Laster MJ (2003) GABA(A) receptor blockade antagonizes the immobilizing action of propofol but not ketamine or isoflurane in a dose-related manner. Anesth Analg 96:706–712 Sternfeld F, Carling RW, Jelley RA, Ladduwahetty T, Merchant KJ, Moore KW, Reeve AJ, Street LJ, O’Connor D, Sohal B, Atack JR, Cook S, Seabrook G, Wafford K, Tattersall FD, Collinson N, Dawson GR, Castro JL, MacLeod AM (2004) Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers. J Med Chem 47:2176–2179 Sundstrom-Poromaa I, Smith DH, Gong QH, Sabado TN, Li X, Light A, Wiedmann M, Williams K, Smith SS (2002) Hormonally regulated alpha(4)beta(2)delta GABA(A) receptors are a target for alcohol. Nat Neurosci 5:721–722 Sur C, Wafford KA, Reynolds DS, Hadingham KL, Bromidge F, Macaulay A, Collinson N, O’Meara G, Howell O, Newman R, Myers J, Atack JR, Dawson GR, McKernan RM, Whiting PJ, Rosahl TW (2001) Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice. J Neurosci 21:3409–3418 Urban BW, Bleckwenn M, Barann M (2006) Interactions of anesthetics with their targets: nonspecific, specific or both? Pharmacol Ther 111:729–770 Uusi-Oukari M, Heikkila J, Sinkkonen ST, Makela R, Hauer B, Homanics GE, Sieghart W, Wisden W, Korpi ER (2000) Long-range interactions in neuronal gene expression: evidence from gene targeting in the GABA(A) receptor beta2-alpha6-alpha1-gamma2 subunit gene cluster. Mol Cell Neurosci 16:34–41 Wallner M, Hanchar HJ, Olsen RW (2003) Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans. Proc Natl Acad Sci U S A 100:15218–15223 Wallner M, Hanchar HJ, Olsen RW (2006) Low-dose alcohol actions on alpha4beta3delta GABAA receptors are reversed by the behavioral alcohol antagonist Ro15–4513. Proc Natl Acad Sci U S A 103:8540–8545 Werner DF, Blednov YA, Ariwodola OJ, Silberman Y, Logan E, Berry RB, Borghese CM, Matthews DB, Weiner JL, Harrison NL, Harris RA, Homanics GE (2006) Knockin mice with ethanol-insensitive alpha1-containing gamma-aminobutyric acid type A receptors display selective alterations in behavioral responses to ethanol. J Pharmacol Exp Ther 319:219–227 Wieland HA, Luddens H, Seeburg PH (1992) A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem 267:1426–1429 Wong SM, Cheng G, Homanics GE, Kendig JJ (2001) Enflurane actions on spinal cords from mice that lack the beta3 subunit of the GABA(A) receptor. Anesthesiology 95:154–164 Yamakura T, Harris RA (2000) Effects of gaseous anesthetics nitrous oxide and xenon on ligandgated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 93:1095–1101 Yamashita M, Marszalec W, Yeh JZ, Narahashi T (2006) Effects of ethanol on tonic GABA currents in cerebellar granule cells and mammalian cells recombinantly expressing GABA(A) receptors. J Pharmacol Exp Ther 319:431–438 Zeller A, Arras M, Lazaris A, Jurd R, Rudolph U (2005) Distinct molecular targets for the central respiratory and cardiac actions of the general anesthetics etomidate and propofol. FASEB J 19:1677–1679 Zeller A, Arras M, Jurd R, Rudolph U (2007a) Mapping the contribution of beta3-containing GABAA receptors to volatile and intravenous anesthetic actions. BMC Pharmacol 7:2 Zeller A, Arras M, Jurd R, Rudolph U (2007b) Identification of a molecular target mediating the general anesthetic actions of pentobarbital. Mol Pharmacol 71:852–859 Zhang Y, Sonner JM, Eger EI 2nd, Stabernack CR, Laster MJ, Raines DE, Harris RA (2004) Gamma-aminobutyric acidA receptors do not mediate the immobility produced by isoflurane. Anesth Analg 99:85–90
Actions of Anesthetics on Excitatory Transmitter-Gated Channels G. Akk, S. Mennerick, and J.H. Steinbach(* ü)
1
Introduction and Overview .................................................................................................. 1.1 Families of Excitatory Transmitter-Gated Channels................................................... 1.2 Pharmacology ............................................................................................................. 2 Glutamate Receptors ............................................................................................................ 2.1 Glutamate Receptor Overview .................................................................................... 2.2 Gaseous Anesthetics: N2O and Xe .............................................................................. 2.3 Volatile Anesthetics .................................................................................................... 2.4 Injectable Anesthetics: Propofol, Barbiturates, Etomidate ......................................... 2.5 Ketamine ..................................................................................................................... 2.6 Ethanol ........................................................................................................................ 2.7 Steroids ....................................................................................................................... 2.8 Summary ..................................................................................................................... 3 Nicotinic Receptors.............................................................................................................. 3.1 Nicotinic Receptor Overview...................................................................................... 3.2 Gaseous Anesthetics: Xe and N2O .............................................................................. 3.3 Volatile Anesthetics .................................................................................................... 3.4 Anesthetic Steroids ..................................................................................................... 3.5 Propofol ...................................................................................................................... 3.6 Barbiturates ................................................................................................................. 3.7 Etomidate .................................................................................................................... 3.8 Ketamine ..................................................................................................................... 3.9 Summary ..................................................................................................................... 4 Serotonin-Activated Channels ............................................................................................. 5 ATP-Activated Channels ...................................................................................................... 6 Summary .............................................................................................................................. References ..................................................................................................................................
54 54 56 58 58 60 66 66 67 67 68 68 68 68 69 70 71 71 72 73 73 74 74 76 77 77
Abstract Excitatory transmitter-gated receptors are found in three gene families: the glutamate ionotropic receptors, the Cys-loop receptor family (nicotinic and 5HT3), and the purinergic (P2X) receptors. Anesthetic drugs act on many mem-
J.H. Steinbach Departments of Anesthesiology and Anatomy & Neurobiology and the Neurosciences Program, Washington University School of Medicine, 660 South Euclid Avenue, Saint Louis, MO, 63110 USA
[email protected] J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
53
54
G. Akk et al.
bers of these families, but in most cases the effects are unlikely to be related to clinically relevant anesthetic actions. However, the gaseous anesthetics (xenon and nitrous oxide) and the dissociative anesthetics (ketamine) have significant inhibitory activity at one type of glutamate receptor (the NMDA receptor) that is likely to contribute to anesthetic action. It is possible that some actions at neuronal nicotinic receptors may make a smaller contribution to effects of some anesthetics.
1
Introduction and Overview
The overall level of activity in the brain results from the interaction of inhibitory and excitatory inputs, integrated through membrane properties set by voltage-sensitive and intracellular messenger-dependent channels. The transmitter-gated channels whose activation results in excitation in general have channels that allow the passage of monovalent and divalent cations fairly indiscriminately. Both sodium and potassium ions can permeate the open channel so that channel opening results in membrane depolarization, and because calcium ions can often enter there can be a significant calcium flux into the cell. The possible physiological roles for these channels depend on their localization. In the postsynaptic cell, the excitatory transmittergated channels can underlie rapid excitatory synaptic transmission and can also mediate longer-term calcium-dependent changes in cell properties. However, the channels are also found on presynaptic boutons. As a result of the high input impedance and small volume of the bouton, the activation of a relatively small number of channels can significantly affect the release of other transmitters. Since either excitatory or inhibitory transmitter release can be modulated, the overall consequences of activation of presynaptically localized excitatory transmitter-gated channels may be complicated and region- (or pathway)-specific. Overall, clinically used anesthetics affect the function of many excitatory ligandgated channels. However, the evidence that these effects play an important role in clinically desired effects (including immobility, amnesia, and analgesia) is in most cases equivocal. The clearest example of a clinically relevant effect is the action of some anesthetics on the N-methyl-D-aspartate (NMDA) receptor class of glutamategated channels. However, the possibility (but not the certainty) exists that other channels are involved in amnesia, analgesia, or some of the significant side effects of anesthetics. A number of reviews with additional information on this topic have appeared (Franks and Lieb 1998; Dilger 2002; Yamakura et al. 2001; Evers and Maze 2004; Krasowski and Harrison 1999; Sonner et al. 2003).
1.1
Families of Excitatory Transmitter-Gated Channels
There are three gene families containing members that are excitatory transmittergated channels: the glutamate receptor family, the Cys-loop receptor family, and the purinergic family. The glutamate receptor family contains the kainate,
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
55
S-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and NMDA types of channels. The Cys-loop receptor family contains the excitatory nicotinic receptors and 5HT3 receptors, as well as the major inhibitory transmitter-gated channels (see the chapter by A. Zeller et al., this volume; the GABAA, GABAC, and glycine receptors). The purinergic family contains the P2X ATP-gated channels. The glutamate receptors are the major class of transmitter-gated channels mediating rapid excitation in the CNS, with AMPA receptors the predominant postsynaptic subtype. Kainate receptors are thought to be critically involved in some brain pathways (e.g., nociception), and may play a role as presynaptic modulators of transmitter release. NMDA receptors mediate many of the relatively long-lived excitatory postsynaptic potentials (EPSPs) (lasting hundreds of milliseconds), which are thought to be important for pattern generation and rhythmic firing. In addition, NMDA receptors are quite permeable to calcium ions, and the influx of calcium is thought to be very important in modulation, including long term potentiation, which may underlie learning and memory in some regions of the brain. The structure of glutamate receptors is depicted in Fig. 1. The functional receptor is a tetramer of subunits, each of which has an external ligand binding domain and contributes a portion of the channel lining. There are three subtypes of glutamate receptor (AMPA, NMDA, and kainate receptors), and a total of 16 subunits have been identified (AMPA: GluR1–4; NMDA NR1, NR2A–2D, NR3A–3B; kainate: GluR5–7, KA1–2). Not all subunits co-assemble to form receptors; instead there appears to be a set of rules determining which subunits assemble and form hetero-oligomeric receptors that traffic to the surface. Glutamate receptors are expressed on some types of glial cells as well as neurons.
Glutamate family
Nicotinic family
Purinergic P2X family
N
N
C
out
out
in
in
out
N
in C
Fig. 1 Cartoon views of the structures of individual subunits (top row) and the organization of subunits in a functional receptor (bottom row) are shown for the three gene families discussed. In the subunit structures the amino (N) and carboxy (C) termini are indicated, as well as the approximate membrane location (dashed lines; out indicates extracellular). The cylinders represent helices, and the diagonally crosshatched helices indicate the major channel-lining portions. The hatched circles indicate the general location of regions important for transmitter binding. In the lower panels, note that glutamate receptors form as tetramers of subunits, nicotinic family members as pentamers, and P2X receptors as trimers
56
G. Akk et al.
Members of the Cys-loop receptor family assemble as pentamers (Fig. 1). It seems that the nicotinic and 5HT3 receptor subunits do not mingle in a receptor. Among nicotinic receptor subunits a variety of combinations has been observed, both in terms of expressed recombinant receptors and in vivo. In the CNS, the α2–α6 receptors can assemble with the β2–β4 subunits, apparently usually with three α-subunits and two β-subunits. The α7 subunits form homopentamers. The α9 and α10 receptors co-assemble, particularly in the auditory system (the α8 subunit has only been described from chicken brain, not mammalian). In the periphery, the muscle fiber expresses a receptor comprising α1, β1, δ, and ε (adult type) subunits, while a major type of receptor found postsynaptically on ganglionic neurons contains the α3, α5, and β4 subunits. Nicotinic receptors are also expressed on chromaffin cells and a number of nonexcitable cells, including sperm and cells of the immune system, where they could be involved in some side effects of clinically used drugs. Only two subunits have been identified for 5HT3 receptors, 5HT3A and 5HT3B. In addition to being expressed in the central and peripheral nervous systems, 5HT3 receptors are expressed on enterochromaffin cells of the gut, and so may be involved in some gastrointestinal responses. The ATP-gated P2X receptors assemble as trimers (Fig. 1). Seven subunits have been identified (P2X1 through P2X7), and it is clear that at least some combine to form heterotrimers. In addition to neurons, P2X receptors are expressed on microglia (where they may play a role in chronic pain), mast cells, and macrophages.
1.2
Pharmacology
Many studies of anesthetic actions involve examination only of whole cell responses, and the details of the mechanisms of action for most anesthetics are not fully worked out. The types of effects seen most commonly are diagrammed in Fig. 2. Often there can be combinations–for example combined potentiation and noncompetitive block, in which the activation curve for agonist action is shifted to the left but the maximum response is depressed. In other cases, the drug action can depend on the drug concentration: at a low concentration the drug might potentiate while at a higher concentration inhibition may be manifest. These complexities in drug action mean that a full characterization of the pharmacological effects needs a full study of the concentration effect relationship at multiple activator concentrations. Such a comprehensive study has not yet been performed in many cases. Accordingly, we will summarize actions of anesthetics insofar as they are currently understood, but future work could well reveal additional effects. Probably the most complete mechanistic analyses have been made for anesthetic actions on the muscle-type nicotinic receptor, although glutamate receptors have also been well studied for some drugs, so more mechanistic detail will be provided for those receptor types. A nagging question in attempting to relate effects on target proteins, studied in vitro, to clinically relevant actions is relating drug concentrations in vitro to possible
log([agonist])
57
response
response
response
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
log([agonist])
log([agonist])
Fig. 2 Three typical patterns of anesthetic action on the agonist concentration-response curve are shown. In the left panel, potentiation shows as a left shift in the activation curve, without change in the maximum response for the natural transmitter. In the middle panel, (pseudo)-competitive inhibition shows a right shift in the activation curve with no change in the maximum response. In most cases which have been studied, the interaction between agonist and anesthetic does not involve true competitive inhibition of binding of the agonist to the receptor, but appears to reflect negative allosteric interactions. In the right panel, noncompetitive inhibition results in a decrease in the maximum response without a change in the position of the activation curve Table 1 This table gives published estimates for the free concentration of anesthetic at clinically effective doses (the clinically effective concentration, or CEC). These concentrations are assembled from various sources and compiled in the cited references, which should be consulted for details Anesthetic CEC Class Source N2O Xenon Alphaxalone Etomidate R(+) Ketamine S(+) Pentobarbital Propofol Thiopental Enflurane Halothane Isoflurane Sevoflurane
105% 71% 0.46 µM 1.0 µM 4.3 µM 20 µM 1.6 µM 25 µM 600 µM 250 µM 300 µM 300 µM
Gas Gas IV IV IV IV IV IV Volatile Volatile Volatile Volatile
Evers and Crowder 2001 Evers and Crowder 2001 Sewell and Sear 2004 Sewell and Sear 2004 Sewell and Sear 2004 Franks and Lieb 1994 Sewell and Sear 2004 Franks and Lieb 1994 Franks and Lieb 1994 Franks and Lieb 1994 Franks and Lieb 1994 Violet et al. 1997
concentrations in the effect compartment in vivo. We will use the concentrations shown in Table 1, applied in saline solutions in vitro, as relatively close to estimated effective free concentrations producing surgical levels of anesthesia in vivo. Another question is how to relate an action observed in vitro to a possibly clinically relevant effect (see Eger et al. 2001). For example, a small reduction in voltage-gated sodium current can have a major effect on calcium entry into nerve terminals and so produce a large reduction in evoked release as a result of the very nonlinear relationship between intracellular calcium and release (Wu et al. 2004). However, for the majority of the transmitter-gated channel responses the cellular response is much more linearly related to receptor function. Accordingly, as a first approximation it seems reasonable to assume that a small effect (less than a twofold enhancement or reduction of response) at a clinically appropriate concentration suggests that a particular drug–target interaction is less likely to
58
G. Akk et al.
underlie an effect seen in the clinic. However, some clear caveats to this approximation can be envisioned–for example, relatively small block or potentiation of a tonically active channel on a small structure (for example a synaptic bouton) might have larger effects. It can be difficult to connect pharmacological actions to physiological consequences because both steady-state and time-dependent actions must be considered. As an example, a drug that inhibited a receptor both when the channel was closed and when it was open would be expected to block rapid synaptic responses and slower responses equally. However, a drug that only blocked receptors with open channels would have a smaller effect on the peak of a rapid response and a larger effect on relatively slow responses. The dissociative anesthetic, ketamine, is an interesting example because it seems to block open channels (and so produces relatively little effect on the first response), but then becomes trapped in the channel. This trapping results in the steady accumulation of blocked channels and a steady increase in inhibition of both rapid and slow responses. Potentiation, in general, is most effective on small responses. This is because, in all examples studied to date, the mechanism for potentiation is to increase the probability a channel is open at a given dose of agonist. For receptors activated by the natural transmitters, at a high agonist concentration the channel already has a very high probability of being open. Hence, even though a drug may potentiate a response to a high concentration from 95% to 96%, the effect will not be observable. However, at a low concentration of transmitter a channel may have a probability of being open of only 3%, and the same concentration of drug may increase that to 30% (a tenfold potentiation).
2 2.1
Glutamate Receptors Glutamate Receptor Overview
Glutamate receptors are the major excitatory transmitter-gated channels in the CNS. The three classes of ionotropic glutamate receptors serve different functions in the CNS. AMPA receptors (AMPAR) mediate most of the rapid, conventional point-to-point neurotransmission between presynaptic neurons and their postsynaptic targets. NMDA (NMDAR) and kainate (KAR) receptors, in contrast, generally mediate somewhat slower excitatory communication among neurons. These receptors differ from AMPAR in their biophysical properties and cellular localization and thereby sculpt excitatory transmission in ways that AMPAR alone presumably would be incapable of achieving. Extensive reviews of the basic properties of glutamate receptors have been published and should be consulted for more information (Mayer 2005; Mayer and Armstrong 2004; Lerma 2006; Huettner 2003; Dingledine et al. 1999; Palmer et al. 2005). Some of the most exciting work in the glutamate receptor field comes from structural studies
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
59
of receptors (Madden 2002; Mayer and Armstrong 2004; Wollmuth and Sobolevsky 2004; Mayer 2005). It seems likely that detailed structural models will aid the effort to identify anesthetic binding sites. AMPAR form as tetramers of GluR1–4 subunits, and native receptors are typically composed of more than one type of subunit. The properties of the receptors depend on the subunit composition, and AMPA receptor subunit transcripts also undergo alternative splicing, with splice variants exhibiting different deactivation and desensitization kinetics (Dingledine et al. 1999). Clusters of AMPAR are located immediately opposite presynaptic active zones of glutamate synapses and are thus reliably and rapidly activated by a vesicle of glutamate. At individual glutamatergic synaptic contacts, a few tens of AMPAR are activated by each glutamate vesicle. The response develops rapidly (~200 µs) and also decays rapidly (2–12 ms), depending heavily on the properties of the particular AMPAR at the synapse. In a typical neuron the peak postsynaptic current produced by a single vesicle of glutamate will be insufficient to depolarize the membrane potential beyond spike threshold, so synchronous release of several glutamate transmitter packets is usually needed to discharge the postsynaptic neuron. NMDAR share topology and some molecular similarity with AMPAR. NMDAR require the NR1 subunit for a functional channel. The NR1 subunit combines with NR2A, -2B, -2C, or -2D, or with NR3A or -3B subunits. NMDAR exhibit significant permeability for Ca2+ and also strong, voltage-dependent block by Mg2+. There are several splice variants of NR1, which can differentially affect trafficking and function of the receptor (Mu et al. 2003), and the subunit composition dictates important properties such as deactivation kinetics and Mg2+ sensitivity of the channel (Dingledine et al. 1999). Like AMPAR, NMDAR cluster at synaptic junctions in the CNS and respond to synaptic glutamate. However, because of their strong, voltage-dependent channel block by Mg2+, NMDAR-mediated excitatory postsynaptic currents (EPSCs) are not observed, or are very small, during isolated synaptic activation. Instead, NMDAR channels pass ions only when the postsynaptic cell is strongly depolarized, usually by preceding AMPA receptor-mediated EPSPs. Once activated, NMDAR responses mediate Ca2+ influx (in addition to Na+ influx). Because Ca2+ is an important second messenger, NMDAR activation can result in Ca2+-dependent intracellular biochemical cascades (e.g., protein phosphorylation) that alter cell properties, including function of the synapse itself. A particular case is the NMDAR-dependent induction of long-term potentiation, a phenomenon that is a leading candidate as the cellular substrate for memory formation. NMDARmediated EPSCs are also notable for their longevity. After liberation from a synaptic vesicle, glutamate in the synaptic cleft reaches concentrations over 1 mM, but the concentration collapses very quickly (<1 ms) due to diffusion and active uptake. Both AMPAR and NMDAR are activated by this very transient bolus of glutamate. Although AMPA receptor EPSCs decay in a few milliseconds, NMDA receptor currents last for several hundred milliseconds. The difference arises from inherent differences in the deactivation kinetics of the two receptor classes (Lester et al. 1990). The activation and deactivation properties of NMDAR can support cellular bursting properties in some neurons; thus NMDA receptor activation participates in rhythmic behaviors in spinal and other cell types (Dale 1986; however, see Cowley
60
G. Akk et al.
et al. 2005). It is also notable that NMDAR possess a higher equilibrium affinity for glutamate than AMPAR. Therefore, receptors outside the synapses in extrasynaptic regions of the postsynaptic cell can be activated by the levels of glutamate that spill beyond the synaptic borders. Extrasynaptic spillover of glutamate onto NMDAR may therefore influence cell excitability under conditions of high neuronal activity or diminished glutamate transporter activity, which normally helps limit the spread of extrasynaptic glutamate (Kullmann 2000). KAR assemble from homomeric or heteromeric combinations of GluR5–7. In addition KA1 and KA2 subunits can partner with GluR5–7 subunits but are unable, by themselves, to form channels. RNA splicing again imparts an additional level of diversity (Dingledine et al. 1999). KAR are expressed rather ubiquitously, but understanding of their function has lagged that of other ionotropic glutamate receptors because selective pharmacological tools were lacking. Recently, the use of more selective tools and knockout mice has begun to make KAR function clearer. KAR are found both postsynaptically and presynaptically, and both synaptically and extrasynaptically. KAR can participate in EPSCs at certain synapses, including some pain pathways (Li et al. 1999) and certain retinal visual pathways (DeVries and Schwartz 1999). In most cases the kainate EPSC is small, and its time course is intermediate between fast AMPAR and slow NMDAR EPSCs. KAR on presynaptic terminals and axons can regulate release of both glutamate and γ-aminobutyric acid (GABA) (Huettner 2003). In summary, the function of KAR may be seen as more modulatory than either AMPAR or NMDAR, fine-tuning aspects of synaptic transmission through both presynaptic and postsynaptic mechanisms. Table 2 provides a summary of studies examining anesthetic actions on glutamate receptors.
2.2
Gaseous Anesthetics: N2O and Xe
Nitrous oxide robustly inhibits NMDAR at concentrations relevant to anesthetic mechanisms (Jevtovic-Todorovic et al. 1998; Mennerick et al. 1998; Yamakura and Harris 2000). The mechanism is noncompetitive with respect to agonist, but little else is known about it. N2O also mildly inhibits both native (Mennerick et al. 1998) and recombinant GluR2-containing AMPAR (Yamakura and Harris 2000). Evidence clearly indicates that Xe inhibits NMDAR, but the evidence for its effects on other glutamate receptors is more mixed. Some reports suggest little effect of Xe on AMPAR at concentrations that markedly inhibit NMDAR (Franks et al. 1998). The antagonism of NMDAR by Xe, but not that by N2O, was diminished by a point mutation in the transmembrane region 3 (abbreviated TM3) of NR1 and a point mutation in TM4 of NR2A (Ogata et al. 2006). These mutations are notable because they also reduce ethanol antagonism of NMDAR. Even milder inhibition is observed at KAR at these concentrations (Yamakura and Harris 2000). These studies have recently been challenged by a study that found strong effects of Xe on AMPAR and KAR (Dinse et al. 2005). Also, in the invertebrate Caenorhabditis elegans, Xe has its major actions through effects on a non-NMDA glutamate receptor (Nagele et al. 2005).
GluR1/ GluR2 Cortical AMPA AMPA w/ GluR2 AMPA w/o GluR2 AMPA w/ GluR2 GluR1–2
Hippocampal AMPA Cortical AMPA Hippocampal AMPA GluR1/2
–
–
–
–
–
–
–
–
–
0.7, 80% (EC20, EPSCs) 0.8, 100% (EC50) –
–
–
–
–
–
–
–
0.8, 500 (ukn) –
–
–
–
–
–
–
1.0, 60% (EPSCs) 0.5, 60% (EC50–EC90) –
–
–
–
–
0.9, 150 (EC50) 0.8, 500 (ukn) –
–
n.e., 50 (EC50)
–
–
–
–
–
–
–
1200 – (EPSCs) – –
–
–
–
–
n.e., 10 (ukn) –
–
–
–
–
– – –
200 (EC50) 1500 (EC50) 45 (EC50)
–
–
50a (EC20)
–
–
–
–
–
–
–
–
–
–
–
(continued)
Mennerick et al. 1998 Yamakura and Harris 2000 Yamakura et al. 2001 Marszalec and Narahashi 1993 Taverna et al. 1994 Taverna et al. 1994 Yamakura et al. 1995b Yamakura et al. 1995a
De Sousa et al. 2000 Dinse et al. 2005
Table 2 Actions of selected anesthetic drugs on glutamate receptors. The top row gives anesthetic and clinically effective concentration (in volume % or in micromolar from Table 1). The first column gives receptor examined, either as cell type or recombinant receptors expressed. The entries give the normalized effect observed (e.g., 1.6 means the current is increased to 1.6 times the control of agonist alone, while 0.6 means it is reduced to 0.6 times control), followed by the concentration of drug (micromolar or volume %). For many blocking drugs a complete concentration–effect curve has been obtained, in which case the concentration producing half maximal block is given in bold. In essentially all cases block was reported or assumed to be complete at high drug concentrations. The notation n.e. indicates that the study found no significant effect of the drug at the concentration given. Where possible, the approximate effective concentration of agonist is given in parentheses (for example EC10 means that an agonist concentration eliciting approximately 10% of the maximal response was used). EPSC indicates that the drug was tested against post-synaptic currents, while ukn indicates that the effective concentration is not known. Agonist EC values were taken from previous work (Patneau and Mayer 1990; Yamakura and Harris 2000) Halothane Isoflurane Propofol Etomidate Pentobarbital Ketamine Receptor Xe N 2O type (71%) (105%) (250 µM) (300 µM) (1.5 µM) (1.5 µM) (20 µM) (5 µM) Reference
Actions of Anesthetics on Excitatory Transmitter-Gated Channels 61
–
0.7, 100% (EC50) 0.3, 80% (EC50) –
–
–
–
–
–
0.5, 60% (EC50) –
–
GluR6/KA2
GluR5
0.82, 60% (EC50) –
–
–
–
–
0.3, 60% (EPSC) 0.7, 100% (EC50) –
3.8, 2000 (EC100)
–
–
–
–
n.e., 50 (ukn) –
–
–
–
–
–
–
Halothane (250 µM)
–
N 2O (105%)
–
Cortical NMDA NR1/2A, NR1/2B Neuronal NMDA GluR6
Hippocampal NMDA NR1/NR2A
AMPA GluR 2/3, GluR3 Neuronal AMPA/KA Hippocampal NMDA NR1a/NR2A
Table 2 (continued) Receptor Xe type (71%)
1.2, 150 (EC50) 2.5, 2000 (EC100)
–
–
0.8, 600 (ukn) 0.5, 300 (EC90) –
0.75, 310 (EPSC) 0.85, 150 (EC50) –
n.e., 600 (EC90) –
Isoflurane (300 µM)
–
–
–
n.e., 50 (EC90) –
–
–
–
–
–
–
–
Propofol (1.5 µM)
–
–
–
–
–
n.e., 10 (ukn) –
–
–
–
–
–
Etomidate (1.5 µM)
0.85, 100 (EC100)
–
–
–
–
n.e., 100 (ukn) –
–
–
–
–
–
–
–
–
9 (EC90)
–
Yamakura and Harris 2000 Minami et al. 1998
Yamakura et al. 1995a MacDonald et al. 1987 Dinse et al. 2005
Dildy-Mayfield et al. 1996 n.e., 10 MacDonald (EC80) et al. 1987 – De Sousa et al. 2000 – Yamakura and Harris 2000 – Jevtovic-Todorovic et al. 1998 – Yamakura et al. 2001 – Ming et al. 2001
–
Pentobarbital Ketamine (20 µM) (5 µM) Reference
62 G. Akk et al.
–
–
GluR6
GluR6
–
–
–
2.1, 2000 (EC50) 1.4, 250b (EC5) –
1.5, 2000 (EC50) 1.4, 500 (EC5) –
–
– –
–
1.3, 30 – (ukn) GluR6/KA2 – – – – n.e., 50 – (EC100) GluR6/KA2 – – – – n.e., 10 (ukn) a Use-dependent, so the extent of block is dependent on time and agonist concentration b Effects were stronger with pre-incubation
–
GluR6
– – n.e., 100 (ukn)
– – 0.8, 100 (ukn)
0.65, 100 – (1 µM KA) – –
Yamakura et al. 1995a Yamakura et al. 2001
Dildy-Mayfield et al. 1996 Harris et al. 1995
Minami et al. 1998
Actions of Anesthetics on Excitatory Transmitter-Gated Channels 63
α3,5,7; β4, bovine chromaffin α3,5,7; β4, bovine chromaffin
α7, human
α7, chick α7, chick
–
–
–
–
–
– – – – – 19 (EC50) – – – –
–
–
– – – – – – – – – –
–
–
–
23 (ukn)
–
–
–
– –
–
–
33 (EC100) –
– – – – – – – – – –
– – – n.e., 640 n.e., 400 – (EC100) (EC100) – – –
–
–
0.9, 58% (EC50) – –
–
–
– – – – – 85 (EC50) – 67 (EC90) 34 (EC50) –
–
0.9, 46% (EC50) – –
α4β4, rat
–
– – – – – – – – – 0.6, 58% (EC50) –
0.5, 100% 0.7, 100% (EC30) (EC30) – –
–
α4β4, human
α4β4, chick
– – – – – – – – – 0.6, 46% (EC50) –
α2β2, human α2β4, human α3β2, human α3β4, human α4β2, chick α4β2, chick α4β2, human α4β2, human α4β2, rat α4β2, rat
30 (ukn)
–
–
– –
–
–
–
– – – – – – – – – –
–
–
–
Charlesworth and Richards 1995 Shiraishi et al. 2002
Suzuki et al. 2003
Yamakura et al. 2000 Yamakura et al. 2000 Yamakura et al. 2000 Yamakura et al. 2000 Coates and Flood 2001 Flood et al. 1997 Yamakura et al. 2000 Yamashita et al. 2005 Violet et al. 1997 Yamakura and Harris 2000 0.24 (EC100) Flood and Krasowski 2000 18 (~EC45) Yamakura et al. 2000 – Yamakura and Harris 2000 20 (EC100) Coates and Flood 2001 – Flood et al. 1997
92 (~EC45) 29 (~EC45) 50 (~EC45) 9.5 (~EC45) 50 (EC100) – 72 (~EC45) – – –
Table 3 Actions of selected anesthetic drugs on nicotinic receptors. The data are presented as in Table 2. Effective concentrations taken from the reference cited Receptor Isoflurane Propofol Etomidate Pentobarbital Alphaxalone Ketamine (0.5 µM) (5 µM) Reference type Xe (71%) N2O (105%) (300 µM) (1.5 µM) (1.5 µM) (20 µM)
64 G. Akk et al.
–
IC50 for To open is 80% (EC5) – –
α1β1γδ, BC3H1 mouse –
α1β1γδ, BC3H1 mouse –
– –
– –
– –
α1β1γδ, mouse muscle α3,5,7; β2,3,4, PC12 rat
–
–
α3,4,7; β2, rat intra– cardiac neurons α1β1γδ, chick muscle α1β1γδ, mouse muscle
– –
–
– 1160 (EC50) –
–
–
–
– –
–
– – Steady– state: 5.4; peak: 47 (ukn)
–
81 (EC5)
– –
–
42 (EC90) –
–
–
0.6, 50 (ukn) – –
– –
–
99 (EC5)
6 (EC100) –
–
– steadystate: 2.8; peak: 21.4 (ukn)
–
–
– –
–
Yost and Dodson 1993 Furuya et al. 1999
Wachtel and Wegrzynowicz 1992 Wachtel 1995
Gillo and Lass 1984 Violet et al. 1997
Weber et al. 2005
Actions of Anesthetics on Excitatory Transmitter-Gated Channels 65
66
2.3
G. Akk et al.
Volatile Anesthetics
Inhalation anesthetics (halothane, isoflurane, enflurane) generally have weak effects on AMPAR (Dildy-Mayfield et al. 1996). At double the concentration needed for clinical effect, these anesthetics either weakly inhibited recombinant AMPAR or had no detectable effect on receptor function. Halogenated anesthetics are also weak inhibitors of NMDAR (de Sousa et al. 2000; Yamakura and Harris 2000; Yamakura et al. 2001); the effects of isoflurane, halothane, and chloroform ranged from approx. 20%–40% at 1 CEC (clinically effective concentration, see Table 1; Hollmann et al. 2001; Ogata et al. 2006). The combined inhibition of AMPAR and NMDAR by isoflurane is measurable, and possibly functionally significant, when total charge transfer of synaptic events is measured (de Sousa et al. 2000). Fairly robust inhibition of NMDA currents by isoflurane has been reported in cultured cortical neurons (Ming et al. 2001). Inhibition became less robust with time in culture (Ming et al. 2002). This effect was attributed to the lower sensitivity of NR2A subunits, which increase expression with development. KAR (GluR6) are markedly potentiated by the volatile anesthetics halothane, isoflurane, and enflurane (Dildy-Mayfield et al. 1996; Minami et al. 1998). It may seem unlikely that potentiation of excitatory kainate responses might participate in anesthesia; however, KAR are prominent on GABAergic interneurons (Huettner 2003). It is therefore possible that receptor potentiation could result in enhanced GABA release. Potentiation of KAR was explored with chimeras between GluR3 and GluR6, which localized a single amino acid in TM4 as important for the effects of volatile anesthetics on this receptor.
2.4
Injectable Anesthetics: Propofol, Barbiturates, Etomidate
At clinically relevant concentrations, propofol has only very weak effects on glutamate receptors (Yamakura et al. 1995b; Yamakura et al. 2001; Krampfl et al. 2000). Similarly, etomidate has little effect on glutamate receptor function (Yamakura et al. 2001). It therefore appears unlikely that direct glutamatergic effects are important mechanisms for either drug. On the other hand, it is clear that barbiturates inhibit AMPAR currents, and these effects are dependent upon the specific subunit composition of the receptor. For instance, GluR1 homomers are not affected by barbiturates, but GluR1/GluR2 heteromers are strongly inhibited (Taverna et al. 1994; Yamakura et al. 1995a; Dildy-Mayfield et al. 1996; Joo et al. 1999). The block of AMPAR by barbiturates may be partly dependent upon the editing of the Q/R site in GluR2 that determines Ca2+ permeability and channel rectification properties (Yamakura et al. 1995a). In addition, the inhibition exhibits use-dependence, in that repetitive activation of the receptor appears to facilitate inhibition by barbiturates (Marszalec and Narahashi 1993; Jackson et al. 2003). This latter effect has been attributed to trapping of the receptor in an agonist-bound desensitized state (Jackson et al. 2003).
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
67
There is little literature on the effect of barbiturates on NMDAR. Earlier work found no effect on NMDA receptor function (Yamakura et al. 2001), but one recent report suggests that thiopental, at clinically relevant concentrations, inhibits NMDA-gated responses in prefrontal cortex neurons (Liu et al. 2006).
2.5
Ketamine
The dissociative anesthetic ketamine is a strong, noncompetitive blocker of NMDAR with little effect on AMPAR or KAR (Anis et al. 1983; Harrison and Simmonds 1985; Thomson et al. 1985; MacDonald et al. 1987; Orser et al. 1997). The mechanism of ketamine action has been proposed to be twofold. First, it appears to act as an open channel blocker (MacDonald et al. 1991), reflected in a concentration-dependent decrease in mean open channel time (Orser et al. 1997). In addition, ketamine exhibits a closed channel block, resulting in decreased channel opening frequency. The latter effect is seen even in cell-attached patches with ketamine applied to bath solution, indicating that to reduce channel opening frequency the drug passes through or laterally within the lipid bilayer to access its site on the receptor (Orser et al. 1997). Different NMDAR subunit combinations exhibit differing sensitivity to ketamine and other dissociative anesthetics (MK801 and phencyclidine) (Yamakura et al. 1993). Dissociative anesthetic sensitivity is reduced by mutating a critical TM2 arginine residue responsible for Mg2+ block of the channel. However, the effect is not one of full abolition, and the mutation affected block by different dissociative anesthetics by different degrees (Yamakura et al. 1993).
2.6
Ethanol
The effects of ethanol on excitatory amino acid receptors have been of strong interest. Ethanol noncompetitively and relatively selectively inhibits NMDAR over AMPAR or KAR (Hoffman et al. 1989; Lovinger et al. 1989). Ethanol apparently allosterically reduces channel mean open time and open probability without changing the channel conductance (Lima-Landman and Albuquerque 1989; Wright et al. 1996). However, the actions of ethanol are variable and many factors, including the subunit composition of receptors and the expression system used, influence ethanol sensitivity (Woodward 2000; Smothers et al. 2001). Several domains and amino acid residues have been identified as important in ethanol’s antagonism of NMDAR. These include the TM2 region of NR1 (Mirshahi and Woodward 1995) and the C-terminal cytoplasmic domains of the receptor (Mirshahi et al. 1998; Anders et al. 2000). More recent studies have focused on TM3 and TM4 of the NR1 and NR2A subunits, which significantly alter ethanol sensitivity of the receptor (Ronald et al. 2001; Ren et al. 2003; Honse et al. 2004; Smothers and Woodward 2006). Some of
68
G. Akk et al.
these mutations were recently shown to affect the sensitivity of NMDAR to volatile halogenated anesthetics, but not ketamine, N2O, or benzene (Ogata et al. 2006). The diversity of sites associated with ethanol sensitivity is difficult to interpret but could suggest multiple sites of interaction.
2.7
Steroids
A formal publication of studies of anesthetic steroids has not been made, but alphaxalone (Yamakura et al. 2001) and allopregnanolone (Zorumski et al. 2000) are mentioned as having little effect on AMPAR or NMDAR. This is in contrast to the actions of pregnenolone sulfate (a convulsant), which potentiates NMDAR and inhibits AMPAR and KAR at concentrations likely to be present in vivo (Gibbs et al. 2006).
2.8
Summary
Most excitatory transmission at all levels of the mature CNS involves glutamatergic signaling. Therefore, it is conceptually attractive that general anesthetic drugs may have as an important target one or more classes of ionotropic glutamate receptors. The best evidence for glutamate receptors serving as clinically relevant anesthetic targets comes from the actions of nitrous oxide, Xe, and ketamine on NMDAR. In contrast, none of these agents acts on AMPAR at relevant concentrations. It is possible that the NMDAR, which serve a more modulatory function, can be inhibited with a larger safety margin than AMPAR, which mediate most rapid excitatory transmission including synapses in the respiratory centers. It is not known whether animals can be anesthetized by inhibition of AMPAR, while ventilation is maintained mechanically.
3 3.1
Nicotinic Receptors Nicotinic Receptor Overview
Despite the multiple classes of subunits and receptor subtypes, the general features of the nicotinic receptor are remarkably uniform. The functional receptor is a pentamer of subunits. Each subunit forms four transmembrane domains with the second membrane-spanning region being the major contributor to the channel pore (Fig. 1). The channel is cation-selective with preference to monovalent inorganic cations, although some receptor subtypes can efficiently conduct divalent cations
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
69
such as Ca2+. The endogenous activator of the receptor is acetylcholine, with two binding sites per receptor formed at the interfaces between the extracellular domains of the α-subunits and the adjacent (usually non-α) subunit. In the periphery, nicotinic receptors mediate synaptic transmission in autonomic ganglia and the neuromuscular junction, and are important for catecholamine release from adrenal chromaffin cells. The physiological role of nicotinic receptors in the CNS is debated, as is evident in many review articles. A major proposed role is that presynaptically located receptors modulate the release of other transmitters (Dani and Bertrand 2006; Jensen et al. 2005; Dajas-Bailador and Wonnacott 2004). A particular example is the role of enhanced dopamine release in producing nicotine addiction (Dani and Harris 2005; Wonnacott et al. 2005). However, genetic ablation of subunits expressed in the brain results in relatively subtle consequences (Champtiaux and Changeux 2004) that have not provided clear indications of the possible effects of receptor inhibition. Two major subtypes in the CNS are those containing the α4 and β2 subunits (α4β2 receptors) and the homomeric receptor composed of α7 subunits. The α7 receptors allow significant Ca2+ entry, which can initiate intracellular cascades (DajasBailador and Wonnacott 2004). In addition to the reviews just mentioned, an extensive examination of the possible involvement of nicotinic receptors in anesthesia has appeared (Tassonyi et al. 2002).
3.2
Gaseous Anesthetics: Xe and N2O
Both Xe and N2O inhibit the activity of nicotinic receptors (Yamakura and Harris 2000; Suzuki et al. 2003; Wachtel 1995). The effect has been described as a reversible, voltage-independent reduction of peak current. Although the two gasses can act on a wide variety of nicotinic receptor types, receptors containing the β2 subunit are markedly more sensitive to either Xe or N2O than receptors containing the β4 subunit (Yamakura and Harris 2000). Xe and N2O reduce the response from the rat α4β2 receptor by approx. 40% at doses corresponding to approximately half of MAC. In contrast, the same doses of Xe and N2O inhibit the α4β4 receptor by only about 10%. The sensitivity of α7 receptors is intermediate between the two α4 subunitcontaining receptors (Suzuki et al. 2003). In agonist dose-response measurements, the presence of N2O reduces the maximal response to acetylcholine (ACh) but does not affect the EC50 value or the slope of the dose-response curve, suggesting that N2O noncompetitively interferes with activation (Yamakura and Harris 2000; Suzuki et al. 2003). The findings are qualitatively similar for α4β2 and α4β4 receptors, and the α7 homooligomeric receptor. Little, however, is known of the molecular mechanism of inhibition. Studies on nicotinic receptors expressed in BC3H1 cells (muscle, embryonic-type) have shown that N2O leads to a reduction in the mean open duration without affecting the number of events per burst (Wachtel 1995).
70
3.3
G. Akk et al.
Volatile Anesthetics
Isoflurane is among the best-studied halogenated volatile anesthetics. It is extraordinarily effective at inhibiting the α4β2 receptor with IC50 values at 10%–25% of the MAC value (Flood et al. 1997; Violet et al. 1997; Yamashita et al. 2005). The muscle-type nicotinic receptor is less sensitive to isoflurane. Violet et al. (1997) reported an IC50 of over 1 mM (~3 MAC) for muscle-type receptors expressed in oocytes, although in single-channel recordings isoflurane affected several kinetic parameters at concentrations corresponding to 1 MAC or below (Dilger et al. 1992). Finally, the least sensitive nicotinic receptor subtype is one composed of α7 subunits (Flood et al. 1997). Single-channel experiments on muscle-type receptors from BC3H1 cells have provided a mechanistic picture of isoflurane-mediated block (Dilger et al. 1992). Coapplication of isoflurane with ACh transforms the isolated openings into groups or bursts of openings, a pattern suggestive of open channel block (Neher and Steinbach 1978). As expected for such a mechanism, the presence of isoflurane reduces the mean open duration in a dose-dependent manner. However, the number of openings per burst did not increase as much as expected, and the burst duration actually decreased in the presence of isoflurane instead of increasing as simple open channel block would predict. Accordingly, the effect of isoflurane was described as open channel block with a caveat that blocked receptors can close, and that the closing rate of blocked channels is higher than that of unblocked channels. Although isoflurane inhibition of the muscle-type ACh receptor does not contribute to its sedative effects, it should be kept in mind that isoflurane at its typical clinical concentrations reduces the peak current from muscle receptors by 10% or more, and may thus contribute to the side effects of isoflurane, or act in concert with neuromuscular blockers as a muscle relaxant. Isoflurane-mediated inhibition of currents from neuronal α4β2 receptors shows no flickering behavior (Yamashita et al. 2005). Isoflurane slightly reduces the mean open duration and the channel burst duration but affects most strongly channel closed times by increasing the duration of the longest closed time component. Macroscopic studies in which the solution was rapidly switched from ACh to one containing ACh and isoflurane and then back to ACh showed that the recovery from block was relatively slow (~50 s−1). Such a slow dissociation rate for isoflurane likely explains the absence of rapid flickering in single-channel currents from α4β2 receptors exposed to isoflurane. Many other halogenated anesthetics, such as sevoflurane or halothane, act in a manner similar to isoflurane and inhibit the activation of the nicotinic receptor. Again, sensitivity to sevoflurane and halothane is the greatest in α4β2 receptors, which are inhibited at concentrations several-fold less than MAC (Violet et al. 1997; Yamashita et al. 2005). In contrast, α7-containing receptors and the muscletype nicotinic receptor are less sensitive to halothane or sevoflurane, and have IC50 values at several MAC.
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
71
However, a role of the α4β2 receptor in the actions of volatile anesthetics is unlikely, as the ability of isoflurane to anesthetize mice genetically modified to lack the β2 subunit is unaltered from controls (Flood et al. 2002).
3.4
Anesthetic Steroids
Anesthetic steroids, best known for their potentiating actions on the related GABAA receptor, can also inhibit the nicotinic receptor (Gillo and Lass 1984; Paradiso et al. 2000). However, the concentrations required to produce inhibition of nicotinic receptors are several-fold higher than those producing potentiation of the GABAA receptor or loss of righting reflex (LRR) in Xenopus tadpoles (Paradiso et al. 2000). For example, allopregnanolone potentiates GABAA receptor-mediated currents with an EC50 at or below 0.5 µM and produces LRR with an EC50 of 0.5 µM, while the IC50 value for inhibition of the α4β2 nicotinic receptor is greater than 10 µM. On the other hand, there is a correlation between the ability of a steroid anesthetic to cause LRR and inhibition of the α4β2 nicotinic receptor, and it is possible that this receptor is a secondary site of action involved in anesthesia. Alphaxalone, an erstwhile clinical anesthetic, inhibits nicotinic receptor-mediated currents in bovine adrenal chromaffin cells with an IC50 of approximately 30 µM (Shiraishi et al. 2002). The steroid is more potent at blocking whole cell currents from chick embryonic muscle-type receptors [IC50 of 6 µM (Gillo and Lass 1984)]. However, a much lower sensitivity to alphaxalone (IC50=99 µM) was reported for single-channel open times from muscle-type receptors in BC3H1 cells (Wachtel and Wegrzynowicz 1992). These findings suggest that alphaxalone administration can result in inhibition of nicotinic receptors, although the IC50 values are much higher than clinical concentrations. A synthetic steroid (3α,5α,17β)-3-hydroxyandrostane-17-carbonitrile (ACN) blocks the rat α4β2 receptor with an IC50 of 1.5 µM and a Hill slope of greater than 1, indicating that block can involve the binding of more than one steroid molecule (Paradiso et al. 2000). Inhibition is the same at low and high ACh concentrations, and ACN appears to be without effect on the binding of radiolabeled cytisine, indicating that the steroid does not occlude the agonist binding site (Sabey et al. 1999). In addition, block develops at a similar rate in the absence and presence of ACh, and steroid does not interfere with desensitization, suggesting that steroid interactions with the receptor do not depend on the functional status of the receptor.
3.5
Propofol
Propofol acts as a nicotinic receptor blocker at concentrations far exceeding those clinically relevant. ACh-elicited currents from muscle-type receptors are blocked with an IC50 of approx. 50–100 µM (Wachtel and Wegrzynowicz 1992; Dilger et al. 1994; Violet et al. 1997). Although the blocking mechanism has been proposed to
72
G. Akk et al.
be similar to that of halogenated volatile anesthetics, e.g., isoflurane, and mediated by shortened channel open durations, flickering between conducting and nonconducting states is not seen, presumably due to slow dissociation of propofol from the receptor (Dilger et al. 1994). The ability of propofol to inhibit neuronal nicotinic receptor activation is similarly weak. Neuronal-type chicken α4β2 receptors are inhibited by propofol with an IC50 of 19 µM (Flood et al. 1997). The effect is pseudocompetitive in that the drug is more potent at lower concentrations of ACh. In rat pheochromocytoma (PC12) cells [which express α3,5,7 and β2,3,4 subunits (Rogers et al. 1992)], propofol blocks peak current elicited by 30 µM nicotine with an IC50 of 47 µM, and the steady-state current with an IC50 of 5.4 µM (Furuya et al. 1999). The effect was reversible and voltage-independent, and increasing the ACh concentration to 300 µM did not affect the magnitude of the depression of steady-state or peak current. Preincubation with propofol did not increase the magnitude of inhibition, suggesting little effect of propofol on closed channels (or that the effect on open channels is very rapid). Finally, α7 receptors from chicken have been found to be insensitive to 400 µM propofol (Flood et al. 1997).
3.6
Barbiturates
Barbiturates at clinically relevant concentrations inhibit the nicotinic receptor (Flood and Krasowski 2000; Weber et al. 2005). The IC50 values of pentobarbital and thiopental for most nicotinic receptor types are estimated to be less than 100 µM. The presence of barbiturates results in a reduction in peak current and a more rapid desensitization (Krampfl et al. 2000). In oocytes expressing human α7 receptors, thiopental is a competitive inhibitor with IC50 values at 41 µM and 285 µM for 0.1 mM and 1 mM ACh, respectively (Coates et al. 2001). In contrast, Kamiya et al. (2001) found that in rat medial habenula neurons, inhibition of the peak current by thiopental was unchanged when 10 µM (~EC30) or 100 µM (EC100) of nicotine were used to activate the receptors. Thiopental block of steady-state current was actually more potent at higher nicotine concentrations. In single-channel recordings, the presence of pentobarbital leads to shorter open time durations (Gage and McKinnon 1985; Dilger et al. 1997), although a bimodal effect with prolongation of open durations at low pentobarbital concentrations and block at higher concentrations has also been reported (Liu and Madsen 1996). In addition to an effect on open durations, the presence of high concentrations of barbiturates introduces a novel gap closed state. The duration of the gap is 1–3 ms for pentobarbital but much shorter (50 µs) for barbital, probably reflecting difference in dissociation rates (Dilger et al. 1997). The binding of pentobarbital appears to be state-specific; for muscle-type receptors, pentobarbital binds more tightly to open channels but allows closing of open-blocked channels. Dilger et al. (1997) found that pentobarbital and barbital interacted with distinct sites but the binding of one destabilized the binding of the other.
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
73
The number of sites for barbiturates in unclear. Dodson et al. (1987) reported two sites per receptor from Torpedo. Binding of radiolabeled amobarbital was completely inhibited by other barbiturates, and partly inhibited by nicotinic ligands in the absence but not in the presence of α-bungarotoxin, a nicotinic site antagonist. This suggests a negative interaction between the barbiturate site and the ACh site in Torpedo receptor. In contrast, Arias et al. (2001) reported a single high-affinity site for amobarbital on the resting receptor. Interestingly, the data suggested that a desensitized receptor contains several (11, on average) low-affinity sites for amobarbital. Despite the ability of barbiturates to act on nicotinic receptors at clinically relevant concentrations, their role in anesthesia is unlikely, as studies on stereoisomers suggest. Although both stereoisomers of 1-methyl-5-phenyl-5-propyl barbituric acid suppress nicotinic receptor currents in PC12 cells and rat medial habenula neurons (Watanabe et al. 1999; Kamiya et al. 2001), only the R(−) isomer induces LRR. The S(+) isomer, in contrast, is a convulsant (Buch et al. 1973). Similarly, there is lack of correlation between the ability of stereoisomers of thiopental to inhibit the α4β2 and α7 receptors and their anesthetic potencies in mouse (Downie et al. 2000).
3.7
Etomidate
Etomidate also inhibits nicotinic receptor function. In bovine adrenal chromaffin cells, etomidate results in shorter open duration and an excess number of brief closures within bursts. However, the burst durations are shortened rather than prolonged, suggesting that blocked open channels maintain the ability to close (Charlesworth and Richards 1995). Etomidate also inhibits the peak response from the chick α4β4 receptor (Flood and Krasowski 2000). This, however, is likely to be without clinical consequence as the IC50 values for both muscle and neuronal receptors (23 µM and 33 µM, respectively) are far outside the clinically relevant concentration range.
3.8
Ketamine
Both neuronal-type and neuromuscular nicotinic receptors are blocked by ketamine, although the IC50 values are generally above the clinically relevant range (Wachtel and Wegrzynowicz 1992; Yamakura et al. 2000; Coates and Flood 2001; but see Flood and Krasowski 2000). There appears to be little subunit-specificity, although β4-containing receptors are more sensitive than receptors containing the β2 subunit (Yamakura et al. 2000). In macroscopic recordings, block manifests as a reduction of peak and steady-state currents. In PC12 cells, the steady-state current is more sensitive than peak current to ketamine with IC50 values of 3 µM and 21 µM, respectively (Furuya et al. 1999). In clinical practice, S-ketamine is several times more potent than R-ketamine at producing anesthetic effects. Stereoselectivity of ketamine-mediated inhibition of nicotinic receptors in vitro has been observed in some studies (Friederich et al. 2000) but not in others (Sasaki et al. 2000).
74
G. Akk et al.
In single-channel recordings, exposure to ketamine results in a reduction in open time duration accompanied by a new, prominent closed time component (Wachtel and Wegrzynowicz 1992; Scheller et al. 1996). In addition to the open channel block, ketamine can interact with closed channels (Scheller et al. 1996).
3.9
Summary
Among nicotinic receptors, the α4β2 subtype seems most sensitive to anesthetic drugs, especially volatile anesthetics. However, studies of transgenic mice lacking the β2 subunit have shown no difference in the anesthetic actions of isoflurane. Accordingly, it seems unlikely that nicotinic receptors play a major role. On the other hand, actions in the periphery may be important for some side effects, including reductions in the safety factor for neuromuscular transmission, reduction of catecholamine release from chromaffin cells, and inhibition of transmission at ganglionic synapses.
4
Serotonin-Activated Channels
The channels activated by extracellular serotonin (5HT3 receptors) have been less studied than glutamate or nicotinic receptors. 5HT3 receptors have received some attention as possible targets involved in the actions of ethanol and as possible factors in post-operative nausea and vomiting (PONV). The 5HT3 receptor is a member of the gene family including GABAA, GABAC, nicotinic, and glycine receptors, and shares the pentameric structure and basic subunit topology (Fig. 1). Two subunits have been identified for the 5HT3 receptor, designated A and B. The subunit composition of receptors in the brain is not well characterized. Reeves and Lummis (2002) and Peters et al. (2005) provide some recent reviews on 5HT3 receptors. The physiological roles for 5HT3 receptors are not clearly understood, at present. The summary statement is that 5HT3 receptors are not likely to be major targets for the clinically relevant actions of anesthetic drugs, although Xe may be an effective blocker (see Table 4). Even in the case of PONV, it seems more likely that system effects, for example indirect stimulation of the emesis center in the brain, are more likely than a direct effect of anesthetics on the 5HT3 receptor. For example, although all volatile anesthetics increase the risk of PONV (Apfel et al. 2002), some potentiate 5HT3 responses (e.g., halothane) while others inhibit them (e.g., sevoflurane) (Suzuki et al. 2002; Stevens et al. 2005a). In addition to a lack of consistent effect, most effects are relatively small at concentrations near the clinical range. In one study of the binding of a radiolabeled antagonist, several intravenous anesthetics could reduce binding but only at concentrations several-fold higher than concentrations producing functional effects, and much higher than clinically used (Appadu and Lambert 1996). Accordingly, it seems unlikely that drug interactions with the transmitter binding site could underlie the functional effects.
–
–
–
0.5, 35% (EC15) –
–
–
–
–
–
5HT3A
N1E115
5HT3A
h5HT3A
5HT3A
h5HT3A
N1E115
N1E115
5HT3A
N1E115
–
5HT3A
–
–
–
–
–
0.6, 100% (EC15) –
0.85, 58% (EC50)
–
–
–
–
–
2.3, 430 (EC10) –
1.5, 210 (EC15) 1.5, 210 (EC20) –
–
3.0, 5000 (EC5) –
2.0, 1250 (EC5)
–
–
1.9, 550 (EC10) –
1.2, 230 (EC15) 1.5, 600 (EC20) –
1.15, 150 (EC50)
3.5, 5000 (EC5) –
2.0, 5000 (EC5)
–
10
–
–
–
–
–
–
(EC100)
10 (EC90)
–
n.e., 20 (EC5)
–
12
–
–
–
–
–
–
–
–
–
(EC100) –
400 (EC90) –
300 (EC90) –
–
–
–
–
–
–
–
70
–
–
(EC100)
100 (EC20) –
–
–
–
–
–
180 (EC100) Competitive 400, non competitive 900
–
–
–
–
–
–
–
–
–
Machu and Harris 1994 Zhang et al. 1997 Barann et al. 2000a Yamakura and Harris 2000 Suzuki et al. 2002 Jenkins et al. 1996 Barann et al. 2000b Stevens et al. 2005b Barann et al. 1997 Barann et al. 1993 Yamakura et al. 2000
Table 4 Actions of selected anesthetic drugs on 5HT3 receptors. Data are presented as in Table 3. N1E115 are mouse neuroblastoma cells, likely expressing 5HT3A receptors Halothane Isoflurane Propofol Etomidate Pentobarbital Thiopental Ketamine Receptor Xe N 2O type (71%) (105%) (250) (300) (1.5) (1.5) (20) (25) (5) Reference
Actions of Anesthetics on Excitatory Transmitter-Gated Channels 75
76
G. Akk et al.
Ethanol and short chain alcohols potentiate the responses of 5HT3 receptors, at concentrations below anesthetic concentrations (c.f. Machu and Harris 1994), which has suggested that at least some of the intoxication might reflect actions at this receptor. Two studies have provided evidence that potentiation of responses by ethanol (Lovinger et al. 2000) and halothane or isoflurane (Solt et al. 2005) is the result of increased gating efficacy rather than a change in the binding of agonist. In general, coexpression of the 5HT3A and -B subunits reduces the ability of volatile anesthetics (Stevens et al. 2005a) and short chain alcohols (Hayrapetyan et al. 2005) to potentiate responses, while not affecting the ability of some volatile anesthetics or longer chain alcohols to inhibit (Stevens et al. 2005a). Morphine has been reported to potently inhibit receptors composed of recombinant 5HT3A subunits expressed in human embryonic kidney (HEK)293 cells (Wittmann et al. 2006), so opiate anesthetics might also inhibit them. Alphaxalone is a weak inhibitor (Barann et al. 1999), but 17β-estradiol inhibits 5HT3A receptors at low micromolar concentrations (Barann et al. 1999; Wetzel et al. 1998).
5
ATP-Activated Channels
The P2X receptors belong to a different gene family than the glutamate receptors and nicotinic receptors. The P2X receptor family comprises seven identified subunits, named P2X1 through P2X7. Each subunit has only two membrane-spanning regions, with a long extracellularly located loop between them, and a functional receptor is composed of three subunits (Fig. 1). At least some receptors contain more than one type of subunit (e.g., P2X3 and P2X4), but the rules for assembly and the native receptor subunit composition are not worked out. P2X receptors are expressed in nonneural tissues as well as neurons, and are thought to be involved in some inflammatory responses, and when expressed in microglial cells may mediate some aspects of chronic pain. Some recent reviews of various aspects of P2X receptor structure and function are Khakh and North (2006), Khakh et al. (2001), and Chizh and Illes (2001). Relatively few studies were found to examine the actions of anesthetics on P2X receptors. Among volatile anesthetics, sevoflurane is a weak blocker [reduction to 0.6×control at 500 µM (Masaki et al. 2001)], while others have not been studied. Inhibition by sevoflurane is more profound at higher concentrations of ATP, suggesting a noncompetitive mechanism for block (Masaki et al. 2001). In one study of the binding of radiolabeled α,β-methylene ATP to rat brain synaptic membranes, neither isoflurane nor sevoflurane inhibited binding [maximal concentration 1 mM, (Masaki et al. 2004)]. P2X receptors are blocked at high concentrations (>100 µM) of barbiturates (Andoh et al. 1997; Kitahara et al. 2003). Propofol potentiates responses from P2X4 receptors, although only weakly [1.4× at concentrations of 50 µM or more (Tomioka et al. 2000; Davies et al. 2005b)], but has no effect on P2X2 receptors (Tomioka et al. 2000).
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
77
The effects of ethanol depend on the subunit composition of the P2X receptor (Davies et al. 2005a)–ethanol inhibits P2X4 and potentiates P2X3. Propofol may show a reversed subunit sensitivity (Davies et al. 2005b; Tomioka et al. 2000). Opioids inhibit P2X receptors in rat sensory ganglia, apparently not by a direct effect but through a guanosine triphosphate (GTP)-binding protein (Chizhmakov et al. 2005). Anesthetic steroids have not been studied, but 17β-estradiol inhibits recombinant P2X7 (Cario-Toumaniantz et al. 1998) and P2X receptors in rat sensory neurons (Ma et al. 2005) at high nanomolar to micromolar concentrations.
6
Summary
General anesthetics have the reputation of being “dirty” drugs, and they do, indeed, act on multiple classes of excitatory transmitter-gated channels. However, the effects in the clinically relevant range are more restricted. Inhibition of NMDAtype glutamate receptors by gaseous and dissociative anesthetics is the most compelling case for clinical relevance. A number of other channels can be affected by anesthetics at low concentrations, including AMPAR, KAR, and nicotinic α4β2 receptors, but it is difficult to argue for relevance to clinically desired effects.
References Anders DL, Blevins T, Smothers CT, Woodward JJ (2000) Reduced ethanol inhibition of N-methyl-d-aspartate receptors by deletion of the NR1 C0 domain or overexpression of alphaactinin-2 proteins. J Biol Chem 275:15019–15024 Andoh T, Furuya R, Oka K, Hattori S, Watanabe I, Kamiya Y, Okumura F (1997) Differential effects of thiopental on neuronal nicotinic acetylcholine receptors and P2X purinergic receptors in PC12 cells. Anesthesiology 87:1199–1209 Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methylaspartate. Br J Pharmacol 79:565–575 Apfel CC, Kranke P, Katz MH, Goepfert C, Papenfuss T, Rauch S, Heineck R, Greim CA, Roewer N (2002) Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 88:659–668 Appadu BL, Lambert DG (1996) Interaction of i.v. anaesthetic agents with 5-HT3 receptors. Br J Anaesth 76:271–273 Arias HR, McCardy EA, Gallagher MJ, Blanton MP (2001) Interaction of barbiturate analogs with the Torpedo californica nicotinic acetylcholine receptor ion channel. Mol Pharmacol 60:497–506 Barann M, Gothert M, Fink K, Bonisch H (1993) Inhibition by anaesthetics of 14C-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 347:125–132 Barann M, Gothert M, Bonisch H, Dybek A, Urban BW (1997) 5-HT3 receptors in outside-out patches of N1E-115 neuroblastoma cells: basic properties and effects of pentobarbital. Neuropharmacology 36:655–664
78
G. Akk et al.
Barann M, Gothert M, Bruss M, Bonisch H (1999) Inhibition by steroids of [14C]-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 360:234–241 Barann M, Dilger JP, Bonisch H, Gothert M, Dybek A, Urban BW (2000a) Inhibition of 5-HT(3) receptors by propofol: equilibrium and kinetic measurements. Neuropharmacology 39:1064–1074 Barann M, Meder W, Dorner Z, Bruss M, Bonisch H, Gothert M, Urban BW (2000b) Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol 362:255–265 Buch HP, Schneider-Affeld F, Rummel W (1973) Stereochemical dependence of pharmacological activity in a series of optically active N-methylated barbiturates. Naunyn Schmiedebergs Arch Pharmacol 277:191–198 Cario-Toumaniantz C, Loirand G, Ferrier L, Pacaud P (1998) Non-genomic inhibition of human P2X7 purinoceptor by 17beta-oestradiol. J Physiol 508:659–666 Champtiaux N, Changeux JP (2004) Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog Brain Res 145:235–251 Charlesworth P, Richards CD (1995) Anaesthetic modulation of nicotinic ion channel kinetics in bovine chromaffin cells. Br J Pharmacol 114:909–917 Chizh BA, Illes P (2001) P2X receptors and nociception. Pharmacol Rev 53:553–568 Chizhmakov I, Yudin Y, Mamenko N, Prudnikov I, Tamarova Z, Krishtal O (2005) Opioids inhibit purinergic nociceptors in the sensory neurons and fibres of rat via a G protein-dependent mechanism. Neuropharmacology 48:639–647 Coates KM, Flood P (2001) Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br J Pharmacol 134:871–879 Coates KM, Mather LE, Johnson R, Flood P (2001) Thiopental is a competitive inhibitor at the human alpha7 nicotinic acetylcholine receptor. Anesth Analg 92:930–933 Cowley KC, Zaporozhets E, Maclean JN, Schmidt BJ (2005) Is NMDA receptor activation essential for the production of locomotor-like activity in the neonatal rat spinal cord? J Neurophysiol 94:3805–3814 Dajas-Bailador F, Wonnacott S (2004) Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 25:317–324 Dale N (1986) Excitatory synaptic drive for swimming mediated by amino acid receptors in the lamprey. J Neurosci 6:2662–2675 Dani JA, Bertrand D (2006) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699–729 Dani JA, Harris RA (2005) Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci 8:1465–1470 Davies DL, Kochegarov AA, Kuo ST, Kulkarni AA, Woodward JJ, King BF, Alkana RL (2005a) Ethanol differentially affects ATP-gated P2X(3) and P2X(4) receptor subtypes expressed in Xenopus oocytes. Neuropharmacology 49:243–253 Davies DL, Kuo ST, Alkana RL (2005b) Differential effects of propofol and ethanol on P2X4 receptors expressed in Xenopus oocytes. Int Congr Ser 1283:285–287 de Sousa SL, Dickinson R, Lieb WR, Franks NP (2000) Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon. Anesthesiology 92:1055–1066 DeVries SH, Schwartz EA (1999) Kainate receptors mediate synaptic transmission between cones and ‘Off’ bipolar cells in a mammalian retina. Nature 397:157–160 Dildy-Mayfield JE, Eger EI 2nd, Harris RA (1996) Anesthetics produce subunit-selective actions on glutamate receptors. J Pharmacol Exp Ther 276:1058–1065 Dilger JP (2002) The effects of general anaesthetics on ligand-gated ion channels. Br J Anaesth 89:41–51 Dilger JP, Brett RS, Lesko LA (1992) Effects of isoflurane on acetylcholine receptor channels. 1. Single-channel currents. Mol Pharmacol 41:127–133
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
79
Dilger JP, Vidal AM, Mody HI, Liu Y (1994) Evidence for direct actions of general anesthetics on an ion channel protein. A new look at a unified mechanism of action. Anesthesiology 81:431–442 Dilger JP, Boguslavsky R, Barann M, Katz T, Vidal AM (1997) Mechanisms of barbiturate inhibition of acetylcholine receptor channels. J Gen Physiol 109:401–414 Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7–61 Dinse A, Fohr KJ, Georgieff M, Beyer C, Bulling A, Weigt HU (2005) Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones. Br J Anaesth 94:479–485 Dodson BA, Braswell LM, Miller KW (1987) Barbiturates bind to an allosteric regulatory site on nicotinic acetylcholine receptor-rich membranes. Mol Pharmacol 32:119–126 Downie DL, Franks NP, Lieb WR (2000) Effects of thiopental and its optical isomers on nicotinic acetylcholine receptors. Anesthesiology 93:774–783 Eger EI 2nd, Fisher DM, Dilger JP, Sonner JM, Evers A, Franks NP, Harris RA, Kendig JJ, Lieb WR, Yamakura T (2001) Relevant concentrations of inhaled anesthetics for in vitro studies of anesthetic mechanisms. Anesthesiology 94:915–921 Evers A, Crowder C (2001) General anesthetics. In: Hardman J, Limbird L, Gilman A (eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, pp 337–365 Evers AS, Maze M (2004) Anesthetic pharmacology: physiologic principles and clinical practice. Churchill Livingstone, Philadelphia Flood P, Krasowski MD (2000) Intravenous anesthetics differentially modulate ligand-gated ion channels. Anesthesiology 92:1418–1425 Flood P, Ramirez-Latorre J, Role L (1997) Alpha 4 beta 2 neuronal nicotinic acetylcholine receptors in the central nervous system are inhibited by isoflurane and propofol, but alpha 7-type nicotinic acetylcholine receptors are unaffected [see comments]. Anesthesiology 86:859–865 Flood P, Sonner JM, Gong D, Coates KM (2002) Heteromeric nicotinic inhibition by isoflurane does not mediate MAC or loss of righting reflex. Anesthesiology 97:902–905 Franks NP, Lieb WR (1994) Molecular and cellular mechanisms of general anaesthesia. Nature 367:607–614 Franks NP, Lieb WR (1998) Which molecular targets are most relevant to general anaesthesia? Toxicol Lett 100–101:1–8 Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR (1998) How does xenon produce anaesthesia? Nature 396:324 Friederich P, Dybek A, Urban BW (2000) Stereospecific interaction of ketamine with nicotinic acetylcholine receptors in human sympathetic ganglion-like SH-SY5Y cells. Anesthesiology 93:818–824 Furuya R, Oka K, Watanabe I, Kamiya Y, Itoh H, Andoh T (1999) The effects of ketamine and propofol on neuronal nicotinic acetylcholine receptors and P2x purinoceptors in PC12 cells. Anesth Analg 88:174–180 Gage PW, McKinnon D (1985) Effects of pentobarbitone on acetylcholine-activated channels in mammalian muscle. Br J Pharmacol 85:229–235 Gibbs TT, Russek SJ, Farb DH (2006) Sulfated steroids as endogenous neuromodulators. Pharmacol Biochem Behav 84:555–567 Gillo B, Lass Y (1984) The mechanism of steroid anaesthetic (alphaxolone) block of acetylcholineinduced ionic currents. Br J Pharmacol 82:783–789 Harris RA, Mihic SJ, Dildy-Mayfield JE, Machu TK (1995) Actions of anesthetics on ligandgated ion channels: role of receptor subunit composition. FASEB J 9:1454–1462 Harrison NL, Simmonds MA (1985) Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 84:381–391 Hayrapetyan V, Jenschke M, Dillon GH, Machu TK (2005) Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res 142:146–150
80
G. Akk et al.
Hoffman PL, Rabe CS, Moses F, Tabakoff B (1989) N-methyl-D-aspartate receptors and ethanol: inhibition of calcium flux and cyclic GMP production. J Neurochem 52:1937–1940 Hollmann M, Liu H, Hoenemann C, Liu W, Durieux M (2001) Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg 92:1182–1191 Honse Y, Ren H, Lipsky RH, Peoples RW (2004) Sites in the fourth membrane-associated domain regulate alcohol sensitivity of the NMDA receptor. Neuropharmacology 46:647–654 Huettner JE (2003) Kainate receptors and synaptic transmission. Prog Neurobiol 70:387–407 Jackson MF, Joo DT, Al-Mahrouki AA, Orser BA, Macdonald JF (2003) Desensitization of alphaamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors facilitates usedependent inhibition by pentobarbital. Mol Pharmacol 64:395–406 Jenkins A, Franks NP, Lieb WR (1996) Actions of general anaesthetics on 5-HT3 receptors in N1E-115 neuroblastoma cells. Br J Pharmacol 117:1507–1515 Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 48:4705–4745 Jevtovic-Todorovic V, Todorovic SM, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski CF, Olney JW (1998) Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 4:460–463 Joo DT, Xiong Z, MacDonald JF, Jia Z, Roder J, Sonner J, Orser BA (1999) Blockade of glutamate receptors and barbiturate anesthesia: increased sensitivity to pentobarbital-induced anesthesia despite reduced inhibition of AMPA receptors in GluR2 null mutant mice. Anesthesiology 91:1329–1341 Kamiya Y, Andoh T, Watanabe I, Higashi T, Itoh H (2001) Inhibitory effects of barbiturates on nicotinic acetylcholine receptors in rat central nervous system neurons. Anesthesiology 94:694–704 Khakh BS, North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. Nature 442:527–532 Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, Humphrey PP (2001) International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53:107–118 Kitahara S, Yamashita M, Ikemoto Y (2003) Effects of pentobarbital on purinergic P2X receptors of rat dorsal root ganglion neurons. Can J Physiol Pharmacol 81:1085–1091 Krampfl K, Schlesinger F, Dengler R, Bufler J, Klaus K, Friedrich S, Reinhardt D (2000) Pentobarbital has curare-like effects on adult-type nicotinic acetylcholine receptor channel currents. Anesth Analg 90:970–974 Krasowski MD, Harrison NL (1999) General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci 55:1278–1303 Kullmann DM (2000) Spillover and synaptic cross talk mediated by glutamate and GABA in the mammalian brain. Prog Brain Res 125:339–351 Lerma J (2006) Kainate receptor physiology. Curr Opin Pharmacol 6:89–97 Lester RA, Clements JD, Westbrook GL, Jahr CE (1990) Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature 346:565–567 Li P, Wilding TJ, Kim SJ, Calejesan AA, Huettner JE, Zhuo M (1999) Kainate-receptor-mediated sensory synaptic transmission in mammalian spinal cord. Nature 397:161–164 Lima-Landman MT, Albuquerque EX (1989) Ethanol potentiates and blocks NMDA-activated single-channel currents in rat hippocampal pyramidal cells. FEBS Lett 247:61–67 Liu GJ, Madsen BW (1996) Biphasic effect of pentobarbitone on chick myotube nicotinic receptor channel kinetics. Br J Pharmacol 118:1385–1388 Liu H, Dai T, Yao S (2006) Effect of thiopental sodium on N-methyl-D-aspartate-gated currents. Can J Anaesth 53:442–448 Lovinger DM, White G, Weight FF (1989) Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243:1721–1724
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
81
Lovinger DM, Sung KW, Zhou Q (2000) Ethanol and trichloroethanol alter gating of 5-HT3 receptor-channels in NCB-20 neuroblastoma cells. Neuropharmacology 39:561–570 Ma B, Rong W, Dunn PM, Burnstock G (2005) 17beta-estradiol attenuates alpha, beta-meATPinduced currents in rat dorsal root ganglion neurons. Life Sci 76:2547–2558 MacDonald JF, Miljkovic Z, Pennefather P (1987) Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol 58:251–266 MacDonald JF, Bartlett MC, Mody I, Pahapill P, Reynolds JN, Salter MW, Schneiderman JH, Pennefather PS (1991) Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol 432:483–508 Machu TK, Harris RA (1994) Alcohols and anesthetics enhance the function of 5-hydroxytryptamine3 receptors expressed in Xenopus laevis oocytes. J Pharmacol Exp Ther 271:898–905 Madden D (2002) The structure and function of glutamate receptor ion channels. Nat Rev Neurosci 3:91–101 Marszalec W, Narahashi T (1993) Use-dependent pentobarbital block of kainate and quisqualate currents. Brain Res 608:7–15 Masaki E, Kawamura M, Kato F (2001) Reduction by sevoflurane of adenosine 5’-triphosphateactivated inward current of locus coeruleus neurons in pontine slices of rats. Brain Res 921:226–232 Masaki E, Yamazaki K, Hori S, Kawamura M (2004) [3H]alpha,beta-methylene ATP binding to P2X purinoceptor is unaffected by volatile anaesthetics. Eur J Anaesthesiol 21:221–225 Mayer ML (2005) Glutamate receptor ion channels. Curr Opin Neurobiol 15:282–288 Mayer ML, Armstrong N (2004) Structure and function of glutamate receptor ion channels. Annu Rev Physiol 66:161–181 Mennerick S, Jevtovic-Todorovic V, Todorovic SM, Shen W, Olney JW, Zorumski CF (1998) Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci 18:9716–9726 Minami K, Wick MJ, Stern-Bach Y, Dildy-Mayfield JE, Brozowski SJ, Gonzales EL, Trudell JR, Harris RA (1998) Sites of volatile anesthetic action on kainate (Glutamate receptor 6) receptors. J Biol Chem 273:8248–8255 Ming Z, Knapp DJ, Mueller RA, Breese GR, Criswell HE (2001) Differential modulation of GABA- and NMDA-gated currents by ethanol and isoflurane in cultured rat cerebral cortical neurons. Brain Res 920:117–124 Ming Z, Griffith BL, Breese GR, Mueller RA, Criswell HE (2002) Changes in the effect of isoflurane on N-methyl-D-aspartic acid-gated currents in cultured cerebral cortical neurons with time in culture: evidence for subunit specificity. Anesthesiology 97:856–867 Mirshahi T, Woodward JJ (1995) Ethanol sensitivity of heteromeric NMDA receptors: effects of subunit assembly, glycine and NMDAR1 Mg(2+)-insensitive mutants. Neuropharmacology 34:347–355 Mirshahi T, Anders DL, Ronald KM, Woodward JJ (1998) Intracellular calcium enhances the ethanol sensitivity of NMDA receptors through an interaction with the C0 domain of the NR1 subunit. J Neurochem 71:1095–1107 Mu Y, Otsuka T, Horton AC, Scott DB, Ehlers MD (2003) Activity-dependent mRNA splicing controls ER export and synaptic delivery of NMDA receptors. Neuron 40:581–594 Nagele P, Metz LB, Crowder CM (2005) Xenon acts by inhibition of non-N-methyl-D-aspartate receptor-mediated glutamatergic neurotransmission in Caenorhabditis elegans. Anesthesiology 103:508–513 Neher E, Steinbach JH (1978) Local anaesthetics transiently block currents through single acetylcholine-receptor channels. J Physiol 277:153–176 Ogata J, Shiraishi M, Namba T, Smothers CT, Woodward JJ, Harris RA (2006) Effects of anesthetics on mutant N-methyl-D-aspartate receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 318:434–443 Orser BA, Pennefather PS, MacDonald JF (1997) Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 86:903–917
82
G. Akk et al.
Palmer CL, Cotton L, Henley JM (2005) The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 57: 253–277 Paradiso K, Sabey K, Evers AS, Zorumski CF, Covey DF, Steinbach JH (2000) Steroid inhibition of rat neuronal nicotinic alpha 4 beta 2 receptors expressed in HEK 293 cells. Mol Pharmacol 58:341–351 Patneau DK, Mayer ML (1990) Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors. J Neurosci 10: 2385–2399 Peters JA, Hales TG, Lambert JJ (2005) Molecular determinants of single-channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT3 receptor. Trends Pharmacol Sci 26:587–594 Reeves DC, Lummis SC (2002) The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review). Mol Membr Biol 19:11–26 Ren H, Honse Y, Peoples RW (2003) A site of alcohol action in the fourth membrane-associated domain of the N-methyl-D-aspartate receptor. J Biol Chem 278:48815–48820 Rogers SW, Mandelzys A, Deneris ES, Cooper E, Heinemann S (1992) The expression of nicotinic acetylcholine receptors by PC12 cells treated with NGF. J Neurosci 12:4611–4623 Ronald KM, Mirshahi T, Woodward JJ (2001) Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue. J Biol Chem 276:44729–44735 Sabey K, Paradiso K, Zhang J, Steinbach JH (1999) Ligand binding and activation of rat nicotinic alpha 4 beta 2 receptors stably expressed in HEK293 cells. Mol Pharmacol 55:58–66 Sasaki T, Andoh T, Watanabe I, Kamiya Y, Itoh H, Higashi T, Matsuura T (2000) Nonsteroselective inhibition of neuronal nicotinic acetylcholine receptors by ketamine isomers. Anesth Analg 91:741–748 Scheller M, Bufler J, Hertle I, Schneck HJ, Franke C, Kochs E (1996) Ketamine blocks currents through mammalian nicotinic acetylcholine receptor channels by interaction with both the open and the closed state. Anesth Analg 83:830–836 Sewell JC, Sear JW (2004) Derivation of preliminary three-dimensional pharmacophoric maps for chemically diverse intravenous general anaesthetics. Br J Anaesth 92:45–53 Shiraishi M, Shibuya I, Minami K, Uezono Y, Okamoto T, Yanagihara N, Ueno S, Ueta Y, Shigematsu A (2002) A neurosteroid anesthetic, alphaxalone, inhibits nicotinic acetylcholine receptors in cultured bovine adrenal chromaffin cells. Anesth Analg 95:900–906 Smothers CT, Woodward JJ (2006) Effects of amino acid substitutions in transmembrane domains of the NR1 subunit on the ethanol inhibition of recombinant N-methyl-D-aspartate receptors. Alcohol Clin Exp Res 30:523–530 Smothers CT, Clayton R, Blevins T, Woodward JJ (2001) Ethanol sensitivity of recombinant human N-methyl-D-aspartate receptors. Neurochem Int 38:333–340 Solt K, Stevens RJ, Davies PA, Raines DE (2005) General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition. J Pharmacol Exp Ther 315:771–776 Sonner JM, Antognini JF, Dutton RC, Flood P, Gray AT, Harris RA, Homanics GE, Kendig J, Orser B, Raines DE, Rampil IJ, Trudell J, Vissel B, Eger EI 2nd (2003) Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Analg 97:718–740 Stevens R, Rusch D, Solt K, Raines DE, Davies PA (2005a) Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols. J Pharmacol Exp Ther 314:338–345 Stevens RJ, Rusch D, Davies PA, Raines DE (2005b) Molecular properties important for inhaled anesthetic action on human 5-HT3A receptors. Anesth Analg 100:1696–1703 Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T (2002) The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes. Anesthesiology 96:699–704
Actions of Anesthetics on Excitatory Transmitter-Gated Channels
83
Suzuki T, Ueta K, Sugimoto M, Uchida I, Mashimo T (2003) Nitrous oxide and xenon inhibit the human (alpha 7)5 nicotinic acetylcholine receptor expressed in Xenopus oocyte. Anesth Analg 96:443–448 Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D (2002) The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull 57:133–150 Taverna FA, Cameron BR, Hampson DL, Wang LY, MacDonald JF (1994) Sensitivity of AMPA receptors to pentobarbital. Eur J Pharmacol 267:R3–R5 Thomson AM, West DC, Lodge D (1985) An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313:479–481 Tomioka A, Ueno S, Kohama K, Goto F, Inoue K (2000) Propofol potentiates ATP-activated currents of recombinant P2X(4) receptor channels expressed in human embryonic kidney 293 cells. Neurosci Lett 284:167–170 Violet JM, Downie DL, Nakisa RC, Lieb WR, Franks NP (1997) Differential sensitivities of mammalian neuronal and muscle nicotinic acetylcholine receptors to general anesthetics [see comments]. Anesthesiology 86:866–874 Wachtel RE (1995) Relative potencies of volatile anesthetics in altering the kinetics of ion channels in BC3H1 cells. J Pharmacol Exp Ther 274:1355–1361 Wachtel RE, Wegrzynowicz ES (1992) Kinetics of nicotinic acetylcholine ion channels in the presence of intravenous anaesthetics and induction agents. Br J Pharmacol 106:623–627 Watanabe I, Andoh T, Furuya R, Sasaki T, Kamiya Y, Itoh H (1999) Depressant and convulsant barbiturates both inhibit neuronal nicotinic acetylcholine receptors. Anesth Analg 88: 1406–1411 Weaver CE Jr, Park-Chung M, Gibbs TT, Farb DH (1997) 17beta-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res 761:338–341 Weber M, Motin L, Gaul S, Beker F, Fink RH, Adams DJ (2005) Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons. Br J Pharmacol 144:98–107 Wetzel CH, Hermann B, Behl C, Pestel E, Rammes G, Zieglgansberger W, Holsboer F, Rupprecht R (1998) Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol 12:1441–1451 Wittmann M, Peters I, Schaaf T, Wartenberg HC, Wirz S, Nadstawek J, Urban BW, Barann M (2006) The effects of morphine on human 5-HT3A receptors. Anesth Analg 103: 747–752 Wollmuth LP, Sobolevsky AI (2004) Structure and gating of the glutamate receptor ion channel. Trends Neurosci 27:321–328 Wonnacott S, Sidhpura N, Balfour DJ (2005) Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 5:53–59 Woodward JJ (2000) Ethanol and NMDA receptor signaling. Crit Rev Neurobiol 14:69–89 Wright JM, Peoples RW, Weight FF (1996) Single-channel and whole-cell analysis of ethanol inhibition of NMDA-activated currents in cultured mouse cortical and hippocampal neurons. Brain Res 738:249–256 Wu XS, Sun JY, Evers AS, Crowder M, Wu LG (2004) Isoflurane inhibits transmitter release and the presynaptic action potential. Anesthesiology 100:663–670 Yamakura T, Harris RA (2000) Effects of gaseous anesthetics nitrous oxide and xenon on ligandgated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 93:1095–1101 Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M (1993) Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 4:687–690 Yamakura T, Sakimura K, Mishina M, Shimoji K (1995a) The sensitivity of AMPA-selective glutamate receptor channels to pentobarbital is determined by a single amino acid residue of the alpha 2 subunit. FEBS Lett 374:412–414 Yamakura T, Sakimura K, Shimoji K, Mishina M (1995b) Effects of propofol on various AMPA-, kainate- and NMDA-selective glutamate receptor channels expressed in Xenopus oocytes. Neurosci Lett 188:187–190
84
G. Akk et al.
Yamakura T, Chavez-Noriega LE, Harris RA (2000) Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine. Anesthesiology 92:1144–1153 Yamakura T, Bertaccini E, Trudell JR, Harris RA (2001) Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol 41:23–51 Yamashita M, Mori T, Nagata K, Yeh JZ, Narahashi T (2005) Isoflurane modulation of neuronal nicotinic acetylcholine receptors expressed in human embryonic kidney cells. Anesthesiology 102:76–84 Yost CS, Dodson BA (1993) Inhibition of the nicotinic acetylcholine receptor by barbiturates and by procaine: do they act at different sites? Cell Mol Neurobiol 13:159–172 Zhang L, Oz M, Stewart RR, Peoples RW, Weight FF (1997) Volatile general anaesthetic actions on recombinant nACh alpha 7, 5-HT3 and chimeric nACh alpha 7–5-HT3 receptors expressed in Xenopus oocytes. Br J Pharmacol 120:353–355 Zorumski CF, Mennerick S, Isenberg KE, Covey DF (2000) Potential clinical uses of neuroactive steroids. IDrugs 3:1053–1063
Voltage-Gated Ion Channels C. Nau
1 Introduction........................................................................................................................ 2 Voltage-Gated Na+ Channels.............................................................................................. 3 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels ..................................... 4 Two-Pore K+ Channels ....................................................................................................... References ................................................................................................................................
85 86 88 88 90
Abstract How and where simple volatile organic molecules act in the central nervous system to cause loss of consciousness and insensitivity to pain has eluded investigation; yet remarkable progress has been made recently towards identifying possible molecular targets through which the mechanism of anesthesia is tranduced. It is likely that anesthetics act by binding directly to protein targets; several possible candidates have been identified and the debate now focuses on whether general anesthesia is due to large effects at a relatively small number of critical molecular sites or due to the combined effects of small perturbations at a very large number of sites; voltage-gated ion channels are contenders for either possibility and are the subject of this review.
1
Introduction
The superfamily of voltage-gated ion channels and structural relatives, also termed the voltage-gated-like (VGL) ion channel superfamily, is one of the largest superfamilies of signal transduction proteins, only exceeded by G protein-coupled receptors and protein kinases. Many members of this superfamily are common drug targets.
C. Nau Klinik für Anästhesiologie, Universität Erlangen-Nürnberg, Krankenhausstr. 12, 91054 Erlangen, Germany
[email protected] J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
85
86
C. Nau
Fig. 1 Schematic representation of the membrane topology of voltage-gated Na+ (Nav), hyperpolarization-activated cyclic nucleotide-gated (HCN), and two-pore K+ (K2P) channels
The VGL ion channel superfamily comprises the following ion channel families: the four-domain voltage-gated Na+ (Nav) and Ca2+ (Cav) channels; the one-domain voltage-gated K+ channels, including Kv channels, Ca2+-activated K+ (KCa) channels, and cyclic nucleotide-gated (CNG) and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels; the TRP channels; the inwardly rectifying K+ (Kir) channels; and the two-pore K+ (K2P) channels (Yu et al. 2005). Among these ion channel families, Nav, Cav, and Kv channels are directly and rapidly gated by voltage. For KCa and HCN channels, ligand binding and voltage together gate the pore. The other ion channel families are not voltage-gated in the strict sense of the word; however, all of these ion channel families are related in molecular and evolutionary terms. The following chapter will present and discuss the evidence for three of these ion channel families as potential targets for anesthetics, based on their ability to regulate neuronal activity, their expression pattern, and their sensitivity to anesthetics in clinically relevant concentrations. These are the Nav, HCN, and K2P channel families (Fig. 1).
2
Voltage-Gated Na+ Channels
Voltage-gated Na+ channels are dynamic transmembrane proteins that govern action potential initiation and propagation in excitable membranes. Nine mammalian Na+ channel isoforms have been identified and functionally expressed thus far. Their amino acid sequences in the transmembrane and extracellular domains are more than 50% identical (Catterall et al. 2005). All Na+ channel isoforms show the same overall structure: They consist of a large α-subunit and one or more of four auxiliary β-subunits. The primary functional properties of Na+ channels reside in the α-subunit. Associated β-subunits modify kinetics and voltage-dependence of channel gating. The α-subunit comprises four homologous domains (D1–D4), each containing six α-helical transmembrane segments (S1–S6). The linkers between segments S5 and S6 form pore
Voltage-Gated Ion Channels
87
loops from the extracellular side and line the narrow outer part of the channel’s pore. The S5 and S6 segments of each domain line the inner part of the channel’s pore. The highly positively charged S4 segments in each domain serve as voltage sensors. Their outward movements upon depolarization induce conformational changes in the pore resulting in channel activation (Catterall 2000). The structural determinants of Na+ channel fast inactivation are hydrophobic residues in the intracellular D3–D4 loop that may form an inactivation gate. Several residues at the intracellular end of D4–S6 and within intracellular S4–S5 loops of D3 and D4 may function as receptors for the inactivation gate (Catterall 2000). Among the nine mammalian Na+ channel isoforms, three isoforms—Nav1.7, Nav1.8, and Nav1.9—are predominantly expressed in the peripheral nervous system and critically contribute to nociception. Nav1.4 is predominantly expressed in adult skeletal muscle, Nav1.5 in cardiac myocytes, and Nav1.3 in embryonic and prenatal life central neurons. Nav1.1, Nav1.2, and Nav1.6 are predominantly expressed in central neurons (Catterall et al. 2005) and are thus potential targets for general anesthetics. There is evidence that recombinant and native voltage-gated Na+ channels are indeed sensitive to clinically relevant concentrations of volatile anesthetics. Isoflurane, but not propofol, in a clinically relevant concentration inhibited currents of Nav1.2, Nav1.4, and Nav1.6 heterologously expressed in Xenopus oocytes (Shiraishi and Harris 2004). A detailed analysis of the effect of inhalation anesthetics on Nav1.2 heterologously expressed in Chinese hamster ovary cells demonstrated a voltage-dependent interaction resulting in depression of peak Na+ current and in significant frequency-dependent inhibition (Rehberg et al. 1996). Subtype-specific effects of anesthetics have never been shown unequivocally and are considered to be unlikely. Accordingly, inhalation anesthetics inhibit Na+ channels in various in vitro preparations including dorsal root ganglion neurons and isolated nerve terminals (Ouyang and Hemmings 2005). Comprehensive attempts to map the binding region for general anesthetics in voltage-gated Na+ channels, in contrast to local anesthetics (Nau and Wang 2004), have not been documented to date. There is controversy about the relevance of Na+ channel block for anesthetic action. Two findings, however, might be of significance in this respect. First, axonal conduction is depressed by clinically relevant concentrations of halothane in thin, lightly myelinated hippocampal axons in an in vitro brain slice preparation (Mikulec et al. 1998). Second and more importantly, just a small reduction in presynaptic action potential amplitude without any direct effect on Ca2+ currents elicited by isoflurane was sufficient to significantly depress action potential-evoked synaptic vesicle exocytosis and excitatory postsynaptic current in a large, glutamatergic calyx-type synapse in the medial nucleus of the trapezoid body in rat brainstem (calyx of Held) (Wu et al. 2004). This finding suggests that depression of synaptic transmission by general anesthetics might be secondary to effects on the action potential, a hypothesis in stark contrast to a long-standing concept (Perouansky et al. 2004).
88
3
C. Nau
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels
In contrast to most other voltage-gated channels, the HCN channels are activated by hyperpolarization and close at positive potentials. The cyclic nucleotides cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) directly bind to the channel protein and enhance HCN channel activity by shifting activation to more positive voltages. Structurally, HCN channels comprise six transmembrane helical segments, with a pore loop between segment 5 and 6, and assemble in tetramers. Like in Nav channels, the S4 segments are positively charged and serve as voltage sensors. HCN channels govern cation currents termed Ih, If, or Iq, depending on the tissue. They are found in neurons, cardiac pacemakers, and photoreceptors. In neurons, Ih contributes to generation of pacemaker potentials, determination of resting potential, transduction of sour taste, dendritic integration, control of synaptic transmission, and plasticity (Hofmann et al. 2005). In mammals, the HCN family comprises four members (HCN1–HCN4). These channels differ in their speed of activation and the extent of modulation by cAMP. All four subunits are found in brain. HCN2 is found almost ubiquitously in the brain, HCN4 is concentrated in the thalamus, HCN1 in the hippocampus, and HCN3 in some hypothalamic nuclei, but is also expressed at low levels in most other brain areas. Inhalation anesthetics were demonstrated to act directly on rat brainstem motoneurons at clinically relevant concentrations to cause membrane hyperpolarization and decreased excitability via inhibition of Ih (Sirois et al. 2002; Sirois et al. 1998). Anesthetic inhibition of Ih involves a hyperpolarizing shift in voltage dependence of activation and decrease in maximal current amplitude. These effects could be ascribed to HCN1 and HCN2 subunits (Chen et al. 2005). Among intravenous anesthetics, pentobarbital inhibits Ih in thalamic neurons (Wan et al. 2003), and propofol block of Ih was demonstrated to contribute to the suppression of neuronal excitability and rhythmic burst firing in thalamocortical neurons (Ying et al. 2006). Deficits of anesthetic action in genetically engineered animals that lack HCN subunits have not been documented to date. HCN channels might well represent a yet under-appreciated anesthetic target-site.
4
Two-Pore K+ Channels
Background leak K+ currents control cellular excitability. The molecular correlates governing these background leak currents are the K2P channels. Structurally, they comprise two pore-forming loops in tandem in each subunit and four transmembrane domains. Both amino and carboxy termini are intracellular. Unlike the channel families with six transmembrane segments, Nav and HCN, K2P subunits most likely dimerize to form a functional channel.
Voltage-Gated Ion Channels
89
The human K2P family consists of 15 known members (Goldstein et al. 2005). K2P channels are potassium-selective, active at the resting membrane potential, and controlled by various chemical and physical stimuli. A reduction of neuronal excitability by the activation of K+ channels has long been considered a conceivable concept for a mechanism of general anesthesia (Franks and Lieb 1999; Nicoll and Madison 1982). That inhalation anesthetics indeed activate leak K+ currents was first discovered in the mollusc Lymnaea stagnalis (Franks and Lieb 1988). Sequence analysis and functional properties revealed recently the molecular entity to be a member of the TASK family of channels with approx. 47% sequence identity when compared with human TASK-1 (K2p3.1) and TASK-3 (K2P9.1) (Andres-Enguix et al. 2007) (TASK: Twik related acid-sensitive K- channel: TWIK: Tandem of P domain in a weak inward rectifying K+ channel). Other neuronal human K2P channels to be selectively opened by inhalation anesthetics are TREK-1 (K2p2.1), TREK-2 (K2p10.1), and TASK-2 (K2p5.1) (Patel and Honore 2001a) (TREK: TWIK-related K+ channel). Local anesthetics, in contrast, reversibly block K2P channels. Reports of genetically engineered animals that lack TREK-1 or TASK-1 and exhibit diminished anesthetic sensitivity (Heurteaux et al. 2004; Linden et al. 2006) have substantiated a possible role of these two channels for general anesthesia. In contrast, TASK-2 knockout mice did not show any significant alteration in anesthetic sensitivity (Gerstin et al. 2003). Human TREK-1 in the CNS has the highest levels of expression in GABA-containing interneurons of the caudate nucleus and putamen and in hippocampal glutamate-containing neurons. TREK-1 is also expressed in spinal cord and dorsal root ganglion neurons (Hervieu et al. 2001; Medhurst et al. 2001). TREK-1 is gated by membrane stretch and modulated in whole-cell analyses by cellular volume, with hyperosmolarity closing the channel. Heat reversibly opens TREK-1. Low intracellular pH enables channel opening at atmospheric pressure due to a right-shift in the pressure–activation relationship and essentially converts TREK-1 in a constitutively active background channel. Among the chemical substances activating TREK-1 are polyunsaturated fatty acids including arachidonic acids, lysophospholipids, and the neuroprotective drug riluzole. TREK-1 is modulated via various intracellular signaling cascades (Franks and Honore 2004). Heterologously expressed TREK-1 channels are opened by the inhalation anesthetics chloroform, diethyl ether, halothane, and isoflurane. Channel opening leads to cell hyperpolarization. Human TREK-1 is most sensitive to chloroform and is opened by inhalation anesthetics in clinically relevant concentrations (Patel et al. 1998, 1999). Clinically relevant concentrations of nitrous oxide, xenon, and the chloral hydrate metabolite trichloroethanol also open TREK-1 (Gruss et al. 2004; Harinath and Sikdar 2004). Most anesthetics require the C-terminal domain for channel activation. Knockout mice provided more direct evidence for a role of TREK-1 in anesthesia. These mice reportedly did not display any abnormal phenotype, showing normal reflex and cognitive function. However, the sensitivity of these mice toward the inhalation anesthetics chloroform, halothane, sevoflurane, and desflurane was significantly decreased (Franks and Honore 2004; Heurteaux et al. 2004). This applied to both latency for anesthesia (which was longer) and the concentrations required to reach the
90
C. Nau
common anesthetic endpoints loss of righting reflex and failure to respond to a painful stimulus (which were significantly higher). In these experiments, Halothane in a concentration that was sufficient to anesthetize all wild-type mice was essentially without effect in the knockout mice. These experiments, however, also suggested the recruitment of further targets at higher concentrations of anesthetics. Importantly, the effect of pentobarbital, which does not open TREK-1, was similar in wild-type and knockout mice, suggesting that there was no general increase in excitability in knockout mice. Human TASK-1 in the CNS has the highest expression in the cerebellum, thalamus, and pituitary gland (Medhurst et al. 2001). TASK-1 is also abundant in human dorsal root ganglion neurons and in rat carotid body. TASK-1 is sensitive to external pH changes in a narrow range near physiological pH and might be involved in both oxygen- and acid-sensing in peripheral chemoreceptors (Patel and Honore 2001b). TASK-1 is modulated by G protein-coupled receptors. Inhibition of TASK-1 leads to membrane depolarization; activation induces hyperpolarization. TASK1 heterodimerizes with TASK-3 in cell types expressing both genes. TASK-1 is opened by halothane and isoflurane but is insensitive to chloroform (Patel et al. 1999; Sirois et al. 2000). At higher concentrations, isoflurane slightly inhibits TASK-1 homodimeric channels (Berg et al. 2004). A defined region within the C-terminal domain seems to be required for channel activation by anesthetics. A study employing chimeric channel constructs and site-directed mutagenesis has identified a specific amino acid located at the cytosolic interface of transmembrane segment 3 to be a critical determinant of anesthetic sensitivity and a putative part of an anesthetic binding site (Andres-Enguix et al. 2007). TASK-1 knockout mice displayed a largely normal behavioral phenotype; however, they exhibited significantly shorter latencies in the hot-plate test, suggesting enhanced thermal nociception. In low concentrations of halothane, the loss of righting reflex was similar in wild-type and knockout mice. However, the concentration at which mice lost their tail-withdrawal reflex was significantly higher in knockout than in wild-type mice. In the case of isoflurane, knockout mice required a higher concentration for the loss of righting reflex; however, no significant difference was found for the loss of tail-withdrawal (Linden et al. 2006). The less clear effect in TASK-1 knockout mice with respect to anesthetic effects might be due to a compensatory action of TASK-3 in TASK-1 knockout mice and/or the biphasic effect of some anesthetics on TASK-1. Altogether, there is strong evidence for an important role of TREK-1 and possibly TASK-1 in general anesthesia by inhalation anesthetics. Whether or not the effects of anesthetics on Nav, HCN, or K2P channels indeed contribute to any endpoint of the anesthetic state in humans remains a challenging question for future research of mechanisms of anesthesia.
References Andres-Enguix I, Caley A, Yustos R, Schumacher MA, Spanu PD, Dickinson R, Maze M, Franks NP (2007) Determinants of the anesthetic sensitivity of two-pore domain acid-sensitive potassium channels: molecular cloning of an anesthetic-activated potassium channel from Lymnaea stagnalis. J Biol Chem 282:20977–20990
Voltage-Gated Ion Channels
91
Berg AP, Talley EM, Manger JP, Bayliss DA (2004) Motoneurons express heteromeric TWIKrelated acid-sensitive K+ (TASK) channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits. J Neurosci 24:6693–6702 Catterall WA (2000) From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26:13–25 Catterall WA, Goldin AL, Waxman SG (2005) International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57:397–409 Chen X, Sirois JE, Lei Q, Talley EM, Lynch C, Bayliss DA 3rd (2005) HCN subunit-specific and cAMP-modulated effects of anesthetics on neuronal pacemaker currents. J Neurosci 25:5803–5814 Franks NP, Honore E (2004) The TREK K2P channels and their role in general anaesthesia and neuroprotection. Trends Pharmacol Sci 25:601–608 Franks NP, Lieb WR (1988) Volatile general anaesthetics activate a novel neuronal K+ current. Nature 333:662–664 Franks NP, Lieb WR (1999) Background K+ channels: an important target for volatile anesthetics? Nat Neurosci 2:395–396 Gerstin KM, Gong DH, Abdallah M, Winegar BD, Eger EI 2nd, Gray AT (2003) Mutation of KCNK5 or Kir3.2 potassium channels in mice does not change minimum alveolar anesthetic concentration. Anesth Analg 96:1345–1349 Goldstein SA, Bayliss DA, Kim D, Lesage F, Plant LD, Rajan S (2005) International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol Rev 57:527–540 Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP (2004) Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 65:443–452 Harinath S, Sikdar SK (2004) Trichloroethanol enhances the activity of recombinant human TREK-1 and TRAAK channels. Neuropharmacology 46:750–760 Hervieu GJ, Cluderay JE, Gray CW, Green PJ, Ranson JL, Randall AD, Meadows HJ (2001) Distribution and expression of TREK-1, a two-pore-domain potassium channel, in the adult rat CNS. Neuroscience 103:899–919 Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, Romey G, Lazdunski M (2004) TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J 23:2684–2695 Hofmann F, Biel M, Kaupp UB (2005) International Union of Pharmacology. LI. Nomenclature and structure-function relationships of cyclic nucleotide-regulated channels. Pharmacol Rev 57:455–462 Linden AM, Aller MI, Leppa E, Vekovischeva O, Aitta-Aho T, Veale EL, Mathie A, Rosenberg P, Wisden W, Korpi ER (2006) The in vivo contributions of TASK-1-containing channels to the actions of inhalation anesthetics, the alpha(2) adrenergic sedative dexmedetomidine, and cannabinoid agonists. J Pharmacol Exp Ther 317:615–626 Medhurst AD, Rennie G, Chapman CG, Meadows H, Duckworth MD, Kelsell RE, Gloger II, Pangalos MN (2001) Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery. Brain Res Mol Brain Res 86:101–114 Mikulec AA, Pittson S, Amagasu SM, Monroe FA, MacIver MB (1998) Halothane depresses action potential conduction in hippocampal axons. Brain Res 796:231–238 Nau C, Wang GK (2004) Interactions of local anesthetics with voltage-gated Na+ channels. J Membr Biol 201:1–8 Nicoll RA, Madison DV (1982) General anesthetics hyperpolarize neurons in the vertebrate central nervous system. Science 217:1055–1057 Ouyang W, Hemmings HC Jr (2005) Depression by isoflurane of the action potential and underlying voltage-gated ion currents in isolated rat neurohypophysial nerve terminals. J Pharmacol Exp Ther 312:801–808 Patel AJ, Honore E (2001a) Anesthetic-sensitive 2P domain K+ channels. Anesthesiology 95:1013–1021
92
C. Nau
Patel AJ, Honore E (2001b) Molecular physiology of oxygen-sensitive potassium channels. Eur Respir J 18:221–227 Patel AJ, Honore E, Maingret F, Lesage F, Fink M, Duprat F, Lazdunski M (1998) A mammalian two pore domain mechano-gated S-like K+ channel. EMBO J 17:4283–4290 Patel AJ, Honore E, Lesage F, Fink M, Romey G, Lazdunski M (1999) Inhalational anesthetics activate two-pore-domain background K+ channels. Nat Neurosci 2:422–426 Perouansky M, Hemmings HC, Pearce R (2004) Anesthetic effects on glutamatergic neurotransmission: lessons learned from a large synapse. Anesthesiology 100:470–472 Rehberg B, Xiao YH, Duch DS (1996) Central nervous system sodium channels are significantly suppressed at clinical concentrations of volatile anesthetics. Anesthesiology 84:1223–1233 Shiraishi M, Harris RA (2004) Effects of alcohols and anesthetics on recombinant voltage-gated Na+ channels. J Pharmacol Exp Ther 309:987–994 Sirois JE, Pancrazio JJ, Iii CL, Bayliss DA (1998) Multiple ionic mechanisms mediate inhibition of rat motoneurones by inhalation anaesthetics. J Physiol 512:851–862 Sirois JE, Lei Q, Talley EM, Lynch C, Bayliss DA 3rd (2000) The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics. J Neurosci 20:6347–6354 Sirois JE, Lynch C, Bayliss DA 3rd (2002) Convergent and reciprocal modulation of a leak K+ current and I(h) by an inhalational anaesthetic and neurotransmitters in rat brainstem motoneurones. J Physiol 541:717–729 Wan X, Mathers DA, Puil E (2003) Pentobarbital modulates intrinsic and GABA-receptor conductances in thalamocortical inhibition. Neuroscience 121:947–958 Wu XS, Sun JY, Evers AS, Crowder M, Wu LG (2004) Isoflurane inhibits transmitter release and the presynaptic action potential. Anesthesiology 100:663–670 Ying SW, Abbas SY, Harrison NL, Goldstein PA (2006) Propofol block of I(h) contributes to the suppression of neuronal excitability and rhythmic burst firing in thalamocortical neurons. Eur J Neurosci 23:465–480 Yu FH, Yarov-Yarovoy V, Gutman GA, Catterall WA (2005) Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol Rev 57:387–395
G-Protein-Coupled Receptors R.D. Sanders, D. Brian, and M. Maze(* ü)
1
Introduction .......................................................................................................................... 1.1 Structure of G-Protein-Coupled Receptors ................................................................. 1.2 G-Protein-Coupled Receptor Subtypes....................................................................... 1.3 Overview of G-Protein-Coupled Receptor Function .................................................. 1.4 Scope of this Chapter .................................................................................................. 2 Opioid Receptor Signaling................................................................................................... 2.1 Nomenclature .............................................................................................................. 2.2 Morphology ................................................................................................................ 2.3 Pharmacology ............................................................................................................. 2.4 Molecular Mechanisms of Action............................................................................... 2.5 Receptor Effects and Localization .............................................................................. 2.6 Summary of Opioid Receptors ................................................................................... 3 a2 Adrenoceptor Agonists.................................................................................................... 3.1 Molecular Mechanisms of Action............................................................................... 3.2 Hypnotic Mechanisms of Action ................................................................................ 3.3 Analgesic Mechanisms of Action ............................................................................... 3.4 Summary of a2 Adrenoceptor Agonists...................................................................... 4 Muscarinic Cholinergic Agents ........................................................................................... 4.1 Role in the Mechanism of Anesthesia ........................................................................ 5 Orexin Signaling .................................................................................................................. 5.1 Role in the Mechanism of Anesthesia ........................................................................ 6 GABAB Signaling ................................................................................................................ 7 Conclusion ........................................................................................................................... References ..................................................................................................................................
94 94 94 96 97 97 97 98 98 99 101 103 103 104 104 106 107 107 108 108 109 110 110 110
Abstract G-Protein-coupled receptors mediate many of the hypnotic and analgesic actions of the drugs employed in anesthesia. Notably, opioid agonists represent the most successful and efficacious class of analgesic agents employed over the last century. Also, major clinical advances have been made by the study of α2 adrenoceptor agonists, which possess both hypnotic and analgesic qualities that are being increasingly exploited in both anesthetic and critical care settings. Furthermore
M. Maze Academic Anaesthetics, Imperial College, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
[email protected] J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
93
94
R.D. Sanders et al.
orexin, γ-aminobutyric acid (GABA)B, and muscarinic cholinergic receptors have been identified as potential anesthetic targets; clinical exploitation of ligands at these receptors may lead to important advances in anesthetic pharmacology. In this review we discuss the relevant molecular and neural network pharmacology of anesthetic agents acting at G-protein-coupled receptors.
1
Introduction
Guanine nucleotide-binding protein (G-protein)-coupled receptors (GPCRs) are the largest and most versatile group of cell surface receptors, and represent a conserved mechanism for extracellular signal perception in eukaryotic organisms (Pierce et al. 2002). Various stimuli (e.g., photons and odors) and ligands (e.g., neurotransmitters, cytokines, hormones, and drugs) can activate intracellular signaling cascades via G-proteins. Indeed, GPCRs mediate many anesthetic and analgesics effects of the drugs we employ.
1.1
Structure of G-Protein-Coupled Receptors
GPCRs are a superfamily of integral membrane proteins, and possess seven transmembrane helices (I–VII), three extracellular loops (II–III, IV–V, and VI– VII), and three cytosolic loops (I–II, III–IV, and V–VI). They have a periplasmic N-terminal domain (N), and a cytosolic C-terminal (C) domain; domain VIII is also contained in the C-terminal and runs parallel to the cytosolic membrane surface (Palczewski et al. 2000; see Fig. 1). Signal transduction through membrane-bound GPCRs enables diverse intracellular responses to a wide array of chemical ligands in a highly selective fashion. To date, 616 functionally diverse members (2.3% of total genes) have been described (Hemmings and Girault 2004), facilitated by a shift from ligand-based to sequence-based discovery (Lee et al. 2001). Perhaps surprisingly, current evidence suggests that of all drugs targeting GPCRs, the majority exert their effect predominantly on a group of only approximately 30 of these (Wise et al. 2004).
1.2
G-Protein-Coupled Receptor Subtypes
In 1971, Rodbell first outlined how a guanine-nucleotide binding regulatory protein linked receptors with downstream cellular effectors, in the context of hormonal modulation of the adenylyl cyclase system (Rodbell et al. 1971). Subsequent purification led to the identification of a heterotrimeric G-protein, composed of α-, β-, and γ-subunits, and molecular cloning has now defined 35 genes encoding
G-Protein-Coupled Receptors
95
Ligand NH2-terminal I
II
7-transmembrane domain receptor
III
Extracellular 1 2 3 4 5
6 7
Intracellular I Inactive G-protein
II
COOH-terminal
III GDP GTP
GDP
GTP
Activated G-protein
Fig. 1 Illustration of a G-protein-coupled receptor (GPCR), consisting of seven membrane spanning domains (1–7), an extracellular N-terminal and intracellular C-terminal. The three extracellular and three intracellular loops (I–III) are also indicated. Upon ligand binding, the GPCR activates the coupled G-protein, causing it to exchange bound GDP for GTP and dissociate into an α-subunit and β/γ-dimer and stimulate downstream effectors. The GTP bound to the α-subunit is then hydrolyzed to GDP (not shown), allowing re-association of the α- and β/γ-subunits, returning the GPCR to its original resting state
G-proteins in humans, 16 encoding α-, 5 encoding β-, and 14 encoding γ-subunits. The α-subunit is responsible for binding of guanosine diphosphate (GDP) or guanosine triphosphate (GTP), depending on its conformational state. Heterotrimeric G-proteins are classified based on their function and α-subunit; for example, the Gsα protein (abbreviated Gs) couples to a stimulatory α-subunit activating adenylyl cyclase, leading to increased cAMP. The Gi and Go proteins (known as Gi/o) and Gz proteins activate an inhibitory α-subunit that blocks adenylyl cyclase, but activates G-protein-coupled inwardly rectifying potassium (GIRK) channels (Milligan and Kostenis 2006; see Table 1). Agonists of receptors coupled to Gi/o proteins are of importance in anesthesia as they mediate the analgesic and sedative/hypnotic actions of many important anesthetic drugs. Other families include the Gq/11 proteins, causing the activation of phospholipase Cβ and its downstream effectors, and G12 proteins, which cause activation of the Rho small G-proteins, which are involved in cytoskeletal organization (Sah et al. 2000).
96
R.D. Sanders et al.
Table 1 G-protein families, linked receptors, and second messengers Family
Receptors
Effectors
Net response
Gsα
β1, β2, β3 adrenergic; D1, D5-dopamine
Adenylyl cyclase ↑ Cyclic AMP ↑ Maxi K channel ↑ Ca2+ influx ↑ Ca2+ channels ↑
Gi/oα/Gzα
α2 adrenergic; Adenylyl cyclase ↓ K+ channels ↑ D2-dopamine; Ca2+ channels ↓ M2, M4 muscarinic; µ-, δ-, κ-opioid ERK/MAP K ↑
Cyclic AMP ↓ Hyperpolarization Ca2+ influx ↓
Pharmacological modulation Cholera toxin
Pertussis toxin
M1, M3 muscarinic; Gq/11α/ α1 adrenergic G14–16α
Phospholipase Cβ ↑ p63-RhoGEF ↑ K+ channels ↑
IP3, DAG, Ca2+ ↑ Pertussis toxinCytoskeletal insensitive reorganization Hyperpolarization
G12/13α
Not yet fully characterized
Phospholipase D ↑ Phospholipase Cε ↑ iNOS ↑ p115-RhoGEF ↑
Phosphatidic Unknown acid, choline ↑ Cytoskeletal reorganization
Gβ/γ
Numerous, dependent on α-subunit
Phospholipase Cβ ↑ Adenylyl cyclase I ↓ Adenylyl cyclases II, IV, VII↑ PI-3 kinases ↑ K+ channels (GIRK1,2,4) ↑ Ca2+ (N-, P/Q-, R-type) channels Protein kinase D↑ p114-RhoGEF ↑
Unknown IP3, DAG, Ca2+ ↑ Cyclic AMP ↑↓ PIP3 ↑ Hyperpolarization Cytoskeletal reorganization
1.3
Overview of G-Protein-Coupled Receptor Function
Functionally, GPCRs transduce a signal in response to agonist binding by undergoing a conformational change in transmembrane and cytosolic regions of the receptor, leading to exposure of the linked G-protein α-subunit and subsequent exchange of bound GDP for GTP (see Fig. 1). The α- and β/γsubunits dissociate and both the α-subunit and the β/γ-dimer have the capacity to then independently regulate separate cellular effectors (Gilman 1987), depending on the type of GPCR. The GTP bound to the α-subunit is then
G-Protein-Coupled Receptors
97
hydrolyzed to GDP, returning the GPCR to its original resting state with reassociation of the α- and β/γ-subunits.
1.4
Scope of this Chapter
In this article we review the molecular mechanisms of the most important analgesic drugs in medicine, opioids, and share insights from the molecular mechanisms of α2 adrenoceptor agonists, concerning both their sedative/hypnotic and analgesic effects. Having reviewed the drugs in widespread use that have clear evidence for GPCR-related mechanisms of action, we will then address the new developments in this field, notably the potential for drugs that modulate orexinergic, cholinergic, and GABAB signaling to affect anesthetic practice.
2
Opioid Receptor Signaling
The existence of opioid receptors was originally proposed in the mid 1950s by Beckett and Casy (1954) but not demonstrated until the 1970s by Pert and Snyder (1973). Martin and colleagues subsequently began to classify opioid receptors based upon their response patterns to three different opioid compounds in the chronic spinal dog model (Martin et al. 1976). Receptors were named after their prototypic agonists; namely mu (µ), morphine; kappa (κ), ketocyclazocine; and sigma (σ), after the compound SKF 10047. σ, however, is no longer considered an opioid receptor. Subsequently a delta (δ) opioid receptor was discovered in and named after the mouse vas deferens, exhibiting high affinity for enkephalins (Lord et al. 1977).
2.1
Nomenclature
Current views support the presence of these three major classes of opioid receptor within the CNS, but acknowledge the existence of various subgroups within each class (Pasternak 1993). When the genes encoding the different receptors were cloned in 1992, they were renamed accordingly as MOR (µ), DOR (δ), and KOR (κ) receptors and in 1997 they became known as OP1 (δ), OP2 (κ), and OP3 (µ) opioid receptors after the International Union of Pharmacology (IUPHAR) reclassified them in their order of cloning. Later, a fourth, opioid receptor-like receptor 1 (ORL1) or “orphan” receptor was discovered, and was subsequently found to react with the endogenous peptide “nociceptin”, and is thus also referred to as the nociceptin/orphanin FQ (N/OFQ) receptor (Henderson and McKnight 1997).
98
R.D. Sanders et al.
However, as many authors have failed to adopt the new names, the most recent guidelines (in 2005) of the IUPHAR are to revert to the use of the well-defined Greek terminology, with the currently recommended names being µ or MOP, δ or DOP, κ or KOP receptors and ORL1 or N/OFQ being referred to as the NOP receptor (IUPHAR 2005).
2.2
Morphology
Opioid receptors show about 60% homology with one another, greatest within the transmembrane helices, and most diverse in the N- and C-termini and extracellular loops (Chen et al. 1993). Numerous ligands act promiscuously on µ, δ, and κ receptors, though selective ligands also exist for each receptor subtype. Evidence suggests that all opioid receptors share a common opioid-binding pocket situated within transmembrane helices 3–7, but divergent extracellular loops play a role in ligand selectivity (Waldhoer et al. 2004). The opioid receptors all are members of the Rhodopsin class of GPCRs, principally, although not exclusively, mediating their effects via the Gi/o pertussis toxin (PTX)-sensitive heterotrimeric G-protein family (Waldhoer et al. 2004). Additionally, the µ- and δ-receptors also interact with PTX-insensitive inhibitors of adenylyl cyclase, namely the Gz and G16 proteins (Garzon et al. 1998; Hendry et al. 2000), but none of the opioid receptors interact substantially with the stimulatory Gs proteins (Connor and Christie 1999). As discussed previously, each specific G-protein is able to modulate a diverse range of cellular effects.
2.3
Pharmacology
On receptor binding, opiates may act as agonists, neutral antagonists, or inverse agonists; activating, having no effect upon, or inhibiting the coupled G-protein, respectively. Compared to full agonists, partial agonists must occupy a greater fraction of an available pool of functional receptors than full agonists to induce an equivalent response (Cox 1999). Mixed agonists/antagonists (e.g., buprenorphine, butorphanol, nalbuphine, pentazocine) may act as agonists at low doses and as antagonists (at the same or a different receptor) at greater doses (Stein and Rosow 2004). Typically, such compounds exhibit ceiling effects for analgesia. Many G-protein-linked receptors exist as dimers (Cvejic and Devi 1997), and the formation of opioid receptor heterodimers is a possible mechanism underlying the cross communication between different opioid ligands and the variety of downstream effects a given ligand can produce. In the case of δ- and κ-receptors, heterodimerization has been proved to enhance agonist-induced
G-Protein-Coupled Receptors
99
inhibition of adenylyl cyclase as well as alter receptor pharmacology (Jordan and Devi 1999). Interestingly, opioid receptors have also been shown to form heterodimers with certain non-opioid receptors, for example µ-opioid with α2A adrenoceptors (Milligan 2004), although the functional significance of this is currently unclear.
2.4
Molecular Mechanisms of Action
2.4.1
Action on Potassium Conductances
The phenomenon of opioid-mediated inhibition of neuronal excitability is believed to result largely from potassium-mediated membrane hyperpolarization (Corbett et al. 2006), as opioid receptors have been shown to cause activation of a variety of different potassium channels. The most important of these is the GIRK (or KIR3), which is opened by the G-protein β/γ-subunit (see Table 1). These are widely expressed in the brain and are stimulated by all three types of opioid receptor, as well as several other receptors. Mutations and knockout studies have demonstrated GIRK to be important in mediating analgesic responses to opioids (Ikeda et al. 2002), and that mutated forms show reduced coupling to G-proteins (Navarro et al. 1996). In addition, opioids have also been shown to activate delayed rectifier potassium channels, voltage-dependent potassium channels, the BK calciumsensitive potassium channel (Williams et al. 2001), as well as dendrotoxin-sensitive and M-type channels (Corbett et al. 2006).
2.4.2
Action on Adenylyl Cyclase
Physiological studies of opioid effects on neurons have delineated several downstream effects of G-protein-mediated adenylyl cyclase inhibition and the consequent reduction in cyclic AMP (cAMP). First, decreased cAMP increases the threshold for opening of the hyperpolarization-activated cation channels (Ih), and in lowering cAMP, opioids effectively inhibit Ih (Ingram and Williams 1994; Svoboda and Lupica 1998). This results in reduced pacemaker activity and a lowering of the rate of firing of action potentials and thus the flow of nociceptive information to the CNS (Corbett et al. 2006). Second, decreased cAMP results in an inhibition of protein kinase A (PKA)-activated neurotransmitter release at certain synapses (Williams et al. 2001). The role of opioids in modulating this system is supported by the finding that in hyperalgesia, PKA-activated neurotransmitter release is enhanced (Willis 2001), and that the µ-opioid agonist morphine has, via a PKAdependent pathway, been shown to inhibit the pronociceptive responses of vanilloid receptor 1 (TRPV1), which is critical in the development of inflammatory hyperalgesia (Vetter et al. 2006).
100
2.4.3
R.D. Sanders et al.
Action on Neurotransmitter Release
Inhibition of neurotransmitter release by opioids was originally observed in 1917 in the peripheral nervous system by Trendelenburg, who reported that morphine inhibited the peristaltic reflex in guinea pig ileum. It was not until the 1950s, however, that this finding was discovered to be due to the inhibition of acetylcholine release. Subsequently, morphine was shown to inhibit the release of noradrenaline from postganglionic sympathetic nerve endings in animal studies. It is now clear that, throughout the CNS, stimulation of µ-, δ-, κ- or NOP receptors is able to inhibit the release of many neurotransmitters, such as glutamate, GABA, and glycine (Williams et al. 2001), and at least two mechanisms exist by which neurotransmitter release is inhibited in this fashion. Previously, the activation of potassium conductance and/or the inhibition of calcium conductance was thought to account for this effect (Williams et al. 2001). More recently however it has been suggested that inhibition of adenylyl cyclase plays a role in downregulating release of transmitters, although it has been reported that opioid receptors may somehow inhibit neurotransmitter vesicle-release machinery directly, independent of any effect on potassium and calcium conductance (Williams et al. 2001; Capogna et al. 1993).
2.4.4
Action on Phospholipase C and Calcium Currents
In addition to the action of opioid receptors on adenylyl cyclase and membrane conductances, opioid receptors also modulate phospholipase Cβ (PLCβ) via Gi/o and Gq proteins (Ueda et al. 1995; Lee et al. 1998; see Table 1). The exact role of PLCβ in opioid responses is less clear but has been studied in animals (Murthy and Makhlouf 1996; Lee et al. 1998) and of note, PLCβ3 knockout mice exhibit enhanced morphine-induced analgesia (Xie et al. 1999). Because presynaptic calcium ion influx is essential for neurotransmitter release, the role of calcium channels in mediating opioid analgesia has also been investigated. In particular, N-, P/Q-, and R-type voltage-dependent calcium channels (VDCCs) have been studied, as these are directly inhibited by the Gi family protein β/γ-subunits (Herlitze et al. 1996; Ikeda et al. 2002). Although, there is currently no direct evidence for the inhibition of VDCCs in opioid-induced analgesia, in VDCC knockout mice, nociceptive responses are generally reduced (Saegusa et al. 2000; Hatakeyama et al. 2001). However, many studies have demonstrated a transient increase in intracellular calcium following opioid receptor activation (Williams et al. 2001). This effect of opioids on intracellular calcium is sensitive to pertussis toxin and partly results from release of calcium from intracellular stores but also from enhanced dihydropyridine-sensitive entry of calcium. This release of calcium from internal stores appears to be depend on PLC (Jin et al. 1994) and its downstream effectors, inositol triphosphate (IP3) and diacyl-glycerol (DAG), which effect stored calcium release and protein kinase C (PKC) activation, respectively.
G-Protein-Coupled Receptors
2.5
101
Receptor Effects and Localization
Opioid receptors are located throughout the body, in both the CNS and peripheral nervous system, and are found in primary afferent neurons, dorsal root ganglia, spinal cord, brainstem, midbrain, and cortex (Stein 1995; Millan 1993). In addition, they are expressed by neuroendocrine, immune, and ectodermal tissues (Slominski et al. 2000; Sharp 2001). Undoubtedly, the multitude of receptor locations and their numerous downstream effector mechanisms underpin the efficacy of opioid agonists in clinical practice. Opioid receptors modulate responses to pain within the normal nociceptive pathway, at both presynaptic and postsynaptic terminals, and activate descending inhibition of spinal cord nociceptive responses. Importantly, the different responses associated with a given receptor—for example µ (euphoria) vs κ (dysphoria) or µ (supraspinal analgesia) vs NOP (supraspinal antagonism of opioid analgesia)—result from the anatomical distribution of receptors, rather than receptor subtype alone (Corbett et al. 2006).
2.5.1
Supraspinal Effects
Within the brain, the highest densities of opioid receptors are found within the brainstem, specifically in the midbrain periaqueductal gray matter (PAG), the locus coeruleus (LC), and the rostral ventral medulla (RVM). The PAG plays a major role in descending inhibition, and in both the PAG and RVM, µ- and δ-receptors presynaptically inhibit interneuron release of GABA (Christie et al. 2000). The resulting disinhibition causes activation of descending monoaminergic pathways in the dorsolateral funiculus, with a net inhibitory effect on nociceptive processing in the spine (Heinricher and Morgan 1999). Conversely, postsynaptic NOP-receptor stimulation results in pronociception via inhibition of descending neuronal output (Corbett et al. 2006). Other supraspinal sites mediating opioid analgesia include the ventral tegmental area, globus pallidus, hypothalamus, and insular cortex. Additionally, the amygdala has reciprocal connections with the PAG and contains high levels of µ-, δ-, and κ-receptors (Stein and Rosow 2004). µ-Receptors present in the respiratory center of the medulla are responsible for the dose-dependent depression of the ventilatory response to hypercapnia and hypoxia resulting from opioid administration (Weil et al. 1975).
2.5.2
Pronociceptive Effects
Unexpectedly, a large number of clinical studies have demonstrated that opioids can elicit hyperalgesia (enhanced responses to noxious stimulation) and allodynia (pain elicited by normal innocuous stimuli) (Simonnet and Rivat 2003). In evolutionary terms, opioid-induced hyperalgesia may have had biological utility in conditioning behavioral responses serving to avoid noxious stimuli (Simonnet and
102
R.D. Sanders et al.
Rivat 2003). A possible mechanism for this is that opioids can selectively potentiate excitatory postsynaptic N-methyl-d-aspartate (NMDA) receptor-mediated glutamate responses in a PKC-dependent manner (Chen and Huang 1991). However, more recent research has demonstrated that opioid-mediated excitatory glutamate responses appear to be dependent on a specific NMDA receptor subunit or PKC isoform (Williams et al. 2001), as although this effect was reaffirmed in the neurons of the nucleus accumbens and hippocampus (Martin et al. 1997, 1999; Przewlocki et al. 1999), it was not seen in the LC (Oleskevich et al. 1993).
2.5.3
Sedation and Considerations During Co-administration with Other Anesthetic Drugs
Opioid administration leads to sedation, but when given as a single agent the opioids do not induce anesthesia. Notably, however, at subanalgesic doses, the κ-agonist butorphanol has a marked sedative effect, and has been used clinically for this purpose (Dershwitz et al. 1991). Furthermore, many opioids can interact synergistically with other agents, such as midazolam and propofol (Short et al. 1992), to increase their hypnotic effect. In clinical anesthesia, opioids are widely known to cause a considerable reduction in the minimum alveolar concentration (MAC) of inhalational anesthetics, such as isoflurane, that is required to produce immobility in 50% of subjects given a noxious stimulus (McEwan et al. 1993). However, numerous studies have demonstrated that it is not opioid receptors that mediate the capacity of inhaled anesthetics to produce immobility in the face of noxious stimulation, because administration of naloxone (a nonspecific opioid receptor antagonist) does not increase the MAC of inhaled anesthetics (Liao et al. 2006).
2.5.4
Spinal Effects
Within the dorsal horn of the spinal cord all three types of opioid receptors exist, and numerous studies indicate that opioid receptors are also located on terminals of primary afferents originating in the dorsal root ganglion as well as intrinsic spinal cord neurons (Cesselin et al. 1999). In the dorsal horn it appears that enkephalins act to suppress noxious input by acting on µ- and κ-receptors, (Stein and Rosow 2004) and when applied directly to the spinal cord, µ-, δ-, and κ-agonists all produce profound analgesia (Yaksh 1997). Postsynaptically, opioids, in particular µ-agonists, hyperpolarize ascending projection neurons by increasing potassium conductance (Stein and Rosow 2004). One possible mechanism involved in this opioid-induced spinal anesthesia is the suppression of the release of pronociceptive peptides, such as substance P, glutamate, and calcitonin gene-related peptide (CGRP), from peripheral terminals of primary afferent sensory neurons in the spinal cord (Stein 1995). This has been reported to be modulated by µ- and δ-receptorlinked inhibition of Ca2+ influx (Yaksh 1997), although the significance of this effect has also been questioned (Trafton et al. 1999).
G-Protein-Coupled Receptors
2.5.6
103
Peripheral Effects
It was only in the last 20 years that the existence of opioid receptors outside the CNS has been widely acknowledged, but all three type of receptor have now been shown to also mediate analgesia peripherally, especially in inflamed tissue, in both animals and humans (Schäfer 1999). In addition, the µ- and δ-receptor-mediated inhibition of voltage-dependent calcium channels of primary afferent neurons is also an important mechanism decreasing release of substance P into peripheral tissues, with resultant analgesic as well as potent antiinflammatory effects in response to peripheral opioid administration being revealed recently (Stein et al. 2001).
2.6
Summary of Opioid Receptors
The characterization of opioid receptor morphology, signaling mechanisms, and subtypes of receptor, as well as their tissue distribution and cellular localization, has greatly elucidated the manner by which opioid analgesics mediate their effects, both desirable and adverse. However, in spite of ongoing work there has been a lack of significant progress toward the development of a powerful new opioid analgesic that is free from the undesirable effects associated with current agents. Continuing research into the effects of opioids in neuronal and nonneuronal systems, as well as the availability of novel peptides, will bring new insight to the application of these drugs. In future, greater understanding of the role played by phenomena such as opioid-induced hyperalgesia and the contribution of opioid receptor heterodimerization to the pharmacology of analgesia will allow us to refine clinical practice.
3
a2 Adrenoceptor Agonists
Activation of α2 adrenoceptors plays a prominent role in the endogenous hypnotic and antinociceptive systems. There are three known receptor subtypes: α2A, α2B, and α2C adrenoceptors (Maze and Fujinaga 2000). These receptors couple to Gi and Gs (notably α2B adrenoceptors; Pohjanoksa et al. 1997) proteins; however, it is predominantly the pertussis toxin-sensitive Gi α2A adrenoceptors that mediate the anesthetic actions of this group of agents. Using D79N mice that express dysfunctional α2A adrenoceptors, Lakhlani and colleagues showed that α2 adrenoceptor agonist antinociception (assessed by the hot plate test) and sedation were dependent on this receptor subtype (Lakhlani et al. 1997). In the absence of functional α2A adrenoceptors, the agents could not suppress voltage-gated calcium or activate potassium currents. This mutation did not affect morphine analgesia but inhibited dexmedetomidine sedation and analgesia. We have also subsequently shown that the neuroprotective effects of dexmedetomidine are mediated by the α2A adrenoceptor (Ma et al. 2004).
104
3.1
R.D. Sanders et al.
Molecular Mechanisms of Action
In the fifth transmembrane domain of the adrenergic receptors are three critical amino acid residues which modulate agonist binding to adrenoceptors (Peltonen et al. 2003). Human α2A adrenoceptors have one cysteine and two serine residues while rodent α2A adrenoceptors have three serine residues, thus explaining some species-dependent ligand-binding differences (Blaxall et al. 1993). Using sophisticated mutant receptor techniques, the impact of exchanging these serine and cysteine residues has been studied, revealing separate binding and activation roles of differing residues (Peltonen et al. 2003). While imidazoline compounds generally retained their efficacy at mutant receptors, the efficacy of phenethylamine compounds varied. Furthermore while both cysteine 201 and serine 204 are important for receptor binding of catecholamines, only serine 204 is important for receptor activation (Peltonen et al. 2003). These studies will be critical to the development of novel ligands to improve both affinity and efficacy at particular receptor subtypes and to clarify the coupled effectors of G-protein-related signaling. When stimulated, α2A adrenoceptors inhibit adenylyl cyclase through Gi protein coupling, with subsequent effects on ligand-gated ion channels. These include inhibition of N-type calcium channels (Adamson et al. 1989) and P/Q-type calcium channels (Ishibashi and Akaike 1995) and activation of IA potassium channels (North et al. 1987), calcium-activated potassium channels (Ryan et al. 1998), the ATP sensitive potassium channel, voltage-dependent potassium channels (Galeotti et al. 1999) and the Na+/H+ antiporter (Ryan et al. 1998). Furthermore, recent work has highlighted the association of α2 adrenoceptors with GIRK channels (Blednov et al. 2003; Mitrovic et al. 2003) and potentially TASK-1 channels (Linden et al. 2006). Two separate studies investigated the effects of clonidine in GIRK-2-null mutant mice using the hot plate and tail flick latency tests (Blednov et al. 2003; Mitrovic et al. 2003); the mutation reduced clonidine antinociception almost to baseline indicating primarily a postsynaptic action of clonidine. It is also noteworthy that pharmacogenetic analysis of different inbred mouse strains showed significant correlation between strain dependence of morphine and clonidine analgesia (in hot plate and formalin tests; Wilson et al. 2003). Therefore mutual dependency on GIRK channel signaling may account for this effect. The inhibition of adenylyl cyclase by α2 adrenoceptor activation may also hinder the development of hyperalgesia, as cAMP is a key mediator of this process (Hoeger-Bement and Sluka 2003). The net effect is reduced neuronal excitability and hyperpolarization in key populations of neurons that contribute to hypnosis/sedation and analgesia.
3.2
Hypnotic Mechanisms of Action
The neural networks underlying the effects of exogenous α2 adrenoceptor agonists have recently been identified. The hypnotic pathway involves activation of the nonrapid eye movement (NREM) pathway, with the primary site of action the noradrenergic
G-Protein-Coupled Receptors
105
nucleus, the LC. Coupled with lesioning, antagonist, and pharmacogenetic studies, we have used immunohistochemical techniques to sequentially map the neuronal activation and inhibition provoked by the α2 adrenoceptor agonist dexmedetomidine to elucidate the pathway. The interesting discovery that the GABAA antagonist gabazine could reduce dexmedetomidine’s sedative effect combined with evidence of activated inhibitory neurons in the ventrolateral preoptic (VLPO) nucleus in the anterior hypothalamus suggested that α2 adrenoceptor agonist sedation converged on the NREM sleep system. Indeed lesioning of the VLPO reduced dexmedetomidine’s hypnotic efficacy. Therefore α2 adrenoceptor activation inhibited norepinephrine release within the LC, leading to disinhibition of GABAergic neurons in the VLPO nucleus in the anterior hypothalamus, which controls sleep and its maintenance (Nelson et al.; Fig. 2). The resultant effect is release of the inhibitory neurotransmitter
Fig. 2 Diagram depicting a simplified nonrapid eye movement (NREM) sleep-promoting pathway activated by dexmedetomidine. An inhibition of firing of noradrenergic neurons in the locus coeruleus (LC), which accompanies endogenous NREM sleep and is the site of initiation of dexmedetomidine-induced hypnosis, releases a tonic noradrenergic inhibition of the ventrolateral preoptic nucleus (VLPO). The activated VLPO is believed to release γ-aminobutyric acid (GABA) into the tuberomammillary nucleus (TMN), which inhibits its release of arousal-promoting histamine into the cortex and forebrain to induce loss of consciousness. A number of pathways are involved in NREM sleep; the sleep-active VLPO projects to all the ascending monoaminergic, cholinergic, and orexinergic arousal nuclei, which in turn project to the cortex, forebrain, and subcortical areas where they release neurotransmitters of arousal to promote wakefulness. The LC widely innervates the brain, but only projections associated with NREM sleep are shown here. A simplified version of this circuitry, the portion of the pathway highlighted in black, is the focus of this investigation. Ach, acetylcholine; DR, dorsal raphe nuclei; His, histamine; 5-HT, serotonin; LDTg, laterodorsal tegmental nuclei; NE, norepinephrine; OX, orexin (hypocretin); PeF, perifornical area; PPTg, pedunculopontine tegmental nuclei. (Reproduced with permission from Nelson et al. 2003)
106
R.D. Sanders et al.
GABA leading to the inhibition of excitatory pathways notably the histaminergic (tuberomammillary nucleus; TMN), serotonergic (dorsal raphe nucleus; DRN) and cholinergic (basal forebrain; BF) systems. Again these effects were not observed in D79N mutant mice, indicating this effect was mediated by α2A adrenoceptors. It is of course of interest that gabazine can attenuate both α2 adrenoceptor agonist and GABAergic drug (e.g., propofol)-induced sedation/hypnosis yet α2 adrenoceptor antagonists can only reduce α2 adrenoceptor agonist-induced sedation/hypnosis (not that induced by GABAergic drugs; Segal et al. 1988). This is because these GABAergic drugs act downstream of the LC at the VLPO to potentiate the inhibitory neurotransmission from this nucleus. A further interesting discovery has been the profound sensitivity of the young to anesthetic agents; however, they appear particularly sensitive to α2 adrenoceptor agonists with a greater than tenfold difference in the hypnotic potency of dexmedetomidine noted between 7-day-old and adult rats (Sanders et al. 2005). The underlying cause is unknown at present but this may reflect the strength of connections of the LC to other brainstem and higher nuclei in the young. Critical roles for spinophilin and arrestin proteins, which regulate GPCR signaling, have been noted in the sedative efficacy of α2 adrenoceptor agonists (Wang et al. 2004). These two proteins act in an antagonistic manner with spinophilin, blocking stimulated G-protein receptor kinase 2 activity with downstream effects on intracellular signaling such as by the mitogen-activated protein kinase system. Interestingly, spinophilin knockout mice are more sensitive to α2 adrenoceptor agonist-induced sedation, while arrestin-3 knockout mice were more resistant, thus indicating that arrestin-stimulated pathways are important in the sedative effects of α2 adrenoceptor agonists. The downstream effects of this arrestin signaling may be to replenish the number of receptors available for activation at the membrane level (Wang et al. 2004). Intriguingly, an activity linkage between neuronal two-pore domain potassium channels and Gi protein-coupled receptors has recently been discovered (Lesage et al. 2000; Mathie 2007). As activation of TREK channels appears a likely target for general anesthetic action, and activation of Gi proteins activates TREK-2 channels by inhibition of cAMP signaling, an effect of α2 adrenoceptor agonists on this system should be sought. However, the effects of dexmedetomidine on TASK-1 channels have already been approached with TASK-1 knockout mice less sensitive to the sedative effects of dexmedetomidine (Linden et al. 2006), which is likely due to a reduced effect in the LC where TASK1/3 channels are particularly abundant. As TASK-1 knockout mice exhibit increased pain sensitivity, activation of TASK-1 receptors by α2 adrenoceptor agonists may also be involved in their antinociceptive effects.
3.3
Analgesic Mechanisms of Action
Both spinal and supraspinal sites are activated by α2 adrenoceptor agonists (or norepinephrine release) to produce analgesia (Sanders and Maze 2007). The supraspinal sites, provoked primarily by disinhibition of brainstem noradrenergic nuclei, provide
G-Protein-Coupled Receptors
107
analgesia mediated by descending inhibitory neurons (DINs). The LC tonically inhibits the brainstem nuclei; the A5 and A7 are then coupled to DINs. Activation of α2 adrenoceptors in the LC inhibits neuronal firing in this region (Guo et al. 1996). Inhibition of the LC by discrete administration of α2 adrenoceptor agonists leads to “disinhibition” (i.e., activation) of the A5 and A7 and therefore DINs. These DINs inhibit nociceptive responses in the dorsal horn of the spinal cord via release of norepinephrine, enkephalins, and acetylcholine (Li and Zhuo 2001; Eisenach et al. 1996). In the dorsal horn, norepinephrine or exogenous α2 adrenoceptor agonists depress wide-dynamic-range neuron responses after Aδ and C nociceptive fiber activation by stimulation of α2 adrenoceptors (Jones and Gebhart 1986). The subtype of α2 adrenoceptor mediating the spinal antinociceptive effects of adrenergic compounds is not entirely clear in humans despite the strong pharmacogenomic evidence in mice (Lakhlani et al. 1997). Roles for α2A, α2B, and α2C adrenoceptors have been suggested to potentially mediate the differences between endogenously and exogenously stimulated pathways (Maze and Fujinaga 2000); further evaluation of the different receptor subtypes involved would help design future analgesic and hypnotic therapies.
3.4
Summary of a2 Adrenoceptor Agonists
Activation of α2A adrenoceptors represents the most likely molecular target underlying the hypnotic and analgesic effects of the α2 adrenoceptor agonists. Further understanding of both the molecular and neural network systems involved will contribute to the targeting of future pharmacological strategies to improve clinical anesthesia. The development of more efficacious and subtype-selective agonists (and antagonists) would also significantly enhance the utility of this class of agents.
4
Muscarinic Cholinergic Agents
Cholinergic signaling is involved in a multitude of actions including arousal, cognition, learning and memory, and the modulation of pain responses. In addition, acetylcholine plays a critical role in the autonomic nervous system (ANS), and anticholinergic drugs such as atropine and the neuromuscular blocking agents have indisputable importance in anesthesia. The G-protein-coupled muscarinic acetylcholine receptors (mAChR) are either excitatory (odd numbered, M1, M3, M5) or inhibitory (even numbered, M2, M4) in nature. Even numbered channels inhibit adenylyl cyclase via Gi/Go and activate TREK-2 channels while odd numbered channels, coupled to Gq/G11, activate phospholipase C (Caulfield and Birdsall 1998) and inhibit TREK-2 channels (Lesage et al. 2000; Mathie 2007). Similar to opioid and α2 adrenoceptors, M2 receptor activation also activates GIRK channels (Fernandez-Fernandez et al. 1999).
108
4.1
R.D. Sanders et al.
Role in the Mechanism of Anesthesia
In terms of anesthetic actions (beyond effects on the ANS), mAChR primarily have a role in antinociception; for example, morphine antinociception is reduced in M4 and M4/M2 knockout mice (Duttaroy et al. 2000). Furthermore, activation of muscarinic receptors induces antinociception in various pain paradigms including thermal, inflammatory, and neuropathic pain (Wess et al. 2003; Shannon et al. 1997). M2 and M4 receptors couple to Gi proteins, with dual knockout of both these receptors abolishing the antinociception induced by oxotremorine (Duttaroy et al. 2002). Sole knockout of the M2 receptor reduced antinociception (but to a lesser extent than dual knockout) and also reduced the inhibitory action of muscarine on CGRP release from peripheral nerve endings (Bernardini et al. 2002). The antinociceptive action of oxotremorine is reduced in mice with a GIRK-2 null mutation, indicating primarily a postsynaptic action of this drug via GIRK channels. As M2 receptors are known to activate GIRK channels it is likely that M2 and GIRK channels mediate muscarinic antinociception, at least in mice. Muscarinic antinociception is also reduced in the presence of the GABAB receptor antagonist CGP55845. This effect is reasoned to be a presynaptic effect of augmented endogenous GABA release inhibiting other neurotransmitter release (Li et al. 2002). Antagonists of the M2, M3, and M4 receptor subtypes inhibit this GABA release (Zhang et al. 2005). However, M2 receptor activation has also been associated with reduced thalamic GABA release and increased arousal, which would likely affect the anesthetic state (Rowell et al. 2003). Further investigation is required. Anesthetic actions at muscarinic receptors in the CNS are of unknown significance; however, halothane (Durieux 1995), desflurane (Nietgen et al. 1998), and propofol (Murasaki et al. 2003) all inhibit M1 receptor signaling, though isoflurane does not (but does inhibit the M3 receptor). Furthermore, the local anesthetics have been shown to inhibit M1 receptor signaling likely via interaction with the extracellular domain of the G-protein (Hollmann et al. 2000). This effect on Gqα proteins has subsequently been shown to be time dependent and reversible and independent of PKC, protein phosphatases, and increased guanosine triphosphatase activity (Hollmann et al. 2004). These effects may also involve further protein expression. How these effects interact in the short term with anesthetic action is still unclear, though they may contribute significantly to the antiinflammatory and antithrombotic effects of local anesthetics. Due to the putative role of muscarinic signaling in Alzheimer’s dementia, antagonism of M1 receptors (Eglen 2006) may also play a role in the development of postoperative cognitive dysfunction (POCD), if the parallels drawn between Alzheimer’s and POCD hold.
5
Orexin Signaling
Orexinergic signaling plays a key role in the arousal/waking system, and therefore a role in the state of anesthesia has been proposed. The orexins were identified as endogenous ligands for two orphan GPCRs [now named orexin 1 (OX1R) and
G-Protein-Coupled Receptors
109
orexin 2 (OX2R)] and showed no significant homology with previously described peptides (Sakurai 2007; Sakurai et al. 1998; Huang et al. 2001). OX1R couples to G11α and activates phospholipase C with subsequent phosphatidylinositol and Ca2+ signaling, while OX2R couples to both G11α and Gi proteins. In the lateral hypothalamus there is a dense nucleus of orexinergic neurons that project widely throughout the cerebrum but notably innervate the thalamic paraventricular nucleus, arcuate nucleus, DRN, BF, LC, and TMN. The latter two nuclei contain the highest density of orexin receptors consistent with the orexins’ role as arousal-promoting neuropeptides (Marcus et al. 2001; Huang et al. 2001). Indeed orexins have been shown to activate the DRN, BF, LC, and TMN, which are integral parts of the arousal promoting system. Knockout of the OX2R produces a narcoleptic phenotype with abnormal attacks of NREM sleep (Willie et al. 2003) and show abnormal activity of the TMN which, at least in part, mediates the hypnotic effects of anesthetics (Nelson et al. 2002, 2003). Interestingly the VLPO sends inhibitory GABAergic connections to the lateral hypothalamus, and functional inhibition of this area has been achieved with GABAergic drugs such as anesthetics (Nelson et al. 2002).
5.1
Role in the Mechanism of Anesthesia
Functional investigations of the orexin system are underway to analyze their potential therapeutic effects in narcolepsy (agonists), sleep medicine (antagonists), and anesthetic applications (agonists and antagonists). Indeed in anesthesia, inhibition of orexin signaling likely contributes to the anesthetic state (Nelson et al. 2002; Kushikata et al. 2003; Dong et al. 2006) and conceivably activation of the orexin system may prove useful as a pharmacological stimulant to enhance emergence from anesthesia. Furthermore, orexin signaling is associated with antinociceptive effects and therefore may be useful in the post-anesthesia care unit for maintaining arousal and analgesia. In a series of experiments, Kushikata and colleagues showed that an OX1R agonist could reduce barbiturate-induced anesthesia time (assessed by loss of righting reflex; Kushikata et al. 2003). Furthermore in two studies from Japan, the excitatory effects of intracerebroventricularly administered orexins on the electroencephalogram (EEG) under isoflurane anesthesia have been established (Dong et al. 2006; Yasuda et al. 2003). Exogenous orexin-stimulated basal forebrain acetylcholine release correlated with a change in the EEG pattern from burst suppression to arousal, an effect reversed with an OX1R antagonist. It is of interest that while an arousal EEG was obtained the rats did not move, an intriguing set of possibilities may explain this: (1) Cholinergic stimulation may have been insufficient itself to overcome the anesthetic state; (2) the arousal EEG may have reflected a more REM than NREM type of hypnotic state, with arousal EEG and muscle atonia; or (3) activation/inhibition of brainstem nuclei such as the mesopontine tegmental area may play a greater role in the anesthetic state. Nonetheless, further research is required in this area to elucidate the impact of orexin signaling on the anesthetic state.
110
6
R.D. Sanders et al.
GABAB Signaling
The role of GABAA receptor signaling in the mechanism of anesthesia is well established with sophisticated in vitro and in vivo work demonstrating the critical involvement of this receptor (Franks and Lieb 1994; Nelson et al. 2002). However the role of the Gi protein-coupled GABAB receptor is less clear. With only two receptor subtypes known, they can be located both pre- and postsynaptically and generate inhibitory postsynaptic potentials via interaction with potassium channels of the Gβ/γ subunit (Ulrich and Bettler 2007); Gi/oα subunits also act to inhibit adenylyl cyclase. Therefore a biologically plausible interaction could occur; in addition, sevoflurane has been reported to potentiate both GABAA and GABAB receptors (Hirota and Roth 1997). However, at present there are conflicting reports in the literature on whether this interaction is significant to the mechanism of anesthesia. Manson and colleagues showed no effect on halothane anesthesia (using nocifensive behavior as the outcome) of GABAB receptor antagonists administered intrathecally in rats (Mason et al. 1996). In contrast the GABAB receptor agonist baclofen augmented the time to induction and duration of anesthesia (assessed by loss of righting reflex) in mice (Sugimura et al. 2002). The conflict in these results may merely represent different methods of testing anesthesia (analgesia vs hypnosis) and therefore may indicate that GABAB receptor signaling is more important in hypnotic rather than analgesic actions of anesthetics. This conflict, however, requires further investigation to clarify whether GABAB receptor signaling contributes to the anesthetic state.
7
Conclusion
GPCRs mediate many actions of analgesic and anesthetic drugs; it is clear, however, that the downstream effectors beyond the receptor are becoming increasingly understood at least for opioid and α2 adrenoceptor agonists. This increased understanding may precipitate the development of new anesthetic agents in the near future. Knowledge of the roles of other GPCRs including the orexin, GABAB, and cholinergic system may similarly contribute to the development of anesthetic pharmacology. Finally understanding the neural networks transducing the anesthetic effect may yield further targets for future drug development.
References Adamson P, Xiang JZ, Mantzourides T, Brammer MJ, Campbell IC (1989) Presynaptic alpha2adrenoceptor and kappa-opiate receptor occupancy promotes closure of neuronal (N-type) calcium channels. Eur J Pharmacol 174:63–70
G-Protein-Coupled Receptors
111
Beckett AH, Casy AF (1954) Synthetic analgesics: stereochemical considerations. J Pharm Pharmacol 6:986–1001 Bernardini N, Roza C, Sauer SK, Gomeza J, Wess J, Reeh PW (2002) Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. J Neurosci 22:RC229 Blaxall HS, Heck DA, Bylund DB (1993) Molecular determinants of the alpha-2D adrenergic receptor subtype. Life Sci 53:PL255–PL259 Blednov YA, Stoffel M, Alva H, Harris RA (2003) A pervasive mechanism for analgesia: activation of GIRK2 channels. Proc Natl Acad Sci U S A 100:277–282 Capogna M, Gahwiler BH, Thompson SM (1993) Mechanism of mu-opioid receptor-mediated presynaptic inhibition in the rat hippocampus in vitro. J Physiol 470:539–558 Caulfield MP, Birdsall NJ (1998) International Union of Pharmacology. XVII Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279–290 Cesselin F, Benoliel JJ, Bourgoin S, Collin E, Pohl M, Hamon M (1999) Spinal mechanisms of opioid analgesia. In: Stein C (ed) Opioids in pain control: basic and clinical aspects. Cambridge University Press, Cambridge, pp 70–95 Chen L, Huang LY (1991) Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron 7:319–326 Chen SR, Pan HL (2001) Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats. Anesthesiology 95:525–530 Chen SR, Wess J, Pan HL (2005) Functional activity of the m2 and m4 receptor subtypes in the spinal cord studied with muscarinic acetylcholine receptor knockout mice. J Pharmacol Exp Ther 313:765–770 Chen Y, Mestek A, Liu J, Yu L (1993) Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J 295:625–628 Christie MJ, Connor M, Vaughan CW, Ingram SL, Bagley EE (2000) Cellular actions of opioids and other analgesics: implications for synergism in pain relief. Clin Exp Pharmacol Physiol 7:520–523 Connor M, Christie MD (1999) “Opioid receptor signalling mechanisms”. Clin Exp Pharmacol Physiol 26:493–499 Corbett AD, Henderson G, McKnight AT, Paterson SJ (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147[Suppl 1]:S153–S162 Cox BM (1999) Mechanisms of tolerance. In: Stein C (ed) Opioids in pain control: basic and clinical aspects. Cambridge University Press, Cambridge, pp 109–130 Cvejic S, Devi LA (1997) Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem 272:26959–26964 Dershwitz M, Rosow CE, DiBiase PM, Zaslavsky A (1991) Comparison of the sedative effects of butorphanol and midazolam. Anesthesiology 74:717–724 Detweiler DJ, Eisenach JC, Tong C, Jackson C (1993) A cholinergic interaction in alpha2 adrenoreceptor-mediated antinociception in sheep. J Pharmacol Exp Ther 265:536–542 Dong HL, Fukuda S, Murata E, Zhu Z, Higuchi T (2006) Orexins increase cortical acetylcholine release and electroencephalographic activation through orexin-1 receptor in the rat basal forebrain during isoflurane anesthesia. Anesthesiology 104:1023–1032 Durieux ME (1995) Halothane inhibits signaling through m1 muscarinic receptors expressed in Xenopus oocytes. Anesthesiology 82:174–182 Duttaroy A, Gomeza J, Gan JW, Basile AS, Harman WD, Smith PL, Felder CC, Wess J (2000) Analysis of muscarinic agonist-induced analgesia by the use of receptor knockout mice (abstract). Neurosci Abstr 26:616–618 Duttaroy A, Gomeza J, Gan JW, Siddiqui N, Basile AS, Harman WD, Smith PL, Felder CC, Levey AI, Wess J (2002) Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol 62:1084–1093 Eglen RM (2006) Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 26:219–233 Eisenach JC, Detweiler DJ, Tong C, D’Angelo R, Hood DD (1996) Cerebrospinal fluid norepinephrine and acetylcholine concentrations during acute pain. Anesth Analg 82:621–626
112
R.D. Sanders et al.
Fernandez-Fernandez JM, Wanaverbecq N, Halley P, Caulfield MP, Brown DA (1999) Selective activation of heterologously expressed G protein-gated K+ channels by M2 muscarinic receptors in rat sympathetic neurones. J Physiol 515:631–637 Franks NP (2006) Molecular targets underlying general anaesthesia. Br J Pharmacol 147: S72–81 Franks NP, Lieb WR (1994) Molecular and cellular mechanisms of general anaesthesia. Nature 367:607–614 Galeotti N, Ghelardini C, Vinci MC, Bartolini A (1999) Role of potassium channels in the antinociception induced by agonists of alpha2-adrenoceptors. Br J Pharmacol 126:1214–1220 Garzon J, Castro M, Sanchez-Blazquez P (1998) Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to mu receptors. Eur J Neurosci 10:2557–2564 Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56:615–649 Guo TZ, Jiang JY, Buttermann AE, Maze M (1996) Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology 84:873–881 Hatakeyama S, Wakamori M, Ino M, Miyamoto N, Takahashi E, Yoshinaga T, Sawada K, Imoto K, Tanaka I, Yoshizawa T, Nishizawa Y, Mori Y, Niidome T, Shoji S (2001) Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. Neuroreport 12:2423–2427 Heinricher MM, Morgan MM (1999) Supraspinal mechanisms of opioid analgesia. In: Stein C (ed) Opioids in pain control: basic and clinical aspects University Press, Cambridge, pp 46–69 Hemmings HC Jr, Girault JA (2004) Signal transduction mechanisms: receptor-effector coupling. In: Evers AS, Maze M (eds) Anesthetic pharmacology, physiologic principles and clinical practice. Churchill Livingstone, Philadelphia, pp 21–39 Henderson G, McKnight AT (1997) The orphan opioid receptor and its endogenous ligand—nociceptin/orphanin FQ. Trends Pharmacol Sci 18:293–300 Hendry IA, Kelleher KL, Bartlett SE, Leck KJ, Reynolds AJ, Heydon K, Mellick A, Megirian D, Matthaei KI (2000) Hypertolerance to morphine in G(z alpha)-deficient mice. Brain Res 870:10–19 Herlitze S, Garcia DE, Mackie K, Hille B, Scheuer T, Catterall WA (1996) Modulation of Ca2+ channels by G protein beta gamma subunits. Nature 380:258–262 Hirota K, Roth SH (1997) Sevoflurane modulates both GABAA and GABAB receptors in area CA1 of rat hippocampus. Br J Anaesth 78:60–65 Hoeger-Bement MK, Sluka KA (2003) Phosphorylation of CREB, mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections. J Neurosci 23:5437–5445 Hollmann MW, Ritter CH, Henle P, de Klaver M, Kamatchi GL, Durieux ME (2001) Inhibition of m3 muscarinic acetylcholine receptors by local anaesthetics. Br J Pharmacol 133:207–216 Hollmann MW, Herroeder S, Kurz KS, Hoenemann CW, Struemper D, Hahnenkamp K, Durieux ME (2004) Time-dependent inhibition of G protein-coupled receptor signaling by local anesthetics. Anesthesiology 100:852–860 Hood DD, Mallak KA, James RL, Tuttle R, Eisenach JC (1997) Enhancement of analgesia from systemic opioid in humans by spinal cholinesterase inhibition. J Pharmacol Exp Ther 282:86–92 Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T, Urade Y, Hayaishi O (2001) Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 98:9965–9970 Ikeda K, Kobayashi T, Kumanishi T, Yano R, Sora I, Niki H (2002) Molecular mechanisms of analgesia induced by opioids and ethanol: is the GIRK channel one of the keys? Neurosci Res 44:121–131 Ingram SL, Williams JT (1994) Opioid inhibition of Ih via adenylyl cyclase. Neuron 13:179–186
G-Protein-Coupled Receptors
113
Ishibashi H, Akaike N (1995) Norepinephrine modulates high voltage-activated calcium channels in freshly dissociated rat nucleus tractus solitarii neurons. Neuroscience 68:1139–1146 IUPHAR (2005) International Union of Basic and Clinical Pharmacology database website. http:// www.iuphar-db.org/. Cited 12 Jul 2007 Iwasaki H, Collins JG, Saito Y, Uchida H, Kerman-Hinds A (1991) Low dose clonidine enhances pregnancy-induced analgesia to visceral but not somatic stimuli in rats. Anesth Analg 72:325–329 Jin W, Lee NM, Loh HH, Thayer SA (1994) Opioids mobilize calcium from inositol 1,4,5trisphosphate-sensitive stores in NG108–15 cells. J Neurosci 14:1920–1929 Jones SL, Gebhart GF (1986) Characterization of coerulospinal inhibition of the nociceptive tail-flick reflex in the rat: mediation by spinal a2-adrenoreceptors. Brain Res 364:315–330 Jordan BA, Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697–700 Kushikata T, Hirota K, Yoshida H, Kudo M, Lambert DG, Smart D, Jerman JC, Matsuki A (2003) Orexinergic neurons and barbiturate anesthesia. Neuroscience 121:855–863 Lakhlani PP, MacMillan LB, Guo TZ, McCool BA, Lovinger DM, Maze M, Limbird LE (1997) Substitution of a mutant alpha2a-adrenergic receptor via hit and run gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci U S A 94:9950–9955 Lee DK, George SR, Evans JF, Lynch KR, O’Dowd BF (2001) Orphan G protein-coupled receptors in the CNS. Curr Opin Pharmacol 1:31–39 Lee JW, Joshi S, Chan JS, Wong YH (1998) Differential coupling of mu-, delta-, and kappaopioid receptors to G alpha16-mediated stimulation of phospholipase C. J Neurochem 70:2203–2211 Lesage F, Terrenoire C, Romey G, Lazdunski M (2000) Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors. J Biol Chem 275:28398–28405 Li DP, Chen SR, Pan YZ, Levey AI, Pan HL (2002) Role of presynaptic muscarinic and GABA(B) receptors in spinal glutamate release and cholinergic analgesia in rats. J Physiol 543:807–818 Li P, Zhuo M (2001) Cholinergic, noradrenergic, and serotonergic inhibition of fast synaptic transmission in spinal lumbar dorsal horn of rat. Brain Res Bull 54:639–647 Li X, Eisenach JC (2001) alpha2A-adrenoceptor stimulation reduces capsaicin-induced glutamate release from spinal cord synaptosomes. J Pharmacol Exp Ther 299:939–944 Liao M, Laster MJ, Eger EI, Tang M, Sonner JM (2006) Naloxone does not increase the minimum alveolar anesthetic concentration of sevoflurane in mice. Anesth Analg 102:1452–1455 Linden AM, Aller MI, Leppa E, Vekovischeva O, Aitta-Aho T, Veale EL, Mathie A, Rosenberg P, Wisden W, Korpi ER (2006) The in vivo contributions of TASK-1-containing channels to the actions of inhalation anesthetics, the alpha(2) adrenergic sedative dexmedetomidine, and cannabinoid agonists. J Pharmacol Exp Ther 317:615–626 Lord JA, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature 267:495–499 Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M (2004) Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 502:87–97 Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6–25 Martin G, Nie Z, Siggins GR (1997) mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons. J Neurosci 17:11–22 Martin G, Ahmed SH, Blank T, Spiess J, Koob GF, Siggins GR (1999) Chronic morphine treatment alters NMDA receptor-mediated synaptic transmission in the nucleus accumbens. J Neurosci 19:9081–9089
114
R.D. Sanders et al.
Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532 Mason P, Owens CA, Hammond DL (1996) Antagonism of the antinocifensive action of halothane by intrathecal administration of GABAA receptor antagonists. Anesthesiology 84:1205–1214 Mathie A (2007) Neuronal two-pore-domain potassium channels and their regulation by G protein-coupled receptors. J Physiol 578:377–385 Maze M, Fujinaga M (2000) Alpha2 adrenoceptors in pain modulation: which subtype should be targeted to produce analgesia? Anesthesiology 92:934–936 McEwan AI, Smith C, Dyar O, Goodman D, Smith LR, Glass PS (1993) Isoflurane minimum alveolar concentration reduction by fentanyl. Anesthesiology 78:864–869 Millan MJ (1993) Multiple opioid systems and chronic pain. In: Herz A (ed) Opioids II, SpringerVerlag, Berlin Heidelberg New York Milligan G (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1–7 Milligan G, Kostenis E (2006) Heterotrimeric G-proteins: a short history. Br J Pharmacol 147[Suppl 1]:S46–S55 Mitrovic I, Margeta-Mitrovic M, Bader S, Stoffel M, Jan LY, Basbaum AI (2003) Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences. Proc Natl Acad Sci U S A 100:271–276 Murasaki O, Kaibara M, Nagase Y, Mitarai S, Doi Y, Sumikawa K, Taniyama K (2003) Site of action of the general anesthetic propofol in muscarinic M1 receptor-mediated signal transduction. J Pharmacol Exp Ther 307:995–1000 Murthy KS, Makhlouf GM (1996) Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. Mol Pharmacol 50:870–877 Nakamura M, Ferreira SH (1998) Peripheral analgesic action of clonidine: mediation by enkephalinlike substances. Eur J Pharmacol 146:223–228 Navarro B, Kennedy ME, Velimirovic B, Bhat D, Peterson AS, Clapham DE (1996) Nonselective and G betagamma-insensitive weaver K+ channels. Science 272:1950–1953 Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M (2002) The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 5:979–984 Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M (2003) The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 98:428–436 Nietgen GW, Honemann CW, Chan CK, Kamatchi GL, Durieux ME (1998) Volatile anaesthetics have differential effects on recombinant m1 and m3 muscarinic acetylcholine receptor function. Br J Anaesth 81:569–577 North RA, Williams JT, Surprenant A, Christie MJ (1987) Mu and delta opioid receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci U S A 84:5487–5491 Oleskevich S, Clements JD, Williams JT (1993) Opioid-glutamate interactions in rat locus coeruleus neurons. J Neurophysiol 70:931–937 Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739–745 Pan HL, Chen SR, Eisenach JC (1999) Intrathecal clonidine alleviates allodynia in neuropathic rats: interaction with spinal muscarinic and nicotinic receptors. Anesthesiology 90: 509–514 Pan PM, Huang CT, Wei TT, Mok MS (1998) Enhancement of analgesic effect of intrathecal neostigmine and clonidine on bupivacaine spinal anesthesia. Reg Anesth Pain Med 23: 49–56
G-Protein-Coupled Receptors
115
Paqueron X, Li X, Bantel C, Tobin JR, Voytko ML, Eisenach JC (2001) An obligatory role for spinal cholinergic neurons in the antiallodynic effects of clonidine after peripheral nerve injury. Anesthesiology 94:1074–1081 Pasternak GW (1993) Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 16:1–18 Peltonen JM, Nyronen T, Wurster S, Pihlavisto M, Hoffren AM, Marjamaki A, Xhaard H, Kanerva L, Savola JM, Johnson MS, Scheinin M (2003) Molecular mechanisms of ligandreceptor interactions in transmembrane domain V of the alpha2A-adrenoceptor. Br J Pharmacol 140:347–358 Pert CB, Snyder SH (1973) Opiate receptor: demonstration in nervous tissue. Science 179:1011–1014 Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639–650 Pogozheva ID, Lomize AL, Mosberg HI (1998) Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys J 75:612–634 Pohjanoksa K, Jansson CC, Luomala K, Marjamaki A, Savola JM, Scheinin M (1997) Alpha2adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur J Pharmacol 335:53–63 Poree LR, Guo TZ, Kingery WS, Maze M (1998) The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral a2-adrenoreceptors. Anesth Analg 87:941–948 Przewlocki R, Parsons KL, Sweeney DD, Trotter C, Netzeband JG, Siggins GR, Gruol DL (1999) Opioid enhancement of calcium oscillations and burst events involving NMDA receptors and L-type calcium channels in cultured hippocampal neurons. J Neurosci 19:9705–9715 Puke MJ, Wiesenfeld-Hallin Z (1993) The differential effects of morphine and the [alpha]2adrenoceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain. Anesth Analg 77:104–109 Rodbell M, Birnbaumer L, Pohl SL (1971) Characteristics of glucagon action on the hepatic adenylate cyclase system. Biochem J 125:58P–59P Rowell PP, Volk KA, Li J, Bickford ME (2003) Investigations of the cholinergic modulation of GABA release in rat thalamus slices. Neuroscience 116:447–453 Rueter LE, Meyer MD, Decker MW (2000) Spinal mechanisms underlying A-85380-induced effects on acute thermal pain. Brain Res 872:93–101 Ryan JS, Tao QP, Kelly ME (1998) Adrenergic regulation of calcium-activated potassium current in cultured rabbit pigmented ciliary epithelial cells. J Physiol 511:145–157 Sabbe MB, Penning JP, Ozaki GT, Yaksh TL (1994) Spinal and systemic action of the alpha 2 receptor agonist dexmedetomidine in dogs. Anesthesiology 80:1057–1072 Saegusa H, Kurihara T, Zong S, Minowa O, Kazuno A, Han W, Matsuda Y, Yamanaka H, Osanai M, Noda T, Tanabe T (2000) Altered pain responses in mice lacking alpha 1E subunit of the voltagedependent Ca2+ channel. Proc Natl Acad Sci U S A 97:6132–6137 Sah VP, Seasholtz TM, Sagi SA, Brown JH (2000) The role of Rho in G protein-coupled receptor signal transduction. Annu Rev Pharmacol Toxicol 40:459–489 Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8:171–181 Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585 Sanders RD, Maze M (2007) Adrenergic and cholinergic compounds. In: Stein C (ed) Analgesia. (Handbook of Experimental Pharmacology, vol 177) Springer, Berlin Heidelberg New York, pp 251–264
116
R.D. Sanders et al.
Sanders RD, Giombini M, Ma D, Ohashi Y, Hossain M, Fujinaga M, Maze M (2005) Dexmedetomidine exerts dose-dependent age-independent antinociception but age-dependent hypnosis in Fischer rats. Anesth Analg 100:1295–1302 Schäfer M (1999) Peripheral opioid analgesia: from experimental to clinical studies. Curr Opin Anaesthesiol 12:603–607 Segal IS, Vickery RG, Walton JK, Doze VA, Maze M (1988) Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha 2 adrenergic receptor. Anesthesiology 69:818–823 Shannon HE, Sheardown MJ, Bymaster FP, Calligaro DO, Delapp NW, Gidda J, Mitch CH, Sawyer BD, Stengel PW, Ward JS, Wong DT, Olesen PH, Suzdak PD, Sauerberg P, Swedberg MD (1997) Pharmacology of butylthio[2. 2 2] (LY297802/NNC11–1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J Pharmacol Exp Ther 281:884–894 Sharp BM (2001) Opioid receptor expression and intracellular signalling by cells involved in host defence and immunity. In: Machelska H, Stein C (eds) Immune mechanisms of pain and analgesia. Landes Bioscience, Georgetown, pp 98–105 Sheardown MJ, Shannon HE, Swedberg MD, Suzdak PD, Bymaster FP, Olesen PH, Mitch CH, Ward JS, Sauerberg P (1997) M1 receptor agonist activity is not a requirement for muscarinic antinociception. J Pharmacol Exp Ther 281:868–875 Short TG, Plummer JL, Chui PT (1992) Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. Br J Anaesth 69:162–167 Simonnet G, Rivat C (2003) Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport 14:1–7 Slominski A, Wortsman J, Luger T, Paus R, Solomon S (2000) Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 80:979–1020 Stein C (1995) The control of pain in peripheral tissue by opioids. N Engl J Med 332:1685–1690 Stein C, Rosow CE (2004) Analgesics: receptor ligands and opiate narcotics. In: Evers AS, Maze M (eds) Anesthetic pharmacology, physiologic principles and clinical practice. Churchill Livingstone, Philadelphia, pp 457–471 Stein C, Machelska H, Schäfer M (2001) Peripheral analgesic and antiinflammatory effects of opioids. Z Rheumatol 60:416–424 Sugimura M, Kitayama S, Morita K, Imai Y, Irifune M, Takarada T, Kawahara M, Dohi T (2002) Effects of GABAergic agents on anesthesia induced by halothane, isoflurane, and thiamylal in mice. Pharmacol Biochem Behav 72:111–116 Svoboda KR, Lupica CR (1998) Opioid inhibition of hippocampal interneurons via modulation of potassium and hyperpolarization-activated cation (Ih) currents. J Neurosci 18: 7084–7098 Swedberg MD, Sheardown MJ, Sauerberg P, Olesen PH, Suzdak PD, Hansen KT, Bymaster FP, Ward JS, Mitch CH, Calligaro DO, Delapp NW, Shannon HE (1997) Butylthio[2. 2 2] (NNC 11–1053/LY297802): an orally active muscarinic agonist analgesic. J Pharmacol Exp Ther 281:876–883 Takano Y, Yaksh TL (1998) Release of calcitonin gene-related peptide (CGRP) substance P (SP) and vasoactive intestinal polypeptide (VIP) from rat spinal cord: modulation by alpha 2 agonists. Peptides 14:371–378 Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D (2002) The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull 57:133–150 Thomas T, Robinson C, Champion D, McKell M, Pell M (1998) Prediction and assessment of the severity of postoperative pain and of satisfaction with management. Pain 75:177–185 Tjolsen A, Lund A, Hole K (1990) The role of descending noradrenergic systems in regulation of nociception: the effects of intrathecally administered alphaadrenoreceptor antagonists and clonidine. Pain 43:113–120
G-Protein-Coupled Receptors
117
Trafton JA, Abbadie C, Marchand S, Mantyh PW, Basbaum AI (1999) Spinal opioid analgesia: how critical is the regulation of substance P signaling? J Neurosci 19:9642–9653 Traynor JR (1998) Epibatidine and pain. Br J Anaesth 81:69–76 Ueda H, Miyamae T, Hayashi C, Watanabe S, Fukushima N, Sasaki Y, Iwamura T, Misu Y (1995) Protein kinase C involvement in homologous desensitization of delta-opioid receptor coupled to Gi1-phospholipase C activation in Xenopus oocytes. J Neurosci 15:7485–7499 Ulrich D, Bettler B (2007) GABA(B) receptors: synaptic functions and mechanisms of diversity. Curr Opin Neurobiol 17:298–303 Vetter I, Wyse BD, Monteith GR, Roberts-Thomson SJ, Cabot PJ (2006) The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway. Mol Pain 2:22 Waldhoer M, Bartlett SE, Whistler JL (2004) Opioid receptors. Annu Rev Biochem 73:953–990 Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, Greengard P, Limbird LE (2004) Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 304:1940–1944 Weil JV, McCullough RE, Kline JS, Sodal IE (1975) Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med 292:1103–1106 Wess J, Duttaroy A, Gomeza J, Zhang W, Yamada M, Felder CC, Bernardini N, Reeh PW (2003) Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: a review. Life Sci 72:2047–2054 Wilcox GL, Carlsson KH, Jochim A, Jurna I (1987) Mutual potentiation of antinociceptive effects of morphine and clonidine on motor and sensory responses in rat spinal cord. Brain Res 405:84–93 Williams JT, Christie MJ, Manzoni O (2001) Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81:299–343 Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38:715–730 Willis WD (2001) Role of neurotransmitters in sensitization of pain responses. Ann N Y Acad Sci 933:142–156 Wilson SG, Smith SB, Chesler EJ, Melton KA, Haas JJ, Mitton B, Strasburg K, Hubert L, Rodriguez-Zas SL, Mogil JS (2003) The heritability of antinociception: common pharmacogenetic mediation of five neurochemically distinct analgesics. J Pharmacol Exp Ther 304:547–559 Wise A, Jupe SC, Rees S (2004) The identification of ligands at orphan G-protein coupled receptors. Annu Rev Pharmacol Toxicol 44:43–66 Xie W, Samoriski GM, McLaughlin JP, Romoser VA, Smrcka A, Hinkle PM, Bidlack JM, Gross RA, Jiang H, Wu D (1999) Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids. Proc Natl Acad Sci U S A 96:10385–10390 Yaksh TL (1997) Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 41:94–111 Yasuda Y, Takeda A, Fukuda S, Suzuki H, Ishimoto M, Mori Y, Eguchi H, Saitoh R, Fujihara H, Honda K, Higuchi T (2003) Orexin a elicits arousal electroencephalography without sympathetic cardiovascular activation in isoflurane-anesthetized rats. Anesth Analg 97:1663–1666 Zhang HM, Li DP, Chen SR, Pan HL (2005) M2, m3, and m4 receptor subtypes contribute to muscarinic potentiation of GABAergic inputs to spinal dorsal horn neurons. J Pharmacol Exp Ther 313:697–704
Inhalation Anaesthesia: From Diethyl Ether to Xenon J.G. Bovill
1 2
Introduction ........................................................................................................................ Physical Properties ............................................................................................................. 2.1 Vapour Pressure ........................................................................................................ 2.2 Solubility and Anaesthetic Properties ....................................................................... 3 Potency: Minimum Alveolar Concentration ...................................................................... 4 Structure–Activity Relationships ....................................................................................... 5 Non-anaesthetic Effects of Inhalational Anaesthetics ....................................................... 5.1 Cardiovascular System.............................................................................................. 5.2 Respiratory System ................................................................................................... 5.3 Malignant Hyperthermia ........................................................................................... 5.4 Genotoxicity and Mutagenic Potential of Volatile Anaesthetics .............................. 5.5 Liver Damage............................................................................................................ 5.6 Renal Toxicity ........................................................................................................... 6 Carbon Monoxide Production ............................................................................................ 7 Individual Agents ............................................................................................................... 7.1 Of Historical Interest Only ....................................................................................... 7.2 Agents Currently Used in Anaesthesia ..................................................................... 8 Intravenous Volatile Anaesthetics ...................................................................................... References ................................................................................................................................
122 122 122 123 125 126 126 126 127 128 129 129 130 132 133 133 134 139 140
Abstract Modern anaesthesia is said to have began with the successful demonstration of ether anaesthesia by William Morton in October 1846, even though anaesthesia with nitrous oxide had been used in dentistry 2 years before. Anaesthesia with ether, nitrous oxide and chloroform (introduced in 1847) rapidly became commonplace for surgery. Of these, only nitrous oxide remains in use today. All modern volatile anaesthetics, with the exception of halothane (a fluorinated alkane), are halogenated methyl ethyl ethers. Methyl ethyl ethers are more potent, stable and better anaesthetics than diethyl ethers. They all cause myocardial depression, most markedly halothane, while isoflurane and sevoflurane cause minimal cardiovascular depression. The halogenated ethers also depress the normal respiratory response to carbon dioxide and to hypoxia. Other adverse effects include hepatic and renal damage. Hepatitis J.G. Bovill Department of Anaesthesiology, Leiden University Medical Centre, Leiden, The Netherlands
[email protected] J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
121
122
J.G. Bovill
occurs most frequently with halothane, although rare cases have been reported with the other agents. Liver damage is not caused by the anaesthetics themselves, but by reactive metabolites. Type I hepatitis occurs fairly commonly and takes the form of a minor disturbance of liver enzymes, which usually resolves without treatment. Type II, thought to be immune-mediated, is rare, unpredictable and results in a severe fulminant hepatitis with a high mortality. Renal damage is rare, and was most often associated with methoxyflurane because of excessive plasma fluoride concentrations resulting from its metabolism. Methoxyflurane was withdrawn from the market because of the high incidence of nephrotoxicity. Among the contemporary anaesthetics, the highest fluoride concentrations have been reported with sevoflurane, but there are no reports of renal dysfunction associated with its use. Recently there has been a renewed interest in xenon, one of the noble gases. Xenon has many of the properties of an ideal anaesthetic. The major factor limiting its more widespread is the high cost, about 2,000 times the cost of nitrous oxide.
1
Introduction
On the morning of Friday 16th October 1846, in front of an invited audience in the Bullfinch operating theatre of the Massachusetts General Hospital in Boston, the dentist William Morton administered diethyl ether to Edward Abbott for the excision of a tumour from his neck. This was the first successful demonstration of anaesthesia with ether in man, although anaesthesia with nitrous oxide had been used in dentistry 2 years before. Although the patient subsequently admitted being conscious during the procedure, he had experienced no pain. A newspaper reporter was present in the audience, and the discovery of surgical anaesthesia soon spread worldwide, and ether anaesthesia soon became commonplace. Chloroform was introduced as an anaesthetic almost simultaneously with ether (1847) and for a time largely replaced it in popularity. It was not until the introduction of halothane in 1956 that the popularity of ether waned. The first half of the twentieth century saw the introduction of a variety of volatile liquids and gases as anaesthetics, most of which are now only of historical interest. Developments in organic fluorine chemistry in the 1950s paved the way for the synthesis of the fluorinated anaesthetic alkanes and ethers used in modern anaesthesia.
2 2.1
Physical Properties Vapour Pressure
Inhalational anaesthetics are either gases or the vapours of volatile liquids. A substance is a gas when above its critical temperature (the temperature above which it cannot be liquefied irrespective of how much pressure is applied), and a vapour
Inhalation Anaesthesia: From Diethyl Ether to Xenon
123
when below the critical temperature. Thus nitrous oxide (N2O), which has a critical temperature of +36.4°C, is a vapour when inhaled at 20°C, but a gas when exhaled at 37°C. In the gaseous phase, vapours exert a measurable pressure, the vapour pressure. When a vapour is in equilibrium with the liquid agent, the vapour pressure is referred to as the saturated vapour pressure or SVP. The lower the SVP the more volatile is the anaesthetic. In the early days of anaesthesia ether and chloroform were commonly administered using a Schimmelbusch mask, a wire frame covered with gauze on to which the liquid was dropped from a suitable bottle. This technique relied on high volatility for its success. An advance on the Schimmelbusch mask was the draw-over vaporiser, in which the anaesthetic was vaporised in a glass container by a flow of air or oxygen. A major drawback of these devices was that the process of vaporisation cooled the liquid (latent heat of vaporisation). Since SVP decreases with temperature, with time the concentration of anaesthetic being delivered decreased, necessitating frequent adjustments to the vaporiser to maintain a constant inspired concentration. Modern vaporisers are designed to compensate for changes in the temperature of the liquid, so that for any setting of the device the concentration delivered to the patient remains constant.
2.2
Solubility and Anaesthetic Properties
Solubility in blood and brain is important if anaesthetics are to cross the alveolar– capillary membrane and the blood–brain barrier. Solubility is quantified by the partition coefficient, ‘the ratio of the concentration of dissolved gas/vapour in the blood or tissue to the concentration in the gaseous phase at equilibrium’. There is a good correlation between the oil/gas partition coefficient of an anaesthetic and its potency (Fig. 1). The blood/gas solubility values for modern anaesthetic drugs vary fourfold (Table 1) from the least soluble (N2O, 0.47) to the most soluble (halothane, 2.4). The most soluble drugs have the slowest induction and recovery characteristics. This seeming paradox occurs because the speed of induction and recovery are not related to the mass of drug absorbed by or removed from the blood but to its relative partial pressure (tension) in the alveoli and the brain. The anaesthetic delivered to the lungs diffuses into the blood until its partial pressure in the alveoli and blood are in equilibrium. Likewise the transfer to the tissues (including the brain) also proceeds towards equilibrium of the partial pressures. For agents with high blood/ gas solubility, the blood has a tremendous capacity for absorbing the agent so that it is constantly being removed from the alveoli. Consequently it takes a long time for the alveolar tension to approach the inspired tension (Fig. 2). As alveolar tension is virtually synonymous with brain tension, both induction of and recovery from anaesthesia with these drugs will be slow. Because the partial pressures of inhaled anaesthetics equilibrate throughout the body, monitoring their alveolar concentration provides a reliable way of monitoring their effect on the brain.
124
J.G. Bovill
Fig. 1 Correlation between the potencies of a wide variety of inhalational anaesthetics and their oil/gas solubility
Table 1 Physical properties of inhalational anaesthetics Agent
MW
Boiling SVP (kPa) point (°C) at 20°C λB/G
Nitrous oxide Xenon
44.02 131.3
−88.5 −108.1
5,200
0.47 1.4 0.114
None None
No No
Diethyl ether
74.1
34.6
58.6
12.1
6
Yes
Chloroform Cyclopropane Trichlorethylene Fluroxene Halothane Methoxyflurane Isoflurane Enflurane Sevoflurane Desflurane
113.4
62
21.15
87.5 197.4 164.97 184.5 184.5 200.5 168
50.2 104.97 48.5 56.5 58.5 23.5
10.3 0.415 57 mmHg 9.15 286 mmHg 1.37 32.3 2.4 13.0 33.2 1.46 22.9 1.9 21.3 0.65 88.3 0.42
λO/G
65
Metabo- Inflam- MAC lism % mable in O2
265 Low 11.2 960 47.7 224 20–50 825 90.8 0.2 96.5 2 42 3 18.7 0.02
No Yes No Yes No No No No No No
Airway irritability
105% No 60%– No 70% 12% Very marked 0.5% No 10% No 0.17% No 3.4% No 0.8% Minimal 0.16% None 1.2% Marked 2–8% Some 1.8% Minimal 6.5% Marked
The rate of induction of anaesthesia is influenced by other factors in addition to the physical characteristics of the anaesthetic. The higher the inspired concentration, the more rapid the rise in alveolar concentration and hence the more quickly equilibrium is attained between tensions in the alveoli and the brain. An increase in alveolar ventilation will also increase the alveolar concentration of the inhaled
Inhalation Anaesthesia: From Diethyl Ether to Xenon
125
Fig. 2 Graph showing how the ratio between the inspired (FI) and alveolar (FA) concentrations of inhalational anaesthetics changes with time of administration. The least soluble drugs approach equilibrium (FA/FI) the fastest
agent. A decrease in cardiac output, by slowing the transit time through the pulmonary circulation, will allow the tension of the inhaled agent in the blood to increase more rapidly, and consequently induction of anaesthesia will be faster. In contrast, an increase in cardiac output will slow induction, as in patients who are anxious.
3
Potency: Minimum Alveolar Concentration
The ‘minimum alveolar concentration’ (MAC) has become accepted as the standard measure of clinical potency of the inhaled anaesthetics. MAC is defined as the minimum alveolar concentration of an anaesthetic at one atmosphere ambient pressure that suppresses gross movement in response to a defined painful stimulus in 50% of subjects. It is thus the equivalent of the EC50 for intravenous drugs. It is important to note that MAC only measures the potency of an anaesthetic to suppress the motor response to a noxious stimulus, which is mediated by the spinal cord, not the brain (Sonner et al. 2003). Rampil and Laster (1992) showed that there was no correlation between immobility during noxious stimulation and electroencephalographic (EEG) activity, suggesting that the cortex is not the site at which anaesthetics act to block motor responses to noxious stimulation. In rats, precollicular decerebration (Rampil et al. 1993) or complete section of the upper thoracic spinal cord (Rampil 1994) minimally affected the capacity of isoflurane to suppress movement. In goats, the MAC for isoflurane delivered to the whole body was 1.2%, but delivery only to the brain increased
126
J.G. Bovill
MAC to nearly 3% (Antognini and Schwartz 1993). For halothane whole body MAC was 0.9%, but delivery confined to the head required 3.4% to abolish movement (Antognini et al. 2002). Some goats moved in response to noxious stimuli at the largest cerebral halothane concentrations tested and even during EEG silence.
4
Structure–Activity Relationships
All modern volatile anaesthetics, with the exception of halothane (a fluorinated alkane), are halogenated methyl ethyl ethers. No alkanes after halothane were developed because they predispose the heart to ventricular arrhythmias. An ether link reduces the tendency to cause ventricular arrhythmias by a factor of four. Methyl ethyl ethers are more potent, stable and better anaesthetics than diethyl ethers (Eger et al. 1994). Fluorine or other halogen substitution on the ether molecule lowers the boiling point, increases chemical stability and generally decreases toxicity and flammability. Addition of halogens also decreases blood/gas solubility (compare isoflurane and ether). However, the presence of at least one hydrogen atom is necessary for anaesthetic potency, and full halogenation results in compounds that are convulsive (Targ et al. 1989). Fluorine atoms form a strong chemical bond with carbon atoms, which contributes to the stability of fluorinated anaesthetics. However, among structurally similar compounds, an increase in molecular weight is associated with an increase in anaesthetic potency. The potency of isoflurane is four times that of desflurane as a result of replacing one fluoride atom in desflurane by a chloride atom. Compared to other halogens, fluorine is also extremely electronegative, and this confers a strong polarity to the carbon-fluorine bond. This may contribute to the ability of fluorinated agents to interact with proteins that mediate their anaesthetic activity.
5 5.1
Non-anaesthetic Effects of Inhalational Anaesthetics Cardiovascular System
All the volatile anaesthetics cause a concentration-dependent myocardial depression. The main mechanisms are a decrease in transsarcolemmal calcium entry and changes in sarcoplasmic reticulum function (Wheeler et al. 1994; Connelly and Coronado 1994). Halothane has the most negative inotropic effect of the currently used volatile agents. It also inhibits muscarinic receptor regulation of myocardial adenylyl cyclase activity and stimulates G protein-dependent adenylyl cyclase activity (Vulliemoz and Verosky 1988; Bohm et al. 1994). Increased adenylyl cyclase activity may explain why halothane sensitises the myocardium to catecholamine-induced arrhythmias. Low concentrations of enflurane cause less myocardial depression than halothane,
Inhalation Anaesthesia: From Diethyl Ether to Xenon
127
although this advantage is lost at higher concentrations. Isoflurane causes minimal cardiovascular depression at concentrations below 2 MAC, but decreases systemic vascular resistance more than the other agents. It also causes more coronary arterial vasodilatation, which has led to the suggestion that it might cause a “coronary steal” in patients with coronary artery disease. This arises from the inability of diseased coronary arteries to dilate further during isoflurane anaesthesia while at the same time normal, non-diseased vessels in other areas dilate. In this way normal vascular beds could ‘steal’ blood from diseased beds, thereby worsening oxygen lack and ischaemia in those areas of myocardium. There is no evidence, however, that the risks associated with the careful administration of isoflurane to patients with coronary artery disease exceed those of other volatile agents. Sevoflurane causes myocardial depression and a reduction in vascular resistance similar to isoflurane, but has minimal effects on heart rate. A rapid increase in the inspired concentration of desflurane causes an increase in heart rate and blood pressure. This is associated with an increase in sympathetic activity, possibly mediated by receptors in the upper airways, lungs and systemic receptors (Muzi et al. 1996). Although similar responses do occur with isoflurane, the increases in heart rate and blood pressure are less prominent. Anaesthetics may have various effects on the duration of the QT interval in the electrocardiogram (ECG). Prolongation of the QT interval may result in polymorphous ventricular tachycardia of the ‘torsades de pointes’ type and ventricular fibrillation. Sevoflurane, isoflurane and desflurane prolong QT, whereas the influence of halothane is controversial (Booker et al. 2003). Currently there is considerable interest in the ability of volatile anaesthetics to protect the myocardium form ischaemic insults, in a manner similar to ischaemic preconditioning. This is a phenomenon whereby brief episodes of sublethal cardiac ischaemia protect against subsequent prolonged ischaemia. While the mechanism by which this effect is produced is not fully understood, broadly similar mechanisms appear to be involved in both ischaemic and anaesthetic-induced preconditioning. Myocardial preconditioning by volatile anaesthetics is discussed in detail in the chapter by N.C. Weber and W. Schlack, this volume.
5.2
Respiratory System
All the halogenated ethers cause a dose-dependent respiratory depression. The normal ventilatory response to carbon dioxide is depressed, as is the response to hypoxia, even at sub-anaesthetic concentrations (van den Elsen et al. 1998). The greatest effect occurs with enflurane and the least with desflurane. Depression of ventilation results from a general depression of the respiratory centres in the central nervous system, loss of wakefulness drive and suppression of the function of motor neurones, intercostal muscles and the diaphragm. The peripheral drive of ventilation from the chemoreceptors in the carotid bodies is also abolished. Isoflurane and desflurane are irritants to the respiratory tract. This can result in breath holding and
128
J.G. Bovill
laryngospasm, and makes them unsuitable for induction of anaesthesia. Sevoflurane produces little respiratory tract irritation, and high concentrations are well tolerated. This, combined with low blood solubility, makes it highly suitable for induction of anaesthesia, particularly in children. A rapid increase in pulmonary ventilation (time constant 2–10 s) in response to acute hypoxaemia (acute hypoxic response) is a physiological response initiated by oxygen-sensitive glomus type I cells in the carotid bodies. Volatile anaesthetics suppress or abolish the acute hypoxic response at concentrations that can be found in patients up to several hours after discontinuation of anaesthesia (Dahan and Teppema 2003). The end-tidal C50 concentrations for reduction of the response vary from 0.08% for halothane to 0.27% for sevoflurane. The mechanism of volatile anaesthetic-induced impairment of oxygen sensing in the carotid bodies is not completely understood. A decrease in arterial oxygen tension in the blood leads to closure of TASK-1 and KV potassium channels in the membrane of carotid body type I cells, followed by membrane depolarisation, an influx of Ca2+ ions and activation of afferent fibres in the carotid sinus nerve (López-Barneo et al. 2001). While hypoxia closes potassium channels, volatile anaesthetics open them (Patel and Honoré 2001). Volatile anaesthetics, with the possible exception of desflurane, also cause the formation of reactive oxygen species (ROS) during hypoxia. Probably because desflurane undergoes minimal metabolism, it produces few ROS and causes minimal depression of the acute hypoxic response (Dahan et al. 1996). There is a good correlation between the extent of metabolism of volatile anaesthetics and their suppression of the acute hypoxic response. Administration of the anti-oxidants ascorbic acid and α-tocopherol completely reversed the reduction in the acute hypoxic response by halothane (Teppema et al. 2002) and isoflurane (Teppema et al. 2005). In the case of isoflurane, the acute hypoxic response decreased from the control value of 0.82±0.41 (mean±SD) l min−1 %−1 to 0.49±0.23 l min−1 %−1 (p=0.0013) during isoflurane. This reduction of the acute hypoxic response was completely reversed when isoflurane was combined with anti-oxidants.
5.3
Malignant Hyperthermia
Malignant hyperthermia is an uncommon inherited genetic disorder of skeletal muscle affecting humans and certain strains of swine, dogs, horses and other animals (Brandon 2005). In susceptible individuals, triggering agents induce a hypermetabolic state characterised by increased CO2 production, elevated O2 consumption, acid-base disturbances, muscle rigidity and muscle breakdown. This cascade is set in motion by excessive release of calcium from intracellular stores. Among the common triggering agents are the depolarising muscle relaxant suxamethonium, and the halogenated volatile anaesthetics. Halothane is a particularly potent trigger, although none of the volatile agents is safe. With early recognition and treatment (the specific treatment is dantrolene) the mortality is about 10%. Before the use of dantrolene mortality was about 80%.
Inhalation Anaesthesia: From Diethyl Ether to Xenon
5.4
129
Genotoxicity and Mutagenic Potential of Volatile Anaesthetics
Inhalation anaesthetics have the potential to be mutagenic or carcinogenic, raising concerns about health risks to patients and to operating theatre personnel through occupational exposure (Horeauf et al. 1999). They may increase the frequency of spontaneous abortion among female operating room personnel or affect human reproduction in other ways (Boivin 1997). Genetic damage, with changes in DNA structure or increases in sister chromatid exchanges, have been demonstrated for all inhalational anaesthetics (Karelova et al. 1992; Akin et al 2005). However, Krause et al. (2003) investigated the formation of sister chromatid exchanges in mitogenstimulated T lymphocytes of 40 children undergoing sevoflurane anaesthesia for minor surgical procedures and did not observe any genotoxic effects. Xenon can halt cell division by blocking mitosis at the metaphase–anaphase stage, although this is reversible on withdrawing xenon (Petzelt et al 1999)
5.5
Liver Damage
Hepatotoxicity caused by inhalational anaesthetics was recognised in the 1850s in patients anaesthetised with chloroform, but did not occur in patients given ether. Liver damage is not caused by the anaesthetics themselves, but rather by reactive metabolites produced by their biotransformation by cytochrome P450 (Kenna and van Pelt 1994). Concerning the modern anaesthetics, hepatitis occurs most frequently with halothane, although rare cases have been reported with the other agents. Halothane-related hepatitis was first reported in 1958 just 2 years after the drug’s introduction. There are two types of halothane-related hepatotoxicity.
5.5.1
Type I Halothane Hepatitis
Type I halothane hepatitis occurs fairly commonly (estimates vary from 1 in 20 to perhaps as often as 1 in 3 patients) and takes the form of a minor disturbance of liver enzymes. There is an asymptomatic rise in serum transaminases 1–2 weeks after exposure, which resolves without treatment. Repeat exposure is not a requirement and the clinical significance of the biochemical changes is uncertain. The cause of type I hepatitis is not fully understood. It is thought to result either directly from the toxic effects of halothane or indirectly after covalent bonding of halothane with cellular components. The latter reaction is more likely to occur under hypoxic condition, e.g. global reduction in hepatic perfusion or localised hypoxia during periods of hypotension. The first step in the reductive pathway of halothane metabolism is the insertion of a single electron into the halothane molecule to produce a highly reactive metabolite, which then undergoes
130
J.G. Bovill
debromination to another free radical intermediate. Liver macromolecules may interact with these free radicals or other metabolic intermediates, causing an autocatalytic peroxidative chain reaction in the liver, with breakdown and necrosis of cell membranes.
5.5.2
Type II Halothane Hepatitis
The second form of hepatitis is rare (1 in 35,000 halothane anaesthetics), unpredictable and results in a severe fulminant hepatitis with a high mortality. Previous exposure to halothane is usual and there may be a history of delayed onset postoperative pyrexia or jaundice. The first signs of fulminant injury (pyrexia, rash and/or joint pains) can precede jaundice that may be delayed for up to a month after halothane anaesthesia. Without liver transplantation, fulminant halothane hepatitis has a very high mortality rate. Reports of liver damage after halothane exposure in children are rare and the overall incidence has been estimated at 1 in 82,000 halothane anaesthetics. It is now accepted that type II halothane hepatitis is immune mediated, with the immune response directed against hepatocytes. Cytochrome P450 2E1 (CYP2E1)mediated oxidation of halothane to a reactive intermediate (trifluoroacetyl chloride) that covalently binds to hepatic proteins forming trifluoroacetylated neoantigens is believed to be the initiating event in a complex immunologic cascade culminating in antibody formation and severe hepatic necrosis in susceptible patients. Oxidative metabolism of sevoflurane produces no reactive intermediaries and therefore is not associated with immune-mediated hepatotoxicity. Serum from patients with type II halothane hepatitis contains antibodies that react with an acyl halide that is covalently bounded to liver cell membranes. This acyl halide (CF3COCl) acts as an epitope or hapten that is presented to the immunocompetent cells, setting up an antibody reaction. This form of immune sensitisation is specific to patients with halothane hepatitis (Neuberger et al 1983). Patients suffering from halothane hepatitis develop auto-antibodies specifically targeting CYP2E1, the cytochrome P450 enzyme responsible for the biotransformation of halogenated hydrocarbons such as halothane (Bourdi et al. 1996). Similar auto-antibodies in high titres have also been detected in paediatric anaesthesiologists exposed to halogenated anaesthetics (Njoku et al. 2002). However, since few of these individuals develop hepatitis the pathogenetic role of auto-antibodies in anaesthetic-induced hepatitis remains questionable.
5.6
Renal Toxicity
5.6.1
Fluoride-Induced
Inorganic fluoride nephrotoxicity was first recognised in 1960 with the introduction of methoxyflurane (2-2 dichlorofluroethyl methyl ether). Methoxyflurane was
Inhalation Anaesthesia: From Diethyl Ether to Xenon
131
withdrawn from the market because of the high incidence of nephrotoxicity, with a high output renal failure unresponsive to vasopressin. This was associated with plasma fluoride concentrations exceeding 50 µmol l−1. Among the contemporary anaesthetics, the highest fluoride concentrations have been reported with sevoflurane. After only two MAC-hours of sevoflurane, anaesthesia concentrations of fluoride exceeding 50 µmol l−1 have been documented. However, no reports of renal dysfunction associated with prolonged exposure to sevoflurane have been published. The important difference between methoxyflurane and sevoflurane is that the fluoride liberated during methoxyflurane anaesthesia is produced in the kidney causing direct renal damage (Kharasch et al. 1995). This is in part related to the presence in the kidneys of multiple cytochrome P450 enzymes (CYP2A6, CYP3A, CYP2E1) responsible for the metabolism of methoxyflurane. Renal metabolism of sevoflurane is four times lower, so that much lower fluoride levels are reached within the kidney.
5.6.2
Degradation Products
Sevoflurane (2-(fluoromethoxy)-1,1,1,3,3,3-hexafluoropropane) undergoes spontaneous degradation when exposed to temperatures in excess of 50°C in the presence of carbon dioxide absorbents to produce fluoromethyl-2,2-difluoro-1(trifluoromethyl)vinyl ether (FDVE), also known as compound A (Fig. 3), and trace amounts of 2-(fluoromethoxy)-3-methoxy-1,1,1,3,3-pentafluoropropane (compound B). These degradation products result from the extraction of the
Fig. 3 The formation of compounds A and B from exposure of sevoflurane at temperatures above 60°C to the strong bases, NaOH and KOH, present in soda lime and Baralyme (Allied Healthcare Products, St. Louis)
132
J.G. Bovill
acidic proton from sevoflurane in the presence of a strong base (KOH and/or NaOH). Baralyme (Allied Healthcare Products, St. Louis) causes more FDVE production than does soda lime. FDVE is metabolised in rats and humans to glutathione S -conjugates that are hydrolysed to the corresponding cysteine S -conjugates. Uptake of these S-conjugates by the kidneys and their subsequent metabolism by β-lyase is thought to be responsible for the renal tubular necrosis caused by FDVE in rats (Kharasch and Spracklin 1996). In contrast to rats, patient exposure to FDVE during sevoflurane anaesthesia has no clinically significant renal effects. In humans, renal function was unaffected by low-flow sevoflurane, in which compound A concentrations averaged 8–32 ppm, and exposures were as high as 400 ppm·h (Kharasch et al. 2003). The differences between rats and humans may be the result of an inherent susceptibility to FDVE nephrotoxicity in rats, since human renal β-lyase activity is much lower than the rat’s.
6
Carbon Monoxide Production
When volatile anaesthetics are passed through dry CO2 absorbents, carbon monoxide (CO) may be produced in potentially life-threatening concentrations (Fang et al. 1995; Wissing et al. 2001). CO production is highest with desflurane and enflurane, less with isoflurane, and insignificant with sevoflurane and halothane (Fig. 4) (Keijzer et al. 2006). For all anaesthetics CO production is higher with Baralyme than with soda lime. The exact mechanism of CO production is uncertain. For desflurane it has been proposed that the initial reaction is a base-catalysed abstraction of a proton from the difluoromethylethyl group of desflurane, a moiety not present in sevoflurane or halothane. The amount of CO produced depends on the
Fig. 4 CO production in dry soda lime by inhalational anaesthetics: Note the different scales in the two graphs. (From Keijzer et al. 2006, with permission)
Inhalation Anaesthesia: From Diethyl Ether to Xenon
133
quantity of dry absorbent with which desflurane makes contact, the water content of the absorbent and the fresh gas flow. The water content needed to prevent CO production is approximately 4.8% for soda lime and 9.7% for Baralyme.
7
Individual Agents
7.1
Of Historical Interest Only
7.1.1
Diethyl Ether (CH5)2O
Ether is a colourless, volatile and highly inflammable liquid with a characteristic pungent smell. Low concentrations of ether burn whereas, in the presence of oxygen, high concentrations of ether vapour can explode with potentially devastating consequences. Ether has a high blood/gas solubility (Table 1), slowing both induction of and recovery from anaesthesia. Its low potency and the fact that it is an irritant to the respiratory tract further slowed inhalational uptake, resulting in prolonged induction times (15–25 min to achieve deep anaesthesia). Despite its many disadvantages, ether is a relatively safe anaesthetic largely because, with overdose, respiratory depression occurs before serious cardiac depression. This is advantageous as, with progressive respiratory depression, the amount of ether taken up by the lungs falls, thereby reducing the depth of anaesthesia.
7.1.2
Chloroform (CHCl3)
Chloroform is a highly volatile, non-flammable liquid with a sweet-smelling odour. Induction and recovery were more rapid than with ether. Because of the lack of airway irritation induction was also much more pleasant than that with ether. In 1847, the Edinburgh obstetrician James Young Simpson first used chloroform for general anaesthesia during childbirth. John Snow set the seal of propriety on anaesthesia in obstetrics when in 1853 he administered chloroform to Queen Victoria during the birth of Prince Leopold, and again in 1857 at the birth of Princess Beatrice. The use of chloroform during surgery expanded rapidly thereafter, and began to replace ether as an anaesthetic. However, it later lost favour because of fears about its toxicity, especially liver damage, and its tendency to cause fatal cardiac arrhythmia.
7.1.3
Cyclopropane (C3H6)
Cyclopropane was introduced into clinical anaesthesia in 1933. It is a pleasant, sweet-smelling gas, irritating to the respiratory tract in concentrations over 40%
134
J.G. Bovill
(20%–30% was required for deep anaesthesia). It was stored as a liquid at a pressure of 505 kPa in light metal cylinders. The low blood–gas solubility coefficient resulted in rapid induction and recovery. Cyclopropane is explosive when mixed with air, oxygen or nitrous oxide.
7.2
Agents Currently Used in Anaesthesia
7.2.1
Nitrous Oxide
Nitrous oxide (N2O) is a stable, colourless gas used as an inhalation anaesthetic. Of the three pillars of early anaesthetic practice—nitrous oxide, chloroform and ether—only nitrous oxide remains in regular use, although its popularity has waned in recent years, and it is no longer used in a number of hospitals. Due to its low blood gas solubility (Table 1), equilibrium between alveoli and blood, and across the blood–brain barrier is rapidly established. The vast majority of N2O is exhaled unchanged although a small amount may defuse through the skin or be excreted in the urine. Because it is 34 times more soluble in blood than nitrogen it will diffuse into and out of air-containing cavities more rapidly than nitrogen. Thus, during nitrous oxide anaesthesia, air-filled cavities, e.g. lung bullae, middle ear cavity, will tend to expand with the risk of rupture and pneumothorax. Nitrous oxide is a potent analgesic; 20% N2O is equivalent to 15 mg subcutaneous morphine. Entonox (BOC Gases, Wiesbaden, Germany) is a gas mixture containing 50% N2O in oxygen, is widely used to provide analgesia during labour, for trauma victims or other emergencies. It is manufactured by bubbling O2 through liquid N2O, with vaporisation of the liquid to form a gaseous O2/N2O mixture. Entonox is supplied in cylinders at a pressure of 137 bar and must be stored above −6°C. Below this temperature the N2O liquefies and the two gases separate in a process called lamination. If this occurs, a high concentration of O2 will be delivered first, but as the cylinder empties the mixture will become progressively more hypoxic as it approaches 100% N2O. Toxicity Monovalent cobalamin is essential for the synthesis of methionine and tetrahydrofolate, and necessary for the synthesis of DNA in rapidly proliferating tissues. The activated form of methionine, S-adenosylmethionine, is also the principal substrate for methylation in many other biochemical reactions, including assembly of the myelin sheath and methyl substitutions in neurotransmitters. Nitrous oxide within 2–4 h of exposure irreversibly oxidises the cobalt atom of vitamin B12, converting monovalent cobalamin to a bivalent form which cannot participate in these reactions. As a result, the activity of the cobalamin-dependent enzyme, methionine synthase (5-methyltetrahydrofolate-homocysteine S-methyltransferase) is completely and irreversibly inhibited. Recovery of methionine synthase activity requires synthesis
Inhalation Anaesthesia: From Diethyl Ether to Xenon
135
of new enzymes, which in humans takes 3–4 days, although full recovery may need several weeks. Chronic exposure to nitrous oxide can cause megaloblastic erythropoiesis, neurone death and damage to the spinal cord. Reversible megaloblastic changes can be detected in the bone marrow after 12- to 24-h exposure. Patients have developed severe myelopathy or neurological impairment following nitrous oxide anaesthesia (McNeely et al. 2000; Lacassie et al. 2006). Nitrous oxide toxicity may affect staff as well as patients. However, after extensive investigation there is still no evidence linking low-level occupational exposure with an increased incidence of spontaneous abortion. Although nitrous oxide does not appear to be fetotoxic in humans, it is prudent to avoid exposures in the first trimester of pregnancy, given its effects on DNA synthesis.
7.2.2
Xenon
Xenon, one of the four noble gases, is colourless, odourless, tasteless and four times denser than air. Both its density and viscosity are substantially higher than those of other inhalational anaesthetics. It occurs in extremely low concentrations (0.0875 ppm) in the atmosphere, hence its name from the Greek ‘xenos’ meaning ‘stranger’. Xenon has been used experimentally as an anaesthetic for more than 50 years (Cullen and Gross 1951). Recently there has been a renewed interest in xenon as a safe, effective and more environmentally friendly substitute for nitrous oxide (Sanders et al. 2003). It is manufactured by fractional distillation of liquefied air, currently at a cost of US $10 per litre (i.e. about 2,000 times the cost of producing N2O). This high cost is the major factor limiting its more widespread use, even when used in low-flow delivery systems. At the time of writing, xenon is only approved for clinical use in Russia and Germany. Xenon has many of the properties of an ideal anaesthetic. Its blood/gas partition coefficient (0.12) is lower than that of any other anaesthetic, giving rapid induction and emergence. It is unlikely to be involved in any biochemical events in the body, and is not metabolised. Xenon causes no significant changes in myocardial contractility, blood pressure or systemic vascular resistance, even in the presence of severe cardiac disease (Sanders et al. 2005). The unique combination of analgesia, hypnosis, and lack of haemodynamic depression in one agent would make xenon a very attractive choice for patients with limited cardiovascular reserve and under some circumstances may compensate for its high cost. In contrast to other inhaled anaesthetic agents, xenon slows the respiratory rate and increases the tidal volume, thereby maintaining minute ventilation constant. Airway pressure is increased during xenon anaesthesia, due to its higher density and viscosity rather than direct changes in airway resistance (Baumert et al 2002). Because of its high cost xenon must be used in low-flow closed circuits. Crucial to this method of administration is accurate measurement of the concentration of xenon in the circuit. This measurement is generally difficult as xenon is diamagnetic and does not absorb infrared radiation (commonly used to measure the concentrations
136
J.G. Bovill
of other agents), and its low reactivity precludes the use of specific fuel cell or electrode-type devices. Xenon conducts heat better than other gases, and a technique based on thermal conductivity has proved to be effective (Luginbuhl et al 2002). Because xenon is heavier than air, the speed of sound is slower in xenon than that in air, and this difference has been also been used to measure xenon concentration. Because xenon is a normal constituent of the atmosphere, it does not add to atmospheric pollution when emitted from the anaesthesia circuit. This is in contrast to the other inhalational anaesthetics, which have ozone-depleting potential and pollute the atmosphere when released from the anaesthesia system (Marx et al. 2001). On a molecular basis, N2O is 230 times more potent as a greenhouse gas than carbon dioxide. N2O released as a waste anaesthetic contributes roughly 0.1% of total global warming. The lifetime of N2O in the atmosphere is long—approximately 120 years. The anaesthetic actions of xenon are thought to result primarily from noncompetitive inhibition of N-methyl-d-aspartate (NMDA) receptors (De Sousa et al. 2000), a property it shares with nitrous oxide. In common with other NMDA receptor antagonists, xenon appears to have neuroprotective properties (Sanders et al. 2003). Xenon is also an excellent analgesic, an action mediated by NMDA receptors (De Sousa et al. 2000). Xenon also inhibits the plasma membrane Ca2+ pump, altering neuronal excitability and inhibiting the nociceptive responsiveness of spinal dorsal horn neurones.
7.2.3
The Fluorinated Hydrocarbons
In fluorinated hydrocarbons (Fig. 5) the fluorine atoms form a strong chemical bond with the carbon atoms. The result is that the fluorine atom is quite non-reactive, particularly when the compound contains a CF2 or CF3 grouping. As a result this group is highly stable, volatile and non-inflammable under clinical conditions
Halothane Halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) was introduced into clinical anaesthesia in 1956. It was not the first fluorinated anaesthetic—fluroxene holds that distinction—but it was the first to achieve widespread acceptability. It is the most potent of the currently used volatile anaesthetics. Halothane is non-inflammable and non-irritating to the respiratory tract. Despite its molecular stability, due to the CF3 group, halothane oxidises spontaneously and is decomposed by UV light to HCI, HBr, free chlorine and bromine ions and phosgene (COCl2). To prevent decomposition it is stored in amber-coloured bottles, with thymol added as a preservative and to help prevent the liberation of free bromine. Between 20% and 50% of halothane undergoes metabolism, much higher than other currently available volatile anaesthetics.
Inhalation Anaesthesia: From Diethyl Ether to Xenon
137
Fig. 5 Molecular structure of the fluorinated hydrocarbon anaesthetics
Halothane is readily soluble in rubber and less so in polyethylene. When halothane was first introduced large amounts of rubber were commonly used in anaesthetic systems, and uptake in the anaesthetic circuit was often significant. Nowadays rubber tubing has been universally replaced by plastic tubing that does not absorb halothane or other anaesthetics. The most prominent effect of halothane on the circulation is a dose-related decrease in arterial blood pressure. This is due mainly to reduced myocardial contractility and ventricular slowing. Systemic vascular resistance also falls but this is less pronounced than with some other agents. Halothane sensitises the myocardium to the effects of catecholamines, and this can result in the development of ventricular arrhythmias.
Isoflurane Isoflurane, a halogenated methyl ethyl ether (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether), is a structural isomer of enflurane. It is a clear, colourless liquid with a slightly pungent smell. Isoflurane is non-flammable in oxygen, air and nitrous oxide under all normal conditions. It does not require a preservative and is stable in the presence of UV light. With a blood/gas solubility coefficient of 1.4 it occupies an intermediate position between the highly insoluble agents desflurane and sevoflurane and the more soluble enflurane and halothane.
138
J.G. Bovill
Hepatic toxicity after isoflurane is uncommon. There is some evidence that volatile anaesthetic agents share a common immunological mechanism for hepatic damage, but the exact aetiological role of auto-antibodies in volatile agent-induced hepatitis remains uncertain. The potential for liver injury appears to be related to the extent to which the agents are metabolised. Less than 0.2% of inhaled isoflurane is metabolised, so it is not surprising that it should have negligible toxic effects on the liver.
Enflurane Enflurane (2-chloro-1,1,2,-trifluoroethyl-difluomethyl ether) is a structural isomer of isoflurane. First synthesised in 1963 and introduced into clinical practice in 1966, it was commonly used for inhalational anaesthesia during the 1970s and 1980s, but its popularity waned with the arrival of newer agents. Because of its low metabolism (2.5%) it was widely used as an alternative to halothane, particularly for multiple administrations. It is relatively insoluble in blood (blood/gas solubility 1.8) and this facilitates rapid induction and recovery. A characteristic of enflurane is its ability to induce seizure complexes in the electroencephalogram. Episodes of paroxysmal activity and burst suppression are most marked during deep anaesthesia in the presence of hypocarbia. However, patients with epilepsy are not thought to be at increased risk of seizures during or after enflurane anaesthesia. Enflurane is metabolised by the cytochrome P450 series, specifically P450 2E1, but the agent is much less extensively metabolised than halothane (see Sect. 7.2.3.1). Metabolites include trifluoroacetic acid (TFA) and inorganic fluoride ion. A small number of cases of ‘enflurane hepatitis’ have been reported. However, the overall incidence of liver damage following enflurane anaesthesia is low, estimated to be only 1 in 800,000. In normal clinical use the peak plasma fluoride concentration rarely exceeds 25 µmol l−1 and is well within the threshold for renal toxicity.
Desflurane Desflurane (1,2,2,2-tetrafluoroethyl-difluoromethylether) was synthesised in the early 1960s and was the 653rd of a series of compounds evaluated for their anaesthetic potential. It is the least soluble of all the volatile anaesthetics with the same blood–gas solubility as nitrous oxide (0.42). Desflurane differs from isoflurane by just one atom; a fluorine atom is substituted for chlorine on the α-ethyl group. This replacement decreases blood and tissue solubility and potency (Table 1). Further, the complete fluorination of the methyl ether molecule results in a higher vapour pressure, and this together with the low boiling point of desflurane necessitates the use of a special vaporiser. The desflurane vaporiser is heated, thus requiring electrical power, Desflurane undergoes the least metabolism of the halogenated hydrocarbons (Table 1). Because of its very low metabolism desflurane is generally not considered
Inhalation Anaesthesia: From Diethyl Ether to Xenon
139
to be associated with liver injury. However, there are three case reports of patients who developed acute hepatotoxicity after desflurane anaesthesia (Martin et al. 1995; Berghaus et al. 1999, Tung et al. 2005). Although desflurane resists degradation by soda lime, carbon monoxide can be generated under certain conditions and may accumulate in the breathing system (see Sect. 6).
Sevoflurane Sevoflurane is a fluorinated methyl isopropyl ether. Its low solubility (blood gas solubility coefficient, 0.68), lack of airway irritability and moderate potency make it particularly useful for induction in children. Approximately 5% of a given dose of sevoflurane is metabolised, a higher proportion than with isoflurane or enflurane. As with other volatile agents, cytochrome P450 2E1 appears to be the specific enzyme involved. Sevoflurane is broken down to organic and inorganic fluorides and hexafluoroisopropanol. These compounds are excreted as fluoride ions in the urine and as conjugates in the bile. Despite the relatively high proportion of drug metabolised, hepatitis is unlikely since the putative metabolic pathway does not include a reactive metabolite with potential to bind to lipid or protein.
8
Intravenous Volatile Anaesthetics
Although the primary route of administration of volatile anaesthetics is through the lungs, attempts have been made to circumvent the anaesthesia circuitry and the lung’s functional residual capacity by giving these drugs directly intravenously. Unfortunately direct intravenous administration of liquid volatile anaesthetics is usually lethal. There are a number of case reports of self-administered or accidental administration of IV halothane that resulted in the production of an acute respiratory distress-like syndrome and often death (Berman and Tattersall 1982; Dwyer and Coppel 1989). Less than 9 ml of IV liquid halothane resulted in immediate tachycardia, apnoea, and loss of consciousness. In addition, these patients experienced hypotension, right bundle branch block, pulmonary oedema, cyanosis, hypoxia, and acidosis within 30 min of administration. In contrast, the intravenous administration of volatile anaesthetics dissolved in fat or as emulsions was without adverse effects in animals (Johannesson et al. 1984; Eger and MacLeod 1995; Musser et al. 1999). Haynes and Kirkpatrick (1985) injected a lecithin-coated methoxyflurane preparation into the tails of rats without the toxicity observed with the injection of liquid methoxyflurane. Zhou et al. (2006) successfully induced anaesthesia in rats by IV emulsified isoflurane. Recovery of anaesthesia after IV emulsified isoflurane was faster than with propofol. Intravenous infusions of lipid emulsions of isoflurane, enflurane or sevoflurane had no haemodynamic effects in rabbits, but produced acute and delayed preconditioning against myocardial infarction, similar to that seen with inhalation of the same anaesthetics (Chiari et al. 2004).
140
J.G. Bovill
References Akin A, Ugur F, Ozkul Y, Esmaoglu A, Gunes I, Ergul H (2005) Desflurane anaesthesia increases sister chromatid exchanges in human lymphocytes. Acta Anaesthesiol Scand 49:1559–1561 Antognini JF, Schwartz K (1993) Exaggerated anesthetic requirements in the preferentially anesthetized brain. Anesthesiology 79:1244–1249 Antognini JF, Carstens E, Atherley R (2002) Does the immobilizing effect of thiopental in brain exceed that of halothane? Anesthesiology 96:980–986 Baumert JH, Reyle-Hahn M, Hecker K, Tenbrinck T, Kuhlen R, Rossaint R (2002) Increased airway resistance during xenon anaesthesia in pigs is attributed to physical properties of the gas. Br J Anaesth 88:540–545 Berghaus TM, Baron A, Geier A, Lamerz R, Paumgartner G (1999) Hepatotoxicity following desflurane anesthesia. Hepatology 29:613–614 Berman P, Tattersall M (1982) Self-poisoning with intravenous halothane. Lancet 1:340 Bohm M, Schmidt U, Gierschik P, Schwinger RHG, Bohm S, Erdmann E (1994) Sensitization of adenylate cyclase by halothane in human myocardium and S49 lymphoma wild-type and cyccells: evidence for an inactivation of the inhibitory G protein (Gi alpha). Mol Pharmacol 45:380–389 Boivin JF (1997) Risk of spontaneous abortion in women occupationally exposed to anaesthetic gases: a meta-analysis. Occup Environ Med 54:541–548 Booker PD, Whyte SD, Ladusans EJ (2003) Long QT syndrome and anaesthesia. Br J Anaesth 90:349–366 Bourdi M, Chen W, Peter RM, Martin JL, Buters JTM, Nelson SD, Pohl LR (1996) Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 9:1159–1166 Brandon BW (2005) The genetics of malignant hyperthermia. Anesthesiol Clin North America 23:615–619 Chiari PC, Pagel PS, Tanaka K, et al (2004) Intravenous emulsified halogenated anesthetics produce acute and delayed preconditioning against myocardial infarction in rabbits. Anesthesiology 101:1160–1166 Connelly TJ, Coronado R (1994) Activation of the calcium release channel of cardiac sarcoplasmic reticulum by volatile anesthetics. Anesthesiology 81:459–469 Cullen SC, Gross EG (1951) The anaesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 113:580–582 Dahan A, Teppema LJ (2003) Influence of anaesthesia and analgesia on the control of breathing. Br J Anaesth 91:40–49 Dahan A, Sarton E, van den Elsen M, van Kleef J, Teppema L, Berkenbosch A (1996) Ventilatory response to hypoxia: influences of subanesthetic desflurane. Anesthesiology 85:60–68 De Sousa SLM, Dickinson R, Lieb WR, Franks NP (2000) Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon. Anesthesiology 92:1055–1066 Dwyer R, Coppel DL (1989) Intravenous injection of liquid halothane. Anesth Analg 69:250–255 Eger EI 2nd, Liu J, Koblin DD, et al (1994) Molecular properties of the “ideal” inhaled anesthetic: studies of fluorinated methanes, ethanes, propanes, and butanes. Anesth Analg 79:245–251 Eger RP, MacLeod BA (1995) Anaesthesia by intravenous emulsified isoflurane in mice. Can J Anaesth 42:173–176 Fang ZX, Eger EI 2nd, Laster MJ, Chortkoff BS, Kandel L, Ionescu P (1995) Carbon monoxide production from degradation of desflurane, enflurane, isoflurane, halothane and sevoflurane by soda lime and Baralyme. Anesth Analg 80:1187–1193 Haynes DH, Kirkpatrick AF (1985) Ultra-long-duration local anesthesia produced by injection of lecithin-coated methoxyflurane microdroplets. Anesthesiology 63:490–499 Horeauf K, Lierz M, Wiesner G, Schroegendorfer K, Lierz P, Spacek A, et al (1999) Genetic damage in operating room personnel exposed to isoflurane and nitrous oxide. Occup Environ Med 56:433–437
Inhalation Anaesthesia: From Diethyl Ether to Xenon
141
Johannesson G, Alm P, Biber B, et al (1984) Halothane dissolved in fat as an intravenous anaesthetic to rats. Acta Anaesthesiol Scand 28:381–384 Karelova J, Jablonicka A, Gavora J, Hano L (1992) Chromosome and sister-chromatid exchange analysis in peripheral lymphocytes, and mutagenicity of urine in anesthesiology personnel. Int Arch Occup Environ Health 64:303–306 Keijzer C, Perez RS, De Lange JJ (2005) Carbon monoxide production from five volatile anesthetics in dry sodalime in a patient model: halothane and sevoflurane do produce carbon monoxide; temperature is a poor predictor of carbon monoxide production. BMC Anesthesiol 5:1–11 Kenna JG, van Pelt FN (1994) The metabolism and toxicity of inhaled anaesthetic agents. Anaesth Pharmacol Rev 2:29–42 Kharasch ED, Spracklin DK (1996) Evidence for metabolism of fluoromethyl 2,2-difluoro-1(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate β-lyase. Chem Res Toxicol 9:696–702 Kharasch ED, Hankins DC, Thummel KE (1995) Human kidney methoxyflurane and sevoflurane metabolism: intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 82:689–699 Kharasch ED, Conzen PF, Michalowski P, Weiss BM, Rooke GA, Artru AA, Ebert TJ, Czerner SF, Reichle FM (2003) Safety of low-flow sevoflurane anesthesia in patients. Anesthesiology 99:752–754 Krause T, Scholz J, Jansen L, Boettcher H, Koch C, Wappler F (2003) Sevoflurane anaesthesia does not induce the formation of sister chromatid exchanges in peripheral blood lymphocytes of children. Br J Anaesth 90:233–235 Lacassie HJ, Nazar C, Yonish B, et al (2006) Reversible nitrous oxide myelopathy and a polymorphism in the gene encoding 5,10-methylenetetrahydrofolate reductase. Br J Anaesth 96:222–225 López-Barneo J, Pardal R, Ortega-Sáenz P (2001) Cellular mechanisms of oxygen sensing. Annu Rev Physiol 63:259–287 Luginbuhl M, Lauber R, Feigenwinter P, Zbinden AM (2002) Monitoring xenon in the breathing circuit with a thermal conductivity sensor. Comparison with a mass spectrometer and implications on monitoring other gases. J Clin Monit Comput 17:23–30 Martin JL, Plevak DJ, Flannery KD, et al (1995) Hepatotoxicity after desflurane anesthesia. Anesthesiology 83:1125–1129 Marx T, Schmidt M, Schirmer U, Reinelt H (2001) Pollution of the environment and the workplace with anesthetic gases. Int Anesthesiol Clin 39:15–27 McNeely JK, Buczulinski B, Rosner DR (2000) Severe neurological impairment in an infant after nitrous oxide anesthesia. Anesthesiology 93:1549–1550 Musser JB, Fontana JL, Mongan PD (1999) The anesthetic and physiologic effects of intravenous administration of halothane lipid emulsion (5% vol/vol). Anesth Analg 88:671–675 Muzi M, Ebert TJ, Hope WG, Robinson BJ, Bell LB (1996) Site(s) mediating sympathetic activation with desflurane. Anesthesiology 85:737–747 Neuberger J, Gimson AES, Davis M, Williams R (1983) Specific serological markers in the diagnosis of fulminant hepatic failure associated with halothane anaesthesia. Br J Anaesth 55:15–19 Njoku DB, Greenberg RS, Bourdi M, Borkowf CB, Dake EM, Martin JL, Pohl LR (2002) Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 94:239–240 Patel AJ, Honoré E (2001) Anesthetic-sensitive 2P domain K+ channels. Anesthesiology 95:1013–1021 Petzelt C, Taschenberger G, Schmehl W, Hafner M, Kox WJ (1999) Xenon induces metaphase arrest in rat astrocytes. Life Sci 65:901–913 Rampil IJ (1994) Anesthetic potency is not altered after hypothermic spinal cord transection in rats. Anesthesiology 80:606–610 Rampil IJ, Laster MJ (1992) No correlation between quantitative electroencephalographic measurements and movement response to noxious stimuli during isoflurane anesthesia in rats. Anesthesiology 77:920–925
142
J.G. Bovill
Rampil IJ, Mason P, Singh H (1993) Anesthetic potency (MAC) is independent of forebrain structures in the rat. Anesthesiology 78:707–712 Sanders RD, Franks NP, Maze M (2003) Xenon: no stranger to anaesthesia. Br J Anaesth 91:709–717 Sanders RD, Ma D, Maze M (2005) Xenon: elemental anaesthesia in clinical practice. Br Med Bull 71:115–135 Sonner JM, Antognini JF, Dutton RC, et al (2003) Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Analg 97:718–740 Targ AG, Yasuda N, Eger EI, et al (1989) Halogenation and anesthetic potency. Anesth Analg 68:599–602 Teppema LJ, Nieuwenhuijs D, Sarton E, Romberg R, Olievier CN, Ward DS, Dahan A (2002) Antioxidants prevent depression of the acute hypoxic ventilatory response by subanaesthetic halothane in men. J Physiol 544:931–938 Teppema LJ, Romberg RR, Dahan A (2005) Antioxidants reverse reduction of the human hypoxic ventilatory response by subanesthetic isoflurane. Anesthesiology 102:747–753 Tung D, Yoshida EM, Wang CSK, Steinbrecher US (2005) Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth 52:133–136 van den Elsen M, Sarton E, Teppema L, Berkenbosch A, Dahan A (1998) Influence of 0.1 minimum alveolar concentration of sevoflurane, desflurane and isoflurane on dynamic ventilatory response to hypercapnia in humans. Br J Anaesth 80:174–182 Vulliemoz Y, Verosky M (1988) Halothane interaction with guanine nucleotide binding proteins in mouse heart. Anesthesiology 69:876–880 Wheeler DM, Katz A, Rice RT, Hansford RG (1994) Volatile anesthetic effects on sarcoplasmic reticulum calcium content and sarcolemmal calcium flux in isolated rat cardiac cell suspensions. Anesthesiology 80:372–382 Wissing H, Kuhn I, Warnken U, Dudziak R (2001) Carbon monoxide production from desflurane, enflurane, halothane, isoflurane, and sevoflurane with dry soda lime. Anesthesiology 95:1205–1212 Zhou JX, Luo NF, Liang XM, Liu J (2006) The efficacy and safety of intravenous emulsified isoflurane in rats. Anesth Analg 102:129–134
General Anesthetics and Long-Term Neurotoxicity M. Perouansky
1 Introduction ........................................................................................................................ 2 The Altered Brain .............................................................................................................. 2.1 Anesthetics and Brain Genomics .............................................................................. 2.2 Anesthetics and Brain Proteomics ............................................................................ 2.3 Anesthetic Neurotoxicity: Fact or Fiction? ............................................................... 3 Anesthetic Neurotoxicity In Vitro ...................................................................................... 4 Anesthetic Neurotoxicity In Vivo ...................................................................................... 4.1 The Mature Brain: Adult vs Aged ............................................................................ 4.2 The Immature Brain .................................................................................................. 5 Summary ............................................................................................................................ References ................................................................................................................................
144 145 145 145 146 148 149 149 151 154 155
Abstract We do not know how general anesthetics cause their desired effects. Contrary to what has been thought until relatively recently, the clinical state of anesthesia consists of multiple components that are mediated via interaction of the anesthetic drugs with different targets on the molecular–cellular, the network, and the structural–anatomical levels. The molecular targets by which some of these drugs induce the different components of “anesthesia” may be rather specific: discrete mutations of single amino acids in specific proteins profoundly affect the ability of certain anesthetics to achieve specific endpoints. Despite this potential specificity, inhalational anesthetics are present in the body at very high concentrations during surgical anesthesia. Due to their lipid solubility, general anesthetics dissolve in every membrane, penetrate into every organelle, and can interact with numerous cellular structures in multiple ways. A priori, it is therefore not unreasonable to assume that these drugs have the potential to cause insidious changes in the body other than those acute and readily apparent ones that we routinely monitor. Some changes may wane within a short time after
M. Perouansky Department of Anesthesiology, University of Wisconsin School of Medicine, B6/319 Clinical Science Center, 600 Highland Ave., Madison, WI, USA
[email protected] J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
143
144
M. Perouansky
removal of the drug (e.g., the suppression of immune cell function). Others may persist after complete removal of the drug and even become self-propagating [e.g., β-oligomerization of proteins (Eckenhoff et al. 2004)], still others may be irreversible [e.g., the induction of apoptosis in the CNS (Jevtovic-Todorovic et al. 2003)] but of unclear significance. This article will focus on evidence for anesthetic toxicity in the central nervous system (CNS). The CNS appears to be susceptible to anesthetic neurotoxicity primarily at the extremes of ages, possibly via different pathways: in the neonate, during the period of most intense synaptogenesis, anesthetics can induce excessive apoptosis; in the aging CNS subtle cognitive dysfunction can persist long after clearance of the drug, and processes reminiscent of neurodegenerative disorders may be accelerated (Eckenhoff et al. 2004). At all ages, anesthetics affect gene expression-regulating protein synthesis in poorly understood ways. While it seems reasonable to assume that the vast majority of our patients completely restore homeostasis after general anesthesia, it is also time to acknowledge that exposure to these drugs has more profound and longer lasting effects on the brain than heretofore imagined.
1
Introduction
Anesthetic agents are some of the most potent and fastest acting drugs available in clinical medicine. The speed of onset of most drugs is limited only by the body’s ability to deliver them to their targets, leading to almost immediate profound changes in fundamental physiological parameters. Conversely, it is also generally assumed that the effects of these pharmacological interventions dissipate almost as quickly as they arise and without long-term sequelae. Nowhere is the change of state as profound as in the organ that is most closely associated with our identity—the brain: deep coma, gives way to normal consciousness. Unresponsiveness is followed by alertness. Complete amnesia is gradually replaced by normal memory function. The belief that general anesthetics are drugs with profound, instantaneous but fully reversible effects on the most critical organs is shared by the majority of healthcare professionals. Implicit in this belief is also the notion that once the drugs have been cleared, the body returns to the same state that it occupied before anesthesia (except for the effects of surgery). Recent laboratory data indicate that it is time for a cautious reassessment of this assumption. It appears that the drugs that brought about a revolution in medical practice more than 150 years ago may, in addition to their profound immediate effects, also have subtle but measurable long-term consequences. The purpose of this review is to provide an overview of the current research into effects of anesthetics on the brain that appear to have consequences that persist beyond the complete removal of the drugs. I would also like to acknowledge that this direction in anesthesia-related research is only in its infancy; some of the data presented are only preliminary and our understanding of this topic is likely to change dramatically within the foreseeable future.
General Anesthetics and Long-Term Neurotoxicity
2 2.1
145
The Altered Brain Anesthetics and Brain Genomics
More than a decade ago the capacity of general anesthetics to induce changes in gene expression in the brain was noted. Initially, only changes in the highly reactive acute early genes c-fos and c-jun were reported (Marota et al. 1992). These acute, anesthetic-induced changes were primarily considered to be a confounding problem for investigators, and recommendations for the use of the optimal anesthesia protocol for experimental purposes were based on the findings of differential anesthetic drug effects on the expression of these genes (Takayama et al. 1994). Since then, effects on gene expression during and/or immediately following anesthesia have been observed with newer anesthetic agents, in other vital organs, and with genes other than the immediate early genes (Hamaya et al. 2000). Recent preliminary results indicate that changes in gene expression may also persist long beyond the time frame required to clear the anesthetic drug. In the hippocampus of aged rats the expression of dozens of genes was affected 48 h after an inhalational anesthetic (Culley et al. 2004a). The significance of the majority of observed changes on the gene expression level remains, however, unclear. Changes in RNA expression are common and do not necessarily imply quantitative or qualitative changes in protein synthesis. Therefore changes in gene expression do not in themselves prove that the organism underwent “constitutive” changes and do not answer the question whether or not the organism that emerges from general anesthesia without any apparent insult to its homeostasis is “identical” to the organism that was anesthetized.
2.2
Anesthetics and Brain Proteomics
This question has been recently addressed for the first time using the proteomic approach. The proteome is defined as the complement of proteins expressed by a genome at a certain point in time. Proteomics refers to the quantitative and qualitative analysis of this complement of proteins over time and under varying conditions. The purpose of such an analysis is to gain insight into the functional state at a certain point in time of the biological unit whose proteome is under scrutiny. It is a task of staggering complexity: the human genome contains 30,000–40,000 genes. The number of proteins, however, is thought to exceed one million. Many factors account for the difference between gene number and protein diversity. Two important ones are alternate splicing of the transcriptional unit and posttranslational modifications of the assembled protein. Thus, multiple proteins can be synthesized from a single gene template e.g., more than 1,000 different proteins could originate from the three neurexin genes (Ullrich et al. 1995). Not all proteins are present in detectable amounts at every single point in time. The proteome therefore resembles
146
M. Perouansky
a snapshot out of the constantly changing movie of life. Detailed analysis of large numbers of proteins (including isoforms and modifications) was made possible by the advent of high-throughput methodologies such as two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. These methods are now being used to analyze the effect of anesthesia on the mammalian proteome. Fütterer et al. (2004) exposed rats to 3 h of 5.7% desflurane in air and prepared whole-brain homogenates immediately after the exposure as well as 24 and 72 h thereafter. The cytosolic proteins obtained at these time points were compared with proteins obtained from rats that were not anesthetized (except very briefly for sacrifice). Out of the thousands of proteins that are present simultaneously in a living rat brain, 263 “spots” representing individual proteins met the inclusion criteria for further analysis. Even within this limited sample, the researchers found that the abundance of a number of proteins was changed (either decreased or increased) for up to 72 h after exposure. The change ranged from a decrease to 60% to an increase to 179% of control. The authors controlled a number of experimental variables (hypotension, hypoxia, hypoventilation, gender) in order to increase the likelihood that the observed changes could be attributed to the tested drug. Although no firm conclusions about the long-term consequences or functional implications of these changes can be drawn from this work—single doses for single durations of single agents do not support firm or generalizable deductions—they do warrant attention as they indicate that “constitutive” changes are indeed induced by anesthetics. In the coming years it will be possible to extend these investigations using alternatives to gelbased detection methods with increased sensitivity and reduced variation and this may allow the analysis of the functional consequences of the reported fluctuations in protein expression. Nevertheless, the results of these experiments indicate that on the molecular level, general anesthesia is not as reversible a condition as the phenotype suggests. Under certain conditions, these lasting changes may be used to the advantage of the anesthetized subject: protection of the myocardium from ischemia by anesthetic preconditioning was an unexpected benefit derived from a class of drugs used to achieve completely unrelated endpoints. Recent data suggest that the benefits of anesthetic preconditioning may also extend to nervous tissue (Xiong et al. 2003). However, these discoveries should remind us that familiar drugs can have unexpected side effects and that not all of them are bound to be beneficial.
2.3
Anesthetic Neurotoxicity: Fact or Fiction?
2.3.1
Clinical Evidence
The existing evidence pointing toward the existence of anesthetic neurotoxicity is diametrically opposite in the two age groups that are under scrutiny. In the aged population, the International Study of Post-Operative Cognitive Dysfunction (ISPOCD) has convincingly demonstrated the existence of POCD in the clinical setting (Moller et al. 1998). Animal models replicating this clinical entity are in the
General Anesthetics and Long-Term Neurotoxicity
147
process of being established and the available data will be reviewed. One possibility, proposed more than a decade ago but never substantiated (Houx et al. 1991), linking age and anesthesia with cognitive dysfunction is that exposure to (surgery and) anesthesia accelerates preexisting but heretofore latent neurodegenerative disorders, e.g., Alzheimer’s disease (AD), that then become manifest sometime in the postoperative period as POCD or mild cognitive impairment (MCI; a prelude to AD). Could anesthetic drugs affect the progression of neurodegenerative disorders? Where in the pathogenetic chain of cognitive dysfunction could these small and relatively inert molecules play a role? By contrast, no human data suggest that brief exposure to clinically used general anesthetics causes neurotoxicity at the other extreme of age, the neonate. Here, however, there is solid laboratory evidence suggesting that the immature central nervous system (CNS) might be susceptible to deleterious effects induced by commonly used anesthetic drugs, and that evidence for such an effect in humans might (I repeat might) simply await a concerted effort, on the scale of the ISPOCD studies, at identifying it.
2.3.2
Oligomerization and Neurodegeneration
One proposed mechanism of AD (and possibly of other neurodegenerative disorders) that is supported by extensive experimental data is that uncontrolled oligomerization (microaggregation) of peptides or proteins that are normally present in the brain leads to neurotoxic effects. The suspected peptide in AD is the amyloid β peptide (Aβ), 35 to 42 amino acids in length (e.g., Aβ42), that is constitutively released after proteolytic cleavage of the amyloid precursor protein (APP). Amorphous deposits of Aβ, i.e., the nonfibrillar form, can be found in large amounts in the brains of AD patients but also, to a lesser extent, in normal aged humans, and their toxic potential is unknown. Under certain environmental circumstances, however, these peptides are capable of changing their secondary structure from α-helix to β-sheet and self-assemble to oligomers of varying and increasing sizes. The oligomers produce the characteristic fibrils, the building blocks of the pathognomonic AD plaques. The other typical AD lesion, the neurofibrillary tangle, is composed of bundles of the microtubuleassociated protein τ. While it is not entirely clear how and what products of oligomerization cause neurodegeneration, the following lines of evidence bolster the “amyloid (or more precisely Aβ) hypothesis of AD” (reviewed by Hardy and Selkoe 2002; Walsh and Selkoe 2004): • Mutations of the APP that increase its cleavage to Aβ peptide are associated with AD • Some inherited mutations in the presenilin genes (PS1 and PS2, which code for the active site of the APP cleaving enzyme) increase the formation of Aβ and cause extremely early and aggressive forms of AD • Aβ is the subunit of amyloid that is progressively deposited in innumerable neuritic plaques in the limbic and association cortices of all AD patients
148
M. Perouansky
• Synthetic Aβ peptides are toxic to hippocampal and cortical neurons • Similarities in the neuropathology of Down’s syndrome and AD point to a pathogenetic role of the APP gene, congruent with the Aβ hypothesis The following evidence provides direct links between the Ab protein, particularly in its oligomerized form, and impairment of learning and memory: • Injection of Aβ protein into the cerebral ventricles prevented the induction of long-term potentiation (LTP, a cellular form of learning and memory), while wash-out of Aβ protein restored inducibility of LTP (Walsh et al. 2002). • Inhibitors of Aβ oligomerization rescue LTP (Klyubin et al. 2005) • Neutralization of Aβ prevents some manifestations of AD in some models (Klyubin et al. 2005) Current thinking within the framework of the Aβ hypothesis envisages the neurotoxic element to be the intermediate-sized oligomer and not the mature fibril. Therefore, the possibility that the physicochemical nature of inhalational anesthetics could favor oligomerization of Aβ as they have been shown to do for other proteins is intriguing.
3
Anesthetic Neurotoxicity In Vitro
The interaction of anesthetic molecules and Aβ peptides was tested recently by Eckenhoff and colleagues in a cell-free experimental system (Eckenhoff et al. 2004). The presence of halothane and isoflurane in the protein suspension significantly accelerated the oligomerization of Aβ42 and led to an increase in the total amount of oligomerized peptide (note, however, that the lowest concentration tested was 1 mM, i.e., more than three times the “minimal alveolar concentration” or MAC that is necessary to achieve a surgical plane of anesthesia). This effect was specific for the substrate (human serum albumin, a hydrophobic protein used as control, was not affected) and for inhalational drugs: Propofol and alcohol, when tested at “clinical” concentrations, mildly inhibited oligomerization (but enhanced oligomerization at very high concentrations). Removal of halothane from the protein suspension after 1 h of incubation did not reverse this process immediately: Enhanced amounts of oligomers were detectable for up to 3 days thereafter. In a second series of experiments, the authors examined the toxicity of the oligomer-anesthetic combination in rat pheochromocytoma cells, a cell type that, being of neural crest origin, is frequently used as a model for nerve cells. Toxicity was assayed by measuring the release of lactate dehydrogenase (LDH) from cultured pheochromocytoma cells incubated with 15 µM Aβ42 for 72 h with or without different anesthetic drugs. Neither isoflurane nor halothane, when given alone, increased LDH release, indicating lack of toxicity in this model. By contrast, incubation of pheochromocytoma cells with Aβ42 increased LDH release above control levels. Addition of the equivalent of 1 MAC of the volatile agents to
General Anesthetics and Long-Term Neurotoxicity
149
Aβ42 increased its toxicity while addition of propofol or ethanol did not. The researchers concluded that under their experimental conditions volatile anesthetics enhanced the formation of amyloid and its toxicity in cell culture. If similar processes occurred in vivo, volatile anesthetics could lead to long-lasting increases of Aβ42, a neurotoxic form of amyloid in the brain of susceptible subjects. Recently, this same group presented preliminary data indicating that the AD-promoting PS-1 mutation, transfected into pheochromocytoma cells, rendered these cells more susceptible to isoflurane-induced toxicity (Wei et al. 2005). Recently, the apoptogenic potential of isoflurane was confirmed in cultured human neuroglioma cells and was found to be reinforced by increased levels of APP C-terminal fragments (Xie 2006).
4
Anesthetic Neurotoxicity In Vivo
The most extensive clinical trials published to date (Rasmussen et al. 2003) has neither proved nor excluded a direct causal link between general anesthetic drugs and cognitive impairment. Therefore, some investigators have turned to animal models to test the hypothesis that general anesthetics can induce changes in the brain that outlast their physical presence there and that these changes lead to longlasting, measurable functional consequences.
4.1
The Mature Brain: Adult vs Aged
General anesthetics affect learning and memory. Temporary amnesia is a highly desirable component of the anesthetic state that can be reliably achieved with general anesthetics. Prolonged memory impairment, by contrast, is one essential component of POCD. In the early 1990s, laboratory studies of anesthetic interaction with memory reported a seemingly paradoxical improvement of memory consolidation. Adult mice anesthetized with halothane, isoflurane, or enflurane immediately after aversive conditioning had improved performance when tested on the same task 24 h later compared to unanesthetized controls (Komatsu et al. 1993). The mechanisms underlying the observed memory improvement by anesthesia were not further investigated, but it was noted that in these experiments anesthetic drugs were present in the brain at anesthetic concentrations during a time window that might be important for memory consolidation on the cellular-molecular level. Improvement of memory by anesthetics not explainable by the same mechanism was observed in Crosby’s laboratory, where researchers have worked to establish an animal model of long-term anesthetic effects on cognitive performance (Culley et al. 2003). The prototypical experiment consisted of evaluating the effects of a standardized anesthetic (2 h of 1.2% isoflurane/70% N2O/30% oxygen) on
150
M. Perouansky
performance in a 12-arm radial-arm maze (RAM, a standard test to evaluate spatial orientation skills). The animals were either adult (6 months old) or aged (18–20 months old) Fischer 344 rats (median life expectancy 26 months) and were randomly assigned to either the test or the age-matched control group. The experimental protocols differed in the relative timing of anesthesia (before or after training), the degree of training, and the duration of the observation period after anesthesia. In contrast to the work by Komatsu et al. (1993), when training followed anesthesia, it was separated from anesthesia by a time interval sufficient to eliminate the drugs. In their initial publication, Culley et al. reported that anesthesia administered 24 h after the training had differential effects in adult vs aged rats: it improved performance in the former and impaired it in the latter. These effects remained measurable for 3 weeks and were undetectable by 8 weeks after anesthesia (Culley et al. 2003). However, at the time of anesthesia the adult animals (who learned faster) were overtrained compared to the old animals and learning continued to take place during the post-anesthesia testing sessions. Therefore, this experimental protocol did not allow for a separation between effects on acquisition of new information (learning) vs retrieval of stored information (memory). When, by contrast, the effect of anesthesia was tested on the ability to acquire new memories (training/testing took place only after anesthesia), the same investigators found that learning was impaired in both adult and aged animals even when the training began for up to 2 weeks after anesthesia, i.e., the impairment lasted for considerably longer than predicted by the pharmacokinetics of the drugs used (Crosby et al. 2005; Culley et al. 2004b). Interestingly, the researchers were not able to demonstrate any age-by-anesthesia interactions, i.e., both age groups were equally impaired. The authors attributed this apparent inconsistency with their earlier study to differences in the protocol: retrieval of stored information in the first study vs acquisition of new memory (arguably more susceptible to disruption and therefore affected in both age groups) in the later ones. In summary, this group of investigators concluded that inhalational anesthetics had effects on spatial learning and memory that outlasted their physical presence in the body. The mechanism(s) of these protracted memory effects and whether or not they are related in any way to either in vitro or to clinical observations is unclear, and the results have not yet been replicated in other laboratories or using other memory paradigms. The reported cognitive impairment was not accompanied by an identifiable reduction of life expectancy (based on a sample of 16 aged rats; Culley et al. 2006). In summary, the establishment of an experimental model for long-term cognitive effects of volatile anesthetics is just beginning. The aged rodent may prove to be useful, but the most useful experimental paradigms have yet to be defined. The intriguing Aβ-neurodegenerative hypothesis provides a potential link between anesthetics and long-term cognitive consequences in the aged brain, but other mechanisms interlinking anesthetic drugs and persistent neurological impairment should be explored, e.g., a possible link between the effects of anesthetics on mitochondrial function (Miro et al. 1999; Kayser et al. 1999) and CNS dysfunction (Morgan et al. 2002).
General Anesthetics and Long-Term Neurotoxicity
4.2
The Immature Brain
4.2.1
Neurotoxicity, Apoptosis, Alcohol
151
Among the proteins expressed in the brain whose function is affected by anesthetic drugs at concentrations achieved during clinical anesthesia are receptors for the most abundant excitatory and inhibitory neurotransmitters in the mammalian CNS: l-glutamate and γ-aminobutyric acid (GABA). Both transmitter systems play important roles also in the developing brain. All clinically used general anesthetics enhance GABAA receptors, block N-methyl-d-aspartate (NMDA) receptors, or do both (it is not known with certainty, however, to what degree these effects contribute to the clinical phenomenon of general anesthesia). In the adult and the developing brain, excessive activation of l-glutamate receptors, primarily of the NMDA type, is associated with neurotoxicity. In contrast to the mature brain, however, it has been recently discovered that transient pharmacological blockade of NMDA receptors in the developing rodent brain causes excessive neuronal apoptosis. This excess is seen only in brain areas that undergo physiological apoptosis in normal development and only if NMDA receptors are blocked at specific time points within a period of accelerated synaptogenesis (Ikonomidou et al. 1999). It appears that during this brain growth spurt, neurons that do not receive sufficient excitation are doomed to apoptotic degeneration (Mennerick and Zorumski 2000). Ethanol, in the same model, caused neuronal degeneration that is even wider spread than that caused by selective NMDA receptor blockade (Fig. 1). While
Numerical density Degenerating neurons/mm3
80.0k Early Mid Late
60.0k
40.0k
20.0k
0.0 E17
P0
P3
P7
P14
P21
Developmental age (days)
Fig. 1 Induction of apoptosis by ethanol depends on developmental stage and is brain regionspecific. Brain regions were categorized as developing either at an early, intermediate, or a late stage. The lines are individual brain regions that are representative of the different temporal profiles: ventromedial hypothalamus, early; laterodorsal thalamus, intermediate; frontal cortex, late. The window of maximum sensitivity to apoptosis induction by alcohol changed with development from P0 (early), to P3 (intermediate), to P7 (late). (Redrawn with permission from Ikonomidou et al. 2000)
152
M. Perouansky
alcohol is not used clinically as an anesthetic drug, it is important to note that alcohols are model anesthetics that share targets and mechanisms with clinically used anesthetics. An apoptogenic potential of alcohol on the developing human brain (synaptogenesis in humans lasts throughout the last trimester of pregnancy and continues postnatally) would be therefore clinically relevant. The widespread alcohol-induced apoptosis could be attributed to the fact that alcohol in addition to blocking NMDA receptors also enhances GABAA receptors, i.e., developing neurons are “silenced” via two pathways and are therefore more likely to commit to apoptosis. Similarly to the NMDA blockers, alcoholic neurotoxicity was only observed when the alcohol was administered during the critical developmental period of intense synaptogenesis (Ikonomidou et al. 2000). In the rat, synaptogenesis is most intense in the last 2 days of pregnancy (gestation lasts 21 days in the rat) and the first two postnatal weeks. Within this time window, different brain regions show peak sensitivity to alcohol’s proapoptotic effects at different times. When administered on the seventh postnatal day (P7), alcohol caused a approximately 20-fold increase in the density of degenerating cells in the CA1 area of the hippocampus, and increases of the same order of magnitude were found in the thalamus, the septum, basal ganglia, and some cortical areas (Ikonomidou et al. 2000). Alcoholic neurodegeneration was also associated with a decreased brain mass, leading the authors to conclude that neurodegeneration mediated by alcohol’s effects on NMDA and GABAA receptors could explain some aspects of the clinical presentation of fetal alcohol syndrome. It should be noted, however, that alcohol also affects other aspects of neuronal development in detrimental ways, e.g., interference with second messenger signaling leading to aberrant neuronal migration in the fetal brain (Kumada et al. 2006).
4.2.2
Anesthesia and Apoptosis
The issue of anesthesia and apoptosis has been addressed recently in a series of experiments that approximated clinical conditions. Jevtovic-Todorovic et al. (2003) anesthetized rat pups on P7 with combinations of midazolam, isoflurane, and nitrous oxide sufficient to maintain a surgical plane of anesthesia for 6 h. Controls were exposed to 6 h of mock anesthesia. After recovery the animals were divided into three randomly selected groups. The first group was used for histopathological studies. The second group was used for behavioral studies in adulthood, which involved evaluating the rats on several tests over a 160-day period. The third group was used to study hippocampal plasticity in vitro (a model for learning and memory) at P29–P33. Daily inspection and weighing was performed on the latter two groups at P6–P21 to evaluate general health and development. Histopathology revealed that isoflurane (0.75%–1.5%) caused a dose-dependent increase in apoptotic neurodegeneration. Midazolam (3–9 mg/kg) and N2O (50%–150% in a hyperbaric chamber) when given alone did not cause increased rates of apoptosis compared to control animals. However, when midazolam
General Anesthetics and Long-Term Neurotoxicity
153
was followed by maintenance with isoflurane (double cocktail) the damage caused by the latter was increased primarily in the thalamus and the parietal cortex. The damage was further augmented by adding N2O to the maintenance phase of anesthesia (triple cocktail: midazolam 9 mg/kg, isoflurane 0.75%, N2O 75%). The triple cocktail caused widespread, more than 15-fold increases in the number of apoptotic neurons. When the hippocampi (a structure important for memory formation) from rats treated with the triple cocktail at P7 were evaluated electrophysiologically at P29–P33, it was found that the ability of neuronal connections to express long-term potentiation was severely reduced, suggesting that learning and memory may also be impaired. This deficit was confirmed in behavioral tests: animals exposed to the triple cocktail as neonates had measurable deficits in spatial memory tests when tested in the water maze and the radial arms maze as adults. Recently, this group of researchers proposed that anesthetics activate both the intrinsic and the extrinsic apoptotic pathways, depending on the length of the exposure (Yon et al. 2005). In neonatal rats the intrinsic pathway is activated within 2 h of anesthesia exposure, while activation of the extrinsic pathway occurs later— within 6 h. It was also noted that the susceptibility to induction of apoptosis decreased dramatically from the 7th to the 14th postnatal day, coinciding with reduced rate of synaptogenesis.
4.2.3
Are Anesthetics to Blame?
It has been suggested that the reported histopathological damage and neurological deficits could be attributed to factors other than the anesthetic drugs (e.g., hypoxia or malnutrition; Anand and Soriano 2004). A recent investigation directly addressed the issue of metabolic homeostasis in anesthetized neonatal mice. Loepke et al. found that mouse pups anesthetized with 1.8% isoflurane developed marked hypoglycemia within 90 min (to below 40 mg% in 50% of animals), while control pups separated from the dam for the same amount of time did not (Loepke et al. 2006). Hypoglycemia of this severity has been shown to cause neuronal damage in adult rodents in some models, although primarily of the necrotic (Auer 2004) as opposed to the apoptotic type described by Jevtovic-Todorovic. Moreover, the neonate brain is more adept at using alternate fuel sources and therefore may be more resistant to hypoglycemia-induced damage (Belik et al. 1989). In addition to posing the interesting question of how isoflurane induces hypoglycemia in neonates (hyperglycemia is seen in adult rodents under isoflurane), this finding also offers an additional potential mechanism for the neurodegeneration attributed solely to anesthetics by Jevtovic-Todorovic et al. (2003). However, preliminary results indicate that neurodegeneration is also observed when guinea pig fetuses are exposed to anesthetics in utero, when they should be far less susceptible to developing hypoglycemia, as the dam remains normoglycemic throughout the experiment (Rizzi et al. 2005). Moreover, isoflurane neurotoxicity has been also tested in cultured slices from rat hippocampi harvested at 3, 7, and 14 days postnatally. This
154
M. Perouansky
“in vitro” model has the advantage of eliminating homeostatic confounding factors present in vivo (hypoxemia, acidosis, hypoglycemia etc.). The results were in general agreement with the in vivo findings, even though in vivo the hippocampus is not the structure most affected by excessive induction of apoptosis. Isoflurane 1.5% for 5 h, caused a significant increase in the number of apoptotic neurons in slices obtained from 7-day-old animals. Cultures obtained from either younger or older animals or exposed to isoflurane for shorter time periods were less affected (Wise-Faberowski et al. 2005). A conclusion that can be drawn from this study is that hypoglycemia is not the sole mechanism by which anesthetics can induce neuronal apoptosis. Nevertheless, the role of hypoglycemia in the anestheticinduced apoptotic neurodegeneration requires further clarification. The other major problem for extrapolations from rodent data is the different developmental stages and life spans. In other words, are 6 h of drug exposure during synaptogenesis such an extreme insult to the rodent brain that it may not be appropriate to extrapolate these findings to clinical anesthesia in humans? Or are some of the developmental problems in the pup, secondary to behavioral changes in the mother, induced by separation, which has an effect on epigenetic imprinting (Meaney and Szyf 2005)? While detailed dose-response data for the anesthetic cocktail of predominantly GABAA-enhancing drugs is not available, it appears that ketamine (a potent NMDA receptor blocker) induce dose-dependent incremental apoptosis and identifiable toxicity occurs even at subanesthetic doses in rodents (Olney et al. 2004). Recently the neurotoxic potential of a single “mildly” anesthetic dose (defined as preservation of pain response and righting reflex) of both ketamine and midazolam (individually and combined) in rat pups has been demonstrated (Young et al. 2005). Before conclusions for clinical practice can be drawn, however, the hypothesis that anesthetic agents cause excessive neurodegeneration that has measurable long-term consequences requires testing in species with different patterns of synaptogenesis. Preliminary results from guinea pig (synaptogenesis in this species takes place prenatally and over a much longer time period than in rats; Rizzi et al. 2005) and piglet (synaptogenesis is prolonged and spans pre- and postnatal time periods; Rizzi et al. 2005) models indicate that these animals are also susceptible to anesthetic neurotoxicity if exposed to midazolam, isoflurane, and nitrous oxide pre- (guinea pigs) and postnatally (piglets). Whether the neurotoxicity has long-term consequences in models other then rodents remains to be established. A nonhuman primate model may provide particularly useful information but is also the most difficult to establish.
5
Summary
Laboratory evidence of anesthetic-induced lasting changes in, or potentially affecting, the CNS include • Increased β-oligomerization of proteins after exposure to volatile anesthetics (Eckenhoff et al. 2004)
General Anesthetics and Long-Term Neurotoxicity
155
• Increased cytotoxicity of β-oligomers if combined with anesthetics in cultured cells (Eckenhoff et al. 2004) • Brief exposure to desflurane, causing changes in protein expression in the brain that far outlast the presence of the drug (Futterer et al. 2004) • Neuronal degeneration in the developing brain, with the effect of combined application of drugs acting via different mechanisms having more than additive effects (Jevtovic-Todorovic et al. 2003) • Neurodegeneration in the developing brain caused by activation of both the intrinsic and the extrinsic apoptotic pathways (Yon et al. 2005) • Neonatal exposure to anesthetic drugs that has measurable effects on learning in adulthood (Jevtovic-Todorovic et al. 2003) • Exposure of aged rats to inhalational anesthetics causing lasting impairment of spatial memory performance (Culley et al. 2004c) In light of the existing evidence, the question is not so much whether long-lasting, anesthetic-induced changes in the CNS do occur but whether they have any identifiable or preventable deleterious impact. Convincing clinical evidence attesting to such changes is lacking but may not be obtainable due to the methodological constraints of studies in human subjects. Therefore, more evidence will have to be gathered from animal models for whom the neurodevelopmental profile better matches that of humans. Until proved otherwise, however, it may be prudent to assume that there are no side effect-free pharmacological interventions. The ideal of stress-free surgery may be more difficult to achieve then expected, especially in the most vulnerable patient populations.
References Anand KJ, Soriano SG (2004) Anesthetic agents and the immature brain: are these toxic or therapeutic? Anesthesiology 101:527–530 Auer RN (2004) Hypoglycemic brain damage. Metab Brain Dis 19:169–175 Belik J, Wagerle LC, Stanley CA, Sacks LM, Herbert DW, Delivoriapapadopoulos M (1989) Cerebral metabolic response and mitochondrial activity following insulin-induced hypoglycemia in newborn lambs. Biol Neonate 55:281–289 Crosby C, Culley DJ, Baxter MG, Yukhananov R, Crosby G (2005) Spatial memory performance 2 weeks after general anesthesia in adult rats. Anesth Analg 101:1389–1392 Culley DJ, Baxter M, Yukhananov R, Crosby G (2003) The memory effects of general anesthesia persist for weeks in young and aged rats. Anesth Analg 96:1004–1009 Culley DJ, Yukhananov RY, Crosby G (2004a) Hippocampal gene expression is altered 48 hours after general anesthesia in aged rats. Anesthesiology 101:A64 Culley DJ, Baxter MG, Crosby CA, Yukhananov R, Crosby G (2004b) Impaired acquisition of spatial memory 2 weeks after isoflurane and isoflurane-nitrous oxide anesthesia in aged rats. Anesth Analg 99:1393–1397 Culley DJ, Baxter MG, Yukhananov R, Crosby G (2004c) Long-term impairment of acquisition of a spatial memory task following isoflurane-nitrous oxide anesthesia in rats. Anesthesiology 100:309–314 Culley DJ, Loguinov A, Yukhananov R, Crosby G (2006) General anesthesia does not reduce life expectancy in aged rats. Anesth Analg 102:956–959
156
M. Perouansky
Eckenhoff RG, Johansson JS, Wei HF, Carnini A, Kang BB, Wei WL, Pidikiti R, Keller JM, Eckenhoff MF (2004) Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 101:703–709 Fütterer CD, Maurer MH, Schmitt A, Feldmann RE, Kuschinsky W, Waschke KF (2004) Alterations in rat brain proteins after desflurane anesthesia. Anesthesiology 100:302–308 Hamaya Y, Takeda T, Dohi S, Nakashima S, Nozawa Y (2000) The effects of pentobarbital, isoflurane, and propofol on immediate-early gene expression in the vital organs of the rat. Anesth Analg 90:1177–1183 Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356 Houx PJ, Vreeling FW, Jolles J (1991) Age-associated cognitive decline is related to biological life events. In: Iqbal K, McLachlan DRC, Winblad B, Wisniewski HS (eds) Alzheimer’s disease: basic mechanisms, diagnosis, and therapeutic strategies. John Wiley & Sons, Chichester, pp 353–358 Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283:70–74 Ikonomidou C, Bittigau P, Ishimaru MJ, Wozniak DF, Koch C, Genz K, Price MT, Stefovska V, Horster F, Tenkova T, Dikranian K, Olney JW (2000) Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 287:1056–1060 Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF (2003) Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 23:876–882 Kayser EB, Morgan PG, Sedensky MM (1999) GAS-1: a mitochondrial protein controls sensitivity to volatile anesthetics in the nematode Caenorhabditis elegans. Anesthesiology 90:545–554 Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556–561 Komatsu H, Nogaya J, Anabuki D, Yokono S, Kinoshita H, Shirakawa Y, Ogli K (1993) Memory facilitation by posttraining exposure to halothane, enflurane, and isoflurane in ddN mice. Anesth Analg 76:609–612 Kumada T, Lakshmana MK, Komuro H (2006) Reversal of neuronal migration in a mouse model of fetal alcohol syndrome by controlling second-messenger signalings. J Neurosci 26:742–756 Loepke AW, McCann JC, Kurth D, McAuliffe JJ (2006) The physiologic effects of isoflurane anesthesia in neonatal mice. Anesth Analg 102:75–80 Marota JJ, Crosby G, Uhl GR (1992) Selective effects of pentobarbital and halothane on c-fos and jun-B gene expression in rat brain. Anesthesiology 77:365–371 Meaney MJ, Szyf M (2005) Maternal care as a model for experience-dependent chromatin plasticity? Trends Neurosci 28:456–463 Mennerick S, Zorumski CF (2000) Neural activity and survival in the developing nervous system. Mol Neurobiol 22:41–54 Miro O, Barrientos A, Alonso JR, Casademont J, Jarreta D, Urbano-Marquez A, Cardellach F (1999) Effects of general anaesthetic procedures on mitochondrial function of human skeletal muscle. Eur J Clin Pharmacol 55:35–41 Moller JT, Cluitmans P, Rasmussen LS, Houx P, Rasmussen H, Canet J, Rabbitt P, Jolles J, Larsen K, Hanning CD, Langeron O, Johnson T, Lauven PM, Kristensen PA, Biedler A, van Beem H, Fraidakis O, Silverstein JH, Beneken JEW, Gravenstein JS (1998) Long-term postoperative cognitive dysfunction in the elderly: ISPOCD1 study. Lancet 351:857–861 Morgan PG, Hoppel CL, Sedensky MM (2002) Mitochondrial defects and anesthetic sensitivity. Anesthesiology 96:1268–1270
General Anesthetics and Long-Term Neurotoxicity
157
Olney JW, Young C, Wozniak DF, Ikonomidou C, Jevtovic-Todorovic V (2004) Anesthesiainduced developmental neuroapoptosis. Does it happen in humans? Anesthesiology 101:273–275 Rasmussen LS, Johnson T, Kuipers HM, Kristensen D, Siersma VD, Vila P, Jolles J, Papaioannou A, Abildstrom H, Silverstein JH, Bonal JA, Raeder J, Nielsen IK, Korttila K, Munoz L, Dodds C, Hanning CD, Moller JT (2003) Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiologica Scandinavica 47:260–266 Rizzi S, Carter LB, Jevtovic-Todorovic V (2005) Clinically used general anesthetics induce neuroapoptosis in the developing piglet brain. Society for Neuroscience Program No. 251.7 Rizzi S, Yon JH, Carter LB, Jevtovic-Todorovic V (2005) Short exposure to general anesthesia caused widespread neuronal suicide in the developing guinea pig brain. Society for Neuroscience Program No. 241.6 Takayama K, Suzuki T, Miura M (1994) The comparison of effects of various anesthetics on expression of Fos protein in the rat-brain. Neurosci Lett 176:59–62 Ullrich B, Ushkaryov YA, Sudhof TC (1995) Cartography of neurexins—more than 1000 isoforms generated by alternative splicing and expressed in distinct subsets of neurons. Neuron 14:497–507 Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44:181–193 Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539 Wei H, Liang G, Wei W, Li Y, Eckenhoff RG (2005) Volatile anesthetics induce neurotoxicity differently in PC12 cells featured with Alzheimer’s disease. Anesthesiology 103:A121 Wise-Faberowski L, Zhang H, Ing R, Pearlstein RD, Warner DS (2005) Isoflurane-induced neuronal degeneration: an evaluation in organotypic hippocampal slice cultures. Anesth Analg 101:651–657 Xie Z, Dong Y, Maeda U, Alfille P, Culley DJ, Crosby G, Tanzi RE (2006) Anesthetic isoflurane induces apoptosis and increases Abeta levels in H4 human neuroglioma cells overexpressing APP. J Am Geriatr Soc 54:S7 Xiong L, Zheng Y, Wu M, Hou L, Zhu Z, Zhang X, Lu Z (2003) Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. Anesth Analg 96:233–237 Yon JH, Daniel-Johnson J, Carter LB, Jevtovic-Todorovic V (2005) Anesthesia induces neuronal cell death in the developing rat brain via the intrinsic and extrinsic apoptotic pathways. Neuroscience 135:815–827 Young C, Jevtovic-Todorovic V, Qin YQ, Tenkova T, Wang H, Labruyere J, Olney JW (2005) Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. Br J Pharmacol 146:189–197
Special Aspects of Pharmacokinetics of Inhalation Anesthesia* J.F.A. Hendrickx(* ü ) and A. De Wolf
1 2
Introduction: Nuts and Bolts of the Circle System .............................................................. How and Why Kinetics of Intravenous and Inhaled Anesthetics Have Been Modeled Differently............................................................................................................. 3 Expanding the Interpretation of the FA/FI Curve .................................................................. 4 The General Anesthetic Equation Concept.......................................................................... 5 The Ideal FGF–FD Sequence................................................................................................ 6 Compartment Modeling of Sevoflurane Liquid Injection by the AnaConDa® .................... References ..................................................................................................................................
160 162 167 174 178 182 183
Safe anesthesia requires the dedicated attention to the patient by a safe anesthesiologist no matter which method, device, or kind of apparatus is in vogue. Lucien Morris, inventor of the copper kettle (Morris 1994)
Abstract Recent interest in the use of low-flow or closed circuit anesthesia has rekindled interest in the pharmacokinetics of inhaled anesthetics. The kinetic properties of inhaled anesthetics are most often modeled by physiologic models because of the abundant information that is available on tissue solubilities and organ perfusion. These models are intuitively attractive because they can be easily understood in terms of the underlying anatomy and physiology. The use of classical compartment modeling, on the other hand, allows modeling of data that are routinely available to the anesthesiologist, and eliminates the need to account for every possible confounding factor at each step of the partial pressure cascade of potent inhaled agents. Concepts used to describe IV kinetics can readily be applied to inhaled agents (e.g., context-sensitive half-time and effect site concentrations).
J.F.A. Hendrickx Department of Anesthesiology and Intensive Care, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium
[email protected] * Parts of this chapter appeared in Dr. Jan Hendrickx’s doctoral thesis (Hendrickx 2004). J. Schüttler and H. Schwilden (eds.) Modern Anesthetics. Handbook of Experimental Pharmacology 182. © Springer-Verlag Berlin Heidelberg 2008
159
160
J.F.A. Hendrickx, A. De Wolf
The interpretation of the FA/FI vs time curve is expanded by reintroducing the concept of the general anesthetic equation—the focus is shifted from “how FA approaches FI” to “what combination of delivered concentration and fresh gas flow (FGF) can be used to attain the desired FA.” When the desired FA is maintained with a FGF that is lower than minute ventilation, rebreathing causes a discrepancy between the concentration delivered by the anesthesia machine (=selected by the anesthesiologist on the vaporizer, FD) and that inspired by the patient. This FD–FI discrepancy may be perceived as “lack of control” and has been the rationale to use a high FGF to ensure the delivered matched the inspired concentration. Also, with low FGF there is larger variability in FD because of interpatient variability in uptake. The FD–FI discrepancy increases with lower FGF because of more rebreathing, and as a consequence the uptake pattern seems to be more reflected in the FD required to keep FA constant. The clinical implication for the anesthesiologist is that with high FGF few FD adjustments have to be made, while with a low FGF FD has to be adjusted according to a pattern that follows the decreasing uptake pattern in the body. The ability to model and predict the uptake pattern of the individual patient and the resulting kinetics in a circle system could therefore help guide the anesthesiologist in the use of low-flow anesthesia with conventional anesthesia machines. Several authors have developed modelbased low FGF administration schedules, but biologic variability limits the performance of any model, and therefore end-expired gas analysis is obligatory. Because some fine-tuning based on end-expired gas analysis will always be needed, some clinicians may not be inclined to use very low FGF in a busy operating room, considering the perceived increase in complexity. This practice may be facilitated by the development of anesthesia machines that use closed circuit anesthesia (CCA) with end-expired feedback control—they “black box” these issues (see Chapter 21).
In this chapter, we first explore how and why the kinetic properties of intravenous and inhaled anesthetics have been modeled differently. Next, we will review the method most commonly used to describe the kinetics of inhaled agents, the FA/FI vs time curve that describes how the alveolar (FA) approaches the inspired (FI) fraction (in the gas phase, either “fraction,” “concentration,” or “partial pressure” can be used). Finally, we will reintroduce the concept of the general anesthetic equation to explain why the use of low-flow or closed circuit anesthesia has rekindled interest in the modeling of pharmacokinetics of inhaled anesthetics. Clinical applications of some of these models are reviewed. A basic understanding of the circle system is required, and will be provided in the introduction.
1
Introduction: Nuts and Bolts of the Circle System
The circle system is the anesthesia breathing system most widely used with adults. The kinetic properties of inhaled vapors and carrier gases are significantly affected by the manner in which the anesthesiologist uses the system. A sound understanding
Special Aspects of Pharmacokinetics of Inhalation Anesthesia
161
Fig. 1 Nuts and bolts of the circle system
of its composition is essential to understand the remainder of this chapter. We describe the circle system (Fig. 1) by following gases and vapors along their partial pressure cascade. The fresh gas flow rate (FGF) of a carrier gas or gases (O2, N2O, and/or air) is selected by adjusting the knobs of the rotameter(s) (Fig. 1, part a). By turning the wheel of the vaporizer (Fig. 1, part b) of the agent of choice, the appropriate amount of anesthetic vapor is added. The concentration of gases and vapors entering the circle system via the common gas outlet (Fig. 1, part c) is referred to as the delivered concentration (FD). Once these gases enter the inspiratory limb (Fig. 1, part d) they are labeled “inspired mixture” (with concentrations FI). The composition of the mixture may match that of the delivered gas FD, or it may be a mixture of delivered gas and some gas that is returning from the previously exhaled tidal volume(s) (see the next section). During inspiration, gases enter the lungs (Fig. 1, part e) from where they are taken up by the body (during wash-in and maintenance). The composition of the exhaled gas is a complex mixture of alveolar gas (FA) and dead space gas (FI, since by definition no gas exchange has occurred), and the correct term to describe its concentration is the mixed-expired concentration. Anesthesiologists measure the end-expired or end-tidal concentration, which is the concentration of anesthetic gas in the alveolar part of the exhaled gas, FA. The sampling port of the gas analyzer is located at the Y-piece (Fig. 1, part f) connecting the circle system to the patient’s airway. Exhaled gas then moves along the expiratory limb (Fig. 1, part g) toward either the breathing bag (Fig. 1, part h) when the patient is breathing spontaneously, or toward the bellows of the ventilator (Fig. 1, part i) when ventilation is controlled. Once the breathing bag or the bellows are full, the remainder of the gas still flowing through the expiratory limb is vented to the atmosphere (Fig. 1, part j).
162
J.F.A. Hendrickx, A. De Wolf
Only when the precise amount of gas and vapor that is being administered is taken up by the patient and/or is lost via leaks and sampling (closed-circuit anesthesia, CCA) will no excess gas be vented. If FGF is higher than minute ventilation, the bag or bellows will be filled with fresh gas only, and all the gas coming from the expiratory limb of the circle system will be vented. However, if FGF is lower than minute ventilation, the bag or bellows will fill with a mixture of fresh gas and exhaled gas coming form the expiratory limb—exhaled gas will therefore be reinhaled or rebreathed. Before reaching the inspiratory limb, rebreathed gases pass though a CO2 absorber (Fig. 1, part k) to avoid rebreathing of CO2. With rebreathing, the composition of the inspired mixture (FI) will differ from the FD selected by the anesthesiologist.
2
How and Why Kinetics of Intravenous and Inhaled Anesthetics Have Been Modeled Differently
During general anesthesia, the goal of an anesthesiologist is to attain and maintain those concentrations of anesthetic drugs in the blood (and ultimately the effect site) to ensure hypnosis and immobility (suppression of movement after noxious stimulation) (Eger and Sonner 2006). Kinetic models attempt to describe and predict these concentrations, and can be broadly categorized as either physiologic or classic compartmental (“empiric”). With a physiologic model the investigator incorporates the underlying physiologic processes that may affect drug kinetics into the model— the model describes the data as well as the processes by which the observations came to be. With the empiric approach, the only goal is to describe the data. Because blood concentrations of intravenous anesthetics cannot be measured continuously in the operating room, kinetic models are very useful to optimize maintenance of the desired blood concentration; kinetic models are incorporated in the software that steers syringe pumps (target-controlled infusion, TCI). Pharmacokinetic models for intravenous agents have most often been built empirically because frequently not enough information is available to build physiologic models. Programs like NONMEM fit (multi)exponential curves to the course of the concentrations of the agent of interest using dose history and covariates (e.g., age, gender, weight) as inputs (NONMEM Project Group 1992). The parameters of the model equations are intuitively most accessible when they are expressed as volumes of distributions and clearances because they have a physiologic flavor to it. Nevertheless, these volumes of distribution and clearances are fictitious entities that are not directly related to any underlying anatomic compartments or physiologic processes. The model most often consists of one central and one or two peripheral compartments. The concentration in the central compartment (which matches the blood concentrations which the model predicts) is considered to be the result of drug input into and elimination from a central compartment and drug transfer between compartments (distribution). After the model is derived, it is prospectively tested in a different group of patients using performance criteria such as those
Special Aspects of Pharmacokinetics of Inhalation Anesthesia
163
developed by Varvel et al.—performance error (PE), median PE (MDPE), median absolute PE, (MDAPE), divergence, and wobble (Varvel et al. 1992). The kinetic models can be incorporated into more complex pharmacokinetic/pharmacodynamic (PK/PD) models that use the effect site concentration to link blood concentrations to a desired clinical end-point, e.g., an EEG derivative such as Bispectral Index (BIS; Aspect Medical Systems, Norwood, MA) when the end-point is hypnosis, or the degree of neuromuscular blockade when muscle relaxants are used. These models can be incorporated in closed-loop systems. If enough physiologic information is available (such as tissue solubilities, tissue volumes, and perfusion), a physiologic model can also be used to describe the kinetics of intravenous agents. For example, a physiologic model predicted lidocaine (Benowitz et al. 1974) and propofol (Levitt and Schnider 2005) plasma concentrations well. The latter study is one of the few quantitative comparisons of physiologic and compartment models available. The uptake and distribution of inhaled anesthetics have most often been modeled by physiologic models such as Eger’s four compartment (4C) model (Eger 1974). Plenty of information is available to build a physiologic model. The parameters needed to calculate the course of tissue partial pressures (tissue volumes, tissue solubilities, and tissue blood flows) can be readily retrieved from the literature (Eger and Saidman 2005). The models assume uptake of anesthetic gases is perfusion limited. Organ vapor capacity depends on the size of the organ and the solubility of the agent in that particular organ. The rate at which the partial pressure in the organ increases, and eventually saturates toward the partial pressure in blood, depends both on the organ’s capacity and organ blood flow. This rate is described by a time constant (tissue storage capacity divided by blood flow). Based on both tissue storage capacity and blood flow, Eger grouped organs and tissues into the vessel rich group (VRG), muscle group (MG), fat group (FG), and vessel poor group (VPG) (Eger 1974). Uptake according to the 4C model is presented in Fig. 2, where it is compared with uptake according to the square root of time model (SqRT; see below) and with clinical uptake data. In Eger’s five-compartment (5C) model the VRG, MG, and FG from the 4C model are retained; the VPG is deleted because its contribution to uptake is considered insignificant, but a lung and an “intertissue diffusion” compartment are added (Carpenter et al. 1986). The intertissue diffusion group is hypothesized to be fat adjacent to well-perfused tissues. The model has recently been reviewed by Eger and Saidman (2005). The SqRT model was developed by Lowe and Ernst specifically to facilitate the practice of CCA in an era when multigas analyzers were not available (Lowe and Ernst 1981). The sum of uptake by the individual organs was found to increase according to the square root of time, an observation first made by Severinghaus for N2O (Severinghaus 1954). When the arterial concentration is maintained, the same amount of agent is taken up by the tissues during each subsequent “square root of time” interval (0–1 min, 1–4 min, 4–9 min, 9–16 min, etc.). This amount is called the “unit dose,” and is calculated based on patient weight. At the start, a “prime dose” is given to prime the circuit, functional residual capacity, and blood pool. Uptake according to the SqRT model is presented in Fig. 2.
164
J.F.A. Hendrickx, A. De Wolf
Fig. 2 Comparison of the sevoflurane uptake rate (mg.min−1) determined by Fick’s method (mean ± standard deviation) with that predicted by the 4C model and the square root of time model (SqRT) model. FA was maintained at 1.3% (Frietman et al. 2001)
Using modern computer technology, the number of differential equations that can be solved simultaneously is enormous, spurring the development of models with everincreasing numbers of compartments (Fukui and Smith 1981; Heffernan et al. 1982; Lerou et al. 1991; Vermeulen et al. 1995; Lerou and Booij 2001a). An 18-compartment model by Fukui and Smith (1981), for example, carries over 88 equations and 124 parameter settings. Some of the models simulate how a drug affects its own uptake by, e.g., altering cardiac output (i.e., nonlinear pharmacokinetics). How complex a model needs to be depends on the goal of the investigator. The more complex models should only be used if they better represent what actually happens or when more sophistication is required, such as when there is the need to study the effect of changes in physiologic parameters on uptake (Vermeulen 2000). The 4C model is intuitive and didactic, and is incorporated in GasMan (Med Man Simulations, Chestnut Hill, MA).The SqRT model by Lowe and Ernst is useful to provide dosing guidelines during CCA. Both models tend to overestimate initial uptake and underestimate it after 30–45 min (Fig. 2 ; Hendrickx et al. 1997, 1998a, 2003; Frietman et al. 2001). Interest in Heffernan’s 10-compartment model (Heffernan et al. 1982), first described more than 20 years ago, has rekindled recently in a series of studies by Kennedy to help predict concentrations of inhaled anesthetics during reduced FGF (Kennedy et al. 2002) (see Sect. 5). Sophisticated physiologic models offer advantages over simpler models for the study of interactions among ventilation, circulation, and the uptake and distribution of inhaled agents, and provide the basis for training simulators. Especially with the multicompartment physiologic models, it is important “not to be carried away with uncritical enthusiasm, because these models require an
Special Aspects of Pharmacokinetics of Inhalation Anesthesia
165
Table 1 Parameters of the classic two-compartment model of inhaled anesthetics derived from inspired and expired tidal volumes and concentrations of desflurane, isoflurane, and sevoflurane in O2/N2O by Wissing et al. (2000). The estimated pharmacokinetic variables and extrapolated parameters are given as median and range (in parentheses) Isoflurane Sevoflurane Desflurane k12 (min-1) k21 (min-1) Cl12 (mlvaporkg-1 min-1) V1 (mlvapor kgbw-1) V2 (mlvapor kgbw-1) Vss (mlvapor kgbw-1)
0.158 0.007 30.7 196 4,112 4,285
(0.065–0.583) (0.001–0.014) (15.9–38.7) (37–332) (1,472–9,396) (1,509–9,640)
0.117 0.007 13 106 1,634 1,748
(0.070–0.344) (0.001–0.019) (9.8–22.4) (57–171) (762–8,842) (819–8,997)
0.078 0.011 7 75 612 698
(0.029–0.186) (0.003–0.022) (4.4–11.1) (49–140) (343–1,850) (408–1,917)
Cl12, transport clearance from central to peripheral compartment; k12, microconstant for transport from central to peripheral compartment; k21, microconstant for transport from peripheral to central compartment; V1, volume of distribution of the central compartment; V2, volume of distribution of the peripheral compartment; Vss, volume of distribution during steady state. V1, V2, and Vss are given as milliliters of inhaled anesthetic in relation to body weight
immense amount of detailed information, much of which must be assumed, estimated, or simply guessed” (Hull 1997). Even with simple physiologic models many assumptions are made (Hendrickx et al. 1997). Tissue solubilities vary up to 150% between authors (Yasuda et al. 1989), and the tissue homogenates used to determine these coefficients may not represent in vivo conditions. Arterial to end-expired gradients exist that may not be explained by ventilation/perfusion mismatching alone (Landon et al. 1993; Doolette et al. 1998; Doolette et al. 2001). Brain time constants in vivo may be longer than the theoretically calculated values (Lockhart et al. 1991). In addition, from a more practical point, physiologic models are not well suited for the analysis of the FA vs time curves that are available in a clinical setting (Bouillon and Shafer 2000). One of the strengths of classic compartment modeling is that it can be used without having to take into account these confounding factors, and that they are well suited for the analysis of the FA vs time curves. Wissing describes classic compartmental parameters for isoflurane, sevoflurane, and desflurane based on inspired and expired concentrations and tidal volumes (Table 1; Rietbrock et al. 2000; Wissing et al. 2000). Yasuda et al. also used classic compartment modeling to describe the kinetics of inhaled anesthetics (Yasuda et al. 1991a, b). The exhaled concentrations of sevoflurane, desflurane, isoflurane, and halothane were measured using chromatography up to a week after these agents had been concomitantly administered for 30 min, and a five-compartment model was derived. In more recent work, arterial and mixed venous blood concentration profiles were linked to uptake derived from inspired and expired tidal volumes and partial pressures using compartment modeling (Ishibashi et al. 2006). Using lung uptake as the input function, the time course profiles of the arterial and the mixed venous blood concentrations were best described by a two- and one-compartment model, respectively. The use of compartment modeling of inhaled agents is currently being applied to derive dosing guidelines for the liquid infusion rate of sevoflurane with a commercially available device AnaConDa® (Hudson RCI, Upplands Väsby, Sweden) (Enlund et al. 2006).
166
J.F.A. Hendrickx, A. De Wolf
Fig. 3 Five-compartment model derived from end-expired wash-out data (Yasuda et al. 1991a, b)
Can distribution volumes and clearances, the parameters of compartment models, be interpreted in terms of tissue volumes and blood flows? Yasuda et al. (1991a, b; see above) tried to relate the distribution volumes and clearances with tissue volumes and tissue blood flows of a physiologic model. Thus, the first, second, third, fourth, and fifth compartment were interpreted as representing lungs, VRG, MG, intertissue diffusion, and the FG (Fig. 3). In a model developed by Ishibashi et al. (2006) that links arterial and mixed venous blood concentrations to uptake derived from inspired and expired tidal volumes and partial pressures, the relationship between distribution volumes and clearances (the parameters of compartment models) and covariates cardiac output and patient demographic data was not a straightforward one, suggesting that correlating clearances and distribution volumes with tissue volumes and blood flows should be done with care, if at all. Hull also argues that “[while] it is often suggested that some particular tissue or organ (such as the brain) be ‘in’ one compartment or another, such suggestions are ill-founded because parameters of the fit to the uptake data contain no information that might support such assumptions” (Hull 1997; Shafer 1998). Similarly, Wissing argues that a precise allocation of several hypothetical peripheral compartments to anatomically defined tissues is hardly feasible (Rietbrock et al. 2000). In a theoretical analysis, we documented that both classic compartment modeling and physiologic modeling describe the course of the anesthetic concentrations equally well, but the relationship between the parameters of the two models was complex (Hendrickx et al. 2006a). However, because both physiologic and compartment modeling described the course of the anesthetic concentrations equally well, concepts applied to IV anesthetics such as context-sensitive half-times (Bailey 1997; Eger and Shafer 2005) or keo (the plasma-effect site equilibration rate constant; Kennedy 2005) can equally well be applied to inhaled agents. In contrast to the clinical requirement for kinetic models when a specific target concentration of an intravenous agent is aimed for, some authors have suggested that there is no clinical need for kinetic models of potent inhaled anesthetics
Special Aspects of Pharmacokinetics of Inhalation Anesthesia
167
(Vermeulen 2000). First, FA can be continuously measured. Second, FA defines the concentrations needed to ensure the relevant clinical endpoints of hypnosis and immobility (mediated at the spinal and supraspinal level respectively) through the concepts of MACawake and MAC (Eger et al. 1965; Stoelting et al. 1970). This doseresponse curve for suppression of movement and hypnosis is steep—within a population, MAC varies by not more than 10%–15% among individuals (Sani and Shafer 2003; de Jong and Eger 1975; Eger et al. 2001). Third, the partial pressure in the brain lags behind that in the alveoli with only a modest delay for modern agents—the equilibration half-time of this process (determined using EEG power spectrum) is 2.4 min for isoflurane and sevoflurane and 1.1 min for desflurane (Rehberg et al. 1999). We would therefore argue that the MAC and MACawake concepts by definition make any kinetic model for inhaled agents also a PK/PD model for the end-points immobility and hypnosis. Some authors prefer to incorporate this delay in their model by introducing an effect site concentration in their model (see Sect. 5) (Kennedy 2005). And finally, automated closed-loop administration of inhaled agents has now enabled the anesthesiologist to select an FA without having to bother about uptake or delivered or inspired partial pressure to achieve that particular FA (see Chapter 21). While we concur that inhaled anesthetics can be and are being administered safe